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Risk and Maintenance Factors for 
Eating Disorders: An Exploration 
of Multivariate Models on Clinical 
and Non-Clinical Populations
Stefania Cella, Mara Iannaccone, Annarosa Cipriano  
and Paolo Cotrufo
Abstract
The recognition of factors involved in the development and maintenance of eat-
ing disorders (EDs) may support the choice of therapeutic strategies and improve 
the prevention/treatment of eating pathologies and their outcomes. Based on this 
consideration, the overall purpose of the chapter is to investigate how some psycho-
logical characteristics link to EDs. It is organized as follows. First, the epidemiologi-
cal aspects, risk, and maintaining factors for ED are outlined. Next, we present 
the findings from our two studies. The purpose of the first study was to identify 
predictors associated with the severity of eating symptomatology. Then, the objec-
tive of the second study was to provide an understanding of the relationship among 
perceived parental bonding, self-esteem, perfectionism, body shame, body mass 
index, and ED risk and mainly to test a predictive ED risk model in a non-clinical 
sample. In conclusion, the major findings and practical implications are discussed.
Keywords: perceived parental bonding, self-esteem, perfectionism, body shame, 
body mass index, eating disorders, risk factors
1. Eating disorder risk and maintaining factors: an overview
Eating disorders (EDs) are highly prevalent psychological conditions character-
ized by abnormal eating behaviors that may lead to serious health problems and 
even cause death [1]. The existing diagnostic classifications of EDs include anorexia 
nervosa (AN), bulimia nervosa (BN), eating disorders not otherwise specified 
(EDNOS), avoidant/restrictive food intake disorder (ARFID), pica and rumination 
disorder. Additionally, the Diagnostic and Statistical Manual of Mental Disorders-5 
(DSM-5) [2] supports binge eating disorder (BED) as a correct diagnosis on par 
with AN and BN.
In the framework of the European Study of the Epidemiology of Mental 
Disorders (ESEMeD) project, a lifetime prevalence rate of 0.93% for AN, 0.88% for 
BN, and 1.92% for BED have been found for females [3]. In a large population-based 
survey in the United States, Hudson and colleagues [4] have reported a lifetime 
prevalence of 0.9, 1.5, and 3.5% for AN, BN, and BED, respectively. More recently, 
a national survey has found a lifetime prevalence of DSM-5 defined AN, BN, and 
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BED of 0.80, 0.28, and 0.85%, respectively. Individuals with lifetime BED were 
found to have a later age of onset of ED and longer ED episodes duration [5].
Even though eating pathologies have been traditionally associated with females [6], 
males are also at risk for developing EDs [7, 8]. It was estimated that approximately 
14% of AN [9], 10–15% of BN [10], and 40% of BED cases [11] were men. Prevalence 
rates of 0.3, 0.5, and 2.0% were found for AN, BN, and BED among men, who also 
accounted for approximately 25% of all EDs cases [4]. However, several studies 
have pointed out an upward trend in EDs prevalence rates among males [12–13]. 
Furthermore, empirical research shows that, in males, homosexual orientation is 
associated with higher body dissatisfaction and abnormal eating behaviors [14].
Adolescence to young adulthood is the peak risk period of onset for EDs 
symptomatology [15]. A recent longitudinal study, for instance, showed increases 
in weight preoccupation, body dissatisfaction, and bulimic behaviors from 11 to 
25 years [16]. The Growing Up Today Study found that binge eating increased 
with age and peaked in late adolescence [17]. More generally, several authors have 
reported the presence of body dissatisfaction and drive for thinness even in children 
aged between 5 and 11 [18, 19] and have demonstrated that weight concerns, body 
dissatisfaction, and weight status increase with age [20, 21].
Some studies have found that the levels of EDs are highest in younger individu-
als [22]. Women with EDs with later age of onset (>25 years) might report less 
severe eating symptomatology compared with women with the typical age of onset 
(<25 years) [23].
In terms of the ED occurrence, several variables have been suggested as possible 
predisposing factors for these pathologies. In this section, we review some of the 
known risks and maintaining factors for the development of eating disturbances.
1.1 Parental bonding
It has long been recognized that family factors are essential features in the 
development, maintenance, and therapeutic outcome of EDs.
Selvini Palazzoli [24] was one of the first authors who observed some typical 
patterns in ED families functioning, such as an overprotective relationship with 
mother and a distant relationship with father.
Similarly, psychosomatic family model [25] suggested that a family environment 
characterized by enmeshment, overprotectiveness, and rigidity plays a key role in 
the etiology of AN. On the other hand, insecure attachment patterns were found to 
be prevalent in ED patients [26].
Overall, empirical evidence on parental bonding—generally assessed by the 
Parental Bonding Instrument [27]—highlights the importance of low paternal care 
and high maternal overprotection in the occurrence of ED symptomology in both 
clinical and non-clinical samples [28, 29]. Parental care refers to a continuum of 
behaviors ranging from affection and warmth to coldness and rejection. In con-
trast, parental protectiveness exists along a continuum that ranges from behaviors 
indicating encouragement of autonomy/independence as opposed to strict control 
with regulations and intrusiveness [27].
Yet, up till now, few studies have investigated whether parental bonding 
might be correlated with the severity of disordered eating symptoms. Among ED 
patients, high parental overprotection is associated with suicidal behavior [30]. 
Body image disturbances, considered as one of the major clinical features of eating 
pathology [31], resulted in being predicted by low parental care and high parental 
 overprotection [29, 32].
In the study by Canetti and colleagues [33], anorexic participants reported 
perceiving both parents as less caring and fathers as more controlling than control 
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group participants; moreover, maternal control and paternal care were associated 
with higher symptom severity. A recent cross-sectional study has shown that the 
quality of the father-daughter relationship (i.e., overprotective and avoidant) plays 
a critical role in understanding the ED onset and maintenance [29].
Similar findings were reported by Rienecke and colleagues [34], the presence of 
paternal criticism—and not maternal—showed a significant predictive power for 
less psychological improvement in ED psychopathology at the end of family-based 
treatment for adolescents AN.
Overall, the overprotective behavior of the parents might be a result of the ED 
and often starts as a consequence of the disorder [35]. Researchers suggest that eat-
ing pathology may influence family dynamics and environment, which in turn may 
unconsciously affect ED symptoms maintenance and evolution [36].
In terms of the psychological dynamics underlying the association between 
parental bonding and eating pathologies, several researchers have suggested the 
existence of potential mediating mechanisms involved in such association. Turner 
and colleagues [37], for instance, reported that paternal care and maternal over-
protection had an indirect effect on ED symptoms through the mediating effect 
of maladaptive core beliefs (i.e., schemas related to defectiveness/shame and 
dependence/incompetence).
Likewise, maladaptive perfectionism was found to mediate the pathway from 
parental psychological control and ED patterns [38]. In our previous study [28], 
on a large sample of adolescents, the link between the parental bonding pattern 
typified by low paternal care/maternal overprotection and dysfunctional eating 
attitudes were found to be mediated by self-concept. Our data were consistent with 
the study of Perry and colleagues [39] in which a parental bonding pattern charac-
terized by low care and over-protection affected self-concept formation, which, in 
turn, affected eating psychopathologies in adulthood.
1.2 Self-esteem
The literature on EDs shows that a patient’s self-concept is fundamentally 
characterized by low self-esteem, which is considered a critical vulnerability factor 
in the development of these diseases [40]. In a review focusing on causes of EDs, 
low self-esteem is one of the prominent features strongly implicated in the onset of 
the pathology [41].
In a series of interesting papers exploring the self-esteem dimensions, Geller and 
colleagues found that shape- and weight-based self-esteem and intimate relation-
ship-based self-esteem were related to higher ED symptoms [42, 43].
It seems that white women are most at risk for having low self-esteem and dif-
ficulty with eating problems [44]. Still, several studies have shown that an impover-
ished sense of self is an essential contributor to ED symptomatology [45], and it is 
correlated with a negative treatment outcome [46]. Similarly, in a study carried out 
by Brechan and Kvalem [47], the effect of body dissatisfaction on restrained eating, 
binge eating, and compensatory behavior was completely mediated by self-esteem.
However, some studies do not support the existence of a direct relationship 
between low self-esteem and eating pathology. In some studies, self-esteem did 
not emerge as a significant predictor of disordered eating [48, 49]. Moreover, some 
researchers suggest that future studies should focus on a more informative multi-
faceted construct of self-esteem [50] and investigate interactive effects with other 
predisposing factors for a better understanding of the link between self-esteem 
and eating problems [45]. In this regard, self-esteem has been suggested to predict 
disordered eating via body shame [51], also among obese youth [52]. A study by 
Goossens and colleagues [53] provided evidence for the hypothesis that an insecure 
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relationship with parents may act as a mediating variable in the pathway from self-
esteem and dysfunctional eating patterns.
1.3 Perfectionsim
Perfectionism is a personality trait that is characterized by setting excessively 
high personal standards of performance [54]. Frost and colleagues [54] viewed 
perfectionism as being constituted of adaptive (healthy) and maladaptive (dys-
functional) perfectionism.
In a cross-sectional research designed to explore perfectionism across different 
stages of EDs recovery, ED patients scored significantly higher than healthy con-
trols on the maladaptive perfectionism factor [55]. Further studies have reported 
that elevated levels of both adaptive and maladaptive perfectionism are strongly 
associated with body dissatisfaction [56] and ED psychopathology [57–59], 
including BN [60]. A percentage of about 40% of AN patients (Mage = 15.3 years) 
have a very high score on self-oriented perfectionism and perfectionistic self-
presentation. The authors concluded that in this subgroup of patients, it would be 
necessary to address these psychological characteristics to achieve a good outcome 
[61]. Several studies have highlighted that a higher level of perfectionism might 
be detrimental for disease duration and prognoses [62, 63], also among children 
and adolescents with EDs [64, 65]. Previous studies have shown that perfection-
ism predicts ED onset and maintaining [66]. Similarly, an experimental study 
has suggested that perfectionism represents a causal risk factor for ED pathology 
[67]. On the other hand, these findings are not systematically replicated in other 
studies: perfectionism—adaptive and maladaptive types—does not emerge as a 
risk factor for eating disturbances [68, 69], and the specific mechanism by which 
perfectionism uses its influence on eating psychopathology has, up till now, to be 
recognized.
In this regard, Bardone-Cone and colleagues [58] have reported that the inves-
tigation of mediating pathways from perfectionism to ED pathology was mostly 
absent from the literature. How perfectionism related to the EDs risk factors and 
potential mediating variables affecting the relationship between perfectionism and 
disordered eating remain mostly unknown.
Several studies support the association between low self-esteem, perfection-
ism, and varying degrees of ED patterns [70], “Indeed, the combination of 
low self-esteem and perfectionism is not unusual among those who binge, and 
especially those with BN, AN, or an atypical ED, and it may well contribute to 
the development of the problem” ([71], p. 65). Still, “as he was nearing the end of 
his life, Michelangelo began working on what many people believe to be his most 
important work, the Florentine Pietà. After working intensely for almost a decade, 
he entered his studio one day and took a sledgehammer to the sculpture. He broke 
away the hands and legs and nearly shattered the work before his assistants dragged 
him away. Why did Michelangelo attempt to destroy one of his greatest creations, 
a statue that has been described as among the finest works of the Renaissance? 
Disillusioned and isolated in the last decades of his life, Michelangelo had a height-
ened sense of perfectionism that was exarcebed by his failure to live up to the excep-
tions of his father, who viewed being a sculptor as akin to begin a manual laborer. 
Michelangelo, it seems, had self-esteem issues” ([72], p. 158).
Literature supports the hypothesis that a combination of low perception of 
control and low self-esteem moderates the effects of perfectionism on drive for 
thinness, BN, and body [73].
In conclusion, as previously suggested [74], the role of perfectionism in the 
etiology and maintenance of EDs remains unclear.
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1.4 Body shame
Eating pathologies have been described as “disorders of shame” [75]. A positive 
relationship between shame and eating pathology has been found [76, 77].
However, several studies have concentrated upon shame explicitly associated 
with the body rather than to general shame.
Body shame is the shame one feels about one’s body or any part of it [78]. 
Moreover, body shame can also relate to how one’s body functions [79], and it repre-
sents a better concept than “body dissatisfaction” in work with EDs [80].
Body shame is a strong predictor of disordered eating [81, 82].
In a longitudinal study designed to explore the role of body shame and general 
shame in predicting increases in eating symptoms over 2.5 years in a sample of 
women with a past or current ED, body shame exclusively predicted an increase 
in AN symptoms [83]. Dorian and colleagues [84] have found that body shame is 
uniquely predictive of eating disturbance in a female clinical sample and in a male 
non-clinical sample. However, both body and characterological shame predicted 
eating psychopathology in a non-clinical female sample. In sum, body shame would 
seem to have a causal role in the ED onset.
In addition, the severity of ED symptomatology has been linked to feelings of 
bodily shame in the eating context [81, 85]. Troop and colleagues [83], for instance, 
found that shame was uniquely associated with the severity of both AN and BN 
symptoms. Goss and Gilbert [79] proposed a model based on the functional role of 
eating disordered beliefs and behaviors in the management of shame. The authors 
offered a model process based on risk factors (i.e., genetic factors, personality, early 
attachment history, abuse or rejection experiences, and cultural factors) that might 
predispose people to develop both shame proneness and ED proneness. These factors 
cause shame, and to defend themselves against adverse social outcomes, individuals 
may attempt to change their body shape and weight. Then, they may feel around in 
their ability to manage their weight, but when they are not able to do so, they feel 
further shame. This leads to a shame-pride circle that maintains the pathology.
Overall, shame can be described both as cause and consequence of symptoms in 
eating pathology [80]. Unfortunately, there are few findings about body shame, and 
much is unknown about how it operates in ED development. Literature supports 
the suggestion that body shame may act as a mediator in the relationship between 
self-esteem and disordered eating [51].
Regarding the determinants of body shame, some research has provided evidence 
associating poor perceived parenting and subsequent shame [86]. The perception 
of low parental care and high parental protectiveness in childhood was found to be 
related to shame in young adulthood [87]. Murray and colleagues [88] suggested that 
dysfunctional parenting practices may lead to individuals’ feelings of inadequacy and 
worthlessness, so it might be clinically essential to examine the psychological conse-
quences of such a family experience, such as shame. Specifically, the authors found 
that paternal overprotection was related to bulimic symptoms through the mediation 
effect of shame. On the other hand, it has been shown that parenting practices failed 
to predict the vulnerability to body image shame, directly or indirectly. In a study 
examining the determinants of body shame, Markham and colleagues [89] found 
that body-image esteem, global self-worth, appearance comparison, and internaliza-
tion of the thin ideal accounted for 62% of the variance in body-image shame.
1.5 Body mass index
It would seem that the body mass index (BMI) plays a more critical role in pro-
moting the risk factors for EDs than indirectly maintaining eating pathology [90]. 
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Obese individuals are at higher risk for developing an eating pathology [91]. Indeed, 
a low BMI represents a protective factor against the development of disturbed eat-
ing in adolescent girls [92, 93]. Moreover, BMI in childhood is a significant predictor 
of restrained eating in early adolescence [94].
BMI at admission can be considered as a significant predictor of outcome in AN 
[95]. The link between BMI and mortality in BN has also been investigated. Severe 
BN patients may be at higher risk of death, especially if suicide has been attempted 
previously or in case of a low minimum BMI at admission [96].
In terms of the underlying mechanisms that linked BMI and eating psychopa-
thology, in a study by Fan and colleagues [97], BMI was not found to have a direct 
influence on ED symptoms, and the authors concluded that weight control concerns 
and behaviors could mediate this relationship. To answer the question of what 
causes a high BMI, risk factors for obesity included parental fatness—although only 
a few longitudinal studies have investigated the parent-child fatness association—
social factors, birth weight, timing or rate of maturation, physical activity, dietary 
factors, and other behavioral and psychological factors [98, 99].
Parental overweight is one of the main predictors for the development of child-
hood overweight and obesity [100], but parents can influence child body weight 
through specific feeding behaviors and practices, such as restriction, pressure to 
eat, and monitoring [101, 102], or more broadly through their general parental 
attitudes and style of interacting with children (for a review, see [103]). In a study 
about the influence of parental care in childhood on the risk of obesity in young 
adulthood, parental neglect was found to significantly affect the risk of adult 
obesity, independent of age and body mass index in childhood, sex, and social 
background. Instead, receiving overprotective parental support did not affect [104].
In terms of the psychological dynamics underlying parental-child relationship, 
possible mediating factors are considered. Overall, a growing body of research has 
focused on maternal sensitivity and emotion regulation. A poor quality of the early 
maternal-child relationship, characterized by low levels of maternal sensitivity, may 
be linked to childhood overweight and obesity through the development of potential 
difficulties in children’s ability to regulate emotions [105]. In this regard, emotion 
dysregulation in early childhood is implicated in the development of obesity in early 
adolescence [106]. Similarly, empirical research suggested that authoritarian parent-
ing (high control and low levels of emotionally responsiveness) may influence 
children’s self-regulation skills [107] and, in turn, to be positively associated with 
child weight status [108, 109]. A longitudinal study showed that more inadequate 
maternal emotional regulation abilities during pregnancy were able to predict, at 
7 months of age of the baby, the quality of the early mother-child feeding patterns 
[110], and the body mass index of the child at three years of age [111].
1.6 Multivariate etiologic models
Most of the studies about the ED onset have focused on the risk factors uncon-
nectedly, precluding understanding about interactive effects.
In one of the few research in this area studies, Bardone-Cone and colleagues 
[112] found that perfectionism, body dissatisfaction, and self-esteem interact 
to predict bulimic symptoms. Specifically, women who perceived themselves to 
be overweight and who had elevated levels of perfectionism and lower levels of 
self-esteem were most at risk for bulimic symptoms. However, this interactive 
model has received mixed support [113–115], for example, it has been considered 
valid concerning maintenance and exacerbation, but not with the onset of bulimic 
symptoms [116]. Expanding the model to EDs patients under psychotherapy treat-
ment, Watson and colleagues [74] found that binge eating and purging were not 
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significantly predicted by the three-way interaction term neither in concurrent nor 
in prospective analyses (i.e., examined as a moderator of treatment outcome). The 
authors concluded raising concerns about the robustness of the three-way model. 
Otherwise, it could have been affected by an inadequate conceptualization of the 
perfectionism construct.
A study by Ghaderi [117] suggested that a combination of low self-esteem, high 
body concern, low perceived support from the family, and more relative use of 
escape avoidance coping constitute a risk profile that later would lead to the devel-
opment of ED. However, the author did not investigate if and how the predictor 
variables interact with each other in explaining ED onset.
In terms of the mechanism that perpetuates EDs, according to the cognitive-
behavioral theory of the maintenance of BN [118], a dysfunctional system for 
evaluating self-worth is central to the continuation of the pathology. People with 
eating disturbances judge themselves principally based on their eating behaviors, 
shape, or weight and their ability to control them. Most of the other clinical features 
can be considered as stemming directly from this overvaluation of eating, shape, 
and weight that represents the “core of psychopathology”. This original theory of 
continuance on BN could embrace four additional maintaining mechanisms, which 
concern the influence of clinical perfectionism, low core self-esteem, mood intoler-
ance, and interpersonal difficulties. However, a common mechanism is involved 
in the persistence of BN, AN, and the atypical EDs resulting in the transdiagnostic 
theory of the maintenance of the full range of eating disturbances [119]. Moving 
from this theory, Lampard and colleagues [120] concluded that a mixture of factors 
(i.e., transdiagnostic and disorder-specific) might be involved in the maintaining 
mechanism of ED disorder symptomatology. The transdiagnostic model of EDs 
might be applied to improve our understanding of muscle dysmorphia, additionally 
to eating psychopathology [121].
2.  Identifying predictors associated with the severity of eating concerns 
in females with eating disorders
Investigating factors that contribute to the onset and development of EDs has 
been the focus of previous studies. Several variables have been suggested as pos-
sible predisposing and perpetuating factors for EDs pathologies: perceived parental 
bonding, self-esteem, perfectionism, and body shame are among the factors that 
have been investigated separately. However, studies explicitly evaluating different 
predictors associated with the risk and severity of eating symptoms are limited in 
the literature [122, 123].
Based on this consideration, we have conducted a study [124] to identify predic-
tors associated with the severity of disordered eating symptomatology. Identifying 
which of the individual variables (self-esteem, perceived parental care and pro-
tectiveness, body shame, and perfectionism) significantly predicted the severity 
of eating symptomatology for ED patients was the main research question that has 
driven our work.
The study was approved by the ethics committee of the Faculty of Psychology 
(University of Campania “Luigi Vanvitelli”).
We gathered data from inpatients and outpatients referred to specialized 
residential ED treatment units in Northern, Central, and Southern Italy. At intake, 
a clinical interview was administered by ED clinicians for the assessment of diag-
nosis. All participants had a primary ED diagnosis DSM-IV [125]. Participants were 
tested at early stages—in order to avoid strong treatment effects—and at variables 
points during the treatment.
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We screened 80 female eating disordered patients aged 13–40 years old through 
the self-report measures of parental behavior, self-esteem, perfectionism, body 
shame, and ED risk.
It is worth noting that the comparisons between AN, BN, and BED patients on 
the study variables highlighted only a few statistically significant differences. Based 
on these findings, patients who fall below the different diagnostic categories for 
eating disturbances seem to share several psychological characteristics. However, 
results indicate that greater severity of the eating symptomatology could be related 
to the diagnosis of BN. In our opinion, these results seem to further support the 
hypothesis of a shared psychopathological core of EDs, and BN could be regarded 
as a “failed” AN [126, 127]. Future treatment research should broaden the clinical 
understanding of this suggestion.
In line with empirical research, maladaptive perfectionism was found to be 
strongly linked to eating concerns, followed by body shame and low self-esteem. On 
the other hand, differently from previous studies, parental care and protectiveness 
were not related to the level of eating symptomatology. Linear regression analysis, 
as displayed in Table 1, demonstrated that maladaptive perfectionism (p < 0.001), 
body shame (p < 0.05), and self-esteem (p < 0.05), significantly predicted ED 
symptom severity, and explained a significant proportion of variance in ED symp-
tomatology (adjusted R2 = 0.450).
While both adaptive and maladaptive perfectionism were found to be correlated 
to EDs symptomatology, only maladaptive perfectionism was significantly and 
positively associated with eating concerns. These findings seem to support recent 
studies pointing out the role of maladaptive perfectionism—but not adaptive—in 
the prediction of eating symptomatology [57]. However, this datum could be due 
to an inadequate assessment of the adaptive perfectionism. Future studies should 
look at perfectionism as a multidimensional construct and further investigate the 
specificity of both functional and dysfunctional perfectionism contribution and 
their interplay with ED maintenance.
In line with previous findings [84], shame about the body emerged as a signifi-
cant predictor of the level of eating concerns. However, research is needed because 
few studies have investigated the role of shame in ED maintenance, and further 
investigation might examine other forms of shame (specific and generalized).
Interestingly, these results seem to contradict the findings of previous research 
[49], and suggest that low self-esteem is a strong predictor of ED symptomatology. 
In this sense, low self-esteem consistently emerges as one of the core features of ED 
pathology.
Model B Standard 
error
β T P R2 Adjusted 
R2
F






















Bodily Shame 2.629 .689 .353 3.815 .000











Bodily Shame 2.173 .669 3.248 .002
Self-Esteem -1.106 .354 -3.126 .003
Table 1. 
Stepwise regression model and statistics for dependent variable [124].
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Unexpectedly, perceived parental care and protectiveness were not found being 
associated with the level of eating concerns. In contrast with ED literature, these 
findings might be due to cultural differences. Furthermore, it is possible that per-
ceived parental bonding might participate in promoting the risk factors for eating 
pathology rather than indirectly maintaining the disturbance. It would be interest-
ing to clarify this question.
In our opinion, it is helpful to recognize psychological variables significant 
for considerations in the treatment of these patients. Identifying potential 
predisposing and maintaining factors may enhance our understanding of ED 
symptomatology and support the choice of targeted therapeutic strategies to 
improve ED treatments and outcomes. Specific attention should be paid to 
helping ED patients to improve overall self-esteem. In addition, the treatment 
of maladaptive perfectionism and body shame might help in reducing ED 
symptomatology.
In conclusion, our findings stress the need to investigate these factors further as 
they might represent negative prognostic factors.
3.  Structural equation modeling of possible risk factors for eating 
disorder onset in female and male adolescents
Given the limited number of studies evaluating multivariate models explaining 
ED risk, research intended to fill this empirical gap was undertaken. Specifically, 
we have conducted a study [128] to assess the relationships among perceived 
parental bonding, self-esteem, maladaptive and adaptive perfectionism, body 
shame, body mass index, and ED risk with structural equation modeling. Several 
predictions were advanced concerning these potentially contributing factors. We 
hypothesized that perceived parental bonding, self-esteem, perfectionism, and 
BMI do not have a direct effect on ED risk. In our opinion, one potential mean by 
which these variables are related to ED vulnerability is through their effects on 
body shame.
Obtaining a clearer picture of how ED relates to these variables could result in 
an enhanced understanding of the mechanism through which such factors may 
lead to eating pathology.
This research was conducted on a sample of 1156 high school students—males 
and females—who ranged in age from 13 to 20 years. Participants were screened 
through self-report measures of parental behavior, self-esteem, perfectionism, body 
shame, and ED risk. The height and weight of each individual were measured. This 
age group was chosen as this cohort is at the most significant risk for eating distur-
bances, with ED incidences peaking during adolescence to early adulthood [129].
The study received the institutional review board approval.
The results only partially supported the hypothesized model (Figure 1), and 
several interesting findings emerged.
Several studies have documented an association between a bonding behavior 
pattern characterized by low care and high protectiveness and eating symptom-
atology [130, 131]. In line with previous empirical research [36], the model tested 
showed that poor parental care does not have a direct effect on ED risk, but it has a 
significant indirect effect through low self-esteem. Parental care has also an indirect 
effect on ED risk through the mediational effect of the BMI. Thus, perceiving 
neglectful parents may put adolescents at risk of developing obesity and eating 
problems.
Bearing in mind this suggestion, it seems reasonable that a high BMI is predicted 
by low parental care, but not parental protectiveness.
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Bodily Shame 2.173 .669 3.248 .002
Self-Esteem -1.106 .354 -3.126 .003
Table 1. 
Stepwise regression model and statistics for dependent variable [124].
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Unexpectedly, perceived parental care and protectiveness were not found being 
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and females—who ranged in age from 13 to 20 years. Participants were screened 
through self-report measures of parental behavior, self-esteem, perfectionism, body 
shame, and ED risk. The height and weight of each individual were measured. This 
age group was chosen as this cohort is at the most significant risk for eating distur-
bances, with ED incidences peaking during adolescence to early adulthood [129].
The study received the institutional review board approval.
The results only partially supported the hypothesized model (Figure 1), and 
several interesting findings emerged.
Several studies have documented an association between a bonding behavior 
pattern characterized by low care and high protectiveness and eating symptom-
atology [130, 131]. In line with previous empirical research [36], the model tested 
showed that poor parental care does not have a direct effect on ED risk, but it has a 
significant indirect effect through low self-esteem. Parental care has also an indirect 
effect on ED risk through the mediational effect of the BMI. Thus, perceiving 
neglectful parents may put adolescents at risk of developing obesity and eating 
problems.
Bearing in mind this suggestion, it seems reasonable that a high BMI is predicted 
by low parental care, but not parental protectiveness.
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Speculatively, it could be hypothesized that the relationship between parental 
overprotectiveness and ED risk might be mediated by the existence of other inter-
vening variables, such as interoceptive awareness.
In this regard, parental protectiveness could not allow individuals to develop a 
sense of personal needs, altering their interoceptive awareness and, consequently, 
their eating behavior. Future empirical studies should investigate this suggestion.
Consistent with our hypothesis, parental protectiveness did have both direct 
and indirect effects—via low self-esteem—on ED risk, as previously suggested 
[39]. These findings are consistent with research that converges on the role of 
psychological control (i.e., parental protectiveness) in ED proneness. As such, this 
finding suggests that overprotectiveness may be more directly relevant to eating 
disturbance development. Research should further explore this datum and examine 
the unique contribution of each parent in the etiology of eating pathologies.
Results showed that self-esteem has a direct effect on both maladaptive and adap-
tive perfectionism. Specifically, the linkage between low self-esteem and maladaptive 
perfectionism was particularly strong. These findings offer further support to previous 
studies suggesting that striving to appear perfect is an attempt to compensate for low 
self-esteem [132]. Individuals with an ED may interpret their mistakes as evidence of 
personal deficiencies [133]. In this perspective, to be flawless represents an obligation.
Moreover, even if indirectly via self-esteem, a link between parental bonding 
and perfectionist orientation emerged. This datum partially supports the findings 
of Soenens and colleagues [38] who have evidenced a relationship between parental 
psychological control and maladaptive perfectionism.
Contrary to the initial hypothesis, parental care and protectiveness were not 
found as significant predictors of body shame. This agrees with findings from other 
Figure 1. 
Illustration of the final model with standardized path coefficients and percentage of variance explained [128].
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researchers [89]. One potential explanation may be that parental bonding exerts an 
indirect influence on body shame via self-esteem and BMI. Indeed, as predicted, 
both low self-esteem and BMI emerged as significant predictors of increased 
vulnerability to body shame. In this regard, low self-esteem may be regarded as a 
source of body shame. People who perceive themselves as inadequate or unworthy 
may be at the most significant risk of experiencing body shame [89].
Model results showed that perfectionism did not predict body shame, contrary 
to our initial hypothesis. However, the non-significant pathway from both mal-
adaptive and adaptive perfectionism to ED risk offers further support, alongside 
other studies [68], that these variables may not be vulnerability factors for eating 
disturbances.
Due to its association with self-esteem, perfectionism could be regarded as a 
psychological characteristic typically associated with eating disturbances, rather 
than a risk factor for EDs. However, future research is needed to investigate vari-
ables that may intervene in the pathway from perfectionism to ED risk.
In line with previous studies [51], body shame emerged as a mediator in the 
relationship between self-esteem and ED vulnerability—explaining 71% of the 
variance. Notwithstanding, self-esteem has also a direct influence on ED. These 
results further corroborate previous studies recognizing low self-esteem as a critical 
predictor of ED vulnerability [40, 41].
Although body shame partially mediated the relationship between BMI and eat-
ing disturbance vulnerability, BMI had also a positive effect on ED risk. Undeniably, 
a high BMI has long been considered as a strong ED risk factor [91]. Our results 
support findings of previous studies [82, 83] suggesting that the experience of 
shame related to one’s body exerts a strong influence on eating disturbances vulner-
ability. Yet our results suggest that in addition to a direct effect, body shame also 
serves as a mediator between other risk factors and eating disturbance risk. In this 
regard, body shame may be a key variable in the pathway to eating disturbances 
risk and a core diagnostic feature of all eating disturbances. Notwithstanding, only 
a few studies have investigated the role of body shame in ED onset. Further studies 
on this construct would be beneficial.
Finally, the evaluation of measurement invariance allowed to conclude that 
the final model was invariant across gender: no gender differences emerged in the 
hypothesized pathway to ED risk. Therefore, our study suggests that adopting 
the same prevention and treatment programs for both males and females may be 
appropriate.
In conclusion, we extend the work of others who have separately examined 
the role of perceived parental bonding, self-esteem, body mass index, perfection-
ism, and shame in EDs, identifying the possible mechanisms through which these 
variables increase the likelihood of eating problem development.
This is the first study that conceptualizes how several risk factors may work 
together to create a pathway to eating pathologies. Collectively, perceived parental 
care and protectiveness, self-esteem, maladaptive and adaptive perfectionism, body 
shame, and BMI account for 58% of the variance in ED risk. Therefore, these initial 
findings suggest a promising model.
Provided that the present findings can be replicated longitudinally, they have 
noteworthy implications for EDs prevention and treatment. Identifying which 
interpersonal characteristics and personal factors are most relevant in the etiol-
ogy of EDs may help mental health professionals designing targeted prevention 
and/or intervention programs during adolescence. Clinicians should consider the 
routine assessment and treatment of these factors. First and foremost, intervention 
programs ought to be addressed to reduce subjective feelings of ineffectiveness and 
shame. Particular attention should be paid to obese youth.
Weight Management
12
Speculatively, it could be hypothesized that the relationship between parental 
overprotectiveness and ED risk might be mediated by the existence of other inter-
vening variables, such as interoceptive awareness.
In this regard, parental protectiveness could not allow individuals to develop a 
sense of personal needs, altering their interoceptive awareness and, consequently, 
their eating behavior. Future empirical studies should investigate this suggestion.
Consistent with our hypothesis, parental protectiveness did have both direct 
and indirect effects—via low self-esteem—on ED risk, as previously suggested 
[39]. These findings are consistent with research that converges on the role of 
psychological control (i.e., parental protectiveness) in ED proneness. As such, this 
finding suggests that overprotectiveness may be more directly relevant to eating 
disturbance development. Research should further explore this datum and examine 
the unique contribution of each parent in the etiology of eating pathologies.
Results showed that self-esteem has a direct effect on both maladaptive and adap-
tive perfectionism. Specifically, the linkage between low self-esteem and maladaptive 
perfectionism was particularly strong. These findings offer further support to previous 
studies suggesting that striving to appear perfect is an attempt to compensate for low 
self-esteem [132]. Individuals with an ED may interpret their mistakes as evidence of 
personal deficiencies [133]. In this perspective, to be flawless represents an obligation.
Moreover, even if indirectly via self-esteem, a link between parental bonding 
and perfectionist orientation emerged. This datum partially supports the findings 
of Soenens and colleagues [38] who have evidenced a relationship between parental 
psychological control and maladaptive perfectionism.
Contrary to the initial hypothesis, parental care and protectiveness were not 
found as significant predictors of body shame. This agrees with findings from other 
Figure 1. 
Illustration of the final model with standardized path coefficients and percentage of variance explained [128].
13
Risk and Maintenance Factors for Eating Disorders: An Exploration of Multivariate Models…
DOI: http://dx.doi.org/10.5772/intechopen.91063
researchers [89]. One potential explanation may be that parental bonding exerts an 
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vulnerability to body shame. In this regard, low self-esteem may be regarded as a 
source of body shame. People who perceive themselves as inadequate or unworthy 
may be at the most significant risk of experiencing body shame [89].
Model results showed that perfectionism did not predict body shame, contrary 
to our initial hypothesis. However, the non-significant pathway from both mal-
adaptive and adaptive perfectionism to ED risk offers further support, alongside 
other studies [68], that these variables may not be vulnerability factors for eating 
disturbances.
Due to its association with self-esteem, perfectionism could be regarded as a 
psychological characteristic typically associated with eating disturbances, rather 
than a risk factor for EDs. However, future research is needed to investigate vari-
ables that may intervene in the pathway from perfectionism to ED risk.
In line with previous studies [51], body shame emerged as a mediator in the 
relationship between self-esteem and ED vulnerability—explaining 71% of the 
variance. Notwithstanding, self-esteem has also a direct influence on ED. These 
results further corroborate previous studies recognizing low self-esteem as a critical 
predictor of ED vulnerability [40, 41].
Although body shame partially mediated the relationship between BMI and eat-
ing disturbance vulnerability, BMI had also a positive effect on ED risk. Undeniably, 
a high BMI has long been considered as a strong ED risk factor [91]. Our results 
support findings of previous studies [82, 83] suggesting that the experience of 
shame related to one’s body exerts a strong influence on eating disturbances vulner-
ability. Yet our results suggest that in addition to a direct effect, body shame also 
serves as a mediator between other risk factors and eating disturbance risk. In this 
regard, body shame may be a key variable in the pathway to eating disturbances 
risk and a core diagnostic feature of all eating disturbances. Notwithstanding, only 
a few studies have investigated the role of body shame in ED onset. Further studies 
on this construct would be beneficial.
Finally, the evaluation of measurement invariance allowed to conclude that 
the final model was invariant across gender: no gender differences emerged in the 
hypothesized pathway to ED risk. Therefore, our study suggests that adopting 
the same prevention and treatment programs for both males and females may be 
appropriate.
In conclusion, we extend the work of others who have separately examined 
the role of perceived parental bonding, self-esteem, body mass index, perfection-
ism, and shame in EDs, identifying the possible mechanisms through which these 
variables increase the likelihood of eating problem development.
This is the first study that conceptualizes how several risk factors may work 
together to create a pathway to eating pathologies. Collectively, perceived parental 
care and protectiveness, self-esteem, maladaptive and adaptive perfectionism, body 
shame, and BMI account for 58% of the variance in ED risk. Therefore, these initial 
findings suggest a promising model.
Provided that the present findings can be replicated longitudinally, they have 
noteworthy implications for EDs prevention and treatment. Identifying which 
interpersonal characteristics and personal factors are most relevant in the etiol-
ogy of EDs may help mental health professionals designing targeted prevention 
and/or intervention programs during adolescence. Clinicians should consider the 
routine assessment and treatment of these factors. First and foremost, intervention 
programs ought to be addressed to reduce subjective feelings of ineffectiveness and 




Among psychiatric illnesses, EDs have the highest rate of mortality [1], and early 
detection of cases is essential. Several researchers have investigated the factors that 
lead to these pathologies in the hope that this information would help in the design 
of more efficient programs of prevention and treatment. However, few studies have 
been devoted to understanding how these risk factors work in concert to promote 
eating disturbance development. A psychological model of risk factors for develop-
ing eating pathologies in female and male adolescents was validated in our study 
[128]. From this model, we can conclude that several ED risk factors are linked 
among them and occur together to cause the eating disturbance opening up the 
possibility of translating these findings into a form of intervention.
Notably, a potential mechanism for eating problem onset has been identified.
Overprotective parents often anticipate the physical needs of their children and 
compromise, albeit unconsciously, their ability to recognize their own need and 
their autonomy. The perception of parental hyper-involvement and lack of suf-
ficient caring may produce a feeling of ineffectiveness and an impoverished self, 
which, in our opinion, maybe the root of eating psychopathologies. It would seem 
that the sense of ineffectiveness that these individuals feel toward themselves has 
been moved in their bodies through a defense mechanism that works by substitut-
ing the object of a painful or dangerous feeling with an acceptable object. Such a 
mechanism would produce body shame: “I am not inadequate, but my body is”. In 
Freudian psychology, this unconscious mechanism of defense is called displacement 
[134]. From that perspective, EDs could be an attempt to modify and/or to punish 
the ashamed body, which has been considered responsible for an individual’s inef-
fectiveness. The body becomes the stage of the illness. This potential mechanism of 
action (parental overprotectiveness/low care → low self-esteem → body shame → 
eating pathology) might work in both obese and normal-weight adolescents, but 
among obese people, this would occur more often because it comes more natural to 
consider a fat body responsible for the sense of ineffectiveness [52]. In that respect, 
a person with a high BMI would be at greater risk of developing an ED than others.
This investigation presents a unique contribution to the literature by illustrating 
a promise predictive ED risk model. However, it is not possible to use the present 
data to argue for specific casual links, and more research is needed to validate these 
hopeful results.
Understanding the potential causes of eating problems would permit us to 
formulate aids in planning prevention/treatment. This etiological model for eating 
pathology onset could be transformed into a model for early and preventive inter-
ventions. Prevention programs that specifically target risk factors may be of benefit. 
However, the practical utility and clinical significance of this model ought to be 
examined in prevention studies.
As well, understanding possible psychopathological maintenance mechanism 
present enormous potential for eating disturbance treatment. Another goal was to 
determine the relationship of well knows ED risk factors with the severity of eating 
symptomatology. More specifically, we carry out a study aimed at examining whether 
BMI, perceived parental care and protectiveness, self-esteem, body shame, and 
perfectionism (adaptive and maladaptive) provide more information about the level 
of eating concerns among ED patients [124]. The small size of the sample limited 
this study: consequently, the structural equation model test could not be used for the 
clinical population. Overall, our results suggest that maladaptive perfectionism, body 
shame, and low self-esteem may represent an obstruction for successful treatment, 
and consequently, it ought to be targeted in psychotherapy. Particular attention 
should be paid to people with high BMI because they may present more severe eating 
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symptomatology. To sum up, the current results propose the necessity to consider 
these potential maintaining factors when designing treatment for this population.
The non-significant pathway from perfectionism to ED risk among non-clinical 
people seems to suggest that maladaptive perfectionism might represent a perpetu-
ating factor in the ED maintenance exclusively. Perfectionism may correspond to a 
psychological correlate of the low self-esteem resulted from the need to compensate 
for a feeling of inadequacy as well as to a factor that makes the individuals more 
tenacious in achieving their own goal such as diet. In this perspective, perfectionism 
may be more substantially associated with AN.
On the other hand, parental bonding may play a key role in promoting the 
predisposing factors for eating pathologies rather than indirectly maintaining the 
pathology. As previously stated, parental bonding may create a vulnerability to 
eating disturbances principally through the development of a poor self-concept. 
The association between low self-esteem and eating disturbance development has 
been confirmed in our studies. By the potential mechanism of action described 
above, low self-esteem may represent the root of eating psychopathology and have a 
fundamental role in the onset as well as in the maintenance of the disorder.
The possible role of BMI in the beginning of EDs has also been established. It is 
known that obese people are more at risk of developing an ED. In our opinion, this 
might happen because obese individuals are more likely to move in their bodies the 
sense of ineffectiveness that they feel toward themselves, and this potential mecha-
nism could also fuel the continuance of the pathology.
Finally, one of the strengths of these two studies includes the unique nature 
in investigating the role of body shame in EDs, a previously under-researched 
construct. Our data highlight the potential role of body shame as a critical variable 
in both ED onset and maintenance and as a core diagnostic feature of all eating 
disturbances. Further research is needed, but the preliminary results prove promis-
ing for application in a clinical setting.
Even though the current results contribute to valuable novel insights into EDs 
risk factors model, a large body of research proposes a biological model suggesting 
that genetic, immunological and metabolic aspects contribute to the development 
of EDs as well (for a review, see [135, 136]).
In conclusion, we focused on psychological risk factors that are important for 
the development and the maintenance of EDs. To differentiate between those 
predisposing, precipitating and perpetuating factors might help to develop more 
successful strategies for the prevention and treatment of these disorders.
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Nowadays, obesity is considered as one of the fastest escalating nutritional 
disorders that reached pandemic throughout the world. Obesity is a condition in 
which overaccumulation of energy in the form of fat happens in an individual’s 
subcutaneous and/or abdominal visceral tissue. It is described as an abnormal 
growth of adipose tissue due to the enlargement of fat cell size (hypertrophic 
obesity) or fat cell number (hyperplastic obesity) or a condition of both. Earlier, it 
was reported that the most common type of obesity that affects the general popula-
tion is the polygenic form that results from a result of a positive energy balance 
between energy consumption and its expenditure – or a combination of both. The 
pandemic of obesity has enforced to analyze the link between the role of inflamma-
tion and complications of overweight and obesity. This led to crossroads of the field 
of nutrition, diet therapy, physiology, immunology, and epidemiology and makes 
the understanding that they are linked inexplicably. The remodeling of obesity as an 
inflammatory state has led a wide impression in our conceptualization of obesity-
related diseases. In this chapter, we highlight the endocrine aspect of adipose tissue, 
the effect of dysregulated secretion of adipokines due to inflammation and dietary 
components that affect obesity related to inflammation.
Keywords: nutritional disorder, obesity, adipokines, inflammation, 
dietary components
1. Introduction
A famous ancient proverb states that “Eat breakfast like a king, lunch like a 
prince, and dinner like a pauper.” In today’s era, these words have long been dis-
carded. The magnitude of obesity has reached in pandemic proportion due to new 
technology and modern life, which makes life easier and less active along with the 
intake of high energy dense food for better taste [1–3]. This is one of the biggest 
public health concerns of today’s era, which affects the individual not only physi-
cally but also physiologically and psychologically.
The World Health Organization (WHO) has reported that obesity has been 
growing at an alarming rate worldwide and has nearly been tripled between 1975 
and 2016. It was also reported by WHO in the year 2016 that more than 1.9 billion 
adults, 18 years and older, were overweight; of these over 650 million were obese 
(https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight) [4].
Nowadays, obesity is regarded as a complex dysfunctional neuroendocrine 
problem in which genetic makeup and environmental factors act in concert. 
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environmental, and behavioral factors. Sedentary lifestyle and overconsumption 
of high-fat and energy dense foods are a major contributor to energy imbalance. 
The altered phenomenon of hunger and satiety, lack of physical activity, decreased 
thermogenesis, and resting metabolic rate over a long period of time may lead to the 
energy imbalance.
In addition, other external factors such as age, gender, food preference, break-
fast skipping, medications, chemical toxicity, disorders of the endocrine system, 
socioeconomic status, and a psychological factor may give rise to weight gain prob-
lems. It is considered as a major contributor to the global burden of chronic diseases 
like hypertension, type 2 diabetes, hypercholesterolemia, heart diseases, insulin 
resistance, atherosclerosis, ischemic heart diseases, respiratory diseases, orthopedic 
disorders, several types of cancer, hormonal imbalance, disability, and many other 
diseases. Overweight and obesity also play a pivotal role in the development of 
low-grade inflammation, which contribute to the development of obesity-linked 
disorders, in particular to metabolic dysfunction [5]. However, a growing body of 
knowledge suggests that a possible convergence of an inflammatory state, which 
results in chronic inflammation and oxidative stress, is localized within adipose 
tissue [6] as shown in Figure 1. Adipose tissue inflammation plays a crucial role in 
promulgating obesity-related metabolic complications including the development 
of insulin resistance [6–8].
2. Adipose tissue: manager of inflammation
Over the past decades, it is well established that adipose tissue is not merely a 
fat storage depot but has been recognized as an endocrine organ capable of pro-
ducing various bioactive substances. It then became evident that white adipose 
tissue (WAT) secretes ample of peptides. Few of them regulate the inflammatory 
Figure 1. 
Overnutrition (overconsumption of high-fat and energy dense foods), lack of physical activity, sedentary 
lifestyle, and genetic susceptibility are the leading factors associated with the development of obesity. In 
addition to dysfunctional angiogenesis, an obese state is characterized by an abnormal inflammatory response, 
low antioxidant capacity, and reduced insulin sensitivity that may eventually lead to the generation of 
inflammation, oxidative stress, and insulin resistance. The figure was modified from the following review paper 




processes such as leptin and adiponectin, whereas others are well-known cytokines 
such as interleukin (IL)-6, IL-1 and its receptor antagonist (IL-1Ra), and tumor 
necrosis factor (TNF)-α [9]. As we know, obesity is one of the major causes of 
atherosclerosis, which is recognized as a chronic vascular inflammatory process in 
which cytokines and chemokines play a dramatic role [9–10]. White adipose tissue 
plays an important role in metabolism and inflammation as illustrated in Figure 2.
Cytokines are categorized as interleukins, interferons, chemokines, hemato-
poietic factors, and growth factors. They are knotted in many biological processes 
such as growth, differentiation, cell division, apoptosis, immunity, and inflam-
mation [9]. Cytokines are produced by numerous cell types of the hematopoietic 
lineage including T cells, B cells, mast cells, macrophages, dendritic cells, and 
natural killer cells. In spite of these, cytokines are also produced by nonhemato-
poietic cells such as epithelial cells, hepatocytes, and fibroblasts [9, 12]. Evidence 
revealed that IL-1, IL-6, and TNF-α are characterized as a proinflammatory cyto-
kine that activates both acute and chronic inflammatory responses [9]. Inhibitors 
that control inflammation can be categorized as anti-inflammatory cytokines, 
soluble receptors to cytokines, and naturally occurring proteins. Types of anti-
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are IL-1 and TNF-α; and naturally occurring proteins are IL-1Ra receptors. The 
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Chemokines are a type of cytokine that is a part of family molecules that are 
indulged in the chemotaxis of inflammatory cells via the generation of local concen-
tration gradients. Chemokines play an important role in various physiological and 
pathological processes such as cell recruitment process and development of lym-
phoid organs or metastases. In spite of these, chemokines also participate in meta-
bolic and inflammatory disorders such as rheumatoid arthritis, glomerulonephritis, 
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and atherosclerosis via their innate ability to recruit and activate the inflammatory 
cells [9]. They are categorized into four subclasses according to the position of 
their cysteines (CXC, C, CX3C, and CC) [9, 13]. Chemokines that are produced 
from WAT are interferon-γ inducible protein 10 (IP-10 or CXCL10) and IL-8 
(or CXCL8) belong to the CXC chemokines, while monocyte chemo-attractant 
protein-1 (MCP-1 or CCL2) and regulated upon activation normal T-cell express 
sequence (RANTES or CCL5) are CC chemokines [9, 13]. Previous studies showed 
that chemokines are paracrine rather than systemic factors, the significance of 
their secretion via adipose tissue may be seen in the context of fat depots found in 
close proximity to their target tissues, for example, subcutaneous fat in inflamma-
tory skin diseases, perivascular adipose tissue in obesity-associated cardiovascular 
diseases, and perirenal fat in glomerulonephritis [9, 14].
In addition, several other metabolically important proteins with immunomodu-
latory actions are secreted by adipose tissue, including leptin, adiponectin, and 
resistin. The dysregulated expression of these factors, caused by excess adiposity 
and adipocyte dysfunction, has been linked to the pathogenesis of various disease 
processes through altered immune responses. As such, much attention has been 
paid to develop a better understanding of the immunoregulatory functions of adi-
pose tissue. New factors secreted by adipose tissue have been identified that either 
promote inflammatory responses and metabolic dysfunction or contribute to the 
resolution of inflammation and have beneficial effects on obesity-linked metabolic 
disorders. These findings lend additional support to the notion that an imbalance 
of pro- and anti-inflammatory adipokines secreted by adipose tissue contributes to 
metabolic dysfunction [5].
3. Obesity: state of low-grade inflammation
Obesity is associated with alterations in immunity, a chronic low-grade inflam-
mation, which is characterized by abnormal secretion of adipokines, that is, there 
is an increment in circulating proinflammatory cytokines and a decrement in 
anti-inflammatory cytokines. It is also linked with alteration in immunity. However, 
Figure 3. 
Classification of cytokines. (a) Classes of inflammatory cytokines. (b) Anti-inflammatory mediators. The 




with the reduction in body weight, these parameters may reverse or come to the 
normal level. Although, it is still debatable how obesity triggers inflammation. 
Earlier, several hypotheses were proposed regarding the inflammation of obesity. 
The first one stated that overburden of nutrients in the adipocytes leads to intracel-
lular stress that results in the stimulation of inflammatory cytokines [15–17].
The excessive nutrients may lead to aggregation of unfolded proteins in the 
endoplasmic reticulum (ER) via activation of the unfolded protein response (UPR) 
pathway [15, 17]. The pathway of UPR depends on basically three main sensors 
of ER, that is, PKR-like eukaryotic initiation factor 2α kinase (PERK), inositol-
requiring enzyme 1 (IRE-1), and activating transcription factor 6 (ATF-6) [15, 18]. 
The activity of the C-Jun amino-terminal kinase (JNK) and inhibitor of IκB (IKK-β), 
serine-phosphorylation of insulin-receptor substrate protein 1 (IRS-1), and the 
nuclear factor-κB (NF-κB) pathway may increase by the activated sensors of ER that 
results in increased expression of proinflammatory cytokines [15–16, 19–21].
The second hypothesis enumerates that overburdened adipocytes with fat cells 
intensely increase the infiltration of macrophages, which may lead to subsequent 
differentiation and activation of cytotoxic T cells. As a result, initiation and 
propagation of inflammatory cytokines cascades occur [15, 22]. Third hypothesis 
proposes that as during obesity, enlargement of adipose tissue happens as a result 
tissue becomes relatively hypoxic. Hypoxia within the adipose tissues results in the 
activation of inflammatory pathways [15, 23–24]. Above all, the last hypothesis 
suggests that overburdened adipocytes themselves may directly activate immune 
pathogen sensors that result in chronic inflammation [15, 25].
4. Dietary components that affect obesity related to inflammation
The analysis of dietary intake is an approach to investigate a link between diet 
and overweight and obesity-related inflammation. Various studies reported that 
bioactive nutrients and dietary non-nutrients strongly influence health, metabo-
lism, and progression of pathologic states that ultimately result in chronic degen-
erative diseases [26]. Many studies indicate that diet may affect body weight by 
controlling satiety and metabolic efficiency or by harmonizing insulin secretion and 
action [3, 27]. It is an essential key factor for immune response. Earlier, evidence 
revealed that undernutrition brings about immunosuppression due to susceptibility 
to infection. Whereas, overnutrition brings about immunoactivation due to suscep-
tibility to inflammatory diseases. As a result, optimum nutrition is mandatory for a 
healthy immune balance of an individual [15] as shown in Figure 4.
Dietary components play an important role in obesity-related inflammation as 
enumerated below:
4.1 Carbohydrates
Carbohydrates are the main food source of a living organism and a major source 
of energy. Carbohydrates are also known as energy giving foods. The source of 
energy was estimated based on their glycemic index (GI) or glycemic load (GL) 
values. GI is the value given to the foods on how quickly they increase the glucose 
level postprandially and measures the quality of carbohydrate. GL calculates both 
the quality and quantity of carbohydrates [15, 28]. Earlier studies reported that, 
positive correlation exists between dietary GI and GL and biomarkers of inflam-
mation because a low GI diet decreases the rate of glucose absorption in the body 
that subsequently reduces hyperglycemia and hyperinsulinemia that results in the 
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enumerated below:
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values. GI is the value given to the foods on how quickly they increase the glucose 
level postprandially and measures the quality of carbohydrate. GL calculates both 
the quality and quantity of carbohydrates [15, 28]. Earlier studies reported that, 
positive correlation exists between dietary GI and GL and biomarkers of inflam-
mation because a low GI diet decreases the rate of glucose absorption in the body 
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leads to improvement in insulin sensitivity and a reduction in the level of proin-
flammatory cytokines. Various health organization also reported that low GI diets 
help in managing diabetes and coronary heart diseases and considered as a weapon 
against obesity [29–30].
Neuhouser et al. [31] revealed from randomized, crossover feeding study 
that respondents with high-fat mass (>32.0% for male and >25.0% for female) 
showed reduced CRP (P = 0.02) and marginally increased adiponectin (P = 0.06). 
Therefore, it was concluded that the quality of carbohydrates independent of 
energy was very important as low-GL foods improve the inflammatory and adi-
pokine profiles of overweight and obese individuals [31]. Another study done by 
Levitan et al., among women (n = 18,137, >45 years of age), reported that diets 
characterized by lower GI and GL were associated with somewhat more favorable 
lipid profiles and lower CRP [32]. Interestingly, one of the epidemiological stud-
ies done by Vrolix and Mensick found that consumption of a diet with decreased 
GL does not decrease the metabolic risk parameters in overweight subjects [33]. 
Another study done by Kelly et al. also supports the above findings, that is, it does 
not found any additional benefit of including a low glycemic diet with exercise on 
insulin sensitivity and adipokine concentrations [34]. Above all, it may be stated 
that observational studies showed a positive association between intake of GI/GL 
diet and markers of inflammation. However, interventional studies do not found 
such an association.
4.2 Dietary fat
Fat is also one of the important sources of energy that serves both structural 
and metabolic functions of living organisms. The excessive accumulation of fat in 
the body leads to impairment of the immune system. A number of fatty acids have 
been studied including saturated, trans-fatty acids, and polyunsaturated fatty acids 
(PUFA) for their effect on inflammatory status [15].
4.2.1 Polyunsaturated fatty acids
The omega-3 (n-3) and omega-6 (n-6) PUFA families are precursors of 
eicosanoids, which play a vital role in the immune response [15]. Simpoulos [35] 
Figure 4. 
Healthy immune balance between undernutrition and overnutrition. The figure was modified from the 




stated that high omega-6 fatty acids increase leptin and insulin resistance, whereas 
omega-3 fatty acids lead to homeostasis and weight loss. This is so because the high 
omega-6/omega-3 ratio is associated with overweight/obesity, whereas a balanced 
ratio decreases obesity and weight gain [35]. Another study showed that an increase 
in the intake of n-6:n-3 PUFA potentiates the inflammatory processes that ulti-
mately lead to many inflammatory diseases such as nonalcoholic fatty liver disease 
(NAFLD), cardiovascular disease, diabetes, obesity, inflammatory bowel disease 
(IBD), rheumatoid arthritis, and Alzheimer’s disease. This change in the ratio of 
consumption of n-3/n-6 fatty acids changes the production of important mediators 
and regulators of inflammation and immune response that leads toward the pro-
inflammatory state. Hence, it was concluded in the study that increasing the ratio 
of (n-3)/(n-6) PUFA in the diet may lead to a reduction in the incidence of chronic 
inflammatory diseases [36].
A clinical trial and in-vitro experiment study reported that supplementation 
of fish oil delineates the expression of adipose inflammatory genes including 
inflammasome-associated IL-18 and IL-1b and circulating IL-18 levels. In spite of 
this, it was also stated that both eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) decrease the inflammasome gene expression in obese human adipose 
and human adipocyte and macrophages [37]. Above all, various studies concluded 
that omega-3 fatty acids, namely EPA and DHA, have an anti-inflammatory effect.
4.2.2 Trans and saturated fatty acids
A review study was done by Rogero and Calder stated that saturated fatty acids 
induce inflammation by activating the TLR4 signaling pathway (TLR4 signaling 
pathway is recognized as the main pathway that triggers in obesity-induced inflam-
mation) [38]. Another study revealed that the ingestion of excessive amounts 
of trans-fatty acids and saturated fatty acids is considered to be a risk factor for 
metabolic and degenerative diseases. It was also emphasized that saturated and 
trans-fatty acids favor a proinflammatory state leading to insulin resistance. 
These fatty acids can be indulged in several inflammatory pathways, contributing 
to disease progression in chronic inflammation, autoimmunity, allergy, cancer, 
atherosclerosis, hypertension, and heart hypertrophy as well as other metabolic and 
degenerative diseases. As a consequence, intake of dietary saturated and trans-fatty 
acids leads to lipotoxicity in several target organs by direct effects, represented by 
various inflammatory pathways, and through indirect effects, including an impor-
tant alteration in the gut microbiota associated with endotoxemia process [39].
4.3 Fruits and vegetables
Fruits and vegetables comprise a myriad of nutrients, that is, vitamins, minerals, 
and many food compounds that have been inversely correlated with metabolic risk 
factors such as oxidative stress and inflammation. In a randomized controlled trial 
study, it was found that fruits and vegetables reduce the risk of metabolic disease 
that may be via modulation of gut microbiota. The study also revealed that fruits 
and vegetables decrease the secretion of interleukin-6 (IL-6) and lipopolysaccha-
ride-binding protein (LBP) [40]. Another study done by Navarro et al. through fac-
tor analysis found that dietary patterns loaded with fruits and vegetables strongly 
negatively correlated with the secretion of hs-CRP among prepubertal girls [41]. An 
almost similar result was observed by Julia et al. that dietary pattern characterized 
by intake rich in vegetable and vegetable oil leads to the supply of essential fatty 
acids and antioxidant micronutrients showed a negative correlation with the risk 
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that may be via modulation of gut microbiota. The study also revealed that fruits 
and vegetables decrease the secretion of interleukin-6 (IL-6) and lipopolysaccha-
ride-binding protein (LBP) [40]. Another study done by Navarro et al. through fac-
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almost similar result was observed by Julia et al. that dietary pattern characterized 
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Koreans found that an inverse correlation exists between vegetable pattern and CRP 
and the association appeared to be more predominant in men having hypertensive 
blood pressure [43]. Surprisingly, the study done by Salas-Salvado et al. (n = 772, 
55–80 years of age) and Freese et al. (n = 77, 19–52 years of age) did not found any 
association between a diet rich in vegetables and fruits with inflammatory markers 
[adiponectin, CRP, IL-6, intercellular adhesion molecule-1 (ICAM-1), and vascular 
cell adhesion molecule-1 (VCAM-1)] [15, 44–45]. Another study done by Morand 
et al. (n = 24, mean age of 56 years) also showed a similar pattern of above finding 
that a single fruit supplementation (500 mL of orange juice/d for 4 weeks) did not 
change the levels of CRP, IL-6, ICAM-1, and VCAM-1 [15, 46].
4.4 Other nutrients
Oxidative stress and imbalance in immune responses play a crucial role in the 
development of obesity and its associated comorbidities. Various epidemiological 
shown that several vitamins and minerals have a favorable response on the level of 
inflammatory markers, that is, CRP, IL-6, and TNF-α.
4.4.1 Vitamin A
Various cross-sectional and intervention studies reported regarding over-
weight and obese respondents that they have lower circulating carotenoids in the 
plasma because of a high proportion of carotenoids, as lipid-soluble compounds, 
being stored in adipose tissue [15, 47]. The Women’s Health Study (n = 2895, aged 
≥45 years of age) reported that higher plasma concentrations of α- and β-carotene 
were associated with low levels of plasma CRP. In spite of this, plasma carotenoids 
were associated with obesity, HDL-cholesterol, LDL-cholesterol, HbA1c, and smok-
ing [15, 48]. Another study done by Julia et al. suggested that the β-carotene status 
was inversely associated with low-grade inflammation [49]. Another cross-sectional 
meta-analysis study focusing on Syndrome X respondents showed an inverse asso-
ciation between total plasma carotenoids and metabolic syndrome. Respondents 
with the highest total circulating carotenoids had a 24% reduced risk for developing 
metabolic syndrome. Interestingly, when, individual carotenoids were included, 
and significant associations were found for β-carotene, lycopene, α-carotene, and 
β-cryptoxanthin [50–51].
4.4.2 Vitamin C
Vitamin C is effective in strengthening the immune system, capillary blood 
vessels, and protecting the dental health, as well as in the convenient use of iron, 
calcium, thiamine, riboflavin, folic acid, and vitamins A and E in the body. Vitamin 
C also acts as a cofactor for 15 different enzymes and shows the antioxidant activity 
as an electron donor reducing agent. It acts as a powerful free radical scavenger by 
protecting tissues against oxidative stress and reduces inflammation [52]. Totan 
et al. reported that vitamin C reduces the systemic inflammation by inhibiting CRP 
and TNF-α pathways. In spite of this, vitamin C inhibits hypoxia in adipose tissue 
that has the potential for protection against free radicals and decreasing lipid per-
oxidation. On the other hand, the study also revealed that vitamin C inhibits mature 
adipocyte formation and cell growth, inhibits lipolysis, and can be considered as a 
treatment model for obesity to offer solutions for abnormal fat accumulation [52]. 
Another study reported that vitamin C may improve inflammation by reducing the 
pro-inflammatory and inflammatory markers such as CRP, IL-6, and TNF-α [53]. 




trial study (n = 42, 18–80 years of age) that vitamin C supplementation (750 mg/d 
for 8 weeks) did not change blood levels of CRP [15, 54].
4.4.3 Magnesium
Magnesium is the second most abundant intracellular cation and is involved in 
about 300 biochemical reactions related to anabolic and catabolic actions in the 
body, such as glycolysis and protein and lipid metabolism [55–56]. The Women’s 
Health Initiative Observational Study (n = 3713 postmenopausal women, aged 
50–79 years) reported that intake of dietary magnesium was independently and 
inversely associated with plasma concentrations of hs-CRP, IL-6, and sVCAM-1 in 
postmenopausal women after an adjustment for multiple variables including 
dietary fiber, fruit, vegetables, folate, and saturated and trans-fatty intake [57]. 
Another study done by Guerrero-Romero and Rodriguez- Moran found that low 
serum Mg levels were independently related to elevated CRP concentration, in 
nondiabetic, nonhypertensive obese subjects (n = 371) [15, 58].
4.4.4 Flavonoids
Flavonoids, a group of natural substances with variable phenolic structures, 
are found in fruits, vegetables, grains, bark, roots, stems, flowers, tea, and wine. 
Nowadays, flavonoids are considered essential components in various applications 
such as nutraceutical, pharmaceutical, medicinal, and cosmetic. This is attributed 
to their anti-oxidative, anti-inflammatory, anti-mutagenic, and anti-carcinogenic 
properties coupled with their capacity to modulate key cellular enzyme function 
[59]. According to National Health and Nutrition Examination Survey (NHANES), 
a large, cross-sectional survey National Centre for Health Statistic (n = 9551 adults) 
showed that flavonoid consumption was inversely associated with obesity in both 
men and women in multivariate models. It was also observed that adults in the high-
est quartile of flavonoid intake had significantly lower body mass index and waist 
circumference than those in the lowest quartile of flavonoid intake (P < 0.03 and 
P < 0.04, respectively). The study also revealed that flavonoid intake was inversely 
related to C-reactive protein levels in women (p-trend, 0.01) [60]. The Nurses’ 
Health Cohort Study (n = 2115 women, aged 43–70 years) reported that among 
flavonoid-rich foods, higher intake of grapefruit was significantly associated with 
lower concentrations of CRP and sTNF-R2. In spite of this, it was also reported 
in the study that flavonoids typically found in citrus fruits were modestly associ-
ated with lower plasma IL-18 concentrations [61]. Interestingly, a double-blind, 
placebo-controlled crossover study (n = 14, 35–53 years of age) reported that the 
supplementation of sea buckthorn flavonol extract for 4 weeks did not reduce CRP 
levels (p < 0.05) [15, 62].
4.4.5 Phytoestrogens
Phytoestrogens are plant-derived dietary compounds found in beans, seeds, 
and grains. The structure of phytoestrogens is similar to 17-β-oestradiol (E2), the 
primary female sex hormone. This structural similarity to E2 enables phytoestro-
gens to cause (anti) oestrogenic effects by binding to the oestrogen receptors [63]. 
Phytoestrogens had so many health benefits such as a lowered risk of menopausal 
symptoms such as hot flushes and osteoporosis, obesity, metabolic syndrome, and 
type 2 diabetes and lowered risks of cardiovascular disease, brain function disor-
ders, breast cancer, prostate cancer, bowel cancer, and other cancers [63]. A ran-
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symptoms such as hot flushes and osteoporosis, obesity, metabolic syndrome, and 
type 2 diabetes and lowered risks of cardiovascular disease, brain function disor-
ders, breast cancer, prostate cancer, bowel cancer, and other cancers [63]. A ran-
domized crossover clinical trial for 8 weeks (n = 42, postmenopausal women with 
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metabolic syndrome) reported that soy nut consumption reduces interleukin-18 
[64]. On the other hand, in a randomized, double-blind, controlled trial study 
(n = 50, post-menopausal women age = 58 ± 5 years), it was found that supplemen-
tation of soy isoflavone for 6 months had no effects on plasma CRP level [65].
4.4.6 Probiotics, prebiotics and synbiotics
According to the Food and Agriculture Organization of the United Nations 
(FAO) and WHO, probiotics are defined as “live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the host” [66–67]. 
Earlier studies reported that probiotic bacteria, when administered orally, are able 
to modulate the immune system; however, differences exist in the immunomodula-
tory effects of different probiotic strains [15]. A randomized, double-blind, and 
placebo-controlled parallel-group intervention study compared Lactobacillus rham-
nosus with Bifidobacterium animalis ssp. Lactis Bb12 and Propionibacterium freuden-
reichii ssp. Shermanii JS for 3 weeks in healthy respondents (n = 81, 23–58 years of 
age). The study showed no effect on serum levels of TNF-α, IL-6, IL-10, or IFN-γ 
but a decreased level of CRP in the L. rhamnosus supplementation group [15, 68].
According to FAO/WHO, prebiotics is defined as “non-digestible food ingre-
dients that beneficially affect the host by selectively stimulating the growth and/
or activity of one or a limited number of bacterial species already established in the 
colon, and thus improve the host health” [67, 69]. Russo et al. reported in the study 
that intake of 11% enriched inulin-enriched pasta for 5 weeks improved lipidic and 
glicidic metabolism as well as insulin resistance in healthy young subjects [70]. 
Another study reported that intake of oligofructose (type of prebiotics) supple-
mentation (8 g/day for 3 weeks) in the elderly (n = 19, mean age = 85 years) showed 
a decrease in the expression of IL-6 mRNA in peripheral blood monocytes [71]. In 
contrary to the above study, the intervention study showed that supplementation 
of oligofructose (1.95–3.9 g/day for 12 weeks) did not affect plasma levels of IL-6 or 
TNF-α in poorly nourished elderly subjects (mean age of 70 years) [15, 72].
Synbiotics are defined as a combination of suitable probiotics and prebiotics 
that enhances survival and activity of the organism, for example, a fructooligosac-
charide (FOS) in conjunction with a Bifidobacterium strain or lactitol in conjunc-
tion with Lactobacillus strains [73–74]. Ferrarese et al. reported in the study that 
diet supplementation with Synbiotics prepared using selected strains (such as 
Lactobacillus gasseri strains) showed to exert weight reduction and anti-inflam-
matory activity. In spite of this, it was also concluded that their administration, 
together with galactomannan and/or inulin fibers, may increase weight manage-
ment effects due to synergistic effect on short-chain fatty acid production and 
microbiota “re-configuration” [75].
5. Discussion
The pandemic of obesity and its associated comorbidities derives our attention 
to the mechanism associated with a pathological condition. Earlier investigations 
revealed how cells and tissues respond to the stress of overnutrition and about the 
interplay between adipose tissue and other cell types that are critically involved 
in energy homeostasis. These findings also suggest the inflammatory response of 
obesity that might be beneficial or harmful, depending on the stage and degree of 
obesity, as well as other factors [76]. Previously, it was also reported that obesity 




genetic, metabolic, and environmental factors in which dietary pattern plays a 
central role [77].
The current review is a narrative review of the impact of inflammation on 
weight management. In this review, a model is outlined in which inflammation is 
closely associated with obesity. However, this is a simplified view. Earlier studies 
reveal that severely underweight people such as patients with anorexia nervosa 
(AN) also display an overproduction of inflammatory cytokines. Dalton et al. 
reported from an exploratory cross-sectional study that interleukin (IL)-6, IL-15, 
and vascular cell adhesion molecule (VCAM)-1 concentrations were significantly 
elevated, and concentrations of BDNF (brain-derived neurotrophic factor), tumor 
necrosis factor (TNF)-β, and vascular endothelial growth factor (VEGF)-A were 
significantly lower in anorexia nervosa (AN) participants [78]. An almost simi-
lar result was reported through meta-analysis by Solmi et al. that patients with 
anorexia nervosa (AN) have increased TNF-α, IL6, IL1-β, and TNF-R-II levels but 
decreased C-reactive protein and IL-6R [79]. Earlier studies also reported that 
immunosuppressive medications such as corticosteroids lead to visceral adipos-
ity. Galitzky and Bouloumie reported that long-term exposure of glucocorticoids 
(GCs), either due to anti-inflammatory and immunosuppressive therapies or 
endocrine disturbances, accumulation of abdominal fat was observed in individu-
als with Cushing syndrome [80]. Lee et al. stated in the study that glucocorticoids 
(GCs) have profound effects on adipose tissue, adipogenesis, adipose tissue 
metabolic, and endocrine function. In the study, it was found that glucocorticoids 
(GCs) have multiple, depot-dependent effects on adipocyte gene expression and 
metabolism that enhances central fat deposition and lead to visceral obesity [81]. 
Further, contradicting study results are not included in the current study in order to 
provide a stringent model. Additionally, due to the limited space, important aspects 
of the topic such as physical activity and its influence on body weight regulation and 
cytokine production in detail are not included in the current study.
6. Conclusion
As we know that obesity is the condition of excessive accumulation of fat as a 
result of disequilibrium between energy intake and its expenditure. Several studies 
showed that adipose tissue acts as an endocrine organ that plays a critical role in 
maintaining the homeostasis of immunity. Studies also reported that obesity plays 
a pivotal role in the development of low-grade inflammation. As a result, optimal 
nutrition is required for maintaining a healthy immune balance. A healthy diet 
comprising of appropriate GI/GL, n-3 PUFAs, less amount of saturated and trans-
fatty acids, vitamins, minerals, flavonoids, phytoestrogens, probiotics, prebiotics, 
and Synbiotics is beneficial in combating the obesity and its related complications.
Therefore, it is concluded that consuming different dietary components rather 
than a single component may prove beneficial in combating the burden of weight 
gain as its associated comorbidities.
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Orexin and Psychoneurobiology: 
A Hidden Treasure
Hayder M. Alkuraishy, Ali I. Al-Gareeb  
and Naseer A. Al-Harchan
Abstract
Orexin is a neuropeptide secreted from the lateral hypothalamus and prefrontal 
cortex concerned in wakefulness and excitement. This study aimed to review the pos-
sible neurobiological effect of orexin. A diversity of search strategies was adopted and 
assumed which included electronic database searches of Medline and PubMed using 
MeSH terms, keywords, and title words. Orexin plays a vital role in activation of learn-
ing, memory acquisition, and consolidation through activation of the monoaminergic 
system, which affects cognitive flexibility and cognitive function. Orexin stimulates 
adrenocorticotrophin (ACTH) and corticosteroid secretions via activation of the cen-
tral corticotropin-releasing hormone (CRH). Cerebrospinal (CSF) and serum orexin 
serum levels are reduced in depression, schizophrenia, and narcolepsy. However, high 
orexin serum levels are revealed in drug addictions. Regarding neurodegenerative 
brain diseases, CSF and serum orexin levels are reduced in Parkinson’s disease (PD), 
Alzheimer’s disease (AD), Huntington’s disease (HD), amyotrophic lateral sclerosis 
(ALS), and multiple sclerosis (MS). Orexin antagonist leads to significant reduction 
of sympathetic overactivity during withdrawal syndrome. Also, orexin antagonist 
improves sleep pattern. The orexinergic system is involved in different psychiatric and 
neurological disorders; therefore targeting of this system could be a possible novel 
pathway in the management of these disorders. In addition measurement of CSF and 
serum orexin levels might predict the relapse and withdrawal of addict patients.
Keywords: orexin, sleep disorders, psychiatric disorders, neurodegenerative 
disorders
1. Introduction
Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, 
wakefulness, and appetite. The most common form of narcolepsy, in which the 
sufferer experiences brief losses of muscle tone (cataplexy), is caused by a lack of 
orexin in the brain due to destruction of the cells that produce it. There are only 
10,000–20,000 orexin-producing neurons in the human brain, located predomi-
nantly in the perifornical area and lateral hypothalamus. They project widely 
throughout the central nervous system, regulating wakefulness, feeding, and other 
behaviors. The orexin system was initially suggested to be primarily involved in 
the stimulation of food intake, based on the finding that central administration of 
orexin-A and orexin-B increased food intake. In addition, it stimulates wakefulness, 
regulates energy expenditure, and modulates visceral function [1, 2].
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Two distinct types of orexin, orexin-A and orexin-B, were identified; they act 
on specific receptors called orexin receptor type 1 (OX1R) and orexin receptor type 
2 (OX2R). Orexin-A activates both of these receptors equally, while orexin-B has 
a five times higher affinity to OX2R than OX1R. Upon activation, prepro-orexin 
will split to orexin-A and orexin-B, which act on their G protein-coupled receptors 
(Figure 1) [3].
Orexin receptors are distributed mainly in the lateral hypothalamus and adjacent 
areas, and their nerve fibers project to multiple brain regions. Orexinergic neurons 
in the lateral hypothalamus group are closely associated with reward-related func-
tions. These neurons preferentially innervate the ventral tegmental area and the 
ventromedial prefrontal cortex. In contrast, the perifornical-dorsal group of orex-
inergic neurons is involved in functions related to arousal and autonomic response. 
These neurons project inter-hypothalamically, as well as to the brainstem, where 
the release of orexin modulates various autonomic processes. Indeed, accumulating 
evidence shows that the orexin/receptor system is ectopically expressed in several 
neurological disorders, suggesting that it plays an important role in the incidence 
and pathogenesis of these diseases [4].
It has been verified that hypothalamic orexigenic neurons are involved in reward 
functions, while prefrontal orexigenic neurons are linked in the regulation of auto-
nomic and arousal functions. Moreover, orexin provokes and stimulates food intake 
via inhibition of autonomic digestive feedbacks. Orexigenic neurons are inhibited 
by leptin and food intake, while hypoglycemia and ghrelin activate orexigenic neu-
rons. Amino acid and high-protein diets paradoxically provoke the hyperpolariza-
tion of orexigenic neurons and block glucose-induced orexigenic neuron activations 
[5]. Animal model studies have shown that orexin is a very important link between 
sleep and body metabolism since sleep deprivation leads to higher food intake and 
induction of catabolism [6].
Additionally, orexin stimulates different neurotransmitters which are linked 
to the activation of the central nervous system, including acetylcholine, hista-
mine, noradrenaline, and dopamine. Therefore, mutations of orexin receptors 
lead to sleep disorders. Mice with orexin knockout are subjected to narcolepsy 
and excessive daytime sleepiness [7]. Alizamini et al. study showed that central 
Figure 1. 
Schematic representation of orexin system.
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administration of orexin leads to stimulation of locomotion, psychomotor perfor-
mance, body temperature, and energy expenditure. Furthermore, mice with orexin 
deficiency are subjected to obesity due to reduction of basal metabolic and energy 
expenditure rates. Beside, orexin knockout out mice is characterized by a reduction 
in brown adipose tissue thermogenesis with poor differentiation of pre-adipocyte 
into adipocytes in the adipose tissue [8]. Central and peripheral effects of orexin are 
illustrated in Figure 2.
The aim of this study was to provide a narrative review of the neurobiological 
effect of orexin system and to examine the association between orexin neuro-
transmission and different psychoneurological disorders, including depression, 
schizophrenia, addiction, Parkinson’s disease, and dementia. Evidence from experi-
mental, preclinical and clinical studies is evaluated for bidirectional relationships 
between orexin neurobiology and psychoneurological disorders. Given the nature 
of the subject area, it remains clear that this literature search cannot be regarded as 
a systemic review.
2. Method and search strategy
A diversity of search strategies was adopted and assumed which included 
electronic database searches of Medline and PubMed using MeSH terms, keywords, 
and title words. There is no limitation for publication year. The terms used for these 
searches were as follows: [orexin OR hypocretin] AND [cognitive function OR 
vigilance OR depression OR schizophrenia OR addiction OR Alzheimer dementia 
OR stroke OR sleep disorders]. [suvorexant OR orexin antagonists] AND [sleep 
disorders OR vigilance OR depression OR schizophrenia OR addiction]. Reference 
lists of identified and notorious articles were reviewed. Besides, only English 
articles were considered, and case reports were not involved in the review. The key 
Figure 2. 
Central and peripheral effects of orexin.
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features of recognized relevant search studies were considered, and the conclusions 
were summarized in a narrative review.
2.1 Orexin and cognitive function
Orexin regulates behavioral and neuroendocrine response during stressful con-
ditions as these events lead to the impairment of cognitive flexibility and function. 
Also, patients with psychiatric disorders such as panic disorder are associated with 
significant reduction of hypothalamic orexin activations [9].
It has been shown that stress improves male cognitive flexibility, but it 
worsens female cognitive flexibility due to gender differences in stress-induced 
orexin neuropeptide activations. Women are twice as likely as men to suffer 
from stress-related psychiatric disorders, such as post-traumatic stress disorder 
(PTSD) and major depressive disorder (MDD); however, the biological basis of 
these sex differences is not fully understood. Interestingly, orexins are known 
to be dysregulated in these disorders. Both preclinical and clinical studies 
have reported higher orexin system expression in females, which contributes 
to exaggerated neuroendocrine and behavioral responses to stress. Therefore, 
orexins may be important in the etiology of stress-related psychiatric disorders 
that present differently in men and women [10]. Piantadosi et al. illustrated 
that stimulation of prefrontal cholinergic neurons leads to the release of orexin 
from hypothalamic neurons, which play an important role in cognitive activa-
tion since high orexin activates the arousal state and executive functions via 
activation of cortical cholinergic neurons [11]. Chieffi et al. study reported the 
beneficial effects of exercise in stimulation of orexin release due to enhance-
ment of hippocampal activity as exercise attenuates hippocampal deteriora-
tion and depressive symptoms in elderly persons through regulation of orexin 
release [12].
Notably, cognitive impairment is the main feature of neurological and neuro-
psychiatric disorders as in dementia and narcolepsy, which are linked to orexin 
dysfunction. Therefore, intranasal orexin peptide may be an effective agent for 
cognitive dysfunction [13]. Astonishingly, orexin plays a crucial role in activation 
of learning and memory, as orexin-A provokes memory acquisition and consolida-
tion through activation of monoaminergic system. Consequently, orexin antagonist 
leads to significant memory dysfunction in the experimental rats [14]. Kim et al. 
study revealed that orexin is an important key factor of hippocampal neurogenesis 
as orexin-A participates in the hippocampal neuronal proliferation and neuropro-
tection following stroke; thus orexin agonist participates in prevention of negative 
stroke outcomes [15]. On the other hand, Uslaner et al. exhibited that dual orexin 
receptor antagonists (DORA-22) is an effective sedative agent, with less cogni-
tive disability than GABA allosteric modulators, which cause significant cognitive 
dysfunctions [16, 17]. Therefore, orexin improves cognitive functions as illustrated 
in different human and animal studies (Table 1).
2.2 Orexin and neuroendocrinology
Orexin is involved in the regulation of central and peripheral signals to regulate 
metabolic homeostasis. Alongside, orexin stimulates adrenocorticotrophin (ACTH) 
and corticosteroid secretions via activation of central corticotropin-releasing hor-
mone (CRH) and vasopressin. Therefore, orexin through OX2R receptor controls 
the hypothalamic-pituitary-adrenal axis (HPA) [18]. Previously, Malendowicz 
et al. illustrated that chronic orexin administration led to dose-dependent increase 
in cortisol and aldosterone plasma levels independent of ACTH levels, indicating a 
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direct stimulating effect of orexin on the adrenal cortex [19]. But in spite of these 
findings, Patel et al. study confirmed insignificant effect of orexin antagonists 
on ACTH and cortisol serum levels as well as on the markers of the sympathetic 
nervous system [20].
It has been reported that orexin administration leads to significant suppression 
of the hypothalamic prolactin release, which is not upturned by dopamine recep-
tor antagonists like metoclopramide suggesting a novel pathway in controlling of 
prolactin secretion. The mechanism of prolactin inhibition may be through inhibi-
tion of prolactin-releasing factor or stimulation of prolactin-inhibiting factor. But 
previous study illustrated insignificant effect of orexin antagonist on prolactin 
plasma levels [21, 22].
Many studies showed that the blood glucose is regulated by central orexin 
through regulation of hepatic glucose production, skeletal glucose consumption and 
thermogenesis. High orexin or dysrhythmic in orexin secretion is linked with the 
development of obesity and insulin resistance [23, 24]. Thus, suvorexant and other 
orexin antagonists are effective in the management of obesity and insulin resistance 
via amelioration of body adiposity and augmentation of energy expenditure that 
improve glucose metabolism. Moreover, orexin-A has important roles in the regula-
tion of pancreatic islet biology through activation of insulin secretion and prolonga-
tion of pancreatic islets life span [25].
Tsuneki et al. study illustrated that suvorexant improves glucose tolerance 
through inhibition of hepatic gluconeogenic factors, when administrated at resting 
time. However, administration of suvorexant at awaking time illustrates insignifi-
cant effect on glucose tolerance due to differential effects on the orexin sleep/wake 
operating system [26].
In addition, Flores et al. study illustrated an interaction between endocan-
nabinoid and orexigenic neurons as there is a similarity between OX1R and CB1 
receptors with diffuse overlapping in the anatomical distribution of these neurons. 
Therefore, the pharmacological effect of cannabinoid may be through orexigenic 
receptors [27]. The neuroendocrine effects of orexin are summarized in Table 2.
2.3 Orexin and psychiatric disorders
2.3.1 Orexin and depression
Among important etiological factors involved in the pathophysiology of depres-
sion, disturbances of monoamines and HPA are the main mechanistic pathways 
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features of recognized relevant search studies were considered, and the conclusions 
were summarized in a narrative review.
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leading to functional disorders of neuroplasticity, which is regarded as a cardinal 
step in the onset of depression [28].
Diurnal variation in orexin serum levels revealed that high orexin levels are 
occurring at the middle of night. It has been reported that orexin level is signifi-
cantly decreased in patients with depression in comparison with healthy subjects 
[29]. But paradoxical high orexin serum levels are seen in some depressed patients, 
which is normalized by selective serotonin reuptake inhibitors. Since, orexin-A CSF 
levels are negatively correlated with depressive symptoms [30].
Long-term antidepressant agents improve orexin serum levels regardless of the 
type of antidepressant medications [31]. Nevertheless, there are different findings 
concerning orexin levels in depression. Feng et al. reported that depression is linked 
to reduction of serotonergic neuronal activity which is responsible for modulation 
of orexinergic activity [32]. Thus reduction of serotonergic neuronal activity leads 
to activation of orexin neuroactivity leading to depression. However, orexin levels 
are significantly reduced in depression compared with healthy control [33].
The initial animal model study observed reduction in the orexinergic neurons by 
18% with diminution in size of these neurons in comparison with normal rats. As 
well, prepro-orexin mRNA expression and orexin-A were reduced compared with 
control [34].
Previous preclinical study revealed a strong connection between low orexin 
and risk of depression which are inconsistent with previous studies that illustrated 
hypoactivity of orexinergic neurons in patients with depression since short-term 
antidepressant therapy improves sleep pattern through increasing and decreasing 
the expression of mRNA of orexin-A and orexin-B, respectively [35].
Ito et al. showed that administration of orexin-A leads to significant reduction 
of despair behavior in depression with important hippocampal neurogenesis via 
upregulation of neuropeptide Y (NPY). These changes are inhibited by co-adminis-
tration of orexin-A antagonist [36].
Therefore, orexin levels are different according to the pathophysiology of 
depression. Low orexin in depressed patients is associated with hypersomnia, 
whereas high orexin in depressed patients is associated with insomnia and inter-
rupted sleep [17]. Ji et al. illustrated that orexinergic neurons have direct connection 
to the ventral pallidum (VP) which is concerned with stress response and rewarding 
system. Orexin stimulates the VP and prevents depressive behavior. Therefore, 
high orexin in the VP is associated with elevated serum corticosterone serum levels 
Species Interventions Results References
Animals Orexin administration ↑ ACTH, cortisol Czerwinska et al. [18]
Animals Orexin administration ↑ cortisol, aldosterone Malendowicz et al. [19]
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during acute stress, which per se prevent a depressive reaction against stressful 
events through improvement of stress resilience [37].
2.3.2 Orexin and schizophrenia
The association between orexin and schizophrenia had not been previously 
explored precisely [38]. Clinical and preclinical findings proposed that orexin and 
orexin agonist are of great value and useful in treating cognitive deficit in schizo-
phrenia [39]. There are widespread connection and interaction between orexin and 
dopaminergic neurons in midbrain, thalamocortical region, and amygdala suggest-
ing the potential role of orexinergic neurons in schizophrenia [40].
Modafinil is an atypical dopamine reuptake inhibitor used in the treatment 
of narcolepsy and antipsychotic drug-induced sleep disorder (Figure 3) [41]. 
Modafinil has been revealed as a complement of drugs in therapy of schizophre-
nia, and it reduce negative symptoms with no effect on the positive symptoms. 
Modafinil improves locomotor and psychomotor performances through activation 
of orexinergic neurons [42].
Therefore, activations of orexinergic neurons by modafinil may be an imperative 
step for future antipsychotic medications. These findings document that dopami-
nergic agonists mainly at D1 and D2 receptors modify orexinergic neurotransmis-
sions [43]. Also, dopamine antagonists that cause weight gain lead to activation of 
orexin pathway, but dopamine antagonists which do not cause weight gain do not 
activate orexin pathway [44]. Nevertheless, amphetamine which indirectly activates 
dopamine leads to activation of orexinergic neurotransmission despite induction of 
weight loss. Moreover, clozapine activates only orexinergic neurons in the prefron-
tal cortex [45]. Similarly, orexin antagonists abolish olanzapine and haloperidol 
effect on midbrain dopaminergic neurons, suggesting that orexin is an important 
neurotransmitter mediates the action of antipsychotic drugs [46]. As well, Chen 
et al. illustrated that orexin-A is stimulated and upregulated by non-obesegenic 
antipsychotic drugs [47]. Also, the high orexin level in patients with schizophrenia 
treated with antipsychotic drugs is regarded as a protective factor against the devel-
opment and risk of drug-induced metabolic syndrome [48]. Furthermore, orexin 
agonist like modafinil ameliorates cognitive function, attention, and antipsychotic-
induced sedation.
2.3.3 Orexin and addiction
The orexinergic system has broad projections and connections to different brain 
area which are concerned with drug-induced neuro-adaptation, including midbrain 
dopaminergic neurons, ventral tegmental area (VTA), nucleus accumbens (NA), 
Figure 3. 
Chemical structure of modafinil.
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amygdala, and medial prefrontal cortex (mPFC). Drug abuse leads to augmenta-
tion of dopaminergic activity in NA through activation of orexinergic neurons at 
mesocorticolimbic pathway [49]. Correspondingly, experimental studies illustrated 
that OX1R and OX2R are highly expressed in the NA leading to inhibitory effect 
instead of excitatory effects seen on the VTA, amygdala, and mPFC. Therefore, a 
differential effect of orexin is receptor type dependent [50].
Acute administration of addicting drugs such as methamphetamine, nico-
tine, and amphetamine leads to activation of orexinergic neurons at the lateral 
hypothalamus. However, acute administration of cocaine and morphine does not 
affect orexinergic neurons. Besides, chronic administration of addict drugs causes 
activation of orexinergic neurons mainly at OX2R receptors, but chronic increasing 
dose of addict drugs leads to downregulation of orexinergic receptors [51]. Carr 
and Kalivas reported that orexin is an important mediator which enables cocaine 
to induce addiction-like behavior in rats due to dopaminergic neuronal changes 
[52]. Also, James et al. verified that orexinergic neurons at the lateral hypothalamus 
play a vital role in expression of addiction-like phenotype [53]. Thus, the orexin-
ergic system is regarded as an important novel target for drug therapies to treat 
addiction.
Orexin serum level in chronic smoker subjects is related to craving in the phase 
of abstinence since it increased during addiction phase and reduced during with-
drawal phase. This reduction leads to increase in craving and risk of relapse [54]. 
Therefore, orexin serum level is regarded as a potential biomarker predicts time and 
risk of smoking relapse.
Furthermore, Tsai and Huang reported that the orexin serum level is increased 
in heroin addicts who shifted to methadone maintenance therapy compared with 
controls suggesting that methadone increases orexin serum levels [55]. Similarly, 
orexin serum level is increased in chronic alcoholism, which is positively correlated 
with the severity of alcohol withdrawal. Alleviation of alcohol withdrawal syn-
drome is linked with reduction of the orexin serum level, which monitors the status 
of alcoholic patients during the abstinence period [56].
2.3.4 Orexin and sleep disorders
Narcolepsy is a sleep disorder that causes excessive daytime sleepiness or an 
intractable urge to sleep in, in which duration of rapid eye movement sleep (REM) 
is reduced. Cataplexy is a sudden reduction in muscle tones with preserved con-
sciousness. Narcolepsy is commonly associated with cataplexy, which is triggered 
by emotional stimuli [57]. Methylphenidate, modafinil, and other psychostimulants 
are effective in the management of these sleep disorders [58]. Dysregulation of 
NREM sleep leads to narcolepsy only, whereas dysregulation of REM sleep leads to 
combined narcolepsy with cataplexy [59]. It has been reported that orexin increases 
vigilance through increasing awaking time and decreasing REM and NREM sleep 
periods. Both OX1R and OX2R are involved in the maintenance of arousal state 
directly or indirectly through the activation of monoaminergic neurons (nor-
adrenalin, dopamine, histamine, and serotonin). Also, orexin activates cholinergic 
neurons in the basal forebrain, which is also important for arousal statues [60]. 
Yamanaka et al. study illustrated that activation of OX2R by orexin leads to wake-
fulness which is mediated by a histamine neurotransmitter since antihistamine 
blocks the excitatory effect of orexin, while activation of OX1R by orexin leads to 
wakefulness, through noradrenalin neurotransmitter [61]. Reduction of orexin 
level in the cerebrospinal fluid was documented in patients with narcolepsy and 
nowadays is regarded as one of the diagnostic criteria in the diagnosis of narcolepsy. 
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Likewise, human postmortem study found that orexin peptide and prepro-orexin 
mRNA are deficient in the pons and cerebral cortex [62]. Therefore, these findings 
unveil that orexin is an important neuropeptide in the regulation of sleep and con-
solidated wakefulness. Table 3 summarized the potential role of orexin in common 
psychiatric disorders.
2.4 Orexin in neurodegenerative diseases
2.4.1 Parkinson’s disease
Orexinergic neurons are severely affected in Parkinson’s disease (PD); previ-
ously Fronczek et al. confirmed that orexinergic neuron density was reduced in 
the prefrontal cortex by 40% with significant reduction in CSF orexin levels in PD 
patients compared to the healthy control [63].
Furthermore, animal model study illustrated that 15% damage to the orexin-
ergic neurons did not affect CSF orexin, while damage more than 70% leads to 
50% decline in the CSF orexin [64]. These findings may explain the association of 
narcolepsy with PD since both dopamine and orexin interplay in the regulation of 
sleep pattern through activation of midbrain and thalamocortical pathway [65]. 
Feng et al. illustrated that in PD, there is a deficiency in hypoxia inducible factor 1 
alpha (HIF1-α) due to mitochondrial dysfunction and the administration of orexin-
A leads to significant neuroprotective effect on the dopaminergic neurons through 
the activation of HIF-α [66].
Moreover, orexin-A improves dopaminergic neurons in PD through the reduc-
tion of tyrosine hydroxylase (TH) and activation of brain-derived neurotrophic 
factor (BDNF) in the substantia nigra [43]. Therefore, orexin antagonist may 
increase risk of PD due to reduction of the neuroprotective and stimulating effects 
on the dopaminergic neurons at substantia nigra [67]. Sheng et al. found that 
orexin plays important roles in activation of the subthalamic nucleus which may 
give a new evidence for the participation of the subthalamic orexinergic system 
in PD. Importantly, orexin-A increased the protein level of brain-derived neuro-
trophic factor in dopaminergic neurons of the substantia nigra. The upregulation 
of BDNF is mainly via OX1R [68]. Long-term therapy with ropinirole in PD leads to 
significant reduction in the orexin activity which might explain the adverse effect 
of ropinirole-induced sleep disorder through inhibition of glutamatergic excitatory 
effect on the orexinergic neurons. Therefore, pharmacotherapy of PD should be 
re-evaluated in this context [69].
Psychiatric disorders Species Orexin levels References
Depression Human Decreased Kok et al. [29]
Human Increased Grady et al. [30]
Schizophrenia Human Decreased Mereu et al. [42]
Patel et al. [20]
Chronic smoking Animals Increased Al’Absi et al. [54]
Drug addictions Human Increased James et al. [53]
Alcoholism Human Increased Pan et al. [56]
Narcolepsy Human Decreased Gabelle et al. [62]
Table 3. 
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give a new evidence for the participation of the subthalamic orexinergic system 
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Psychiatric disorders Species Orexin levels References
Depression Human Decreased Kok et al. [29]
Human Increased Grady et al. [30]
Schizophrenia Human Decreased Mereu et al. [42]
Patel et al. [20]
Chronic smoking Animals Increased Al’Absi et al. [54]
Drug addictions Human Increased James et al. [53]
Alcoholism Human Increased Pan et al. [56]
Narcolepsy Human Decreased Gabelle et al. [62]
Table 3. 




Alzheimer’s disease (AD) is a neurodegenerative disease affecting different brain 
areas characterized by cognitive deficit and progressive memory loss [70]. AD also 
affects hypothalamic orexinergic neurons leading to excessive daytime sleepiness, 
which is correlated with low orexin CSF levels, as reduction 40% of the brain cell 
number is linked with a 14% reduction in orexin CSF levels [71]. Normally, orexin 
regulates cholinergic and monoaminergic neuron firing during sleep and wakeful-
ness. In AD a reduction in the cholinergic pathway leads to disturbance in sleep 
patterns leading to daytime sleepiness and insomnia at night which are a hallmark 
of sleep rhythm in AD [72]. Besides, reduction of cholinergic activity causes overac-
tivity of orexinergic neurons, which causes abnormal sleep and cognitive functions. 
These changes lead to an elevation of the orexin CSF level, which is linked with 
reduced REM sleep [73].
Dementia with Lewy bodies is characterized by an elevation in α-synuclein level, 
which is accumulated in orexin-containing neurons at the hypothalamus caus-
ing interference in orexin axonal transport. This effect leads to a reduction in the 
activity of the orexinergic system in dementia with Lewy bodies but not in AD [74]. 
Therefore, there are complexities in the orexinergic system according to the clinical 
presentation and sleep pattern in patients with AD.
2.4.3 Huntington’s disease
Huntington’s disease (HD) is a hereditary neurodegenerative disorder 
characterized by personality changes, motor disturbances, cognitive decline, 
and weight loss [75]. HD is caused by a defect in the gene encoding huntingtin, 
a protein with unclear function, which is essential for cell survival during 
development and in adult life [76]. In HD there is neurodegeneration involving 
the neostriatum and cerebral cortex, with the manifestation of intraneuronal 
aggregates of misfolded huntingtin. Moreover, in patients with end-stage HD, 
there is about 90% of neuronal loss in the tuber nucleus of the lateral hypo-
thalamus. Orexin-A and orexin-B are synthesized from the same precursor 
gene and are expressed in the same neurons with their cell bodies concentrated 
to the lateral hypothalamus [77]. Preclinical and clinical studies observed 
that orexin serum and CSF levels are decreased by 72% in HD. In healthy 
subjects, orexin CSF level is >200pg/ml, but in HD and narcolepsy, this level is 
decreased below 110 pg/ml, due to degeneration of orexinergic neurons in the 
lateral hypothalamus. Therefore, CSF orexin level is regarded as a biomarker to 
evaluate the disease progression and usefulness of therapeutic intervention in 
patients with HD [78, 79]. However, Meier et al. illustrated that CSF and serum 
orexin levels are of no diagnostic value in prediction and follow-up of  
HD [80].
Recently, Cabanas et al. observed that orexin in HD has aberrant effects leading 
to abnormal sleep pattern, and thus orexin antagonist suvorexant may be of great 
value in restoring normal sleep and behavioral disturbance in HD [81] in addition, 
these neurons remain functional and illustrate paradoxical effect, it become more 
modifiable and affect by serotonine and noradrenaline, and less sensitive to the 
effect of suprachiasmatic nucleus (the master clock of the brain) causing abnormal 
biological circadian rhythm [81, 82].
Therefore, orexin level in HD is reduced, but the remaining functional orex-
inergic neurons lead to abnormal circadian biological rhythm causing behavioral, 
motor, and sleep disturbances.
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2.4.4 Multiple sclerosis
Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers 
of nerve cells in the brain and spinal cord are damaged. This damage disrupts the 
ability of parts of the nervous system to transmit signals, resulting in a range of 
signs and symptoms, including physical, mental, and sometimes psychiatric prob-
lems. Specific symptoms can include double vision, blindness in one eye, muscle 
weakness, and trouble with sensation or coordination. MS takes several forms, with 
new symptoms either occurring in isolated attacks (relapsing forms) or building up 
over time (progressive forms). Between attacks, symptoms may disappear com-
pletely; however, permanent neurological problems often remain, especially with 
the advancement of the disease [83, 84].
The three main characteristics of MS are the formation of lesions in the central 
nervous system, inflammation, and the destruction of myelin sheaths of neurons. 
These features interact in a complex and not yet fully understood manner to 
produce the breakdown of nerve tissue and in turn the signs and symptoms of the 
disease. Cholesterol crystals are believed to both impair myelin repair and aggravate 
inflammation. MS is believed to be an immune-mediated disorder that develops 
from an interaction of the individual’s genetics and as yet unidentified environmen-
tal causes. Damage is believed to be caused, at least in part, by attack on the nervous 
system by a person’s own immune system [85].
Considering the multiplicity of symptoms associated with multiple sclerosis 
(MS), there is possibility that hypocretin system function might be involved in 
the pathogenesis of the disease. Papuc et al. showed that high orexin CSF level in 
patients with MS as compared with healthy controls, but it positively correlated 
with fatigue level, suggesting a compensatory mechanism for the production of 
orexin in MS [86]. On the other hand, Nozaki et al. illustrated that orexin CSF level 
is reduced and correlated with symmetrical hypothalamic lesion and spinal cord 
damage in MS. Therefore, low orexin level was implicated in the pathogenesis of 
hypersomnia and cognitive deficit in patients with MS [87]. Recently, Pallais et al. 
confirmed that orexin has a neuroprotective effect in MS through inhibition of 
inflammatory and proinflammatory mediators mainly matrixmetaloproteinases 
(MMP-3, MMP-9) which are involved in damage of neuronal matrix proteins. 
Consequently, low CSF orexin level indicates underlying active disease [88].
Therefore, CSF orexin level is a valuable biomarker in the diagnosis and predic-
tion of the severity of MS.
2.4.5 Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease 
(MND), is a disease that leads the death of neurons controlling voluntary muscles. 
The underlying mechanism involves damage to both upper and lower motor 
neurons. ALS is characterized by stiff muscles, muscle twitching, and muscle 
weakness is still unknown. The cause of ALS is not known in 90% of cases but is 
believed to involve both genetic and environmental factors. The remaining 10% of 
cases is inherited [89]. Previously, Van Rooij et al. illustrated that CSF orexin level 
was normal in patients with ALS and not correlated with age and gender. However, 
a disturbance in the orexinergic system is involved in the pathogenesis of ALS [90]. 
Moreover, the pathogenesis of ALS is associated with lateral hypothalamic lesions, a 
site of the orexinergic system leading to sleep disturbances and hypersomnia [91].
Despite different and large body of literature survey, little is known about CSF 
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Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease 
(MND), is a disease that leads the death of neurons controlling voluntary muscles. 
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Therefore, orexin CSF level and orexinergic activity in different neurodegenera-
tive diseases are summarized in Table 4.
2.5 Orexin antagonists and neurobiology
Regarding orexin antagonists, suvorexant is a dual orexin receptor antagonist 
was approved by the Food and Drug Administration (FDA) on 13 August 2014 
[92]. Other orexin antagonists are almorexant, lemborexant, and filorexant are 
used in the management of insomnia and other sleep disorders. Also, these drugs 
may be of great value in the control of depressive disorders and peripheral diabetic 
neuropathy [93].
Suvorexant (Figure 2) is the first orexin antagonists approved in the United States 
for treatment of insomnia, which is effective in reduction of time to sleep onset and 
increase of total sleeping time [94]. Moreover, administration of SB-33867 which 
is an orexin antagonist leads to significant reduction of sympathetic tone causing a 
reduction in blood pressure, heart rate, and plasma noradrenalin. These findings sug-
gest that orexin through OX1 receptor regulates sympathetic tone since intravenous 
administration of orexin leads to parallel increases in noradrenalin plasma levels [95].
Hatta et al. study confirmed the significant effect of suvorexant in the manage-
ment of delirium in elderly patients in acute care units. The anti-delirium effect is 
due to the regulation of circadian biology [96]. Delirium is proposed to be related of 
suvorexant to disturbances and disorders in sleep pattern in critically ill patients in 
the intensive care unit. Also, attention disorders are caused by disturbances in the 
ascending reticular activating system (ARAS) which is responsible for maintenance of 
human arousal. Normally, the arousal state is regulated and stimulated by ARAS neu-
rotransmitters and by hypothalamic orexin [97]. Therefore, orexin receptor antago-
nists may play important role in the regulation of hypothalamic and brain stem stress 
during acute injury. Moreover, a recent study by Kawada et al. illustrated that suvorex-
ant add-on therapy to ramelteon in the management of sleep disorders in patients with 
acute stroke is more effective than when combined with benzodiazepines [98].
It has been verified that prolonged alcohol consumption is associated with 
sleep disturbance which is a powerful factor for relapse and setback to alcohol use. 
Suvorexant reduces the motivation properties of alcohol, so it plays a crucial role in 
the prevention of alcoholism [99].
Beside, Gentile et al. study revealed the possible role of suvorexant in reduction 
of motor impulsivity of cocaine-induced psychostimulant effects. Thus suvorexant 
may be effective in attenuation of cocaine withdrawal syndrome [100].
As well, suvorexant had placebo-like effect on EEG in comparison with zolpidem 
which has a significant reduction in the spectral density of rapid eye movement and 
non-rapid eye movement sleep (NREM) pattern [101].
Psychiatric disorders Species CSF orexin levels References
Parkinson’s disease Human Decreased Fronczek et al. [63]
Alzheimer’s disease Human Increased Liguori et al. [73]
Huntington’s disease Human Decreased Mignot et al. [78]
Animals Normal Papuc et al. [86]
Multiple sclerosis Human Decreased Nozaki et al. [87]
ALS Human Normal Van Rooij et al. [90]
Table 4. 
Orexin and neurodegenerative diseases.
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In spite of the wide uses of suvorexant in the management of sleep disorders and 
controlling insomnia, it did not reduce the psychomotor performances as docu-
mented by Vermeeren et al. study [102].
Orexin-A is involved in regulation of feeding; it stimulates nocturnal feeding 
through OX1 receptor. Therefore, OX1 receptor antagonist regulates feeding and 
reduced nocturnal feeding; thus, orexin antagonist could be useful in the treatment 
of obesity [103]. Orexin-A is implicated in the pathogenesis of obesity; it promotes 
hyperphagia through central activation of cannabinoid receptors and inhibition 
of melanocyte-stimulating hormone [104]. Both orexin-A and endocannabinoid 
increases glucose response of neuronal excitability in the arcuate nucleus leading to 
induction of feeding and obesity [104].
In summary, more research is required to reinforce the extant information on 
the importance of the limited number of factors studied to date and provide data 
on additional potentially relevant effects. Similarly, rubric for such research should 
shift from preclinical and animal model studies to clinical studies to illustrate 
disease progression and treatment effects in relation to orexin neurobiology. This 
study suggests that orexin system is a future target in the management of different 
psychoneurological disorders after delineating the specific role of orexin receptor 
agonists and antagonists. Moreover, measurement of orexin serum level which is an 
easy method may be of great value in evaluation and assessment of different neuro-
logical disorders. Also, ratio of orexin serum level/CSF orexin level may reflect the 
activity of endogenous orexinergic system.
3. Conclusion
Orexin system is regarded as a potential novel target in the management of 
schizophrenia, depression, addiction, and sleep disorders. Orexin serum level might 
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Anorexia nervosa is characterized as having a significantly low body weight 
because of restricting energy intake or compensating to an excessive rate inten-
tionally in order to attain or maintain an unrealistically thin ideal weight. Patients 
suffer multiple comorbid medical and psychiatric problems; moreover, deficits 
in treatment motivation are commonly seen, which causes a high rate of dropout 
from treatment programs. Thus, recent studies have focused on the etiology in 
order to develop efficient treatment options, as this can become a life-threatening 
problem. Prevention programs are also gaining attention, since full recovery can 
take a significant time and resources nevertheless may not be available for all cases. 
In this chapter, a brief history and basic diagnostic criteria of anorexia nervosa will 
be summarized. A review of comorbid psychiatric and medical conditions will be 
addressed. Prominent theories regarding its etiology and treatment options will be 
discussed in terms of a biopsychosocial approach. Finally, prevention studies will 
be highlighted.
Keywords: eating disorders, anorexia nervosa, body image, body dissatisfaction, 
compensatory behaviors, weight management strategies, dieting
1. Introduction
Weight management is essential for a healthy life, but in extreme cases, it can 
turn into a life-threatening condition. Eating behavior is an important dimension of 
weight management. For most of us, eating is an automatic response to hunger and 
can be as easy or normal as breathing. On the other hand, it may be a challenging 
area for people with eating disorders. Eating disorders (EDs) are serious psychiatric 
problems that have a multiple impact on health and well-being. The prominent 
types of EDs include anorexia nervosa (AN), bulimia nervosa (BN), and binge 
eating disorder (BED). This chapter will focus on anorexia nervosa and start with a 
brief history of AN. In the following sections, basic diagnostic criteria and a review 
of comorbid psychiatric and medical conditions will be addressed. Throughout 
the text, we will discuss prominent theories regarding its etiology and treatment 
options from a biopsychosocial perspective. Finally, prevention studies will be 
highlighted.
Anorexia nervosa is a complex disorder that includes physiological, behavioral, 
cognitive, and emotional components. Historical traces of anorexia can be found 
in ancient times. A group of women who starved themselves for religious reasons 
in Rome in 383 was reported [1]. Fasting is a common ritual in many religions and 
cultures, although starving triggered by psychological factors as a weight manage-
ment strategy can lead to serious medical problems. Cases similar to AN have been 
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brief history of AN. In the following sections, basic diagnostic criteria and a review 
of comorbid psychiatric and medical conditions will be addressed. Throughout 
the text, we will discuss prominent theories regarding its etiology and treatment 
options from a biopsychosocial perspective. Finally, prevention studies will be 
highlighted.
Anorexia nervosa is a complex disorder that includes physiological, behavioral, 
cognitive, and emotional components. Historical traces of anorexia can be found 
in ancient times. A group of women who starved themselves for religious reasons 
in Rome in 383 was reported [1]. Fasting is a common ritual in many religions and 
cultures, although starving triggered by psychological factors as a weight manage-
ment strategy can lead to serious medical problems. Cases similar to AN have been 
reported since the fourteenth century, but as a psychological problem, preliminary 
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cases were defined in 1873 and 1874 [2, 3]. The term anorexia nervosa means 
“nervous loss of appetite”; thus the early descriptions focused on food avoidance as 
the core problem. Then it was realized that people with AN do not suffer a loss of 
appetite; indeed their mind is extremely preoccupied with food. Hence, the psy-
chological component became prominent, and the problem was conceptualized as a 
weight phobia and self-control. In fact, AN has been known about since the seven-
teenth century but was observed in the 1960s in western society and characterized 
as leading to a significantly low body weight because of restricting energy intake 
or compensating to an excessive rate intentionally, in order to attain or maintain 
an unrealistically thin ideal weight [4]. In the fifth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5), the title Feeding and Eating 
Disorders covers problems related to eating behaviors and unhealthy strategies 
for weight management [5]. Feeding disorders include pica, rumination disorder, 
and avoidant/restrictive food intake and can usually be seen in children, resulting 
in malnutrition or delay in growth due to unhealthy feeding behaviors. On the 
other hand, EDs are mostly seen in teenagers and adults. Their onset usually falls 
during puberty when body changes gain importance. DSM-5 defines three types 
of EDs, AN, BN, and BED. The underlying psychological mechanism is similar 
between these types as an intense fear of gaining weight and preoccupation with 
weight, body, and eating that leads to weight management strategies also known 
as compensatory behaviors like dieting, exercise, self-induced vomiting, misuse of 
laxatives, and diuretics [6]. The subtypes of EDs differ in body weight and weight 
management strategies. BN, BED, and other problems related to eating are beyond 
the scope of this chapter. Thus, we will first take a closer look at the clinical presen-
tation of anorexia nervosa.
2. Clinical presentation
The current definition and clinical presentation of anorexia nervosa is deter-
mined by DSM-5 [5]. According to this diagnostic criterion, AN involves the 
following factors: The first criterion is a refusal to maintain a normal body weight 
despite being underweight. The factor of underweight or significantly low weight is 
usually determined by a body mass index (BMI) lower than 18.5 [7]. Nevertheless, 
not every underweight person is considered to have AN, though in this case being 
underweight is extremely important and in order to maintain this situation or to 
lose more weight, compensatory behaviors are evident. These unhealthy weight 
management strategies include excessive dieting or exercise, self-induced vomit-
ing, and misuse of laxatives and diuretics, which leads to serious health problems 
including amenorrhea. The absence of at least three consecutive menstrual cycles 
was a diagnostic criterion for AN in the previous editions of the DSM [8]. Yet some 
women may have their periods even when they are underweight or there can be 
other metabolic problems resulting in amenorrhea. Moreover, it was making diag-
noses difficult in men. In DSM-5, this original amenorrhea criterion was left out, in 
order to cover more cases.
Secondly, there is an intense fear of gaining weight or becoming fat, even though 
the body weight is less than normal. This fear is one of the most important factors 
that maintain compensatory behaviors and may not change despite weight loss. The 
third criterion is a disturbance in body image. Body image is a multidimensional 
framework that contains perceptions, attitudes, cognitions, emotions, and behav-
iors related to the body [9]. It can be defined as a representation of body in mind 
and is presumed to be the core psychological problem in AN [10]. People with AN 




weight; also negative attitudes towards the body, including body dissatisfaction, are 
prevalent [11]. Behaviors related with body such as excess weighing, body check-
ing, and avoiding tight clothes might take up a lot of time on a daily basis. Negative 
body attitudes or body dissatisfaction has become almost a cultural norm in this 
age, especially for women, but for AN sufferers, these disturbances in body image 
are multifaceted and time-consuming, and this decreases functionality; also self-
evaluation is mostly influenced by body shape and weight [12].
In AN diagnosis, two types were specified: restricting type and binge eating/
purging type. Excessive dieting is prominent in the restricting type, whereas 
binge eating/purging type is characterized by recurrent binge eating episodes fol-
lowing by purging as a compensative behavior. A common definition for a binge 
eating episode is eating in a certain (e.g., at least 2 h) period of time an amount 
of food that is larger than most people would eat in a similar time period or 
condition accompanied by a sense of lack of control over eating (feeling that one 
cannot stop eating). Most commonly, self-induced vomiting or excessive dieting/
exercise as purging behaviors follows this type of episode. The subtypes of AN 
are helpful in defining the clinical presentation of cases, but it should be noted 
that the predictive validity is weak, as transition between subtypes (both in AN 
and between AN and BN) is quite common [13]. The difference between the binge 
eating/purging type of AN and BN is that the AN cases are underweight. Also in 
AN, binge eating episodes might be subjective and may not always meet a clinical 
definition. However, there is also evidence that impulsivity, self-harming, social 
withdrawal, and comorbid psychiatric problems are more common in the binge 
eating/purging type, whereas perfectionism is more common in the restricting 
type [14]. Another problem in clinical presentation is that in most cases there is 
a lack of insight regarding their problem and deficits in treatment motivation are 
prevalent [15].
3. Comorbid medical and psychiatric conditions
Patients suffer multiple comorbid medical and psychiatric problems, as eating 
behavior affects health in multiple ways directly or indirectly [16].
Almost every system in the body is affected in AN, including gastrointestinal, 
cardiovascular, skeletal, nervous, endocrinological, and reproductive [17]. Physical 
examination results usually show low blood pressure, bradycardia, low body 
temperature, gastrointestinal problems, dehydration, hormonal deficits, amenor-
rhea or other menstrual problems, hair loss, and lanugo hair [18]. Cardiovascular 
problems include irregular heartbeats, heart attacks, and collapse of heart valves 
and may cause death [19]. Starvation affects menstrual functioning, resulting 
in poor reproductive health, with infertility problems. Even if anorexic women 
become pregnant, there is a high possibility of having small babies with complica-
tions or unhealthy children [20]. Self-induced vomiting may cause tooth erosion or 
calluses on hands [21]. AN usually begins at puberty, and this is an important time 
for the development of bones. Malnutrition can cause stunted growth and osteopo-
rosis in the long term [22]. Anorexia is also associated with changes in the nervous 
system like loss of grey matter in the brain and reduction in pituitary size, resulting 
in deficits in attention, learning, memory, and visuospatial analyses [23, 24]. Above 
all, anorexia has the highest mortality rates among psychiatric disorders [25]. All of 
these medical problems can cause heart attacks or infections, but suicide is the most 
common cause of death [26].
In addition to physical problems, psychological complications are prevalent in 
AN. Almost half of the cases have a comorbid DSM diagnosis, especially depression 
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being the most common among them [27]. Problems related to anxiety like social 
phobia and obsessive-compulsive disorders are highly associated with anorexia [28]. 
Trauma-related problems are more prevalent in the binge eating/purging type [29].  
Comorbid psychological problems have a negative impact on prognosis and 
 predicted suicide attempts [30]. As a result, AN is a chronic condition accompa-
nied with a range of physical and psychological problems that interfere with daily 
functioning, and it has a high mortality rate.
4. Prognosis
Prognosis of anorexia is difficult, and full recovery is only possible in almost 
half of the cases [31]. Even when the physical symptoms are treated and the weight 
is maintained within the normal ranges, cognitive, emotional, and behavioral 
aspects of anorexia might continue. A complete recovery is only possible when all 
the symptoms are gone and especially when a positive body image is developed [10]. 
For this reason, recovery is considered as a long process that may take several years. 
Recurrent episodes of relapse are prevalent and accepted as within the nature of 
the disorder. Moreover, deficits in treatment motivation are quiet common, which 
causes a high rate of dropouts and chronicity of the problem [15]. Several factors 
may affect prognosis. For example, a very low BMI and a prolonged time before 
applying for treatment may worsen the process of prognosis [32]. Therefore, early 
detection and providing evidence-based treatment approaches are crucial to the 
course of anorexia.
5. Epidemiology
Estimating the prevalence of anorexia nervosa is problematic because it is a 
rare problem. The course of illness is variable, and sufferers are usually reluctant 
to report their situation or take part in studies [33]. Lifetime prevalence of DSM-5 
diagnosis of AN in the West varies between 1 and 4% [27], but it has also been 
recently increasing in the non-Western world such as in Asia and the Middle East 
[34]. The problem is that most cases do not meet the full diagnostic criteria; result-
ing subthreshold EDs are more common in at-risk populations like high school and 
college samples [35]. Anorexia nervosa diagnosis is the most sexually based psy-
chiatric problem, and the stereotypical patient is usually considered to be a young, 
white female from a higher socioeconomic class. This stereotype is not true all the 
time. However, the vast majority of the cases are women and the current male-
female ratio is standing at 1:10 [5]. Nevertheless, recent studies show that between 
3 and 20% of AN cases are male [36, 37]. Underdiagnoses of AN in men are a result 
of several factors that include sociocultural expectations towards women and the 
difference in symptom presentation in men. The mean age of onset is 17 in AN and 
the risk decreases with age [38]. However, onset of the disorder can be after age 40 
or even later in some cases [39]. AN has been found to be less common among Black 
than White Americans [40], possibly due to underrepresentation in specialist eating 
disorder services and under detection in primary care [41]. Other than that, there 
is no systematic association between ethnicity/race or socioeconomic status and 
eating disorder occurrence [42]. Being in a sexual minority is a risk factor for EDs 
which is general for both women and men [43, 44]. In conclusion, it is noted that 
anorexia can affect people of all ages, genders, races, ethnic origins, socioeconomic 





Several theories have been proposed to understand the etiology of AN. Although 
these theories will be presented individually, it is recognized that a multidimen-
sional approach is helpful to understand the causes of AN, even though such a 
comprehensive model has not yet been developed. Biological, psychological, and 
social factors interact with each other in the etiology. Prominent models include the 
genetic and neurobiological model, the psychodynamic model, the sociocultural 
model, and the cognitive behavioral model. Significant life events, personality, 
and a family system approach are also productive in understanding the causes of 
anorexia.
6.1 Genetic explanations
Genetic explanations focus on the biological mechanisms behind AN. Family, 
twin, and genetic studies found that AN runs in families [46]. A family history of 
AN puts people fourfold more at risk and relatives of women diagnosed with AN 
are 11 times more at risk of developing AN than controls [47, 48]. Moreover there 
is strong evidence that all types of EDs (AN, BN, and not otherwise specified EDs) 
track together in families without specificity [48]. Twin studies also show a genetic 
heredity for AN of between 28 and 74% but fail to identify specific genes [49]. In 
addition to these, anorexia interacts with other psychiatric problems. For example, 
people with a diagnosis of AN have a higher risk of developing OCD or vice 
versa [50]. Thus, genetic factors are considered responsible for 48–74% of the total 
variance in liability to AN [46]. Nevertheless, genetic factors cannot alone predict 
who will develop AN, as most of the cases do not have a familial history of EDs. 
Furthermore, methodological problems due to small sample size also reduce the 
likelihood of repetition of these studies.
It is evident that genes play an important role in the development of AN, 
although how these genetic predispositions interact with environmental factors 
has been a focus of research lately. Candidate gene and genome-wide studies are 
considered helpful in finding the answers. Research on candidate genes examined 
the serotonergic system (5-HT system), dopaminergic system, and opioidergic 
system that affect appetite, reward mechanism, mood, and weight; nevertheless, 
statistically significant results have not been presented so far [51]. Genome wide 
studies showed a relation between chromosomes 1, 11, and 12 and genes related to 
leptin regulation, lipid and glucose metabolism, serotonin receptor activities, and 
the immune system [52–55]. This genetic presentation is also consistent with the 
clinical presentation of anorexia. Further studies in these areas can be productive in 
order to explain the roles of genes in the AN etiology.
6.2 Neurobiological explanations
Neurobiological studies of AN focus on the brain areas, biological origins of 
symptoms, and neurochemical differences between people diagnosed with AN and 
healthy controls. Severe weight loss in anorexia causes a decrease in gray matter in 
several areas of the brain [56]. Moreover, a review of neuroimaging studies (PET, 
MRI, and fMRI) noted dysfunction in certain brain areas such as the amygdala, 
basal ganglia structures, and hippocampus [57]. On the other hand, research 
indicates dysfunctions in dopaminergic and serotonergic (5-HT) systems that are 
responsible for food, motivation, the reward system, executive function, emotion 
regulation, and impulse control [58]. Thus, food as a natural reward becomes a 
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source of both threat and anxiety, which makes it easier to avoid or restrict [59]. 
Neuroimaging studies also support this explanation. In one fMRI study with AN 
patients, an increase in amygdala activity (threat perception) and a decrease in 
inferior parietal lobe activity (food-related pleasure and interest) were evident 
while patients were looking at food pictures [60]. Furthermore, AN patients give 
different responses to body-related words and pictures than controls. They pay 
more attention to these words and pictures, focusing on the parts of the body rather 
than focusing on the body as a whole; they experience cognitive, perceptual, and 
emotional changes when they look at their own body [61, 62]. These changes can be 
explained through the decrease in occipital and prefrontal cortex activity.
Lastly, the “insula hypothesis” is proposed as a neurological model of anorexia 
nervosa that states that a dysfunction of the neural circuitry integrated by the insula 
can be responsible for the clinical presentation of AN [63, 64]. Symptoms arise 
because of disability in the insula, which establish a homeostatic balance by linking 
the brain’s perception, emotional response, and memory-related regions to each 
other. Thus, it is assumed that this dysfunction causes changes in reactions to foods, 
internal and external bodily sensations, and emotional processing.
6.3 Psychodynamic explanations
Psychodynamic explanations usually offer a unique way to understand patients’ 
experiences of AN. These models emphasize the meanings and functions of 
symptoms and early childhood experiences that may cause fixation or unconscious 
conflicts related to individualization, separation, dependency, and control. From 
a psychoanalytic perspective, restriction of food symbolizes an area of control and 
a denial of growing up or becoming a woman [65]. Thus, the patient can stay as a 
child and can be looked after. Furthermore, family dynamics play an important role 
in these psychodynamic models. Excessive involvement, rigidity, inability to resolve 
conflict, and excessive protectionism are common dynamics in families of AN suf-
ferers [66]. Bruch [67] also stated that this overinvolvement by “perfect” mothers 
may cause ineffectiveness in the child, resulting in these children may be not being 
able to identify and understand their needs or internal states. When food becomes 
a way of self-soothing, relaxing, and communicating, this pattern may result in 
eating related symptoms. Nevertheless, psychodynamic explanations are important 
to understand patients as individuals. However, generalization and causality is 
always a problem within these explanations. Moreover, these models fail to explain 
why childhood relationships are expressed through eating behaviors. In addition, it 
is always difficult to test or evaluate these explanations.
6.4 Cognitive behavioral explanations
Behavioral models of anorexia nervosa regard the disorder as a behavior that has 
been learned and is maintained through reinforcement. Individuals reduce their 
food intake as a means to lose weight due to the social pressure to be thin or other 
experiences, and this behavior is reinforced by sociocultural norms, feelings of 
being in control. These first explanations were criticized for not focusing on causal 
factors, and therefore cognitive explanations were proposed to be linked with these 
behaviors. Slade [68] pointed out that interpersonal problems and family conflicts 
underlie the perfectionistic tendency in anorexia, and this tendency is a triggering 
factor for dieting. Cognitive explanations focus on patients’ thoughts about food, 
eating, weight, and shape which parallel Beck’s model on depression [69]. Moreover, 
predisposing factors for self-starvation such as perfectionism, self-criticizing, and 




reinforced and maintained easily as they become a way of gaining self-esteem. 
With the evidence-based studies, cognitive behavioral therapy (CBT) becomes 
the leading approach in both understanding and treating EDs in general [71]. CBT 
explains the etiology in AN as follows: dysfunctional thoughts of weight shape and 
body are influential in the development and persistence of symptoms, while weight 
control or compensatory methods (dieting, exercise, etc.) continue to reinforce 
the disorder. Symptoms are also conceptualized as a coping mechanism and a way 
of emotion regulation. Lately, Fairburn [6] has developed a transdiagnostic model 
of EDs that conceptualizes EDs beyond the diagnostic categories and targets the 
mechanism that is sustainable in all eating disorders. From Fairburn’s transdiag-
nostic perspective, AN, BN, BED, and ED-NOS share the same core pathology that 
is cognitive in nature. For patients, the overvaluation of body shape and weight 
and their control is the most important part of life that defines and determines the 
worth of one’s self. This pathology both causes and maintains eating and compen-
satory behaviors. In the case of anorexia, the consequences of malnutrition and 
hunger affect the cognitive ability of patients, which also causes rigidity in thoughts 
and behaviors.
6.5 Sociocultural explanations
Sociocultural models focus on the impact of culture and environment on body 
image and emphasize the importance of body image problems in the development 
of AN. Cultural expectations of thinness, usually termed “thin idealization,” come 
from the media, family, friends, and peers [72]. Thinness is generalized within 
the scope of many positive meanings such as beauty, desirability, success, will, 
appreciation, charm, and control. Notably, exposure to images represented in 
the media that are often biologically unreachable for many women or even unreal 
(e.g., photoshopped) suggests thinness as a route to happiness, love, and success. 
Sociocultural models emphasize that the ideals of thinness are internalized through 
messages given by society, the media, peers, and family, resulting in eating and 
body problems and psychological symptoms in people who are dissatisfied with 
their body [73]. Lately, social media applications like Instagram and Tumblr and 
their impact on eating and body problems have become the focus of research in 
this area. Internalization of this thin ideal and an increase in body dissatisfaction 
are correlated with the prevalent pictures and the following of the accounts of thin 
people, celebrities, models, and actors [74]. Consequently, sociocultural factors play 
an important role in the thin idealization, but it is assumed that anorexia nervosa 
is developed through many factors including biological, cognitive, emotional, and 
social ones.
6.6 Risk factors in etiology
Several risk factors that include body dissatisfaction, dieting, being involved in 
body-related activities/sports/professions (dancing, ballet, athletics, modelling, 
acting, etc.), personality traits, family dynamics, and stress/trauma are stated as 
contributing to the etiology of anorexia [75]. Personality traits such as perfection-
ism, an obsessive-compulsive personality, and deficits in emotion regulation are 
prevalent in AN [76, 77]. These personality dimensions can be considered as both 
the predisposing and maintaining factors. Besides family dynamics, as we reviewed 
in the psychoanalytic model, are also important. Insecure attachment styles through 
stressful early childhood experiences and food-/body-related communications [78, 
79] are the prominent factors related to the family. There is also some evidence of 
decreased family functioning in families of AN patients; however this might be a 
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source of both threat and anxiety, which makes it easier to avoid or restrict [59]. 
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result of having an anorexic family member, as EDs affect families and caregivers 
[45]. Finally a wide range of traumatic experiences are prevalent in patients with 
AN. These include childhood neglect, every form of childhood abuse, witnessing 
violence, rape, loss of significant others, accidents, as well as interpersonal stress 
like bullying, humiliation, and body-related teasing [80]. The abovementioned 
factors may have neurodevelopmental effects on the HPA pathway and serotonergic 
system, which play a role in the brain’s response to stress [81].
7. Treatment
Evidence-based research in this area suggests promising results in treatment. 
At the same time, the treatment processes are reported to be long and especially 
expensive, almost like schizophrenia, yet full recovery is only possible for half of 
the patients [82]. A multidimensional treatment with a multidisciplinary team 
is necessary in AN treatment, as the disorder contains biopsychosocial elements 
in nature. Medical nutritional therapy for weight gain and nutritional counsel-
ing is important, especially in the case of severe weight loss. Pharmacotherapy 
has a limited role in the treatment and however can be beneficial in some cases. 
Nevertheless, there is certain evidence that psychotherapy is essential in AN treat-
ment, although a multidisciplinary approach is required that includes nutritional 
therapy and psychiatric and medical evaluation as well [83]. Inpatient treatment is 
suggested in cases with a low BMI (<13.5), rapid decrease in weight, risk of suicide, 
social isolation, failure of outpatient treatment, and medical risk factors (e.g., 
cardiac problems and lowered blood sugars) [84]. Specialized units and clinics are 
also required for AN treatment.
7.1 Medical nutritional therapy
Medical nutritional therapy is an essential part of treatment in AN, especially 
for inpatients. This form of therapy focuses on the evaluation of nutritional 
problems and risks, and after that nutritional counseling is provided to treat the 
nutritional disorder and to prepare the patient for the next stages of treatment. 
In medical nutritional therapy, the first choice is oral feeding (chewing and swal-
lowing), but enteral/tube feeding (giving liquid food to the stomach or intestine) 
or, as a last resort, parenteral feeding (bypassing the digestive process) is also 
applicable [5, 83]. Refusals against weight gain are common in these treatments; the 
nutritional therapist also provides counseling to patients. In severely underweight 
patients, feeding may cause refeeding syndrome. Although weight gain is the first 
goal, weight maintenance is the ultimate goal in the long term. Hence, nutritional 
therapy has a value in the whole treatment process.
7.2 Pharmacotherapy
Research has focused on the impact of several pharmacological agents on 
anorexia, as neurobiological factors are important in the etiology. Even so, antipsy-
chotics and antidepressants have only a limited role in treatment [85]. However, 
there is some evidence about olanzapine, an atypical antipsychotic, whose mecha-
nism of action is unclear, which is thought to block serotonin and dopamine, 
which may be effective in weight gain [86]. In addition, appetite regulators (e.g., 
dronabinol) and hormone (e.g., estrogen) drugs may contribute to both weight gain 




the desired level of benefit, and it is suggested that this may be due to decreased 
5-HT1A receptor activity, which is a consequence of starvation [88]. Nevertheless, 
almost half of the AN cases report using psychotropic medications despite lack of 
evidence supporting their efficacy, which is also concerning due to their severe side 
effects [89].
7.3 Psychotherapy
Psychotherapy is essential in anorexia treatment, and there is a range of psy-
chotherapeutic approaches. The first psychological explanations of AN came from 
psychodynamic models, although psychodynamic treatments still have only limited 
effects [66]. Family therapy is the evidence-based psychotherapy type for younger 
AN patients, and some modifications are offered for adult patients [90]. CBT is 
the first step of treatment in BN and BED, and it also works for AN to some degree 
[91]. Other approaches include third wave behavioral therapies and eye movement 
desensitization and reprocessing (EMDR) therapy, which also show limited evi-
dence of success in treatment.
7.3.1 Family-based approaches
Family dynamics are an important factor in the etiology of AN. The first studies 
in this area suggested family characteristics such as overinvolvement or inability 
to solve conflicts; however, family-based approaches put families as part of the 
solution, not the source of the problem. These approaches originated from the 
Maudsley Hospital in London and focused on the family system as a whole. Several 
randomized control trials proved the efficacy of family-based treatments in adoles-
cents with AN [92]. At a basic level, this kind of therapy analyzes predisposing and 
maintaining family dynamics of anorexia and then plans the treatment procedure 
accordingly. A three-step treatment plan is conducted that is almost a yearlong [93]. 
The first level focuses on families’ parenting skills and whether decisions related to 
eating are under family control. They learn how to help their child to gain weight. 
The aim of the second level is to empower patients to gain control over their eating 
behaviors when they reach the normal weight range. Finally, the last level focuses 
on individualization and developing healthy social relations both between parent 
and child but also in peer relations too. Behavior change is central to this model. A 
family-based approach is also proposed for adult patients. The Maudsley Model of 
Anorexia Nervosa Treatment for Adults (MANTRA) involves caregivers in both 
formulation and administration during the treatment process [94]. This motiva-
tional and client-oriented cognitive interpersonal model is developed specifically 
for AN patients. It focuses on eating related problems and symptoms but also 
obsessive and anxious-avoidant personality traits that are central to the mainte-
nance of AN.
7.3.2 Cognitive behavioral therapy
Cognitive behavioral therapy is the leading empirically supported treatment for 
BN and BED, but also there is evidence of its effectiveness in AN [83]. Enhanced 
CBT (CBT-E) is based on the transdiagnostic theory and is designed to treat eating 
psychopathology rather than being a DSM eating disorders diagnosis [6]. The word 
“enhanced” refers to new strategies and procedures to improve treatment outcomes 
and test the model in different groups (e.g., in patients, day-patients, adults, 
adolescents, etc.). CBT-E can also be conducted in a multistep approach (outpatient, 
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intensive outpatient, and inpatient) by a multidisciplinary team according to the 
patient’s needs. This intervention focuses on understanding the eating disorder 
mindset and its function. It is assumed that a change in the ED mindset will lead 
to symptom reduction. A standard CBT-E is a four-stage model. The first stage 
of treatment is aimed at creating a therapeutic alliance with assessment and case 
formulation. Regulation of eating behavior is the primary goal of this stage, through 
behavioral change. Patients are required to use self-monitoring sheets regarding 
their eating, and every session starts with a review of these records and in ses-
sion weighing. The second stage (traditional CBT does not have this stage) is an 
overview and determination stage for possible barriers to change. Preoccupation 
with food and body is the main theme of the third stage. In addition, interpersonal 
problems, body checking behaviors, emotion regulation, ED mindset, and other 
individual factors related to the symptoms are central areas to work on. The last 
stage is focused on symptom prevention and possible future problems. Many cogni-
tive and behavioral techniques including cognitive restructuring, exposure, and 
problem-solving training are used during this therapy.
Research indicates promising results regarding the efficacy of CBT-based inter-
ventions [95], especially on symptom prevention [91]. Thus, it is concluded that 
CBT-E is a cost-effective alternative to family-based treatments of anorexia [96].
7.3.3 Other psychotherapy approaches
Benefits of family-based interventions for adolescents are evident, and these 
approaches and CBT also work for adult cases to some degree although not for 
all. For these reasons the effect of different psychotherapies has gained attention. 
Research points to the effectiveness of psychodynamic therapy [97], third wave 
therapies (schema therapy, acceptance-commitment therapy, mindfulness-based 
interventions) [98], dialectical behavioral therapy [99], and EMDR [100], but no 
specific approach has shown clear superiority. Adding motivational techniques are 
also helpful [101], as deficits in treatment motivation are common among patients 
with AN. These findings suggest that a combination of nutritional therapy and 
anorexia nervosa-specific psychotherapy is an effective way to treat AN.
8. Prevention strategies
As mentioned above, AN is difficult to treat, as treatment might take a long time 
with high costs and may still not be possible in some cases. This has highlighted 
the importance of preventive studies. Prevention of EDs in general rather than 
AN-specific prevention is more common in research, since interchange between 
diagnoses and subthreshold EDs is more prevalent. Prevention strategies mainly 
work on two dimensions: first by reducing risk factors and second by targeting 
at-risk populations. Risk factors include thin idealization as a sociocultural element; 
dieting or excessive exercise as behavioral risk factors; and perfectionism, body 
dissatisfaction, and problems in emotion regulation as cognitive-emotional risk 
factors. These are more prevalent in high school and college samples as they consti-
tute risky populations. Prevention programs can be school-based, computer-based, 
CBT-focused, media-literacy-focused, or on a sociopolitical level. A review of the 
details and effectiveness of these programs is beyond the scope of this chapter. 
However, longitudinal, structured programs have proven beneficial in reducing 
body dissatisfaction, disordered eating, and weight management behaviors [102]. 
Thus, adding preventive strategies to education and health systems can be a promis-
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9. Conclusion
Anorexia nervosa is a complex psychiatric condition that is accompanied with a 
high morbidity and mortality risk. It is a rare problem and detection of cases with 
anorexia is hard as clinical presentation may vary; also voluntary admission to 
treatment facilities is low. Biological, psychological, and social factors intertwine 
in the etiology. Recent studies provide evidence of advances in understanding the 
psychobiological mechanisms that contribute to and maintain anorexia nervosa. 
Predisposing factors include genetic susceptibility and stressful early childhood 
experiences. On the other hand, psychological and social factors usually play a trig-
gering role in the onset of symptoms. They also maintain the problem with changes 
in neural networks. Treatment of anorexia is a long and challenging process for 
patients, caregivers, and health professionals. Symptoms can become chronic when 
the necessary treatment is not provided. Even with the best treatment options, a full 
recovery is not possible in all cases. A multidimensional treatment provided by a 
multidisciplinary team in a specialized unit is fundamental for efficient treatment 
outcomes. Inpatient treatment can be required in severe cases. Nutritional therapy 
is an important part of treatment. Psychopharmacotherapy, on the other hand, 
has only a limited effect. Thus, psychotherapy is the leading factor in treatment. 
Evidence-based research indicates that adolescent patients with anorexia nervosa 
benefit from family-based interventions. Adults with anorexia nervosa have a good 
chance of achieving recovery or at least a substantial improvement in symptoms. 
CBT is an alternative to family-based interventions. Alongside these, a range of 
other anorexia-specific psychotherapy approaches is presented, although none 
of them has shown a clear superiority so far. This brings us to the importance of 
preventive studies regarding unhealthy eating and weight management behaviors. 
Future research will continue to focus on enhancing our understanding of the 
underlying biopsychosocial factors, in order to improve treatment and prevention.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Future research will continue to focus on enhancing our understanding of the 
underlying biopsychosocial factors, in order to improve treatment and prevention.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Diagnostic Methods in Childhood 
Obesity
Leonardo de Souza Piber, Patrícia Colombo-Souza  
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Abstract
Childhood obesity, the most frequent pediatric disease, a worldwide public 
health problem, is considered a global epidemic and the main risk factor for obesity 
in adulthood. Among its consequences, cardiovascular and metabolic diseases stand 
out, which can be diagnosed during childhood, potentiate morbidity and mortality 
throughout life. Anthropometry, which includes the analysis of body mass index 
and the measurement of waist circumference, has proven efficacy in pediatric 
clinical evaluation. However, these diagnostic methods do not differentiate between 
subcutaneous and intra-abdominal or visceral fat. In this sense, diagnostic imaging 
methods complement the assessment of abdominal fat. In children, ultrasography 
appears as an innocuous, reproducible, and reliable diagnostic imaging method. 
The importance of knowing diagnostic methods for better monitoring of childhood 
obesity is emphasized.
Keywords: pediatric obesity, anthropometry, subcutaneous fat, intra-abdominal fat, 
ultrasonography, diagnostic methods, diagnostic imaging
1. Introduction
Obesity can be defined in a simplified way as a clinical condition in which 
there is an excessive accumulation of body fat, in the form of adipose tissue, 
and not just excess weight [1], as a consequence of a positive energy balance [2], 
capable of causing damage to the health of individuals [3], leading to reduced 
life expectancy [4]. It is known that the etiology of obesity is multifactorial, with 
both environmental and genetic aspects being involved in its genesis [3, 5].
It is believed that the determinants of excess weight make up a complex set of 
biological, behavioral, and environmental factors that interrelate and potentiate 
each other [2, 3].
Childhood is a phase of intense and rapid growth and physical, psychological, and 
social development, which causes an increase in nutritional needs. The advances in 
modern life have caused changes in the lifestyle of families around the world, causing 
these nutritional needs to be inadequately met, through the consumption of high-cal-
orie diets, fats, voracious food, exchanging meals for quick snacks. These factors are 
linked to physical inactivity, the result of changes in children’s games, which currently 
focus on video games and the excessive use of computers and television [6, 7].
The aforementioned aspects corroborate the increase in the prevalence of 
childhood obesity, a chronic disease characterized by increased body fat and 
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Abstract
Childhood obesity, the most frequent pediatric disease, a worldwide public 
health problem, is considered a global epidemic and the main risk factor for obesity 
in adulthood. Among its consequences, cardiovascular and metabolic diseases stand 
out, which can be diagnosed during childhood, potentiate morbidity and mortality 
throughout life. Anthropometry, which includes the analysis of body mass index 
and the measurement of waist circumference, has proven efficacy in pediatric 
clinical evaluation. However, these diagnostic methods do not differentiate between 
subcutaneous and intra-abdominal or visceral fat. In this sense, diagnostic imaging 
methods complement the assessment of abdominal fat. In children, ultrasography 
appears as an innocuous, reproducible, and reliable diagnostic imaging method. 
The importance of knowing diagnostic methods for better monitoring of childhood 
obesity is emphasized.
Keywords: pediatric obesity, anthropometry, subcutaneous fat, intra-abdominal fat, 
ultrasonography, diagnostic methods, diagnostic imaging
1. Introduction
Obesity can be defined in a simplified way as a clinical condition in which 
there is an excessive accumulation of body fat, in the form of adipose tissue, 
and not just excess weight [1], as a consequence of a positive energy balance [2], 
capable of causing damage to the health of individuals [3], leading to reduced 
life expectancy [4]. It is known that the etiology of obesity is multifactorial, with 
both environmental and genetic aspects being involved in its genesis [3, 5].
It is believed that the determinants of excess weight make up a complex set of 
biological, behavioral, and environmental factors that interrelate and potentiate 
each other [2, 3].
Childhood is a phase of intense and rapid growth and physical, psychological, and 
social development, which causes an increase in nutritional needs. The advances in 
modern life have caused changes in the lifestyle of families around the world, causing 
these nutritional needs to be inadequately met, through the consumption of high-cal-
orie diets, fats, voracious food, exchanging meals for quick snacks. These factors are 
linked to physical inactivity, the result of changes in children’s games, which currently 
focus on video games and the excessive use of computers and television [6, 7].
The aforementioned aspects corroborate the increase in the prevalence of 
childhood obesity, a chronic disease characterized by increased body fat and 
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influenced by genetic factors that, combined with environmental factors, make it 
difficult to maintain a healthy weight [6].
Childhood obesity, the most frequent pediatric disease [1] has also become a 
major public health problem in recent decades, being considered a global epidemic 
by the World Health Organization (WHO) [8–10], and the main risk factor for 
obesity in adulthood [1, 2, 10, 11].
Between 1980 and 1994, the proportion of children and adolescents considered 
obese increased 100% in the United States of America (USA). It is estimated that 
15.3% of American children, aged between 6 and 11 years, suffer from obesity. The 
high prevalence of obesity has also been observed in populations in developing 
countries and with low socioeconomic status [12].
In Europe, in the last 10 years, this disease has grown around 10–40% in 
most countries [10, 12]. A study of 9-year-old Irish children found 19.3% to be 
 overweight and 6.6% to be obese. Of children with parents of normal weight, 
14.4% were overweight or obese, while 46.2% of children with obese parents were 
 overweight or obese [9].
Parental obesity is well established as an important risk factor for childhood 
obesity [2]. Having an overweight father doubles the risk of childhood obesity, 
while obesity between the two parents further increases the risk. The relationship 
between the weight of the father and the son is complex, as it is a consequence of 
shared genetic and environmental factors [9].
Brazilian data on the prevalence of overweight and obesity in children aged 
12–59 months; of these, 14.7% were overweight and 4.1% were obese [13, 14]. These 
results, both in relation to overweight and in relation to obesity, placed Brazil as 
the fourth most prevalent country when compared to 12 other countries in Latin 
America and with the data of Mexican children residing in the United States of 
North America [14].
In Brazil, there was an important increase in the number of overweight children 
in the country, mainly in the age group between 5 and 9 years. The number of 
overweight boys more than doubled between 1989 and 2009, from 15 to 34.8%, 
respectively. The number of obese people increased by more than 300% in this 
same age group, going from 4.1% in 1989 to 16.6% in 2008–2009. Among girls, this 
variation was even greater (from 2.4 to 11.8%) [15]. Obesity affects about 30% of 
children, mainly in middle- and high-income families [10].
Excess weight can cause serious health problems for children and adolescents due 
to the increased risk of cardiovascular diseases [16], dyslipidemia, glucose intolerance, 
diabetes, systemic arterial hypertension [17], respiratory diseases (obstructive air-
ways, such as asthma and sleep apnea), orthopedic and postural disorders, dermatitis 
and some types of neoplasms; or even to become obese adults with a greater propen-
sity to develop such pathologies [10, 12, 18, 19]. In addition to disorders in the emo-
tional sphere [3] and non-alcoholic fatty liver disease (NAFLD) [7, 8, 10, 11, 20–22].
The growing trend in childhood obesity is related to the increase in the diagnosis 
of systemic arterial hypertension in children [6, 17, 23] and atherosclerosis in young 
people [24]. Metabolic changes resulting from obesity also increase the risk of 
developing hepatic steatosis [25], which has been proposed as one of the compo-
nents or the hepatic manifestation of the metabolic syndrome [12]. Hepatic steatosis 
(HE) has an overall prevalence of 2.6% in children, ranging from 23 to 53% in obese 
children [10, 25].
NAFLD in childhood reduces life expectancy as it can progress to severe liver 
dysfunction [11, 22]. It is important to understand the natural history of HE not 
only because of the risk of progression of liver disease, but also because of the 
potential association with other pathologies such as type 2 diabetes mellitus and 
cardiovascular diseases [25].
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Metabolic syndrome (MS), a group of disorders that includes obesity, insulin 
resistance, dyslipidemia, and hypertension, has been gaining importance due to 
its association with the subsequent development of cardiovascular disease and 
type 2 diabetes. The extent of coronary atherosclerosis in children and young 
adults increases considerably with the increasing number of multiple risk  
factors [17].
There is evidence that the atherosclerotic process starts in childhood [21], 
progresses with age and exhibits severity directly proportional to the number of 
risk factors presented by the individual. That is why it is believed that the primary 
prevention of cardiovascular diseases should begin in childhood, mainly through 
the process of education for the promotion of cardiovascular health with an empha-
sis on the importance of diet and the maintenance of a regular practice of physical 
activity for life [17, 26].
Pediatricians’ attention to the consequences of obesity in childhood and ado-
lescence probably started because of the significant increase in its prevalence in 
developed and developing countries [12]. In view of the increase in the frequency of 
overweight and obesity among children and adolescents, the diagnosis of nutri-
tional status must be part of the routine medical evaluation [11, 15].
2. Visceral fat
Excess body fat (mainly visceral fat) has been associated with increased mortality, 
as there has been an increase in obesity prevalence rates [14]. It is assumed that vis-
ceral obesity is a risk factor for cardiovascular morbidity and mortality [27], regardless 
of the associated dyslipidemia, hypertension, and diabetes mellitus [28].
Since then, the relationship between subcutaneous, gluteal-femoral, and visceral 
fat with the action of insulin has been extensively studied and, today, it can be 
said that at least the association of visceral fat with the components of MS is well 
established [29].
It has been shown that the accumulation of visceral fat is related to the develop-
ment of steatohepatitis and that this accumulation continuously influences the 
histological changes in NAFLD, from the beginning of the deposition of fat in the 
hepatocytes to the appearance of inflammatory changes [29, 30].
Both steatosis and abdominal visceral fat are independent correlates of cardio-
metabolic risk, but the associations are stronger between visceral fat and steatosis 
[29]. Currently, the type of fat distribution in the body, especially the accumula-
tion of intra-abdominal fat (IAF), is considered the most important factor in the 
associations between these clinical entities [20].
Evidence suggests the importance of measuring abdominal obesity, in addition 
to general obesity, to assess health risks in the first decades of life [18].
Obesity, usually assessed by anthropometric measurements, has idiosyncra-
sies that are beyond common sense. For example, individuals with a low body 
mass index may have a high incidence of typical MS changes. Then, attention is 
drawn to the fact that it would not be the excess of total body fat but the distri-
bution of that fat that would be related to insulin resistance and, consequently, 
to MS [29].
Over the years, research has shown that weight gain alone is less relevant than 
the distribution of body fat in determining metabolic changes [28]. Central obesity, 
characterized by the accumulation of fat in the trunk and abdomen, has visceral 
abdominal fat (VAF) as one of its components, whose thickness measurement is 
of great importance, as it is an indicator of cardiovascular risk due to metabolic 
changes resulting from this fat deposit [30, 31].
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Visceral fat can be assessed by measuring waist circumference or by means of 
imaging tests, such as computed tomography (CT), magnetic resonance imaging 
(MRI), and ultrasonography (US).
3. Assessment of nutritional status
The assessment of nutritional status aims to verify growth and body proportions 
in an individual or in a community, with a view to establishing intervention attitudes. 
Thus, the standardization of the evaluation to be used for each age group is of funda-
mental importance, thus standardizing the criteria used by the health team [32].
With regard to the identification of cases of obesity in children, an important 
issue has been discussed, that is, which is the most accurate method to classify it [6].
When defining methods for assessing the nutritional status, those which best 
detect the nutritional problem that is intended to be corrected in the study popula-
tion should be chosen. The costs for its use, the level of personal skill required to 
apply them properly, the time needed to perform them, the receptivity on the part 
of the population studied, and the possible health risks must be considered [32] .
Determining obesity is, establishing excess body fat [14]. This concern is justi-
fied by the increase in the prevalence of obesity worldwide and the potential risks 
of developing chronic diseases in adulthood [32].
Among the various methods, anthropometric diagnosis and imaging diagnosis 
stand out.
4. Assessment and diagnostic anthropometric
Anthropometry, which consists of assessing the physical dimensions and the 
global composition of the human body, has proved to be the single most used 
method for nutritional diagnosis at the population level, especially in childhood and 
adolescence, due to its ease of execution, low cost, and innocuity. Based on the pub-
lications of Jellife, edited by WHO, in the 1960s, based on studies that had started 
in the 1950s, anthropometry was systematized as a method of assessing nutritional 
status. It was from these studies that anthropometry developed rapidly in indus-
trialized countries, which only occurred in the mid-1970s in developing countries. 
Since then, anthropometry has constantly evolved, being a useful method in popu-
lation, clinical, and intervention studies, and its application has enabled advances 
in interpretations and in the search for mathematical formulations that improve 
the accuracy of body compartment estimation and its predictive power. Since 1978, 
WHO has adopted data from the National Center for Health Statistics (NCHS) as an 
international reference standard [32].
Anthropometric values represent, at the individual or population level, the 
degree of adjustment between the genetic potential for growth and the favorable 
and harmful environmental factors. The ideal anthropometric pattern, then, would 
be that obtained from populations or ethnic groups whose individuals had enjoyed 
the opportunity to fully develop their growth potential. In this sense, we use the 
statistical results obtained from populations in developed areas of the world, or in 
underdeveloped regions, from human groups of high socioeconomic standard, who 
probably had better opportunities to fulfill their genotypic growth possibilities [32].
Results from studies around the world have shown and show the possibility of 
using a single, international benchmark to assess growth and nutrition status in 
different regions. There is evidence that the growth in height and weight of healthy 
children of different ethnic origins, submitted to adequate living conditions, is 
similar up to 5 years of age [32].
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Among the almost unlimited number of possible body measurements, the 
most frequently used measures are intended to determine body mass, expressed 
by weight; linear dimensions, especially height; body composition and energy and 
protein reserves, estimated by the main superficial soft tissues: subcutaneous fat 
and muscle mass [32].
4.1 Body mass index
Anthropometry, then, even considering its limitations, has been the most widely 
used method and also the one proposed by WHO [32].
It is recommended that the weight be measured in kilograms (kg), with an 
anthropometric scale, with the child barefoot, with light clothing and in an 
orthostatic position in the center of the scale, and that the height be measured in 
centimeters (cm), using a stadiometer, to the nearest 0.1 cm, with the child bare-
foot, with the back to the wall, feet together and parallel, in an upright position and 
looking forward in the horizon line.
The body mass index (BMI) is obtained by dividing body weight, in kilos, by 
height in square meters [2]; therefore, in kg/m2 [33–35], it is an anthropometric 
measure widely used to identify excess weight in children, adolescents, and adults 
[2, 6, 27, 36].
The stratification of nutritional status is obtained from the percentiles in the 
BMI/age ratio according to gender, from WHO, and allows children to be clas-
sified as eutrophic, overweight, or obese. Obesity is diagnosed in children with 
the percentile is equal to or greater than 97 and, overweight, in children with the 
percentiles between 85 (inclusive) and 97 [33–35].
The following BMI scores for age are considered, according to the WHO [33–35], 
illustrated in Figure 1.
The values of these anthropometric data should always be analyzed according 
to the child’s age and sex, which are the main determinants of its evolution [2]. 
Although they are usual and simple procedures, they must be applied carefully, 
with standardization, and the instruments used must be calibrated frequently [32].
Obesity in children is not defined by an absolute number, but by a percentile 
[2, 37]. To establish a comparison of a set of anthropometric measurements with a 
reference standard, several scales can be used, the most common being the percen-
tile and the Z score [32].
The percentiles are derived from the distribution in ascending order of the 
values of a parameter, observed for a given age or sex; the classification of a child 
Figure 1. 
Reference values for diagnosing nutritional status using BMI curves for age. World Health Organization, 
Geneva (2000, 2006 and 2007).
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in a given percentile allows to estimate how many children, of the same age and 
sex, are greater or lesser in relation to the evaluated parameter [2, 32]. The Z score 
means, in practical terms, the number of standard deviations that the data obtained 
are removed from their reference median [32].
The WHO Classification can be used for children regardless of age. Regarding 
the assessment of childhood obesity, the following criteria can be used: weight/
height ratio equal to or greater than 120%; percentile equal to or greater than 97; or 
Z score equal to or greater than +2.0 [32].
To monitor growth, the curve (growth graph) is used in at least three successive 
measurements of weight and height, with intervals compatible with their growth 
rate according to age, allowing to assess the nutritional process. This instrument is 
extremely useful in establishing situations of nutritional risk [32].
Such curves are essential for both the diagnosis and the assessment of the 
patient’s evolution during treatment. Only by viewing the child’s graph can it be seen 
how small variations in weight and, consequently, in BMI can be significant [2].
The assessment of body composition becomes difficult in children due to its con-
stant change during growth, in addition to not knowing what percentage of body fat 
increases the risks in relation to their health. It is mainly indicated to verify changes 
presented by children undergoing treatment for obesity [32]. When interpreting the 
data obtained in nutritional assessment, sexual maturation criteria should also be 
considered, given the great individual variability in the maturation process [2, 32].
BMI validity is based on the good correlation it presents with total body fat, 
especially with the amount of internal fat. However, it does not distinguish between 
fat mass and lean mass, making it difficult to differentiate between overweight with 
excess fat and that with hypertrophy of muscle mass [32, 36]. In addition, it does 
not determine the distribution of body fat [6] and does not reflect stunting, com-
mon among children of low socioeconomic status [32].
However, its ease of measurement must be considered since it uses anthro-
pometric data of weight and height, which are easy to obtain and have good 
reproducibility [7, 32].
4.2 Waist circumference
The waist circumference (WC) defined by measuring the smallest circumfer-
ence between the iliac crest and the costal margin is, in particular, a better predic-
tor of visceral obesity, a condition that represents a high risk for the development 
of chronic noncommunicable diseases such as diabetes mellitus type 2, MS, HE, 
and cardiovascular diseases and, thus, it has been highlighted in national and 
international studies [6, 8, 38].
The use of this measure in screening and in primary health care helps in the 
early diagnosis and in the identification of those potential candidates to manifest 
such diseases in adulthood [1]. This measure is noninvasive, uses a minimum of 
equipment when compared to laboratory techniques, is fast to apply, easy to be used 
by trained evaluators, and is very affordable [38].
Waist circumference (WC) is measured in centimeters (cm), using a flex-
ible and inelastic measuring tape, with the child in an orthostatic position, at the 
midpoint between the iliac crest and the costal rim, under clothing and at the end of 
a normal exhalation.
The authors stressed the importance of measuring waist circumference as a 
mandatory part of the pediatric semiological examination [22].
The classification of WC for each child is performed according to age, sex, and 
the percentiles of McCarthy et al. [39], considering the 90th and 95th percentiles to 
identify overweight and obesity, respectively (Figure 2).
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4.3 Relationship between BMI and WC
Regarding the knowledge produced about the use of BMI or WC to assess the 
pattern of body fat, scholars of the subject in search of an answer demonstrated that 
there is a strong correlation coefficient between both measures, indicating that the 
waist circumference can determine, satisfactorily, children with high BMI [6, 7]. 
Investigations found important correlation values between BMI and WC, suggest-
ing the joint use for the diagnosis of obesity, overweight, and central obesity [6], 
including in children and adolescents [7, 8].
BMI expresses changes that may occur in the distribution of fat, but does not 
verify the pattern of body fat. Thus, correlating this measure with other anthropo-
metric measures is necessary, considering that the type of deposit of fat distribution 
is related to the health prognosis. However, WC is the measure that best represents 
the distribution of visceral fat and this, in turn, is more related to metabolic changes 
than subcutaneous fat, indicating the risk of children or adolescents to develop car-
diovascular disease in future life. In addition, the relationship of this anthropomet-
ric measure with dyslipidemia, with arterial hypertension, and with the metabolic 
syndrome is evidenced in the literature and, therefore, should support professional 
practice [6].
McCarthy et al. stated that BMI may be a less sensitive indicator of fat among 
children and does not provide any indication of fat distribution. Information about 
WC in children can be as useful as BMI in population studies [39].
WC can be adopted as an alternative or additional measure to BMI in children. It 
is a direct measure that requires simple and inexpensive equipment, with the regis-
tration of a single value. BMI requires more complex equipment and mathematical 
calculations [39].
Researchers stressed the difference between ethnic groups and the importance 
of developing specific population patterns, as visceral adiposity is highly variable in 
Figure 2. 
Parameters for classifying waist circumference between genders, adapted from McCarthy et al. [39].  
* 6 + = group of children aged 6.00–6.99 years.
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children and is related to ethnicity [39]. The relative distribution of intra-abdom-
inal tissue in relation to the subcutaneous abdominal region is significantly less in 
African American children than in whites [40].
For the same BMI, there may be individuals with more or less cardiovascular and 
metabolic risk, depending on the amount of intra-abdominal fat, which is also true 
for children [41]. It was shown that 23.4% of eutrophic children by BMI had high 
waist circumference [7].
4.4 Other anthropometric measurements
The waist-hip ratio and sagittal diameter are methods that indirectly deter-
mine visceral fat [28], predicting cardiovascular risk [38]. These anthropometric 
measures are methods used to assess body adiposity; however, they are unable to 
differentiate visceral from subcutaneous fat and have relatively high intra- and 
inter-examiner variability [29].
The assessment of adiposity through skinfold measurements is poorly reproduc-
ible and its usefulness in clinical practice is limited [15].
5. Diagnosis by imaging exams
Imaging exams are the methods of choice to assess and quantify visceral fat, 
since anthropometric measurements are unable to differentiate intra-abdominal 
from subcutaneous fat, as they are indirect measures [2, 29].
Dual-energy X-ray absorptiometry (DXA), a “scanning” technique considered to 
be reliable, whose mechanism occurs through two X-ray beams that cross the body, 
is used for the evaluation of the total and regional body composition of lean mass, 
fat mass, and bone mineral density. However, in the case of children, although it is a 
reference method, radiation exposure and high cost must be considered [6, 36].
Studies that concluded that anthropometric measurements have a strong cor-
relation with the fat distribution indicated by DXA [6, 42] stand out. DXA estimates 
abdominal adiposity, but does not specifically quantify intra-abdominal fat [43].
Computed tomography (CT) is the gold standard method for the determination 
of visceral abdominal fat (VAF), due to its ability to differentiate between subcu-
taneous and visceral adiposity [44]. CT has the advantage of not depending on the 
operator’s ability to identify structures during the examination and not be influ-
enced by ultrasound transducer pressure on the abdomen during measurements. 
However, CT is an expensive method and submits patients to ionizing radiation, 
which limits its use mainly in epidemiological studies [31, 44].
Full-body CT measurements are accompanied by high radiation exposure and; 
therefore, they are not recommended for scientific purposes in healthy individuals. 
Thus, CT had to be restricted to some characteristic slices in most studies [36].
Magnetic resonance imaging (MRI) has also developed criteria for assessing vis-
ceral fat, with good accuracy [29, 44]; it is a method with which it is possible to assess 
the distribution of adipose tissue in children [10]. This test has the advantage of not 
emitting ionizing radiation [36] and the ability to quantify the fraction of fat [10]; 
however, it is more subject to artifacts than CT [29]. In addition, due to the high cost, 
greater need for sedation, and its limitation in claustrophobic patients, MRI has not 
been used routinely [10]. Among the limitations of the method for young children, 
there is the need to remain completely immobile during image capture [45].
Ultrasonography, in recent years, has been proposed as a noninvasive technique 
for the assessment of intra-abdominal fat [43], as it is a useful method for the 
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determination of visceral adipose tissue [28, 44]. The possibility of measuring 
visceral fat attributes to US an important role in the assessment of MS [29].
In contrast to the disadvantages of CT, MRI, and anthropometric measurements, 
US has been establishing a simple, low-cost method, without radiation risk [29], 
free of side effects [10], with reproducibility and reliability already proven in the 
quantification of visceral fat [29], despite the need for specific equipment and well-
trained observers, which can be repeated when necessary [28] and on a large scale, 
such as population screening [10].
Ultrasonography appears as one of the methods of diagnosis and character-
ization of abdominal fat, allowing the correlation of its findings with data from 
anthropometric physical examination in all age groups, being of great value in the 
evolutionary monitoring of obesity treatments.
In addition to measuring abdominal fat thickness, the method assesses the pres-
ence of liver fat. While some authors describe a sensitivity of ultrasonography in 
mode B for the detection of hepatic steatosis of just over 60%, other authors report 
a sensitivity of up to 90% [36].
Among its advantages, the ability to differentiate accumulation of intraperi-
toneal, pre-peritoneal, and subcutaneous fats, in addition to the safety of the 
examination, practicality, and speed, especially in the evaluation of the pediatric 
population, stands out.
US in children to measure pre-peritoneal fat and intra-peritoneal fat is a valid 
method for epidemiological and clinical studies [20, 46]. Statistical significance 
was observed between the thickness of intra-abdominal fat and subcutaneous tissue 
in relation to obesity in children [20]. US can be useful in measuring intraperitoneal 
fat in children and adolescents [20, 47]. The thickness of the subcutaneous fat 
showed no statistically significant difference between the sexes, between the age 
groups and in relation to the presence or not of steatosis. However, US can be used 
as a treatment control in individual cases [29].
The ultrasound technique consists of measuring the thickness of the subcutane-
ous and visceral abdominal fat, separately, using a transducer placed 1 cm (cm) 
above the umbilical scar. The thickness of the visceral adipose tissue obtained with 
this technique has a good correlation with the area of  that same tissue quantified by 
computed tomography [29].
The knowledge acquired can be useful to employ a new method of assessing 
visceral fat and also to seek ultrasound parameters that change with the increase 
in BMI [20].
The techniques must be accurate and suitable for use both at the cross-sectional 
level (i.e., a single measure) and for monitoring the effects of interventions (behav-
ioral, pharmacological, and surgical) aimed at promoting a healthy life [45].
6. Conclusions
Considering that the first signs and symptoms of obesity and its consequences 
can be determined in childhood, it becomes evident the importance of assessing 
subcutaneous and visceral fats in children, a population in which obesity may still 
be the only morbidity.
The pediatric detection and control of intra-abdominal obesity are important 
because it is associated with the metabolic syndrome in childhood, adolescence, and 
adulthood, and its progression can increase rates of morbidity and mortality due to 
cardiovascular disease among young adults.
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Therefore, this population should be the target of prevention policies and 
programs, early diagnosis, and medical-nutritional monitoring, aiming to identify 
the risks of these pathologies and their health consequences.
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Obesity: A Risk Factor for 
Infection after Surgery
José Alonso Suclla-Velásquez and Connie Smedts
Abstract
Obesity is a prevalent health problem all over the world. It is associated with 
several diseases including infections. It impairs the immune system function by 
plenty of mechanisms. For instance, leptin and adiponectin are cytokines produced 
by the adipose tissue, both participating in immunity, but their effects are impaired 
in obese patients. Moreover, immune cells also show defects in their functions. They 
produce a pro-inflammatory state and contribute to obesity-related diseases. Innate 
immune system and adaptive immunity are both impaired in obese patients which 
causes a poor response to infections. In addition, in surgical site infections (SSI), 
there are local factors that must be considered. The large adipose panicle and vis-
ceral adipose tissue increase the surgical technique difficulty and extend the opera-
tive time. Besides, the adipose tissue has poor oxygenation and reduces operative 
field. It has been proven that obesity is associated to surgical site infection irrespec-
tive of type of surgery. However, minimal invasive surgery has demonstrated that 
reducing surgical trauma can diminish the risk for surgical site infection.
Keywords: obesity, surgery, surgical site infection, immune deficiency,  
surgical complication
1. Introduction
Nowadays, obesity is a serious health problem which affects all countries 
irrespective of economic status. It is produced by an energy imbalance, and then 
there is an increase in body-fat mass. A body mass index (BMI) more than 30 kg/m2 
is defined as obesity [1].
There are plenty of diseases that are linked to obesity; the most common are 
metabolic syndrome, type 2 diabetes mellitus, coronary disease, and hyperlipid-
emia. Despite not being as well-known as the previous examples, obesity is strongly 
associated with infection [2].
Obese patients have a higher risk of nosocomial infections because medical care 
of these patients requires special procedures, equipment, and staff. Moreover, obese 
patients are usually immobilized which is a risk factor for decubitus ulcers and 
contributes to increase length of stay [3].
Although there are some controversial studies, an association between caries 
rates and elevated BMI has been proven. Dietary habits characterized by high 
consumption of soft drinks, fast food, and refined sugar contribute to dental caries 
as well as obesity [4]. In addition, it is well-known that severe infections in the face 
and neck usually have an odontogenic origin and obesity is a risk factor for the 
infection progression. Besides, an association has been described between the levels 
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of tumor necrosis factor alpha in gingival crevicular fluid and BMI [5]; therefore, 
there is a systemic effect of obesity in oral health.
Obesity is related to respiratory diseases including nosocomial pneumonia and 
community-acquired respiratory tract infections [3]. In these patients, a decreased 
lung volume and a restrictive ventilatory pattern have been noticed. Excess weight 
on the anterior chest wall, abdominal obesity, and the presence of the adipose tissue 
in the intra-abdominal visceral tissue increase muscle work in breathing, diminish 
lung expansion, and increase airway resistance. These mechanical changes and aug-
mented adipose tissue produce an inflammatory state that contributes to metabolic 
disease [6]. Other respiratory diseases associated to obesity are obstructive sleep 
apnea, chronic obstructive pulmonary disease, and asthma [6, 7].
On the other hand, obesity is a risk factor for the development of steatosis 
in patients with chronic hepatitis C infection and biliary disease with infectious 
complications [3]. Skin and soft tissue infections are also more prevalent in obese 
patients [2, 3]. The adipose tissue affects the pharmacokinetics and pharmacody-
namics of antibiotics. Therefore, some special considerations must be taken when 
treating an obese patient [8, 9].
Even though there are some important studies that demonstrate obesity is not 
a risk factor for surgical complications [10], there are still some evidence that 
contrast with these researches [11]. On the other side, it is well-known that obese 
patients have a higher risk for surgical site infections (SSI) particularly when 
open surgery is performed. This phenomenon has been associated to low oxygen 
tension in the adipose tissue as well as a poor immune response observed in obese 
patients [3, 10, 11].
In this chapter we will review the available evidence about obesity as a risk factor 
for surgical infections in most common surgical procedures, considering patho-
physiology as well as relevant clinical information.
2. Pathophysiology of infection in obese patients
There are several mechanisms that cause immune dysfunction in obese patients. 
The adipose tissue produces some cytokines which have effects on immune cells. There 
are other mechanisms that explain the altered immune response in obese patients.
2.1 Leptin and adiponectin
Nowadays, it is well-known that the adipose tissue has an active role in immunity 
by producing factors like leptin and adiponectin [3].
Leptin influences hematopoiesis, angiogenesis, and immune homeostasis. It 
stimulates proliferation and activation of monocytes in vitro and also increases 
the expression of surface markers. Leptin affects maturation of dendritic cells; 
deficiency of this cytokine is related to lower levels of tumor necrosis factor alpha 
and interleukins 12 and 6. It prevents neutrophil apoptosis and stimulates their 
chemotaxes. Leptin affects immune function of natural killer (NK) cells and T cells. 
It promotes T-cell proliferation, cytokine secretion, and migration of these cells. 
Th1-cell immune response is also stimulated by leptin. In addition, B lymphocytes 
are affected by leptin. It controls their development and can augment their popula-
tion by suppressing apoptosis and stimulating proliferation of these cells [12–14]. 
Leptin also plays a role in wound healing. An experimental study has proved that 
leptin accelerates skin wound healing by increasing proliferation and differentiation 
of epidermal keratinocytes as well as promoting angiogenesis [15].
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Congenital leptin deficiency is rare in humans. Diet-induced obesity is related 
to high levels of circulating leptin; however, it has been hypothesized that obesity 
causes some resistance in leptin receptors similar to what happens with insulin 
resistance [16]. Therefore, in obese patients, leptin cannot produce its effect on the 
immune system despite high levels of this cytokine.
Adiponectin is another important circulating adipocytokine that plays a role in 
immunity. It has anti-angiogenic, anti-inflammatory, and anti-apoptotic effects. 
Adiponectin can inhibit the phagocytic activity of macrophages, reduce the produc-
tion of tumor necrosis factor alpha and gamma interferon, as well as induce the 
production of interleukin 10 and interleukin 1 receptor antagonists which are anti-
inflammatory molecules. However, serum/plasma levels of adiponectin are higher 
in immune-mediated diseases [17, 18]. In contrast, in obese patients, adiponectin 
levels are lower than controls, and it has been observed that production of this 
adipocytokine increases after weight loss [19].
2.2 Immune cells
Although, in diabetic patients, neutrophils show defects in their functions, in 
obese patients this phenomenon has not been noticed. Indeed, these cells seem 
to be chronically primed and contribute to the development of obesity-related 
diseases [1].
Monocytes and macrophages also take part in immune response. They can 
change their phenotype getting a pro-inflammatory form (M1 CD11c+) or an 
anti-inflammatory form (M2 CD11c-) [1]. In obesity, a pro-inflammatory state, 
adipose tissue macrophages are more prevalent, these cells have M1 phenotype and 
are considered a factor that increases sepsis mortality. In addition, the percentage of 
macrophages in the adipose tissue is directly proportional to the adipocyte size [20]. 
Current evidence suggest that overnutrition causes adipocyte hypertrophy which 
leads to hypoxia and stimulates macrophage activity [21].
Natural killer cells are lymphocytes of the innate immune system. They are 
defined as CD3-/CD56+ granular lymphocytes and can be subcategorized based on 
the level of CD56 expression. CD56dim NK cell (or low density) subset can produce 
granzymes and perforins and is more cytotoxic than CD56bright (or high density) 
subset. On the other way, CD56bright NK cells have immunoregulatory effects. In 
obesity, there is no clear consensus about the effects on peripheral NK cell num-
ber. However, there is a study that demonstrates a significant more prevalence of 
CD56bright NK cells in obese patients as well as these patients also show a decreased 
percentage of CD56dim NK cells. Therefore, the predominance of CD56bright NK 
cells could be a cause for the impaired lytic activity NK cells against virus-infected 
and tumor cells observed in obese patients [22]. Several other studies have shown 
the impact of obesity on NK cells. An increased expression of activation markers 
such as CD69 and a decreased expression of other molecules such as NKp30 and 
NKp44 have been observed. Moreover, NK cells isolated from obese patients fail 
to engage glycolytic metabolism. They also lose the ability to kill macrophages 
and augment expression of gamma interferon which stimulates the migration of 
macrophages [23].
Dendritic cells (DCs) are also affected by obesity. They can activate or sup-
press immune responses and are characterized as conventional, inflammatory, 
or plasmacytoid dendritic cells. An increase in inflammatory DCs in the adipose 
tissue has been described. These cells are created from inflammatory monocytes 
and contribute to adipose tissue inflammation. However, there is evidence suggest-
ing that conventional dendritic cells also take part in adipose tissue inflammation. 
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Congenital leptin deficiency is rare in humans. Diet-induced obesity is related 
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production of interleukin 10 and interleukin 1 receptor antagonists which are anti-
inflammatory molecules. However, serum/plasma levels of adiponectin are higher 
in immune-mediated diseases [17, 18]. In contrast, in obese patients, adiponectin 
levels are lower than controls, and it has been observed that production of this 
adipocytokine increases after weight loss [19].
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Although, in diabetic patients, neutrophils show defects in their functions, in 
obese patients this phenomenon has not been noticed. Indeed, these cells seem 
to be chronically primed and contribute to the development of obesity-related 
diseases [1].
Monocytes and macrophages also take part in immune response. They can 
change their phenotype getting a pro-inflammatory form (M1 CD11c+) or an 
anti-inflammatory form (M2 CD11c-) [1]. In obesity, a pro-inflammatory state, 
adipose tissue macrophages are more prevalent, these cells have M1 phenotype and 
are considered a factor that increases sepsis mortality. In addition, the percentage of 
macrophages in the adipose tissue is directly proportional to the adipocyte size [20]. 
Current evidence suggest that overnutrition causes adipocyte hypertrophy which 
leads to hypoxia and stimulates macrophage activity [21].
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ber. However, there is a study that demonstrates a significant more prevalence of 
CD56bright NK cells in obese patients as well as these patients also show a decreased 
percentage of CD56dim NK cells. Therefore, the predominance of CD56bright NK 
cells could be a cause for the impaired lytic activity NK cells against virus-infected 
and tumor cells observed in obese patients [22]. Several other studies have shown 
the impact of obesity on NK cells. An increased expression of activation markers 
such as CD69 and a decreased expression of other molecules such as NKp30 and 
NKp44 have been observed. Moreover, NK cells isolated from obese patients fail 
to engage glycolytic metabolism. They also lose the ability to kill macrophages 
and augment expression of gamma interferon which stimulates the migration of 
macrophages [23].
Dendritic cells (DCs) are also affected by obesity. They can activate or sup-
press immune responses and are characterized as conventional, inflammatory, 
or plasmacytoid dendritic cells. An increase in inflammatory DCs in the adipose 
tissue has been described. These cells are created from inflammatory monocytes 
and contribute to adipose tissue inflammation. However, there is evidence suggest-
ing that conventional dendritic cells also take part in adipose tissue inflammation. 
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In addition, this study points out that dendritic cells could act independently of 
monocytes [24]. On the other hand, in obesity DCs failed to upregulate CD83, a 
marker for maturity. Besides, they produce less IL-12 and more IL-10, suggesting an 
inability to stimulate T cells [25].
Adaptive immunity is impaired too. Gamma delta T cells, a subset of T cells 
that takes part in repairing tissue and inducing inflammation, are diminished 
in obese patients and secrete less gamma interferon, contributing to the per-
sistence of chronic, non-healing wounds [1, 26]. On the other side, memory T 
cells in the adipose tissue overexpress some cytokines while underexpress other 
ones. Moreover, obesity increases memory T-cell number which can be related 
to leptin production. Under healthy circumstances, memory T cells contribute 
to control infections; however, they can also mediate the pathogenesis in other 
conditions such as obesity [27]. In contrast, the number of regulatory T cells is 
reduced in the adipose tissue which promotes inflammation and insulin resis-
tance [1, 26] because these cells participate actively maintaining self-tolerance 
and suppressing activity of effector T cells. This reduction can be partially 
explained by the levels of leptin which decreases the proliferation of regula-
tory T cells [28]. Other affected T cells are Th1 and Th17 cells. The first ones are 
increased in the visceral adipose tissue of obese patients contributing to inflam-
mation, whereas Th17 cells are increased in the subcutaneous adipose tissue of 
obese patients and produce IL-17 which promotes inflammation and insulin 
resistance as well [26].
Relating to humoral immunity, there is no clear consensus. However, there is 
some evidence that it is impaired in obese patients. Obesity induces pro-inflam-
matory B cell subsets [29]. In spite of hyperstimulation of B cells and increased 
number of these, they function suboptimally and antibody production is modified. 
The most important factors that influence B-cell antibody production are leptin 
effect and essential fatty acid status [30].
3. Obesity and infection after surgery
Surgical site infection (SSI) is a serious complication that increases morbid-
ity and mortality as well as extends postoperative stay and rises healthcare costs. 
Indeed, one observational study performed in 7020 patients who underwent colon 
surgery finds an increased rate of SSI in obese patients (14.5% vs. 9.5%; p < 0.001). 
In this study SSI increases costs in $17,000 because these patients have longer stays 
and higher rates of hospital readmission [31]. This increased risk for SSI is espe-
cially noticeable in clean and clean-contaminated surgeries. In addition, a study 
described a relation between BMI and the risks for SSI, and then overweight could 
just be a risk factor for SSI in some kinds of surgery [32].
There are several mechanisms that explain this increased risk. Some of them 
have already been mentioned. However, there are other ones that are important in 
surgical site infection. The most important factor is hypoperfusion of adipose tissue 
which is due to less vascularization of adipose tissue. It causes poor tissue oxygen-
ation and extends wound healing. Moreover, there is more dead space, and antibiot-
ics might not get adequate concentrations in the wound [32, 33].
Other important factors are related to surgery. Obese patients have great adipose 
panicle which makes open surgery more difficult. In addition, the visceral abdomi-
nal tissue is also increased and obligates surgeons to take special considerations 
on the surgical technique such as longer incisions, prolonged surgery time, and 
increased mean operative blood loss [32, 33]. Both are known risk factors for surgi-
cal site infection.
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3.1 Obesity and gastrointestinal surgery
A large study performed in the Netherlands evaluated the relation between 
obesity and several types of surgery. Laparoscopic appendectomy, laparoscopic 
cholecystectomy, open colectomy, and laparoscopic colectomy were considered 
gastrointestinal surgery. The study revealed that the risk of superficial SSI gradually 
increased with increasing BMI, except in laparoscopic appendectomy. However, 
deep SSI did not seem related to BMI [32].
A meta-analysis also showed that overweight and obese patients have a 1.2- to 
1.5-fold higher odds of developing SSI after colorectal surgery. Moreover, the same 
study performed a subgroup analysis that included only elective surgery cases, and 
then the results were similar. The authors highlighted the suboptimal tissue concen-
trations of antibiotics in obese patients. It is not only related to the increased volume 
of distribution and altered plasma protein binding; indeed, obese patients have 
changes in hepatic metabolism and renal excretion, and the prevalence of diabetes 
is higher in these patients [34].
Another study performed a separate analysis for right colectomy, left colectomy, 
and rectal resection. Obesity did not affect morbidity and mortality after right col-
ectomy. However, the rate of postoperative intra-abdominal collections was higher 
in obese patients after left colectomy. Moreover, the study showed that obesity was 
a risk factor for anastomotic leakage after rectal resection. Therefore, the authors 
recommended the use of a defunctioning stoma in obese patients when diabetes or 
ASA > 2 is present [35].
On the other hand, laparoscopic surgery has brought to table other consider-
ations. A meta-analysis showed that the incidence of SSI is significantly less after 
laparoscopic surgery than after open surgery (70–80% lower risk). These find-
ings could be related to less surgical trauma and smaller incisions that are used in 
laparoscopic surgery. However, conversion to open surgery has the worst outcomes 
[36]. Despite the advantages of laparoscopic surgery, it is not always easy to perform 
it in obese patients. A meta-analysis demonstrated that visceral obesity is associ-
ated to longer operative time, less lymph node harvest, and higher conversion 
rate. Moreover, laparoscopic surgery in obese patients requires technical expertise 
because of the limited exposure of the surgical field and the thickened mesentery 
which is difficult to maneuver [37].
In obese children the problem is similar, and there is some evidence that dem-
onstrates that laparoscopy is safe in these patients, although it is related to longer 
operative time [38].
Laparoscopic surgery is safe in obese patients. However, there are some special 
considerations: adequate position to expand the surgical field avoiding pressure 
sores and minimizing nerve compression, adequate entry technique, longer opera-
tive time, and thromboprophylaxis [39].
Although there are few studies about obesity and robotic surgery, it has been sug-
gested that it could bring more benefits for obese patients. It has been observed that 
the length of stay and 30-day readmission rate were lower in patients who underwent 
robotic surgery than in patients who underwent laparoscopic surgery. It probably 
happens because of superior stable 3D views and ergonomic wristed instruments 
that robotic surgery offers [40]. However, it must be considered that robotic surgery 
is more expensive than laparoscopic surgery and requires appropriate training.
3.2 Obesity and gynecological surgery
In gynecological surgery there is some controversy. Overweight could be a 
protective factor for SSI in vaginal hysterectomy. However, there is an increased 
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rate. Moreover, laparoscopic surgery in obese patients requires technical expertise 
because of the limited exposure of the surgical field and the thickened mesentery 
which is difficult to maneuver [37].
In obese children the problem is similar, and there is some evidence that dem-
onstrates that laparoscopy is safe in these patients, although it is related to longer 
operative time [38].
Laparoscopic surgery is safe in obese patients. However, there are some special 
considerations: adequate position to expand the surgical field avoiding pressure 
sores and minimizing nerve compression, adequate entry technique, longer opera-
tive time, and thromboprophylaxis [39].
Although there are few studies about obesity and robotic surgery, it has been sug-
gested that it could bring more benefits for obese patients. It has been observed that 
the length of stay and 30-day readmission rate were lower in patients who underwent 
robotic surgery than in patients who underwent laparoscopic surgery. It probably 
happens because of superior stable 3D views and ergonomic wristed instruments 
that robotic surgery offers [40]. However, it must be considered that robotic surgery 
is more expensive than laparoscopic surgery and requires appropriate training.
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In gynecological surgery there is some controversy. Overweight could be a 
protective factor for SSI in vaginal hysterectomy. However, there is an increased 
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risk for deep SSI in morbidly obese patients [32]. In abdominal hysterectomy, the 
findings are similar, and the risk for SSI increases linearly with increasing BMI. The 
same study showed a nonsignificant prevalence of Enterobacteriaceae in obese or 
overweight patients with SSI after abdominal hysterectomy [33].
A large study that included 18,810 patients who underwent hysterectomy for 
benign indications demonstrated that the risk for superficial and deep wound infec-
tion was higher with increasing BMI after total abdominal hysterectomy. However, 
the risk was not different when minimally invasive surgery (total vaginal hysterec-
tomy, laparoscopic assisted vaginal hysterectomy, total laparoscopic hysterectomy) 
was performed. In contrast, the operative time was longer with increasing BMI 
irrespective of the surgical approach [41].
Obesity is a risk factor for leiomyomata, ovulatory dysfunction, and endometrial 
cancer. All of them are common indications for hysterectomy. Therefore, hyster-
ectomy is a common surgical procedure performed in obese women. In that way, it 
is recommended to prefer a minimal invasive approach because of its reduced rate 
of complications. Other aspects to be considered are adequate thromboembolism 
prophylaxis, antibiotic prophylaxis, and adequate surgical technique [42].
In cesarean section, maternal obesity is also associated with surgical and postop-
erative risks such as endometritis, intra-abdominal collection, and surgical wound 
complications. In that way, antibiotic prophylaxis in these patients is different, and 
the actual recommendation is to administer at least 2 g of cefazolin some 60 min-
utes before the cesarean section. Another recommendation is to close the subcuta-
neous tissue layer in obese patients particularly when its depth exceeds 2 cm [43].
Finally, for mastectomy and lumpectomy, it has been observed that the risk of 
developing SSI augmented with increasing BMI. Moreover, obesity is a risk factor 
for major and minor complications after mastectomy irrespective of being unilat-
eral or performing reconstruction [44].
3.3 Obesity and orthopedic surgery
Obesity is an important risk factor for SSI after total hip prosthesis. It has been 
observed that the rate of SSI increased gradually with increasing BMI. Moreover, 
this association was present in both superficial and deep SSI. However, in partial 
hip prosthesis, obesity was related to superficial and deep SSI, but overweight only 
was a risk factor for deep SSI [32]. Another study had similar findings. It showed 
that members of the Enterobacteriaceae were more common among normal-weight 
patients with hip replacement [33].
On the other hand, among the total knee replacement patients, obesity was a risk 
factor for deep SSI but not for superficial SSI. Indeed, only a BMI > 40 was a risk 
factor for superficial SSI [32].
A meta-analysis also demonstrated that the risk of periprosthetic joint infec-
tion in obese patients was 1.9-fold higher than non-obese patients. The authors 
mentioned that this increased risk could be related to prolonged operative time, 
an increased rate of wound complications, and the presence of medical comor-
bidities [45].
Finally, a large study that included 161,785 patients showed that obesity was 
associated to higher rates of complications after total hip arthroplasty than after 
total knee arthroplasty. The study demonstrated that among the obese and mor-
bidly obese patients who underwent primary total hip replacement, the risk of total 
complications, wound complications, deep infection, and reoperation was higher 
than for similar weighted patients who underwent primary total knee arthroplasty. 
This observed difference would be due to the tendency of the adipose tissue to 
deposit in the gluteal region [46].
109
Obesity: A Risk Factor for Infection after Surgery
DOI: http://dx.doi.org/10.5772/intechopen.91216
3.4 Obesity and cardiothoracic surgery
Among the patients who undergo cardiothoracic surgery, obesity is a risk factor 
for SSI. Several studies have shown that the risk for SSI augmented gradually with 
increasing BMI [32, 33]. In cardiac surgery, however, an obesity paradox has been 
described. It means that mildly obese or overweight patients may have some benefit 
instead of an increased risk. Indeed, a large study that included 4740 patients who 
underwent cardiac surgery demonstrated that extremely obese (BMI > 40 kg/m2) 
patients had an increased risk for deep sternal infection, prolonged ventilation after 
cardiac surgery, and postoperative renal dialysis requirement. In contrast, mildly 
obese or overweight patients had minor in-hospital mortality, minor operative mor-
tality, and less ICU hours [47]. Another study showed that obesity and underweight 
were both associated to postoperative adverse events. However, this study did not 
show differences between extremely and mildly obese patients probably because 
both studies used different ways to categorize BMI [48].
3.5 Obesity and neurosurgery
A large study performed in the Netherlands failed to demonstrate an associa-
tion between obesity and surgical site infection after laminectomy [32]. However, 
another study which included 31,763 patients demonstrated that complications 
after lumbar spine surgery were associated to obesity. The stratification by BMI 
established five categories: underweight (BMI < 18.5), normal-overweight (BMI 
20.0–29.9), obesity class I (BMI 30.0–34.9), obesity class II (35.0–39.9). and obesity 
class III (BMI > 40). The study evaluated airway, cardiopulmonary, and infectious 
complications. They found that obese class I was associated to 4 of the 11 complica-
tions analyzed; obesity class II was associated to 6 of the 11 complications analyzed; 
and obesity class III was associated to 9 of the 11 complications analyzed. In addi-
tion, the rate of surgical site infection increased with increasing obesity class [49].
The effect of obesity on cranial surgery is similar to spinal surgery, but the 
impact on surgical outcomes is lower on cranial surgery. It increases the risk of 
major medical complications and may increase the risk for SSI after craniotomy. On 
the other side, in spinal surgery, obesity increases the risk of SSI, venous thrombo-
embolism, and major medical complications [50].
4. Conclusion
Although obesity leads to a pro-inflammatory state, it impairs the immune system 
and is a risk factor for several infections. Moreover, in surgical site infection, there are 
local factors related to obesity that must be taken into account: a large adipose panicle 
with poor oxygenation, a reduced operative field, difficulties in technique, and 
increased operative time. Therefore, obesity is a proven risk factor for surgical site 
infection in plenty of surgeries. However, there are some actions that we could take 
to reduce this risk: performing minimal invasive surgery, ensuring adequate surgical 
technique, prescribing adequate antibiotic doses, and recommending weight loss.
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risk for deep SSI in morbidly obese patients [32]. In abdominal hysterectomy, the 
findings are similar, and the risk for SSI increases linearly with increasing BMI. The 
same study showed a nonsignificant prevalence of Enterobacteriaceae in obese or 
overweight patients with SSI after abdominal hysterectomy [33].
A large study that included 18,810 patients who underwent hysterectomy for 
benign indications demonstrated that the risk for superficial and deep wound infec-
tion was higher with increasing BMI after total abdominal hysterectomy. However, 
the risk was not different when minimally invasive surgery (total vaginal hysterec-
tomy, laparoscopic assisted vaginal hysterectomy, total laparoscopic hysterectomy) 
was performed. In contrast, the operative time was longer with increasing BMI 
irrespective of the surgical approach [41].
Obesity is a risk factor for leiomyomata, ovulatory dysfunction, and endometrial 
cancer. All of them are common indications for hysterectomy. Therefore, hyster-
ectomy is a common surgical procedure performed in obese women. In that way, it 
is recommended to prefer a minimal invasive approach because of its reduced rate 
of complications. Other aspects to be considered are adequate thromboembolism 
prophylaxis, antibiotic prophylaxis, and adequate surgical technique [42].
In cesarean section, maternal obesity is also associated with surgical and postop-
erative risks such as endometritis, intra-abdominal collection, and surgical wound 
complications. In that way, antibiotic prophylaxis in these patients is different, and 
the actual recommendation is to administer at least 2 g of cefazolin some 60 min-
utes before the cesarean section. Another recommendation is to close the subcuta-
neous tissue layer in obese patients particularly when its depth exceeds 2 cm [43].
Finally, for mastectomy and lumpectomy, it has been observed that the risk of 
developing SSI augmented with increasing BMI. Moreover, obesity is a risk factor 
for major and minor complications after mastectomy irrespective of being unilat-
eral or performing reconstruction [44].
3.3 Obesity and orthopedic surgery
Obesity is an important risk factor for SSI after total hip prosthesis. It has been 
observed that the rate of SSI increased gradually with increasing BMI. Moreover, 
this association was present in both superficial and deep SSI. However, in partial 
hip prosthesis, obesity was related to superficial and deep SSI, but overweight only 
was a risk factor for deep SSI [32]. Another study had similar findings. It showed 
that members of the Enterobacteriaceae were more common among normal-weight 
patients with hip replacement [33].
On the other hand, among the total knee replacement patients, obesity was a risk 
factor for deep SSI but not for superficial SSI. Indeed, only a BMI > 40 was a risk 
factor for superficial SSI [32].
A meta-analysis also demonstrated that the risk of periprosthetic joint infec-
tion in obese patients was 1.9-fold higher than non-obese patients. The authors 
mentioned that this increased risk could be related to prolonged operative time, 
an increased rate of wound complications, and the presence of medical comor-
bidities [45].
Finally, a large study that included 161,785 patients showed that obesity was 
associated to higher rates of complications after total hip arthroplasty than after 
total knee arthroplasty. The study demonstrated that among the obese and mor-
bidly obese patients who underwent primary total hip replacement, the risk of total 
complications, wound complications, deep infection, and reoperation was higher 
than for similar weighted patients who underwent primary total knee arthroplasty. 
This observed difference would be due to the tendency of the adipose tissue to 
deposit in the gluteal region [46].
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3.4 Obesity and cardiothoracic surgery
Among the patients who undergo cardiothoracic surgery, obesity is a risk factor 
for SSI. Several studies have shown that the risk for SSI augmented gradually with 
increasing BMI [32, 33]. In cardiac surgery, however, an obesity paradox has been 
described. It means that mildly obese or overweight patients may have some benefit 
instead of an increased risk. Indeed, a large study that included 4740 patients who 
underwent cardiac surgery demonstrated that extremely obese (BMI > 40 kg/m2) 
patients had an increased risk for deep sternal infection, prolonged ventilation after 
cardiac surgery, and postoperative renal dialysis requirement. In contrast, mildly 
obese or overweight patients had minor in-hospital mortality, minor operative mor-
tality, and less ICU hours [47]. Another study showed that obesity and underweight 
were both associated to postoperative adverse events. However, this study did not 
show differences between extremely and mildly obese patients probably because 
both studies used different ways to categorize BMI [48].
3.5 Obesity and neurosurgery
A large study performed in the Netherlands failed to demonstrate an associa-
tion between obesity and surgical site infection after laminectomy [32]. However, 
another study which included 31,763 patients demonstrated that complications 
after lumbar spine surgery were associated to obesity. The stratification by BMI 
established five categories: underweight (BMI < 18.5), normal-overweight (BMI 
20.0–29.9), obesity class I (BMI 30.0–34.9), obesity class II (35.0–39.9). and obesity 
class III (BMI > 40). The study evaluated airway, cardiopulmonary, and infectious 
complications. They found that obese class I was associated to 4 of the 11 complica-
tions analyzed; obesity class II was associated to 6 of the 11 complications analyzed; 
and obesity class III was associated to 9 of the 11 complications analyzed. In addi-
tion, the rate of surgical site infection increased with increasing obesity class [49].
The effect of obesity on cranial surgery is similar to spinal surgery, but the 
impact on surgical outcomes is lower on cranial surgery. It increases the risk of 
major medical complications and may increase the risk for SSI after craniotomy. On 
the other side, in spinal surgery, obesity increases the risk of SSI, venous thrombo-
embolism, and major medical complications [50].
4. Conclusion
Although obesity leads to a pro-inflammatory state, it impairs the immune system 
and is a risk factor for several infections. Moreover, in surgical site infection, there are 
local factors related to obesity that must be taken into account: a large adipose panicle 
with poor oxygenation, a reduced operative field, difficulties in technique, and 
increased operative time. Therefore, obesity is a proven risk factor for surgical site 
infection in plenty of surgeries. However, there are some actions that we could take 
to reduce this risk: performing minimal invasive surgery, ensuring adequate surgical 
technique, prescribing adequate antibiotic doses, and recommending weight loss.
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Diabetes is a ceaseless ailment that is basic in practically all nations. Neuropathy 
is the most well-known constant difficulty of diabetes and is the underlying reason 
for ulceration in the legs of lower appendage removals. The predominance of dia-
betic polyneuropathy shifts from 23 to 29%. Incessant metabolic pressure incited by 
hyperglycemia, either low insulin creation in type 1 diabetes or diminished fringe 
affectability to insulin in type 2 diabetes influences cell homeostasis in practically 
all phone types. Changes in the sign Ca2+ have been recognized in different seclu-
sion tissues from creatures initiated to diabetes just as patients with diabetes. Ca2+ 
homeostasis variations from the norm have likewise been found in an assortment of 
tissues, including bone, heart and smooth muscle, secretory cells, platelets, kidneys 
and osteoblasts. This variation from the norm by and large shows as an expanded 
resting centralization of intracellular Ca2+ ([Ca2+]I), diminished Ca2+ transporter 
movement and diminished boost that produces Ca2+ signals. Ca2+ flagging issue are 
likewise found in neuron-sensory from trial creatures with diabetes.
Keywords: neuropathy, diabetes, calcium, intracellular, dyshomeostasis
1. Introduction
Diabetes is a chronic disease that is common in almost all countries. It is 
estimated that there were around 285 million adults with diabetes in 2010, this 
number will continue to increase globally due to population aging, population size 
growth, urbanization and high prevalence of obesity and lifestyle changes [1]. 
Estimated death rates from diabetes are 3.9 million sufferers worldwide in 2010 
and remain a major problem in each country [2–6]. Whereas in Indonesia alone, it 
was estimated that 7 million people with diabetes mellitus in 2010 became number 
9 in the world [7].
Neuropathy is the most common chronic complication of diabetes and is the 
initial cause of foot ulceration, Charcot type neuroarthropathy and lower limb 
amputation. Epidemiologically, a study based in Europe, the prevalence of diabetic 
polyneuropathy varies from 23 to 29%. One third of all diabetic patients have 
symptoms of neuropathy regardless of deficits or symptoms of neuropathic pain. 
Neuropathic pain due to diabetes is more common in patients with type 2 diabetes, 
women, and people from South Asia [7, 8].
Diabetes mellitus in people causes inconveniences in different tissues and 
organ frameworks, including the heart muscle, retina, secretory organs, kidneys, 
and fringe nerves. Ceaseless metabolic pressure instigated by hyperglycemia, 
either low insulin creation in type 1 diabetes or diminished fringe affectability to 
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insulin in type 2 diabetes influences cell homeostasis in practically all phone types. 
Hyperglycemia is generally viewed as the fundamental driver that triggers cell 
pathology variations from the norm and different downstream instruments, includ-
ing metabolic worry, with the development of receptive oxygen species (ROS) that 
harm layers and other cell frameworks. Ongoing exploration uncovers an early 
decrease of the two intracellular frameworks associated, the Ca2+ signal homeo-
stasis and the mitochondrial physiology. The event of these intracellular changes is 
comparative in each extraordinary cell type and can be viewed as a typical neurotic 
pathway [9, 10].
Diabetes mellitus in people causes entanglements that influence different tissues 
and organ frameworks, including the heart muscle, retina, glandular emissions, 
kidneys, and fringe nerves. Interminable metabolic pressure brought about by 
hyperglycemia coming about because of either low insulin creation in type 1 diabe-
tes or diminished insulin affectability in type 2 diabetes influences cell homeostasis 
in practically all phone types. Hyperglycemia is generally viewed as the principle 
procedure that triggers cell pathology, and different downstream instruments, 
including metabolic pressure and the arrangement of receptive oxygen species 
(ROS) that harm cell layers and different frameworks [11].
Changes in the Ca2+ signal have been identified in different detachment tissues 
from creatures prompted into diabetes just as patients with diabetes. Ca2+ homeo-
stasis variations from the norm have additionally been found in an assortment of 
tissues, including bone, heart and smooth muscle, secretory cells, platelets, kidneys 
and osteoblasts. This issue, for the most part, shows as an expanded resting con-
vergence of intracellular [Ca2+]I, diminished movement of the Ca2+ transporter (in 
spite of the fact that not generally) and diminished improvement that creates Ca2+ 
signals. Ca2+ flagging issue is likewise found in neuron-sensory from trial creatures 
with diabetes [11, 12].
Calcium (Ca2+) homeostasis in nerve cells that is upset or irregular happens in 
different maladies of the sensory system. The most well-known issue of the fringe 
sensory system, neuropathic torment and diabetes polyneuropathy, were seen as 
related with weakened articulation and capacity of Ca2+. Likewise found a connec-
tion between Ca2+ dyshomeostasis and mitochondrial brokenness in neuropathy 
because of diabetes. The primary impacts of changes in Ca2+ flagging happen in 
the plasma film and in intracellular Ca2+ in tactile neurons and are identified with 
irregularities in the endoplasmic reticulum. Impeded Ca2+ axonal motioning in 
diabetic neuropathy will incite axonal degeneration in fringe neuropathy. The near-
ness of Ca2+ dysregulation is influenced by varieties in waterway structure and Ca2+ 
siphon, this is seen in neuropathic and neuropathic structures, making the Ca2+ 
approach in neurons can be utilized for remedial mediations for neuropathic agony 
and fringe neuropathy. Neuropathic torment largely affects personal satisfaction 
and disarranges of physiology and Ca2+ waterway articulation have been embroiled 
in various torments. This investigation will likewise feature the most widely recog-
nized type of fringe neuropathy, which is diabetes polyneuropathy. This issue can 
incorporate agony as a manifestation and in the long run form into degeneration of 
fringe nerve strands described by tangible misfortune [11, 13, 14].
Neural harm both horrible and models of harm with specific illnesses, will harm 
fringe tactile nerves and meddle with essential afferent action. As a rule interrup-
tion of essential afferent movement can likewise add to diligent neuropathic pain. 
The role of Ca2+ flux in the formation of axonal potential and release of neurotrans-
mitters by primary sensory neurons will produce Ca2+ regulatory abnormalities 
which in turn contribute to neuropathic pain [15].
Late research has uncovered early aggravations from two intracellular integra-
tive flagging frameworks, specifically Ca2+ signal homeostasis and mitochondrial 
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physiology. These progressions happen also in an assortment of totally different cell 
types, and can be considered as normal neurotic pathways [11, 16, 17].
2. Homeostasis of Ca2+ signals in cells
A portion of the systems for keeping up the centralization of Ca2+ in intracel-
lularity are through the Ca2+ channel, Ca2+ transport and including the support. 
Various Ca2+-sensors (spoke to by Ca2+-controlled proteins) go about as effectors, 
which make an interpretation of Ca2+ signals into physiological reactions. What 
is significant is that the free Ca2+ resting focus in cells can change, going from 50 
to 100 nM in the cytosol and near 0.5–1.0 mM in the lumen of the endoplasmic 
reticulum (ER). Any move from this fixation go, both the overabundance Ca2+ in 
the cytosol and Ca2+ exhaustion in the ER will make obsessive results, including 
activating different kinds of cell demise [11, 13].
2.1 Calcium channel
Transient changes in intracellular calcium levels can be caused by signals from 
intracellular calcium storage or from extracellular compartments through specific 
regulations. Electrophysiology of calcium channel sub type with kinetic opening 
and its conduct can be divided into [18–20]:
a. Type L, the conductance is strong, long lasting inward current, the antagonist 
is dihydropyridine.
b. Type T, transient inward current.
c. Type N, neither type L or T, many in neurons, are blocked by w-conotoxins 
GVIA
d. Type P, found mostly in cerebellar Purkinje cells, is blocked by IVA agatoxin.
e. Another type found is type Q and R in Purkinje cells.
Different classifications based on open or closed formations can be  
differentiated into:
a. VOC (voltage gate channel), the opening depends on the voltage that occurs.
b. ROC (receptor-operated channels), depending on the specific ligand bond.
c. SOC (store operated channels), the activation depends on the depletion of 
calcium in the ER with the CCE (capacitative calcium entry) mechanism.
The VOC contains four homologous units, each containing six transmembrane 
regions with conduction holes, voltage sensors, and places to open and regulatory 
channels, which can be passed by for example protein kinases, toxins and drugs. 
Dihydropyridine, phenylalanine, and benzodiasepin are attached to sub-unit a1. 
Three types of ROC canals are known, activated by glutamate and some agonists 
that can be attached such as KA, AMPA and NMDA, so they are also named as 
attached agonists. The location is in the synapses post. The canals formed by KA 
and AMPA receptors are permeable to Na+ and K+, some AMPA are also to Ca2+, 
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whereas NMDA is permeable to Na+ and Ca2+. In neuroendocrine cells, activation by 
calcium passes through the SOC canal, this channel cannot be known in detail with 
protein levels but is homologous with transient potential receptors (trp or trp-like) 
from drosophila. The process of SOC through CCE, where the release of a small 
number of chemical factors will induce canal opening, and the second possibility 
is that the physical interaction between ER and plasma membrane stimulates CCE 
opening [18, 21, 22].
2.2 Calcium pumps
Plasma membranes control the exchange of calcium between intracellular and 
extracellular. Calcium in small and controlled amounts of calcium can enter cells 
through specific channels to stimulate intracellular events, including freeing cal-
cium from its storage. An equal amount of calcium must also be excreted extracel-
lularly. There are two known systems, i.e. mostly through the electrical exchange of 
NA+ and Ca2+. Another system is through ATPase (PMCA pump) with high affinity 
but low capacity to remove calcium, so it is also called fine-tuner cellular Ca2+. 
Calcium also exchanges between the cytoplasm and internal organelles, dominated 
by mitochondria and ER which have SERCA pumps that have a mechanism similar 
to PMCA [23, 24].
The total calcium transported in the reticulum depends on the amount of pump 
available, which is high in the heart and skeletal muscles, but low in non-skeletal 
muscles. Calcium pumps are also found in low eukaryotes. In mushrooms there are 
two pumps namely PMR1 and PMC1 which are in the Golgi and Vacuole complex. 
40–50% homologous with SERCA and PMCA, PMC1 does not have the calmodulin 
which is a characteristic of PMCA pumps [23, 24].
2.3 PMCA pumps
The PMCA pump was discovered since 1966 and functions to remove calcium 
from erythrocytes. It was purified in 1979 with a protein weight of 135 kDa. 
The architecture of this protein resembles that of the SERCA pump, having 10 
transmembrane domains and three large hydrophilic units that protrude into the 
cytoplasm, what is different is the existence of a long C-terminal tail that contains a 
place to attach to calmodulin. Calmodulin is the main regulator for PMCA, although 
polyunsaturated fatty acids, phospholipids, protein kinases A or C also activate 
these pumps, with the result of reducing the concentration of calcium. After activa-
tion, it is dimerized by binding with calmodulin and proteolytic enzymes by remov-
ing C terminals. The calmodulin bond at rest will bind to both sides of the cytosol 
part of the pump, so that the pump will remain obstructed [23, 25].
A Ca2+ signalosome signal consists of many Ca2+ signal components. Duplication 
of components is the fact that there are many isoforms that increase the diversity of 
the Ca2+ signal system. Yellow arrows describe the ON reaction that enters Ca2+ into 
the cell, and the blue arrow represents the OFF reaction where Ca2+ will exit the cell or 
return to the endoplasmic reticulum (ER). During a trip through the cytoplasm, Ca2+ 
will temporarily stay in a buffer or inside the mitochondria. For the signal to occur, 
Ca2+ binds to sensors which then use various effectors to stimulate cellular processes. 
Different and suitable components will produce cell-specific signalosomes [26].
2.4 SERCA pumps
An enzyme that hydrolyzes ATP to transport Ca2+ across the SR membrane 
was discovered 40 years ago, then identified as a pump in the ER in non-muscle 
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cells. The ATPase was then called the SERCA pump as a protein weighing around 
100 kDa. SERCA 1a is a major isoform in adult human muscle cells with rapid con-
traction, while SERCA1b in neonates. SERCA2a is found in heart muscle and muscle 
with slow contractions, while SERCA2b is found in smooth muscle and almost in 
non-muscle cells. SERCA3 is expressed only in non-lumen cells [27, 28].
The principle of action of enzymes in calcium pumps is actually almost the 
same. Calcium is bound to one side of the membrane and this reaction does not 
require ATP, then ATP attaches and splits into acyl phosphate as an aspartic residue, 
intermediate formation of phosphorylation is also called a P type pump. After 
phosphorylation, the pump transitions from E1 to E2 form, on E1 forms calcium-
bound pumps with high affinity exposed to the cytosol side; in the E2 form calcium 
bound with low affinity is exposed to the ER/SR lumen or extracellular part, so that 
calcium can be released. After ATP and calcium released, enzymes slowly dephos-
phorylate and return to form E1. The SERCA and PMCA pumps are different in 
calcium-ATP transport [27, 28].
2.5 Calcium-sodium exchange
Sodium/calcium exchange (NCX, Na+/Ca2+ exchangers) in the plasma 
membrane (PM, plasma membrane) is an important factor in homeostasis 
and calcium regulation in almost all cells. The NCX PM was discovered nearly 
35 years ago in cardiac cells and neurons by using sodium electrochemical energy 
gradients, not directly from ATP for calcium transport. So the importance 
of calcium import or export depends on the NCX coupling ratio, membrane 
potential and sodium concentration gradient. Potential membranes and sodium 
gradients are maintained by sodium pumps (Na+, K+-ATPase) that are dependent 
on ATP. Sodium-calcium exchange in the mitochondria has also been identified 
and works similar to NCX [29–31]. Exchange in heart cells and neurons shows the 
coupling ratio is 3 Na+:1 Ca2+.
Sodium-calcium exchange is also present in photoreceptor cells, this cell is also 
dependent on K+ and has a coupling ratio of 4Na+:(1Ca2++K+) so this exchange is also 
referred to as Na/(Ca,K) or NCKX exchange. The family of NCX is NCX2, NCX2 
and NCX3, most of which are NCX1 with distribution on all networks. In the NCKX 
family, there are three sub-types namely NCKX1 in photoreceptors, NCKX2 in rods 
and neurons and NCKX3 expressed in the brain and smooth muscle. Topologically 
NCKX is almost similar to NKCX which both function on ion attachment and 
translocation [29–31].
NCX can facilitate the electronic exchange of sodium-sodium or calcium–calcium, 
also can be for sodium in-calcium exit or sodium in-calcium entry. For calcium- calcium 
exchange it is activated by nontransported alkaline metal ions. The sodium- calcium 
exchange reaction is consistent and sequential, where one calcium or three sodium 
binds to one side of the membrane, then translocates to the other side of the membrane, 
and dissociates before the other ions are bound to that side. In the exchange of sodium 
in and out of calcium and sodium in and out of calcium are both rheogenic (related to 
electric current/current flow) [29–31].
2.6 Calcium buffer
The principle of calcium buffer is that all groups that have negative potential 
can be a chelator for calcium. In this system many are dominated by small molecu-
lar carbosilic groups such as citrate or carbonyl protein groups. Included here are 
EF-hand protein, annexin and C2 protein. Most calcium buffers are included in the 
EF-hand protein group. To find out the buffer mechanism in calcium homeostasis, 
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A Ca2+ signalosome signal consists of many Ca2+ signal components. Duplication 
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An enzyme that hydrolyzes ATP to transport Ca2+ across the SR membrane 
was discovered 40 years ago, then identified as a pump in the ER in non-muscle 
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cells. The ATPase was then called the SERCA pump as a protein weighing around 
100 kDa. SERCA 1a is a major isoform in adult human muscle cells with rapid con-
traction, while SERCA1b in neonates. SERCA2a is found in heart muscle and muscle 
with slow contractions, while SERCA2b is found in smooth muscle and almost in 
non-muscle cells. SERCA3 is expressed only in non-lumen cells [27, 28].
The principle of action of enzymes in calcium pumps is actually almost the 
same. Calcium is bound to one side of the membrane and this reaction does not 
require ATP, then ATP attaches and splits into acyl phosphate as an aspartic residue, 
intermediate formation of phosphorylation is also called a P type pump. After 
phosphorylation, the pump transitions from E1 to E2 form, on E1 forms calcium-
bound pumps with high affinity exposed to the cytosol side; in the E2 form calcium 
bound with low affinity is exposed to the ER/SR lumen or extracellular part, so that 
calcium can be released. After ATP and calcium released, enzymes slowly dephos-
phorylate and return to form E1. The SERCA and PMCA pumps are different in 
calcium-ATP transport [27, 28].
2.5 Calcium-sodium exchange
Sodium/calcium exchange (NCX, Na+/Ca2+ exchangers) in the plasma 
membrane (PM, plasma membrane) is an important factor in homeostasis 
and calcium regulation in almost all cells. The NCX PM was discovered nearly 
35 years ago in cardiac cells and neurons by using sodium electrochemical energy 
gradients, not directly from ATP for calcium transport. So the importance 
of calcium import or export depends on the NCX coupling ratio, membrane 
potential and sodium concentration gradient. Potential membranes and sodium 
gradients are maintained by sodium pumps (Na+, K+-ATPase) that are dependent 
on ATP. Sodium-calcium exchange in the mitochondria has also been identified 
and works similar to NCX [29–31]. Exchange in heart cells and neurons shows the 
coupling ratio is 3 Na+:1 Ca2+.
Sodium-calcium exchange is also present in photoreceptor cells, this cell is also 
dependent on K+ and has a coupling ratio of 4Na+:(1Ca2++K+) so this exchange is also 
referred to as Na/(Ca,K) or NCKX exchange. The family of NCX is NCX2, NCX2 
and NCX3, most of which are NCX1 with distribution on all networks. In the NCKX 
family, there are three sub-types namely NCKX1 in photoreceptors, NCKX2 in rods 
and neurons and NCKX3 expressed in the brain and smooth muscle. Topologically 
NCKX is almost similar to NKCX which both function on ion attachment and 
translocation [29–31].
NCX can facilitate the electronic exchange of sodium-sodium or calcium–calcium, 
also can be for sodium in-calcium exit or sodium in-calcium entry. For calcium- calcium 
exchange it is activated by nontransported alkaline metal ions. The sodium- calcium 
exchange reaction is consistent and sequential, where one calcium or three sodium 
binds to one side of the membrane, then translocates to the other side of the membrane, 
and dissociates before the other ions are bound to that side. In the exchange of sodium 
in and out of calcium and sodium in and out of calcium are both rheogenic (related to 
electric current/current flow) [29–31].
2.6 Calcium buffer
The principle of calcium buffer is that all groups that have negative potential 
can be a chelator for calcium. In this system many are dominated by small molecu-
lar carbosilic groups such as citrate or carbonyl protein groups. Included here are 
EF-hand protein, annexin and C2 protein. Most calcium buffers are included in the 
EF-hand protein group. To find out the buffer mechanism in calcium homeostasis, 
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there are several parameters that influence it, namely: cytosolic concentration, 
affinity for calcium ions or other metal ions, calcium kinetic for attachment and 
release as well as the mobility of calcium itself. In a simple way buffer works is that 
once calcium enters the buffer cells will bind calcium and reduce calcium levels. 
However, a fixed level of calcium concentration is obtained from the calcium 
balance across the cell membrane, not absolutely from the presence of the buffer 
itself [32, 33].
2.7 Mitochondria and calcium signaling
Mitochondria are no longer static organs as ATP producers, but also as a store 
of various lethal proteins which will be released in programmed cell death and this 
is an important intracellular calcium signal. Since the expression of the calcium 
transport membrane in the mitochondria has been found, the process of signaling 
calcium in the mitochondria has become clear [34–36]. Pension movements in the 
mitochondria are driven by several things such as:
a. Uniporter
b. VDAC (voltage dependent anion channel)
c. Exchange xNa+/Ca2+
Calcium is inserted into the membrane in the mitochondria by the uniporter. 
Uniporter activity is influenced by temperature and cation selectivity so that it can 
almost be called a channel rather than a career. Intake of calcium through uniport-
ers is inhibited by red ruterium (RuR) which also blocks many cation channels 
including calcium plasmalemma canals, the ER channel which is sensitive to ryano-
dine to release calcium and vanilloid receptor channels, making it more convincing 
that the uniporter is a canal. Uniporters are regulated by cytosolic calcium levels 
and thus require higher levels to increase mitochondrial calcium levels [34–36].
The outer membrane of the mitochondria is permeable to small ions so it is not 
considered in calcium exchange. However, the outer membrane of the mitochondria 
has an important role in the modulation of calcium by the uniporter to pass the 
VDAC filter. VDAC is permeable to calcium and regulated both calcium levels and 
RuR levels. The most important way for calcium to exit the mitochondria is through 
the exchange of xNa+/Ca2+; initially thought to be the electronic exchange of 2Na+/
Ca2+. It will be doubted because this exchange requires twice as much energy as 
against the sodium gradient. The entry of calcium into the mitochondria is inhib-
ited by mitochondrial depolarization [34–36].
A progression of proteins in MAMs (for example, PML, AKT, GRP-75, SIG-1R, 
Mfn-1/-2, BIP, AKT) controls the arrival of Ca2+ from ER and Ca2+ take-up by mito-
chondria, bringing about various useful outcomes. Cells produce Ca2+ flags through 
two instruments that utilization inside and outer Ca2+ sources. Calcium enters the 
cell through channels and siphons situated on the plasma layer, this is controlled by 
voltage (VOC) or outer ambassadors (ROCs). A progression of upgrades that follow 
up on receptors on the cell surface triggers enactment of the PLC which catalyzes 
the hydrolysis of 4.5-bisphosphate phosphatidylinositol to IP3 and DAG. IP3 official 
with IP3R receptors invigorates the arrival of Ca2+ ER and subsequently moves Ca2+ 
(red specks) from the ER to the mitochondria. The mitochondrial surface collabo-
rates straightforwardly with the ER through the Ca2+ hotspot signal unit. Imports 
of mitochondrial Ca2+ happen through mitochondrial Ca2+ uniporters (MCU) and 
H+/Ca2+ exchangers LETM1; on the other hand, NCLX, mitochondrial Na+/Ca2+ 
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exchangers, together with PTP, send out Ca2+ from the lattice. Ca2+ levels come back 
to resting conditions through a progression of channels and siphons: PMCA and 
NCX bring about particle expulsion to the extracellular condition, SERCA (situated 
in the ER) and SPCA (in the Golgi mechanical assembly) make Ca2+ levels come 
back to basal levels in the capacity zone [17].
2.8 Endoplasmic reticulum (ER) and calcium signaling
ER as a widespread flagging organelle, ER works a ton, as a matter of first 
importance is a spot for protein amalgamation and development. Protein union is 
completed in harsh ER, though handling of protein after interpretation is orches-
trated in escorts some portion of ER, which structures buildings with recently 
integrated proteins, collapsing them into the last tertiary structure and keep 
them from accumulating. In the event that the collapsing procedure falls flat, the 
escorts are still amassed with proteins that neglect to crease, therefore keeping 
them from continuing through the ER and out into the Golgi complex. Each 
time the collapsed protein fixation increments extremely high, ER builds up an 
exceptional response known as ER worry, subsequently, the signs that influence 
translation are sent to the core, which will control quality articulation as indi-
cated by the earth. Other than blend protein, ER is a position of arrangement of 
phospholipids, glycosyl-phosphatidylinositols, and leukotrienes. ER can likewise 
work as a transfer site for different undesirable particles and toxic substances. 
Since ER has a constant lumen, as an expressway that permits transport of RNA, 
secretory items, different proteins and particles between enraptured cell parts. 
This ER is likewise firmly engaged with quick cell signals since it is a powerful 
stockpiling territory of Ca2+ which controls Ca2+ cytosol focus and creates Ca2+ 
transition between the cytosol and ER lumen because of extracellular incitement. 
At last, ER arranges all the different physiological procedures of cells. In this 
manner, ER is characterized as a multifunctional organelle fit for recognizing 
and incorporating approaching signs and creating yield flags because of natural 
changes [37, 38].
The definite system of ER combination is generally unfamiliar, including the 
focal job of Ca2+. Ca2+ is the way in to the info and yield signals from the ER. An 
expansion in Ca2+ cytosol focus influences its fixation in ER, and thusly the exit 
and passage of Ca2+ in the ER influences the cytosolic Ca2+ focus. Various intra-ER 
escorts, for example, calreticulin, calnexin, grp78/BiP, endoplasmin (or glucose 
managed protein, grp94), are Ca2+ restricting proteins, and changes in free Ca2+ 
focuses in ER lumens extraordinarily influence their practical movement. In this 
manner, changes in Ca2+ content in the ER can give a connection between quick 
signals and moderate cell versatile reactions [38, 39]. The essential physiology of 
ER as calcium stockpiling is known in different volatile and non-sensitive cells. ER 
goes about as a powerful stockpiling of Ca2+ alongside the action of Ca2+ directs 
and transporters in the endomembranes, and intraluminal Ca2+ restricting pro-
tein, which works as a high limit Ca2+ cradle framework. Ca2+ that leaves the ER 
is controlled by two Ca2+ channels, Ca2+-gated Ca2+ channels which are normally 
known as ryanodine receptors (RyRs) and InsP3-gated channels which are regularly 
known as InsP3 receptors (InsP3Rs). The aggregation of Ca2+ into the ER lumen 
is the consequence of Ca2+ siphon action from the sarco (endo) plasmic reticulum 
Ca2+-ATPase (SERCA) [37, 38].
The Ca2+ flagging framework in certain cell types is regularly not single, yet 
comprises of various pathways, which are identified with produce cell-explicit 
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in the ER) and SPCA (in the Golgi mechanical assembly) make Ca2+ levels come 
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translation are sent to the core, which will control quality articulation as indi-
cated by the earth. Other than blend protein, ER is a position of arrangement of 
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stockpiling territory of Ca2+ which controls Ca2+ cytosol focus and creates Ca2+ 
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and passage of Ca2+ in the ER influences the cytosolic Ca2+ focus. Various intra-ER 
escorts, for example, calreticulin, calnexin, grp78/BiP, endoplasmin (or glucose 
managed protein, grp94), are Ca2+ restricting proteins, and changes in free Ca2+ 
focuses in ER lumens extraordinarily influence their practical movement. In this 
manner, changes in Ca2+ content in the ER can give a connection between quick 
signals and moderate cell versatile reactions [38, 39]. The essential physiology of 
ER as calcium stockpiling is known in different volatile and non-sensitive cells. ER 
goes about as a powerful stockpiling of Ca2+ alongside the action of Ca2+ directs 
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1. Agonists, for example, glutamate synapses and ATP act straightforwardly on 
channel-worked receptors (ROCs) in the plasma layer to permit outside Ca2+ to 
enter the cell.
2. Second couriers, for example, diacylglycerol (DAG), cyclic AMP, cyclic GMP 
and arachidonic corrosive work on the cytoplasmic side when opening SMOCs 
in the plasma layer.
3. Film depolarization (V) enacts VOC in the plasma layer for permits the passage 
of outside Ca2+ rapidly.
4. Film depolarization (V) enacts certain VOC isoforms, in particular, the L-type 
CaV1.1 channel, which actuates the receptor ryanodine 1 (RYR1) in the skeletal 
muscle through an immediate coupling compliance system.
5. The depolarizing film (V) enacts VOC in the plasma layer for permits the pas-
sage of outside Ca2+ to trigger Ca2+ enacting ryanodine 2 receptor (RyR2) to 
trigger the arrival of Ca2+ stores in the sarcoplasmic reticulum (SR) through 
the Ca2+ incited Ca2+ (CICR) discharge process. This component is found in the 
heart muscle and neurons.
6. Agonists following up on the outside of receptor cells produce 1,4,5-trispho-
sphate inositol, which at that point diffuses into the cell to enact the InsP3 
(InsP3R) receptor to discharge Ca2+ from the ER.
CICR (calcium-induced calcium release) causes the release of Ca2+ from its 
storage site, the endoplasmic reticulum (ER). Canals that are sensitive to Ca2+ 
namely the ryanodine (R) receptor and the InsP3 (I) receptor are in the ER. CICR 
has two stages, namely the first is the transfer of signals from the plasma mem-
brane to the channel receptors in the ER, starting from the opening of the VOC 
canal due to depolarization in the plasma membrane then Ca2+ will enter, diffuse 
then activate the R and I receptors, the second is with the Ca2+ process will be 
released from one canal to the next canal to release Ca2+ again so that the Ca2+ wave 
will arise which will increase the concentration of Ca2+ in the cytosol. Increasing 
the concentration of Ca2+ cytosol will activate the ON system thus activating 
intracellular signals [26, 39].
3. Dyshomeostasis Ca2+ in neurons
Signal unsettling influences and Ca2+ fixations have been recognized in differ-
ent diabetic creature cell disengagement explores just as from diabetic patients. 
Ca2+ homeostasis variations from the norm have been found in most trial tissues, 
including bone, heart and smooth muscle, discharge cells, platelets, kidneys and 
osteoblasts. Diminished (in spite of the fact that not generally) and diminished 
upgrade evoked Ca2+ signals. Ca2+-dealing with disarranges have additionally been 
found in tangible neurons from creatures with diabetes [11, 40, 41].
3.1 Increase in [Ca2+]I break
A huge increment in resting [Ca2+] in diabetic tangible neurons is a typical 
finding, despite the fact that there are a few contrasts between kinds of neurons. 
Research shows an expansion in resting [Ca2+] in dorsal root ganglion neurons 
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(DRG) of rodents with type 1 and type 2 diabetes. Centralization of [Ca2+]I breaks 
30% higher in disconnection of DRG neurons in streptozotocin (STZ)-C57Bl/6, 
(type 1 diabetes model) contrasted with controls (205 ± 16 nM versus 156 ± 16 nM). 
The expansion in [Ca2+]I in little neurons is more noteworthy in db/db mice (type 
2 diabetes model). There was no distinction in [Ca2+]I in huge neurons in the 
two mouse models. In another examination in Wistar-diabetic mice with STZ 
8–14 weeks there was an expansion of 2- to 2.5-overlay resting [Ca2+]I in seclusion 
of enormous and little DRG neurons from L4-L6 lumbar, however expanded [Ca2+]
I rest was not influenced in neurons from the ganglion in the more elevated levels 
of the spinal line (C3-L3). This distinction connects with the lumbar DRG tactile 
neuron vulnerability and the long axon of diabetic neuropathy. A portion of these 
distinctions are identified with contrasts in estimation of [Ca2+]I between considers 
with different models and term of diabetes, maybe likewise because of contrasts in 
different sub-populaces of neurons from the degree of DRG in the spine [11, 40].
3.2 Disruption of Ca2+ entry plasmalemma
The section of Ca2+ into the cytoplasm through the voltage-gated Ca2+ channel 
of plasmalemma is a significant part of the Ca2+ signal in sensitive cells. Tangible 
neurons have a few kinds of voltage-gated Ca2+ channels including low-edge (type T) 
and high-edge (type N and L), which vary in conductance, voltage-reliance and 
pharmacology. The measure of Ca2+ flows at both high and low edges is accounted 
for to increment in diabetic creatures by 40–100%. In any case, the adequacy of 
transient depolarization which is Ca2+ prompted in the separation of DRG neurons 
from diabetic and sound creatures is commonly not influenced, just discouraging 
in disengagement of little DRG neurons from L4-L6. This distinction can be clari-
fied by an expansion in resting [Ca2+], though an increment in waterway Ca2+ flow 
might be redressed [42, 43].
3.3 Ca2+ homeostasis in ER
ER works as a dynamic Ca2+ stockpiling, fit for amassing, appropriating and 
discharging Ca2+ particles. Ca2+ ER homeostasis is accomplished within the sight of 
Ca2+ siphons spoke to by sarco (endo) plasmic reticulum Ca2+ ATP-ases (SERCAs) 
and Ca2+ trenches for discharge, including rianudin receptors (RyR), inositol 
triphosphate receptor (InsP3R) and Ca2+ adenine receptors for discharge, including 
rianudin receptors (RyR), inositol triphosphate receptors (InsP3R) and nicotinic 
adenic corrosive receptors. Dinucleotide phosphate (NAADP) in the endomem-
brane. The grouping of free Ca2+ in the ER lumen ([Ca2+]L) is high, around 
0.5–1.0 mM. The degree of [Ca2+]L is practically significant in light of the fact that 
it will control the speed of SERCA-subordinate Ca2+ take-up, actuation of the Ca2+ 
discharge channel, the Ca2+ sponsor and give tight power over different ER caper-
sons for collapsing post-translational proteins. In this way, any long haul changes in 
[Ca2+]L will have significant sign, practical and adjustment results [44, 45].
ER additionally assumes a job in the quick reaction of neuronal Ca2+ through 
commencement (by means of metabotropically controlled InsP3-actuated Ca2+ 
discharge), enhancement (through Ca2+-actuated Ca2+ discharge), engendering (by 
both regenerative initiation of Ca2+ and Ca2+ ER channels) and end (with SERCA-
intervened Ca2+ uptake in the ER lumen. These procedures are directed by [Ca2+]
I and [Ca2+]L fixations and second emissary digestion including InsP3, cyclic-ADP-
ribose and NAADP. Diabetes will disturb Ca2+ ER homeostasis in tangible neurons 
by diminishing the measure of Ca2+ in the ER, in this way decreasing the plentiful-
ness of the arrival of Ca2+.The measure of Ca2+ discharged from ER is altogether 
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(DRG) of rodents with type 1 and type 2 diabetes. Centralization of [Ca2+]I breaks 
30% higher in disconnection of DRG neurons in streptozotocin (STZ)-C57Bl/6, 
(type 1 diabetes model) contrasted with controls (205 ± 16 nM versus 156 ± 16 nM). 
The expansion in [Ca2+]I in little neurons is more noteworthy in db/db mice (type 
2 diabetes model). There was no distinction in [Ca2+]I in huge neurons in the 
two mouse models. In another examination in Wistar-diabetic mice with STZ 
8–14 weeks there was an expansion of 2- to 2.5-overlay resting [Ca2+]I in seclusion 
of enormous and little DRG neurons from L4-L6 lumbar, however expanded [Ca2+]
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Weight Management
124
decreased in DRG neurons with diabetes. The evacuation of Ca2+ is prompted by 
low-portion ionomycin, caffeine (RyRs actuation) or by ATP (metabotropic initia-
tion from diabetes). InsP3Rs), Ca2+ use diminishes essentially in the disconnection 
of tactile neurons from diabetic creatures after STZ administration. The decrease 
in the measure of Ca2+ ER is more prominent in DRG neurons and L1-L6 lumbar ri 
contrasted and cervical and cylinder DRG. Direct estimations of [Ca2+]L and [Ca2+]I 
indicated a huge reduction in cytosolic-instigated cytosolic Ca2+. Decrease of [Ca2+]L 
and the pace of take-up of Ca2+ in diabetic neurons is related with diminished SERCA 
articulation in the homogenate of DRG L4-L5 from diabetic creatures [45, 46].
The focus of Ca2+ homeostasis regulation has shifted from pericarion/soma to 
axons. In sensory neuron culture from diabetic rats, axons appear to be far more 
susceptible to neurodegeneration because of high glucose levels. Adult sensory 
neurons isolated from diabetic rats after STZ administration for 3–5 months can 
grow in vitro 1–4 days. High-level glucose delivery triggers oxidative stress lead-
ing to an increase in 4-hydroxy-2-nonenal staining (ongoing lipid peroxidation 
measurement), axonal development to be suboptimal and the appearance of axonal 
structural abnormalities similar to axonal dystrophy/axonal degeneration in animal 
and human models with human diabetes. But pericarions/soma from neuron cul-
ture do not show clear signs of oxidative stress or degeneration. Axon toxicity due 
to glucose induced is only seen in neurons from diabetic animals and neurons that 
grow from control mice that match their age do not have sensitivity to high glucose 
levels [11, 45].
Research on Ca2+ homeostasis in axons utilizing continuous confocal imaging 
with Fluo4-AM under high amplification (X100) to investigate Ca2+ drifters in the 
seclusion of grown-up tactile neurons with diabetic rodents after STZ 4–5 months 
organization.
3.4 Ca2+ termination signal
End of the Ca2+ signal is activated during the time of cell action, this is finished 
by expelling Ca2+ in the plasmalemma (siphon Ca2+ ATP-ase plasmalemma, PMCA, 
Na+/Ca2+ exchanger) or retention of Ca2+ to the ER and/or mitochondria. In the 
segregation of neurons from diabetic creatures, the practical limit of the expulsion 
framework has all the earmarks of being hindered as showed by the easing back 
down of the arrival of [Ca2+]I after incitement. This might be because of a lessening 
in PMCA siphon articulation. Simultaneously, prolongation/high Ca2+ levels are 
likewise connected with diminished Ca2+ take-up by intracellular organelles, for 
example, ER and mitochondria. Diminished SERCA articulation is likewise found 
in the core of diabetic creatures with STZ. In neurons, diminished SERCA action 
is showed by an abatement in the ingestion pace of Ca2+ after direct estimation of 
[Ca2+]L. Moreover, mitochondrial buffering Ca2+ additionally debilitates in neurons 
with diabetes [47, 48].
3.5 Mitochondrial depolarization in diabetes
Endothelial cell culture shows that high intracellular glucose levels energize 
extreme electron gifts in the electron transport chain in the mitochondria which 
will result in mitochondrial hyperpolarization and expanded ROS creation. The 
procedure in the mitochondria is a focal arbiter of oxidative worry as a confusion of 
diabetes. This hypothesis recommends that high glucose focuses in the objective tis-
sue as a type of diabetes confusions lead to an expansion in the inventory of NADH 
in the mitochondria which will additionally build the quantity of electrons and/or 
immersion, this can prompt a fractional decrease of oxygen and superoxide radicals 
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in the proximal piece of the electron transport chain. An expansion in ROS will at 
that point empower tissue degeneration. The capability of the inward mitochondrial 
layer depolarizes as opposed to hyperpolarization. Mitochondrial depolarization in 
STZ-diabetes can be forestalled by controlling low-portion insulin or NT-3 [49, 50].
Concentrates in the way of life of tactile neuron incipient organisms show that 
high glucose levels cause ceaseless mitochondrial depolarization followed by apop-
tosis. High glucose focuses do not execute neuronal incipient organisms from the 
passable portion for grown-ups in vitro or grown-up tangible neurons (for about 
a month at 50 mM glucose in vitro). Moreover there are no basic variations from 
the norm in mitochondrial neurons/axons or nerve cell passing in tangible ganglia 
in people with diabetes or autonomic neuropathy. In creature models of type 1 
diabetes found unmyelinated little neuron cell misfortune however there is no data 
of apoptosis or variations from the norm in mitochondrial structure in DRG. Be that 
as it may, morphology and axonal development are upset by high glucose because of 
high oxidative pressure which brings about axonal degeneration [49, 50].
Adult sensory neurons from diabetic rodents with STZ 3–5 months were refined 
for 1 day, at that point given tetramethylrhodamine methyl ester (TMRM) and a 
color used to identify mitochondrial film depolarization. The outcomes demon-
strated that axons from ordinary neurons encountered a pace of mitochondrial 
depolarization much sooner after expansion of uncoupler carbonylcyanide p-triflu-
oromethoxyphenylhydrazone (FCCP). Before the expansion of FCCP, mitochon-
drial axons were more energized than the diabetic neuron bunch [11].
3.6 Mitochondrial dysfunction and Ca2+ dyshomeostasis
Disarranges of Ca2+ homeostasis and mitochondrial film depolarization in 
grown-up tactile neurons happen prior (3–14 weeks) in test diabetes type 1 (STZ) 
and type 2 (db/db), this can be key in tangible neuropathy. The determinant factor 
for mitochondrial brokenness is not the nearness of hyperglycemia yet the nonat-
tendance of insulin-subordinate neurotropic help, this is seen in vivo and in vitro. 
Insulin organization of 1 nM for 6–24 h of solid DRG societies essentially builds 
the capability of the mitochondrial layer and expands the degree of ATP genera-
tion contrasted with societies without insulin. Giving 50 mM glucose within the 
sight of insulin in culture has no impact on the layer potential in the mitochondria. 
Comparative outcomes were gotten in vivo, STZ-diabetic rodents given insulin 
focuses low which did not influence hyperglycemia. Insulin organization com-
pletely standardizes mitochondrial layer polarization, resting [Ca2+] level and speed 
of tangible and engine nerve conductance [49, 51, 52].
Mitochondrial polarization and Ca2+ homeostasis in tangible neurons from 
diabetic creatures additionally become ordinary after organization of the neurotropic 
factor, NT-3. Giving neighborhood insulin to the spinal line at the degree of the lum-
bar (intrathecal) or fringe nerve (little osmotic siphon) or intranasally expands nerve 
conduction and epidermal nerve fiber thickness in STZ-diabetic rodents. Different 
investigations have indicated the job of phosphoinositide 3-kinase (PI3-kinase) and 
protein kinase B (Akt) in guideline of film potential in the mitochondria. This path-
way is managed by insulin plasmalemma receptors (α and β subunit receptor insulin 
communicated in DRG neurons) and neurotrophin receptors. PI3/Akt association 
is checked whether DRG neurons are directed with a particular PI3-kinase inhibitor 
(LY294002), which will hinder insulin-subordinate and neurotrophin-subordinate, 
therefore repressing the guideline of mitochondrial and insulin-subordinate layer 
potential to build ATP levels [14, 16].
Several cell types are with specific Ca2+ signals. The four cells in Table 1 are very 
different in spatial and temporal terms of the Ca2+ pathway, for example striped 
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muscle cells use a specific pathway to deliver Ca2+ quickly for activation of muscle 
contraction, whereas T cell signals have a slower pathway component that is useful.
3.7 Dysregulation of Ca2+ and release of neurotransmitters
Signal contribution from the essential afferent into the spinal line includes the 
arrival of excitation synapses from the nerve terminal to the dorsal horn. Many 
mechanisms of neuropathic pain along with spinal cord sensitization in response to 
primary afferent activity in a state of persistent pain. The arrival of synapses from 
essential afferents is activated by potential activity, nearby film depolarization and 
enactment of high-voltage Ca2+ channels. The passage of Ca2+ will begin docking 
of vesicles containing excitation synapses and modulators, for example, glutamate, 
substance P and CGRP in the presynaptic layer and arrival of this particle into 
neural connections. Obstructing the passage of Ca2+ into the prespinal terminal 
forestalls the section of fringe contribution to the spinal rope, this piece of the 
sedative component hinders the impression of torment by restraining the passage of 
Ca2+ moderator into little tactile neurons through the actuation of narcotic recep-
tors (sub-type) in the essential afferent terminal turns into an option in contrast to 
the objective of hindering the arrival of synapses from neurons. Peptides that are 
specific inhibitors of type N channels have been recognized in snails, conotoxins, 
which can square agony receptors in mice [8, 11].
4. Conclusion
In the fringe nerve, diabetes quite often influences the tactile nerve which brings 
about even tangible neuropathy. At first, diabetes will decrease the speed of nerve 
conduction and patients can likewise encounter an assortment of tactile manifesta-
tions going from torment to reflex issue. The cell and atomic pathophysiology of 
diabetes polyneuropathy stays dubious and a few pathways are related with hyper-
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and impeded help from neurotropics. Elective components for starting the begin-
ning of diabetic neuropathy are those identified with changes in mitochondrial 
work and cell Ca2+ homeostasis that are not legitimately brought about by hypergly-
cemia, however are activated by disabled sign falls identified with insulin receptors 
and neurotropic elements. The underlying pathogenesis of diabetes neuropathy is 
diminished insulin receptor incitement. This triggers mitochondrial brokenness 
and diminished ATP generation. The diminished ATP bolster will influence the 
component of Ca2+ homeostasis, the most evident aggravations are in the plas-
malemma and the Ca2+ siphon in the ER. Diminishing Ca2+ take-up in the ER will 
decrease the Ca2+ focus in intra-ER, causing an ER stress condition. ER worry thus 
impacts union, post-translational alteration and protein transport, which thusly 
diminishes the stock of protein to the voltage-gated channel to the axon, bringing 
about an abatement in nerve conduction speed. These procedures can happen all the 
more effectively found in axons. This is exacerbated by constant hyperglycemia so 
degenerative neuropathy and extreme tactile nerve brokenness will happen.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Hyponatremia and Psychiatric 
Diseases
Ermal Bojdani, Flavia De Souza, Aishwarya Rajagopalan, 
Anderson Chen, Alesia A. Cloutier, Troy R. Nold  
and Dil Tahera
Abstract
Eating disorders, psychotic illnesses, and substance use disorders are some of 
the more common psychiatric conditions encountered in clinical practice that are 
associated with hyponatremia. The mechanisms that lead to hyponatremia vary, 
and at times hyponatremia may be a result of a drug side effect or drug-drug inter-
action. Additionally, hyponatremia from a non-psychiatric condition may lead to 
psychiatric symptomatology. Given the potential for hyponatremia to cause signifi-
cant morbidity and potential mortality, clinicians are urged to consider screening 
for plasma sodium in patients at risk of hyponatremia, such as patients in the three 
categories of psychiatric conditions described above. Treatment of hyponatremia 
consists of various acute interventions, with consideration that treatment of the 
underlying psychiatric condition may help to diminish or eliminate the frequency 
of hyponatremic episodes in the long run.
Keywords: hyponatremia, anorexia nervosa, bulimia nervosa, psychosis,  
alcohol use disorder
1. Introduction
Sodium abnormalities can be seen in various psychiatric diseases. Common 
conditions include eating disorders, psychotic illnesses, and certain substance 
use disorders. Additionally, hyponatremia of any cause, including from drug 
side effects in patients being treated for psychiatric illnesses, can cause or worsen 
psychiatric conditions and may lead to medical comorbidities. References used in 
this chapter include articles from an online PubMed search of hyponatremia and 
psychosis spanning the past 50 years, and various Up-to-date review articles. In this 
chapter we dissect these conditions and open with a typical patient case.
1.1 Case
Lucia is a 19 year old junior majoring in Mathematics and Literature. She runs 
cross-country and has fainted multiple times while training with her teammates. On 
the recommendation of her coach she went to the student medical center for a well-
ness check. She looks thin and athletic. Vital sign checks show postural hypotension 
and orthostatic increase in pulse rate. Her BMI is calculated at 18 kg/m2. She reports 
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otherwise good health and no psychiatric concerns. She is doing well in school and 
excelling on the cross-country team.
1. What additional questions might you ask to elucidate the cause of her synco-
pal episodes? 2. What additional investigation would you find helpful?
2. Eating disorders and hyponatremia
2.1 Three main types of eating disorders
Eating disorders are characterized by a disturbance in eating or eating related 
behavior and body image associated with substantial distress and psychosocial impair-
ment and/or jeopardizing physical health [1]. Anorexia Nervosa, Bulimia Nervosa, and 
Binge Eating Disorder are the most well-known and best understood eating disorders. 
Other recognized eating disorders include avoidant/restrictive food intake disorder, 
pica, and rumination disorder. This classification scheme is mutually exclusive, such 
that during one-episode patients can carry only one diagnosis at a time. In this chapter 
we discuss the diagnostic categories that lead to hyponatremia and then focus on 
detecting and treating hyponatremia in the eating disordered patient [2].
Anorexia Nervosa is distinguished by severe restriction in nutritional intake 
leading to a BMI that is less than 18.5 kg/m2 in adults, an intense fear of becoming 
fat, gaining weight, and distortion in body shape and image. This is accompanied by 
behaviors that continue to interfere with weight gain and that stimulate weight loss. 
These behaviors include exercising, restricting food, eating low calorie foods, or 
purging by using laxatives or diuretics to lose weight.
As defined by DSM-5 [1], anorexia nervosa—restricting subtype describes 
an individual whose weight loss has been accomplished primarily by dieting and 
fasting and has not engaged in recurrent episodes of binge eating or purging in the 
last 3 months. In Anorexia nervosa—binge-eating/purging subtype, the individual 
meets criteria for anorexia nervosa and has engaged in episodes of binge-eating and 
purging over the last 3 months.
Bulimia Nervosa is characterized by recurrent episodes of binge eating and 
compensatory behavior aimed at preventing weight gain, occurring at least once a 
week for at least 3 months. Like in the binge-purge subtype of Anorexia Nervosa, 
these purging behaviors may include self-induced vomiting, misuse of diuretics, or 
laxatives, or excessive exercise. Patients may also restrict by fasting.
2.2 Electrolyte disturbances
If untreated and persistent, these two types of eating disorders result in elec-
trolyte and acid-base disturbances, affecting serum and urine sodium, potassium, 
and chloride, and serum bicarbonate and pH [3]. Common electrolyte disturbances 
include hypokalemia and hyponatremia [4]. Hyponatremia is defined by a serum 
sodium concentration of <135 mEQ/L. Patients who purge consistently lose sodium 
through fluid output; self-induce vomiting, laxatives abuse leading to diarrhea; and 
diuretic abuse, leading to excessive urination. This decrease in effective circulat-
ing vascular volume stimulates the release of antidiuretic hormone (ADH) from 
the pituitary gland leading to water reabsorption through the kidneys. The body’s 
attempt to preserve volume leads to dilution of the sodium already present in 
circulation. Hyponatremia in our eating disordered patients can be associated with 
low, normal or high serum tonicity. Hyponatremia associated with hypovolemia is 
as a result of low serum tonicity. Hyponatremia may also result from excessive water 
intake or impaired renal sodium reabsorption due to chronic starvation.
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2.3 Identifying hyponatremia
A quick screen can be utilized to investigate eating disordered patterns. 
Clinicians should use a validated eating disorder questionnaire, like the Eating 
Disorder Questionnaire Online (EDQ-O) or the SCOFF (Sick Control, One, Fat, 
Food) questionnaire to assess for the presence of an eating disorder [5]. On physical 
examination, patients who purge consistently or who restrict may appear volume 
depleted with orthostatic decreases in blood pressure, increases in pulse rate and 
decreased skin turgor. In addition to a basic metabolic panel, urine electrolyte 
screens should be completed to help elucidate the etiology of the hyponatremia. 
Patients who misuse prescribed diuretics or who use copious amounts of over the 
counter diuretics will not have low urine sodium. On the other hand, patients who 
self-induce vomiting or diarrhea will have low urinary sodium because of increased 
sodium retention through the kidneys.
2.4 Treatment
Treatment depends on the severity of hyponatremia. In the case of patients with 
eating disorders, psychiatrists and nutritionists should be consulted and involved 
in treatment and care to facilitate discontinuation of purging, and excessive water 
drinking [6]. Some hospitals have developed protocols for treating such patients, 
including observed meals and caloric counting to ensure a smooth recovery when 
food is re-introduced and for prevention of refeeding syndrome [7].
3.  Psychotic illnesses, bipolar illnesses, and obsessive-compulsive 
disorder (OCD) affecting serum sodium
3.1 Psychotic illnesses
One of the most common psychotic illnesses that affect serum sodium is schizo-
phrenia. As defined by DSM-5 [1], schizophrenia is characterized by two of more of 
the following symptoms including delusions, hallucinations, disorganized speech, 
grossly disorganized or catatonic behavior, and negative symptoms (i.e. diminished 
emotional expression) that are present for a significant portion of a 1-month period 
and continuous signs of disturbance in functioning level present for at least 6 months. 
Patients with schizophrenia can experience primary psychogenic polydipsia (PPD), 
characterized by an increase of fluid intake along with excretion of excessive amounts 
of dilute urine exceeding 40–50 mL/kg of body weight [8]. It is hypothesized that 
this occurs in patients with schizophrenia due to elevated levels of dopamine that 
stimulate the thirst center [8]. In patients with schizophrenia, polydipsia prevalence 
is estimated at 6–20%, and complications can include not just hyponatremia but rhab-
domyolysis as well [9]. Severe water intoxication has also been reported in a patient 
with delusional skin infestation leading to hyponatremia [10].
3.2 Bipolar illness
PPD has also been implicated in psychiatric patients with bipolar I disorder in a 
manic state whose increase in fluid intake can lead to hyponatremia [8]. As defined 
by DSM 5, a manic episode is a distinct period of abnormally and persistently 
elevated, expansive or irritable mood with increased activity or energy lasting 
at least 1 week that is not attributable to physiological effects of substances with 
three or more of the following symptoms present including inflated self-esteem, 
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Food) questionnaire to assess for the presence of an eating disorder [5]. On physical 
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screens should be completed to help elucidate the etiology of the hyponatremia. 
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counter diuretics will not have low urine sodium. On the other hand, patients who 
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sodium retention through the kidneys.
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Treatment depends on the severity of hyponatremia. In the case of patients with 
eating disorders, psychiatrists and nutritionists should be consulted and involved 
in treatment and care to facilitate discontinuation of purging, and excessive water 
drinking [6]. Some hospitals have developed protocols for treating such patients, 
including observed meals and caloric counting to ensure a smooth recovery when 
food is re-introduced and for prevention of refeeding syndrome [7].
3.  Psychotic illnesses, bipolar illnesses, and obsessive-compulsive 
disorder (OCD) affecting serum sodium
3.1 Psychotic illnesses
One of the most common psychotic illnesses that affect serum sodium is schizo-
phrenia. As defined by DSM-5 [1], schizophrenia is characterized by two of more of 
the following symptoms including delusions, hallucinations, disorganized speech, 
grossly disorganized or catatonic behavior, and negative symptoms (i.e. diminished 
emotional expression) that are present for a significant portion of a 1-month period 
and continuous signs of disturbance in functioning level present for at least 6 months. 
Patients with schizophrenia can experience primary psychogenic polydipsia (PPD), 
characterized by an increase of fluid intake along with excretion of excessive amounts 
of dilute urine exceeding 40–50 mL/kg of body weight [8]. It is hypothesized that 
this occurs in patients with schizophrenia due to elevated levels of dopamine that 
stimulate the thirst center [8]. In patients with schizophrenia, polydipsia prevalence 
is estimated at 6–20%, and complications can include not just hyponatremia but rhab-
domyolysis as well [9]. Severe water intoxication has also been reported in a patient 
with delusional skin infestation leading to hyponatremia [10].
3.2 Bipolar illness
PPD has also been implicated in psychiatric patients with bipolar I disorder in a 
manic state whose increase in fluid intake can lead to hyponatremia [8]. As defined 
by DSM 5, a manic episode is a distinct period of abnormally and persistently 
elevated, expansive or irritable mood with increased activity or energy lasting 
at least 1 week that is not attributable to physiological effects of substances with 
three or more of the following symptoms present including inflated self-esteem, 
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decreased need for sleep, pressured speech, flight of ideas, distractibility, increased 
goal directed activity, and excessive involvement in activities that have a high 
potential for painful consequences such as gambling, sexual indiscretions, and 
unrestrained buying sprees. The presence of mania distinguishes bipolar I from 
bipolar II; in bipolar I a patient must meet criteria for a manic episode, which 
may have been preceded or followed by a hypomanic or major depressive episode. 
Additionally, as defined by DMS 5 [1], bipolar disorder type II is diagnosed when 
the individual meets criteria for a current or past hypomanic episode and a current 
or past major depressive episode. A hypomanic episode is defined by DSM 5 [1] as 
a distinct period of abnormally and persistently elevated, expansive or irritable 
mood with increased activity or energy lasting at least 4 days with three or more 
of the following symptoms present including inflated self-esteem, decreased need 
for sleep, pressured speech, flight of ideas, distractibility, increased goal directed 
activity, and excessive involvement in activities that have a high potential for pain-
ful consequences such as gambling, sexual indiscretions, and unrestrained buying 
sprees. Major depressive episode includes 5 or more of the following symptoms 
over a 2-week period that represent a change from previous functioning such as 
depressed mood, diminished interest in activities, significant change in weight, 
insomnia or hypersomnia, psychomotor agitation or retardation, loss of energy, 
feelings of worthlessness, decreased ability to concentrate, and recurrent thoughts 
of death.
3.3 Obessive compulsive disorder (OCD)
Obsessive-compulsive disorder as defined by DSM 5 [1] is characterized by the 
presence of obsessions, compulsions or both. Obsessions are recurrent or persistent 
intrusive thoughts that cause marked anxiety or distress that individuals try to 
ignore or suppress by performing compulsions such as repetitive behaviors or men-
tal acts including hand washing, praying, or checking behaviors. The obsessions and 
compulsions are time consuming, and distressing, and are not attributed to another 
medical condition. An interesting case of an Indian woman has been reported in 
the literature, where her behaviors of excessive water intake, intrusiveness, exces-
sive washing, cleaning, checking and perfectionism led to a diagnosis of OCD. She 
had experienced recurrent seizures with no benefit from antiepileptic medication, 
and only after further assessment it was discovered that her urge to drink excessive 
water led to consumption of 7 L of water producing hyponatremia and seizure [11]. 
This case is important because it highlights how a psychiatric condition (OCD) can 
present as a neurological emergency [11].
4.  Low serum sodium from other medical conditions contributing to 
mental health conditions
Exclusive relationships between hyponatremia, depression symptoms, and 
cognitive impairments have been reported in patients with chronic kidney disease 
who are also undergoing hemodialysis [12]. In DSM-5 [1], major depressive disorder 
is defined as a change from previous functioning that includes 5 or more of the 
following symptoms over a 2-week period of time such as depressed mood, dimin-
ished interest in activities, significant change in weight, insomnia or hypersomnia, 
psychomotor agitation or retardation, loss of energy, feelings of worthlessness, 
decreased ability to concentrate, and recurrent thoughts of death. Major neuro-
cognitive disorder is characterized by significant cognitive decline from a previous 
level of functioning in one or more cognitive domains including complex attention, 
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executive function, learning and memory, language, perceptual motor, or social 
cognition that interfere with independence in everyday activities.
Hyponatremia has also been reported in association with catatonia and delirium, 
highlighting the profound effect that hyponatremia can have on one’s mental status 
[13]. As defined by DSM 5 [1], catatonia includes a clinical picture dominated 
by three or more of the following symptoms including stupor, catalepsy (passive 
induction of posture held against gravity), waxy flexibility (slight, even positioning 
by examiner), mutism, negativism (opposition or no response), posturing, man-
nerism (odd, circumstantial caricature of normal actions), steryotypy (repetitive, 
abnormally frequent, non-global directed movements), grimacing, agitation, 
echolalia (mimicking another’s speech), and echopraxia (mimicking another’s 
movements). Mechanisms of hyponatremia leading to catatonia are not well 
elucidated. Based on case reports, it has been demonstrated multiple times that 
catatonia and delirium do occur in the context of hyponatremia. Some hypothesize 
that vasopressin regulation mediates the development of hyponatremia when one 
has catatonia with psychosis. While others argue that because only some Addison’s 
disease patients develop hyponatremia (potential implication of aldosterone as 
regulator of sodium and water balance in the distal tubules and collecting ducts 
of the kidneys) and only some of those develop catatonia that therefore there is a 
presence of susceptibility of unknown reasons with hyponatremia causing catato-
nia [13]. DSM 5 [1] defines delirium as a disturbance in attention, awareness, and 
cognition that develops over a short period of time and tends to fluctuate in severity 
over the course of the day.
5.  Drug side effects and drug-drug interactions affecting serum sodium 
in patients being treated for psychiatric conditions
5.1  Antidepressants and non-steroidal anti-inflammatory drugs (NSAIDs) 
implicated in hyponatremia
Among the classes of medications used to treat psychiatric conditions there are 
many side effects and interactions that may alter serum sodium. This is a critical 
consideration as many of the symptoms of hyponatremia, particularly generalized 
malaise and alterations in appetite can mimic symptoms of depression. A recent 
case report documented duloxetine induced hyponatremia, including symptoms 
such as “unsteady gait, dizziness, nausea, general malaise and poor appetite,” 
resolved by discontinuing duloxetine [14]. Serotonin Norepinephrine Reuptake 
Inhibitors (SNRIs), such as duloxetine, have been associated with syndrome 
of inappropriate antidiuretic hormone (SIADH) with resulting hyponatremia. 
Hyponatremia results from an inappropriately high release of antidiuretic hormone 
(ADH) from the posterior pituitary, which results in an excess retention of water 
and a low serum osmolality. In particular SNRIs act primarily to inhibit the reuptake 
of both serotonin and noradrenaline, and in experimental models it has been shown 
that both serotonin and noradrenaline can result in the increased release of ADH 
(in rat models serotonin (5-HT) activated 5-HT1A receptors cause sympathoexcita-
tion of 5HT1C and 5HT2 receptors and the release of ADH; also stimulation of the 
paraventricular and supraoptic nuclei with norepinephrine can increase release of 
ADH within the serum) [14]. Therefore, through these mechanisms it is hypoth-
esized that SNRIs cause SIADH in patients, a life-threatening side effect that must 
be monitored for by clinicians.
A case report of a patient diagnosed with schizophrenia, taking desmopressin 
and meloxicam identified that NSAIDs can significantly augment hyponatremia 
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by “increas[ing] water retention” [15]. Notably, the worsened water retention is 
particularly problematic for patients on desmopressin, and complete resolution 
of symptoms occurred after desmopressin was tapered and meloxicam stopped, 
with normalization in plasma sodium [15] (Figure 1, used with permission from 
authors).
5.2 Other medications and interactions implicated in hyponatremia
Fabrazzo et al. [16] discuss three cases involving delorazepam, olanzapine and 
fluvoxamine, respectively, in which patients with various presentations of bipolar 
disorder were hospitalized, and hyponatremia was discovered on admission. 
Workup revealed SIADH. Multiple interventions were trialed, including adminis-
tration of hypertonic saline, and decreasing doses of various medications. It was not 
until the offending medications were removed that patients demonstrated resolu-
tion of their hyponatremia. Notably, olanzapine, fluvoxamine and delorazepam 
were being administered in conjunction with other medications that may have 
contributed to the hyponatremia. In the case of the patient taking delorazepam, 
they also were prescribed oxcarbazepine, which ultimately was replaced with 
gabapentin. In the case of the patient taking olanzapine, he also was taking delo-
razepam and oxcarbazepine. Likewise, the patient on fluvoxamine was also taking 
oxcarbazepine. These medications in conjunction with one another appear to have 
an additive property on hyponatremia.
5.3 Additional considerations for antipsychotics and hyponatremia
Antipsychotic medications alone have been reported in the literature to be asso-
ciated with hyponatremia; however, recently, the long-acting risperidone injectable 
treatment has been implicated in hyponatremia as well. In this case, the patient did 
not improve simply with the removal of risperidone, due to the extended half-life, 
and ultimately required Tolvaptan administration [17]. The half-life of these medi-
cations may be an important factor in determining the management of subsequent 
hyponatremia. Along a similar vein, Fabrazzo et al. [16] detail that hyponatremia 
and other electrolyte derangements are often only detected in patients with psychi-
atric diagnoses when they are hospitalized. This is a critical consideration for clini-
cians in terms of practice, particularly whether there is an impetus for psychiatrists 
Figure 1. 
Plasma sodium levels over time.
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to consider routinely monitoring electrolytes of patients on longstanding medica-
tions with the potential for these derangements, especially in patients with bipolar 
disorder.
5.4 Practice considerations
There currently are no routine guidelines for screening of electrolyte abnormali-
ties among patients with psychiatric diagnoses and this should be further evaluated 
given the range of dangerous consequences of hyponatremia, including seizure, as 
demonstrated in at least one of the cases delineated above [15].
6. Alcohol and other substance use disorders affecting serum sodium
6.1 Alcohol and hyponatremia
Substance use is also implicated in derangements of serum sodium, particularly 
among patients who abuse alcohol and MDMA. As defined by DSM 5 [1], alcohol 
use disorder is a pattern of alcohol use within the past 12 months that has led to 
significant impairment in one’s life characterized by at least two of the following 
including alcohol taken in larger amounts, persistent desire to cut down, increased 
time obtaining alcohol, cravings, continued use despite recurrent impairment in 
social functioning, developed tolerance, and withdrawal symptoms present when 
alcohol use is ceased. As delineated in previous sections, there are profound poten-
tial consequences of hyponatremia, particularly because of sodium’s role in main-
taining nerve impulse conduction and neuromuscular excitability. Michal et al. [18] 
observed that in patients with likely alcohol use disorder, the level of derangement 
in serum sodium was associated with the worsening of physical and psychological 
quality of life; that is to say, patients with severe hyponatremia (<120 mmol/L) 
were likely to have worse quality of life than patients with low hyponatremia 
(<135 mmol/L) [18]. The specific causal pathways are not delineated; however, beer 
potomania is an observed phenomenon in which dietary insufficiency of protein, 
coupled with dietary sodium results in a sort of dilutional hyponatremia. It is pos-
sible that patients with more severe hyponatremia may be further in their disease 
course, ultimately consuming more alcohol.
6.2 MDMA (3,4-methylenedioxymethamphetamine) and hyponatremia
Stimulant use disorder in DSM-5 [1] is defined as a pattern of stimulant use 
within the past 12 months that has led to significant impairment in one’s life char-
acterized by at least two of the following including the stimulant is taken in larger 
amounts, persistent desire to cut down, increased time obtaining the stimulant, 
cravings, continued use despite recurrent impairment in social functioning, 
developed tolerance, and withdrawal symptoms present when stimulant use is 
ceased. MDMA (3,4-methylenedioxymethamphetamine), a stimulant, is thought to 
be associated with hyponatremia because of increased diaphoresis, yielding sodium 
loss, and compensatory water intoxication. It is not a common side effect of MDMA 
use; however, Armitage et al. [19] presented a case report of an 18-year-old woman 
who had a generalized tonic-clonic seizure in the setting of hyponatremia from 
MDMA intoxication. This woman’s serum sodium was 121, notably close to what 
many would argue is severe hyponatremia. Notably, MDMA related hyponatremia 
with seizure is more common among young women under 30 years of age, particu-
larly because of estrogen inhibiting the Na+-K+-ATPase. This ultimately inhibits 
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by “increas[ing] water retention” [15]. Notably, the worsened water retention is 
particularly problematic for patients on desmopressin, and complete resolution 
of symptoms occurred after desmopressin was tapered and meloxicam stopped, 
with normalization in plasma sodium [15] (Figure 1, used with permission from 
authors).
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disorder were hospitalized, and hyponatremia was discovered on admission. 
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Figure 1. 
Plasma sodium levels over time.
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to consider routinely monitoring electrolytes of patients on longstanding medica-
tions with the potential for these derangements, especially in patients with bipolar 
disorder.
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ceased. MDMA (3,4-methylenedioxymethamphetamine), a stimulant, is thought to 
be associated with hyponatremia because of increased diaphoresis, yielding sodium 
loss, and compensatory water intoxication. It is not a common side effect of MDMA 
use; however, Armitage et al. [19] presented a case report of an 18-year-old woman 
who had a generalized tonic-clonic seizure in the setting of hyponatremia from 
MDMA intoxication. This woman’s serum sodium was 121, notably close to what 
many would argue is severe hyponatremia. Notably, MDMA related hyponatremia 
with seizure is more common among young women under 30 years of age, particu-
larly because of estrogen inhibiting the Na+-K+-ATPase. This ultimately inhibits 
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a known compensatory mechanism for cerebral edema, which may place young 
women at increased risk of neurological impacts of hyponatremia with MDMA 
use. Further, a metabolite of MDMA, 4-hydroxy-3-methoxymethamphetamine 
(HMMA), is documented to stimulate ADH release, which can worsen hyponatre-
mia. These are vital considerations given the potential sequela of seizure, and the 
urgency of its management.
7.  General treatment considerations for hyponatremia in psychiatric 
illnesses
Here, we aim to describe general considerations of hyponatremia by going over 
symptoms, treatment, and cautions.
7.1 Summary of general symptoms of hyponatremia
Symptoms of hyponatremia can be thought of as severe, moderate, and mild. 
Severe symptoms are red flag signs that include seizure and changes in cogni-
tion that can rapidly progress to coma and death. These symptoms are classically 
correlated with serum levels of less than 120. As such, these are the constellation 
of symptoms that would require hospitalization. Moderate and mild symptoms 
differ in severity but include flu like symptoms of headache, myopathy, and general 
malaise; these symptoms are observed mostly with sodium serum level ranges from 
120 to 135. Lastly, there are patients who have low serum levels but are generally 
asymptomatic, with minimal changes in gait or sensorium [20].
7.2 Treatment of hyponatremia and cautions
When treating hyponatremia, it is important to recognize that there is a high 
risk of morbidity and mortality in conditions where hyponatremia develops within 
48 h, post-op hyponatremia in female and pediatric populations, patients with 
history of cerebral pathology, as well as those presenting with psychosis (because 
they could have ingested large amounts of water). Regardless of symptom severity, 
it is important to note that increasing serum sodium level by 4–6 mEq/L in 24 h can 
reverse symptoms, and the rate should never exceed 8 mEq/L in a day, as rates faster 
than this can increase risk of demyelination [20]. Asymptomatic hyponatremia, if 
mild, may be left untreated.
Interventions commonly used in the context of treating hyponatremia include 
fluid restriction, increasing dietary salt, potassium replacements, hypertonic saline, 
and vasopressin antagonists, with selection based on the etiology and severity 
of the hyponatremia. Fluid restriction is most helpful in the context of volume 
overload (such as heart failure or cirrhosis), SIADH, renal failure, or if the patient 
has polydipsia. The amount of fluid restriction is determined often with nutritional 
consultation; this is the gold standard approach in treatment of SIADH. Patients 
may initially start with fluid restriction to 500 mL/d. Pharmacotherapy is typically 
considered if serum sodium has not improved with fluid restriction over 48 h [21].
Pharmacotherapy includes a broad range of options, including dietary salts and 
oral salt tablets, potassium replacements and vasopressin antagonists. Dietary salts 
and oral salt tablets are generally utilized for patients with mild to asymptomatic 
symptoms with SIADH. Potassium replacements are helpful when patients are 
developing conditions that are causing hypokalemic states as well, such as inappro-
priate diuretic uses and excessive vomiting. These may be associated with feeding 
and eating disorders, and additional considerations for the treatment of those 
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disorders may include 1:1 supervision for prevention of continued vomiting, and 
consultation with nutrition to minimize risk of refeeding during early hospitaliza-
tion. Vasopressin antagonists will cause water loss, making it non-ideal for patients 
with volume deficits.
The clinician must always be wary of any contributing factors causing the 
hyponatremia; for example, if the patient has adrenal insufficiency, glucocorti-
coid replacement will be crucial. In this case, endocrinology consultation may be 
appropriate. Likewise, if the patient has drug induced SIADH, it is important to 
re-visit the necessity of the drugs and to find replacements if able; common culprits 
include SSRIs like fluoxetine and sertraline [20]. The clinician and the patient 
should have a conversation about the risks, benefits, and alternatives to continuing 
treatment with an offending agent and informed consent should be documented 
whether the medication is maintained or switched. In patients with psychogenic 
polydipsia associated with antipsychotic medication use, treatment of the underly-
ing psychotic disorder coupled with behavioral intervention to limit water intake 
may decrease the frequency of hyponatremic episodes and lessen morbidity. In 
patients with substance use disorders, particularly alcohol use disorder, psychoedu-
cation and motivational interviewing surrounding their substance use disorder and 
risks of hyponatremia, including increased risk of seizure, may be a helpful part 
of decreasing use of substance. These patients should also be offered medication 
assisted treatment for their substance use disorder when appropriate and desired by 
the patient.
In sum, hyponatremia in psychiatric conditions is best treated in a comprehen-
sive, multi modal approach. With many etiologies, including SIADH, endocrine 
pathologies, feeding and eating disorders, and delirium, consultation with different 
medical specialties and nutritional teams may augment and improve the treatment 
of hyponatremia. Regardless of etiology, psychoeducation and involvement of the 
patient in shared decision making is essential in understanding the future course of 
treatment.
8. Conclusion
Hyponatremia is a complex electrolyte disturbance which can both manifest with 
psychiatric symptoms, and can be associated with psychiatric disease itself. Eating 
disorders, psychotic illnesses, and substance use disorders are some of the more com-
mon psychiatric conditions encountered in practice that are associated with hypona-
tremia. The mechanisms that lead to hyponatremia vary, and at times hyponatremia 
may be a result of a drug side effect or drug-drug interaction. Given the potential for 
hyponatremia to cause significant morbidity and potential mortality, clinicians are 
urged to consider screening for plasma sodium in patients at risk of hyponatremia, 
such as patients in the three categories of psychiatric conditions described above. 
Treatment considerations include: (1) understanding the underlying etiology of the 
hyponatremia, (2) asymptomatic mild hyponatremia may not need treatment, (3) 
fluid restriction is the initial treatment of choice for SIADH, (4) hypertonic saline is 
used to correct moderate-severe hyponatremia, but should be done only under the 
guidance of medical teams to avoid demyelination syndromes, (5) there may be other 
considerations, such as 1:1 supervision for feeding-eating disorders, (6) specialty con-
sultation may be appropriate in determining course of treatment, such as nutrition for 
advancement of diet, or endocrinology for concomitant adrenal pathology. Treatment 
of hyponatremia consists of various acute interventions, with consideration that treat-
ment of the underlying psychiatric condition may help to diminish or eliminate the 
frequency of hyponatremic episodes in the long run.
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has polydipsia. The amount of fluid restriction is determined often with nutritional 
consultation; this is the gold standard approach in treatment of SIADH. Patients 
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Pharmacotherapy includes a broad range of options, including dietary salts and 
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and oral salt tablets are generally utilized for patients with mild to asymptomatic 
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disorders may include 1:1 supervision for prevention of continued vomiting, and 
consultation with nutrition to minimize risk of refeeding during early hospitaliza-
tion. Vasopressin antagonists will cause water loss, making it non-ideal for patients 
with volume deficits.
The clinician must always be wary of any contributing factors causing the 
hyponatremia; for example, if the patient has adrenal insufficiency, glucocorti-
coid replacement will be crucial. In this case, endocrinology consultation may be 
appropriate. Likewise, if the patient has drug induced SIADH, it is important to 
re-visit the necessity of the drugs and to find replacements if able; common culprits 
include SSRIs like fluoxetine and sertraline [20]. The clinician and the patient 
should have a conversation about the risks, benefits, and alternatives to continuing 
treatment with an offending agent and informed consent should be documented 
whether the medication is maintained or switched. In patients with psychogenic 
polydipsia associated with antipsychotic medication use, treatment of the underly-
ing psychotic disorder coupled with behavioral intervention to limit water intake 
may decrease the frequency of hyponatremic episodes and lessen morbidity. In 
patients with substance use disorders, particularly alcohol use disorder, psychoedu-
cation and motivational interviewing surrounding their substance use disorder and 
risks of hyponatremia, including increased risk of seizure, may be a helpful part 
of decreasing use of substance. These patients should also be offered medication 
assisted treatment for their substance use disorder when appropriate and desired by 
the patient.
In sum, hyponatremia in psychiatric conditions is best treated in a comprehen-
sive, multi modal approach. With many etiologies, including SIADH, endocrine 
pathologies, feeding and eating disorders, and delirium, consultation with different 
medical specialties and nutritional teams may augment and improve the treatment 
of hyponatremia. Regardless of etiology, psychoeducation and involvement of the 
patient in shared decision making is essential in understanding the future course of 
treatment.
8. Conclusion
Hyponatremia is a complex electrolyte disturbance which can both manifest with 
psychiatric symptoms, and can be associated with psychiatric disease itself. Eating 
disorders, psychotic illnesses, and substance use disorders are some of the more com-
mon psychiatric conditions encountered in practice that are associated with hypona-
tremia. The mechanisms that lead to hyponatremia vary, and at times hyponatremia 
may be a result of a drug side effect or drug-drug interaction. Given the potential for 
hyponatremia to cause significant morbidity and potential mortality, clinicians are 
urged to consider screening for plasma sodium in patients at risk of hyponatremia, 
such as patients in the three categories of psychiatric conditions described above. 
Treatment considerations include: (1) understanding the underlying etiology of the 
hyponatremia, (2) asymptomatic mild hyponatremia may not need treatment, (3) 
fluid restriction is the initial treatment of choice for SIADH, (4) hypertonic saline is 
used to correct moderate-severe hyponatremia, but should be done only under the 
guidance of medical teams to avoid demyelination syndromes, (5) there may be other 
considerations, such as 1:1 supervision for feeding-eating disorders, (6) specialty con-
sultation may be appropriate in determining course of treatment, such as nutrition for 
advancement of diet, or endocrinology for concomitant adrenal pathology. Treatment 
of hyponatremia consists of various acute interventions, with consideration that treat-
ment of the underlying psychiatric condition may help to diminish or eliminate the 
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9. Case consideration
1. The patient should have a comprehensive assessment, which includes a medical 
interview, physical exam, and tests as needed. This assessment should include 
questions about diet, alcohol and drug use, exercise regimen, and past and 
current medical and psychiatric histories.
2. Additional investigations can include checking blood electrolytes and an 
EKG. In patients with eating disorders, one can see derangements in sodium 
and potassium (usually hyponatremia or hypokalemia or both). EKG may 
show QT prolongation.
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provided the original work is properly cited. 
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Maintenance of accurate postural balance is imperative to avoid falls and inca-
pacities especially in overweight and older population. Normal postural balance is
affected by various factors like age, gender, body characteristics like lean muscle
mass, soft tissue mass, stature, foot anthropometry, etc. A cross-sectional study was
conducted among 1000 young population of north Karnataka in which human
stature, weight, body mass index, foot anthropometric parameters, etc. along with
postural sway were measured. The correlation of these parameters with human
stature, weight and postural sway was studied. Data obtained were tabulated,
graphically represented and statistically analyzed. Correlation coefficient was for-
mulated for each variable. Foot length and width showed positive significant corre-
lation with height, weight and other variables. Study observations were compared
with those obtained from previous studies. The study observations will enable us to
understand the influence of foot anthropometry on postural balance and help
researchers to formulate weight transfer strategies, thereby facilitating manage-
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1. Introduction
Postural balance is dynamic and demands constant amendments to adapt to
external disturbances, by using vision, muscle activity, articular positioning and
proprioception, and the vestibular system to prevent falls [1, 2]. Awareness of the
body’s position in space is determined by the integration of the visual, vestibular
and somatosensory systems [3, 4]. The study of postural control is imperative for
diagnosing balance disorders, as well as for assessing the effects of both therapeutic
interventions and fall prevention programs. Postural stability is determined by
mechanical factors that include both individual and environmental characteristics.
This chapter focuses on various factors influencing the bipedal postural stability and
provides an insight into the measures to facilitate improvement in the accuracy of
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1. Introduction
Postural balance is dynamic and demands constant amendments to adapt to
external disturbances, by using vision, muscle activity, articular positioning and
proprioception, and the vestibular system to prevent falls [1, 2]. Awareness of the
body’s position in space is determined by the integration of the visual, vestibular
and somatosensory systems [3, 4]. The study of postural control is imperative for
diagnosing balance disorders, as well as for assessing the effects of both therapeutic
interventions and fall prevention programs. Postural stability is determined by
mechanical factors that include both individual and environmental characteristics.
This chapter focuses on various factors influencing the bipedal postural stability and
provides an insight into the measures to facilitate improvement in the accuracy of
diagnosis and quality of treatment and rehabilitation, thereby preventing falls and
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2. Evolution of bipedal posture
Our ancestors would have probably become extinct if they had not developed
their bipedal posture including the corresponding transitional behavioral con-
straints. “Bipedalism evolved more as a terrestrial feeding posture than as a walking
adaptation” [5]. The adapted bipedal posture brought various disadvantages like
decreased velocity, increased time for social interaction, more chances of injuries
from fall, more energy consumption, etc.
Advantages of bipedal posture could be many, namely freeing of hands, the visual
advantage of being able to survey the surrounding, ability to acquire the skill of
throwing, ability to carry infants while running, ability to reach out for food, ability
for carrying food or provisioning, etc. But the most important hypothesis is that the
ability to venture into shallow water made the ancestors to adapt bipedal posture.
3. Biomechanics of bipedal posture
Upright postural balance describes the dynamics of body posture to prevent
falling over a relatively small base of support under gravitational field. As for
postural balance without stepping, the stable balancing condition can be analyzed
using the following equation under assumption that a one link inverted pendulum
describes human sway motions.
Fy:xcop–Mg:xcom ¼ I θa: (1)
where Fy is vertical reaction force, Mg is human total weight, xcop is the center
of pressure (COP), xcom is the horizontal component of the center of mass (COM)
(e.g., the center of gravity (COG)), I is the moment of inertia of the total body
about the ankle joint, and θa is the ankle joint angle [6].
Two basic models for biped locomotion are walking and running. A gait of
walking consists of stance and swing phases and a gait of running consists of stance
and flight phases. Stance phase describes the period when a foot remains on the
ground, and either swing or flight describes the period when a foot does not touch
the ground. At midstance, the COM is at its highest point and gravitational potential
energy is at maximal and kinetic energy at minimal. The exchange between kinetic
and gravitational potential energies is cyclical over gaits. On the other hand, a
running leg acts as a spring; therefore, a simple running model is a mass-spring
system. At the braking phase during stance, the spring gets compressed and ener-
gies are stored as elastic energy. At midstance, the COM reaches its lowest point.
The stored elastic energy recoils the spring at propulsive phase during stance to
produce kinetic and gravitational potential energies. Both models principally
exchange and store energies repeatedly to produce forward thrust and stability [6].
4. Factors affecting postural balance
Numerous determinants like age, gender and body characteristics like body
mass, height and body mass index affect postural stability. Anthropometric param-
eters of ankle joint and foot also affect bipedal and unipedal postural stability.
4.1 Effect of age and gender on postural balance
Vijada Raiva et al. [6] stated that females have more postural stability than
males. Hageman et al. [7] stated that compared to younger population, older
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generation showed more tendency to sway. Older adults performed the timed
movement task much slower than the younger adults. Longer response times by the
elderly have been attributed to slower event detection and impaired sensorimotor
integration. Greve et al. [8] stated that women showed less movement on Biodex
Balance System than men did, and these findings were similar to those of Rozzi
et al. [9] who evaluated basketball and American football players using the same
equipment. Lee and Lin [10] studied children and observed that girls presented
better postural balance than boys. This could be due to anthropometric factors
(greater in men), but other factors such as neuromuscular (flexibility) and neuro-
physiologic (processing of inferences), as well as the habit of using higher heels,
may also account for the differences.
4.2 Effect of body mass on postural balance
Ledin and Odkvist [11] demonstrated that a 20% increase in body mass reduced
the ability to make adjustments in response to external perturbations in the ortho-
static position, with a consequent increase in postural instability. Chiari et al. [12]
and Molikova et al. [13] in their respective studies conducted on individuals with
normal or slightly higher than normal BMI have shown low correlations between
body mass and balance. Majority of studies indicate that there was a direct rela-
tionship between obesity and increased postural instability, as evaluated by means
of various tools and methods. Greve et al. [14] showed that in young adult males,
the higher the BMI, the worst the postural balance, needing more postural adjust-
ments to maintain balance in single leg stance. Greve et al. [8] proposed that the
male group demonstrated stronger correlations for overall, anteroposterior and
mediolateral stability index with body mass index (BMI) compared to women. They
stated that there was a need for greater movements to maintain postural balance.
Hue et al. [15] found that body mass was responsible for more than 50% of balance
at speed and Chiari et al. [12] demonstrated a strong correlation between body
mass, anteroposterior movements and the area of detachment. McGraw et al. [16]
reported that greater postural adjustments are necessary to maintain an erect pos-
ture when there is a build-up of adipose tissue, thus causing a reduction in balance
and an increase in injuries and falls. Due to the high degree of correlation between
balance and body mass, we can safely infer that the mechanical factor of body mass
inertia requires greater musculoskeletal force to balance it against the force of
gravity, and therefore, to maintain balance, obese individuals require greater
movement from the center of gravity to remain in the orthostatic position.
4.3 Impact of stature on postural balance
There is a consensus that the greater the height, the worse the balance. Berger
et al. [17] and Alonso et al. [3] stated that ankle displacements and the response of
the gastrocnemius increased with increasing height. Allard et al. [18] and Lee and
Lin [10] reported that tall individuals present greater postural sway than do short
individuals, and they attributed this to the higher position of the center of mass.
Kejonen et al. [19] and Hue et al. [15] have found that body stability is inversely
related to the height of the center of gravity and that, for this reason, posturography
measurements are affected by individuals’ anthropometric characteristics.
4.4 Role of foot anthropometry in maintaining postural balance
The architecture of the vertebral column, upper and lower appendages, and
organs and tissues that attach to or are suspended from the spinal column affects
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postural stability. Very few studies are available on correlation of foot parameters
with unipedal and bipedal postural balance [18].
4.5 Effect of muscle strength and fatigue on postural balance
As the age advances particularly after forties, the muscle mass goes on decreas-
ing so does the muscle strength. Muscle fatigue, which is a common condition
affecting the elderly population, can result in mobility, postural and gait deficien-
cies. The state of mind can influence the activity of the muscular system, that is, the
muscular tonus. The muscular activation or, in the contrary case, the muscular
relaxation influences postures adopted by people. The body height and the lower
limb length constitute partly to weight transfer strategy. The trunk-cephalic length
does not correlate to the postural sway. Body mass is located above the hips, so it is
not the main factor for the mediolateral sway. The weight transfer strategy for men
depends on the size of the basis of support and their lean mass, while, for women,
only the lengths (whole body and lower limbs) are important. Lower basis of
supports leads to higher postural sway in the ML direction (Chiari et al. [11]; Chou
et al., [20]), and to control the increase in body sway, it is necessary to increase the
lean mass, probably and mainly the muscle mass to be able to generate more muscle
force. The increase in body height affects the body mass and soft tissue mass (lean
and fat masses) increases the postural sway. The increase in body mass indeed
enlarges the postural sway.
5. Research study
A study was conducted in central population of northern Karnataka on 1000
young adult population in which foot anthropometry was measured and correlated
with stature, weight, body mass index and bipedal posture stability [21].
6. Methodology
Study design: Descriptive cross-sectional study.
Setting: Anthropometric section of department of Anatomy, ESIC Medical
College and Hospital, Gulbarga, Karnataka.
Duration of study: 14 months; from 31 October 2017 to 31 December 2018.
Sample size: 1000 participants included medical, dental and nursing students
aged between 18 and 21 years of age.
Inclusion criteria: Medical, dental and nursing students aged between 18 and
21 years of age in ESIC Medical College, Gulbarga.
Exclusion criteria: Students of NRI quota and students with poorly defined
wrist creases, deformities of vertebral column and limbs, contractures, missing
limbs, history of trauma to hand and foot, with features suggestive of dysmorphic
syndromes, chronic illness and hormonal therapy were excluded from the study.
Sample selection: Simple random sampling method [13] as we selected 1000
participants out of total 3000 medical, dental and nursing students in our institute
satisfying the inclusion criteria. As subjects belonging to the first to third year, they
were easily accessible and also represented the young adult age group.
6.1 Data collection procedure
Foot length: Each subject will stand on a calibrated foot board with his/her back
against the wall in such a manner that the posterior most point of the heel will
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gently touch the wall. A vertical stop was placed against the anterior most point of
the foot. The distance between the posterior most point of the heel and the anterior
most point of the foot was measured as the foot length [22] (Figure 1).
Foot breadth: It will be measured as distance between metatarsal tibiale
(point projecting most medially on the head of the 1st metatarsal bone) and
metatarsal fibulare (point projecting most laterally on the head of the 5th metatarsal
bone) [23].
Height: Standing height will be measured to the nearest centimeters (cm) using
a stadiometer with the subject standing erect on a horizontal resting plane bare
footed having the palms of the hands turned inward and the fingers pointing
downwards. The height will be measured from the sole of the feet to the vertex of
the head as recommended by International Biological Program [23].
Body weight: It will be taken using the Mechanical Weighing Balance to the
nearest kg according to the standard procedures A. Ibegbu, David et al. [24].
Body mass index: It will be calculated by dividing weight by height squared
[weight/height squared (kg/m2)] David et al. [24].
6.2 Data collection tools
Vernier slide calipers, calibrated foot board, stadiometer, regular weight
machine, questionnaire for collection of personal details, academic scores, lead
pencils, stationary, etc. Data collected were tabulated, graphically represented and
statistically analyzed.
7. Observations
In our study, mean foot length was observed as 24.34 cm on the right side and
24.32 cm on the left side. Mean body mass index was calculated as 20.97. Correla-
tion between foot length and body mass index was done. No statistically significant
correlation between BMI and foot length of the right and left sides (P > 0.05) was
observed. For further details, refer to Table 1.
In the present study, mean foot breadth was observed as 8.95 cm on the right
side and 8.96 cm on the left side. Mean body mass index was calculated as 20.97.
Correlation between foot length and body mass index was done. There was a
Figure 1.
Measurement of foot length.
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statistically significant correlation between BMI and foot breadth of the right and
left sides (P < 0.01). The observations in the study stated that foot breadth of both
sides was considerably more in participants who had higher body mass index.
Linear regression coefficient was derived. For further details, refer to Table 2,
Figure 2.
Variables Minimum Maximum Range Mean SD N Correlation r P value
Body mass index
(kg/m2)
12.22 40.61 28.39 20.97 4.66 1000 — —
Foot length
right (cm)




21.5 29.0 7.5 24.32 1.50 1000 r = 0.024 P > 0.05
NS
Table 1.
Correlation of foot length and body mass index.
Variables Minimum Maximum Range Mean SD N Correlation r P value
Body mass index
(kg/m2)
12.22 40.61 28.39 20.97 4.66 1000 — —
Foot breadth
right (cm)








BMI = 19.306 + 0.168 (foot breadth right)
Linear regression
equation
BMI = 17.214 + 0382 (foot breadth left)
Table 2.
Correlation of foot breadth and body mass index.
Figure 2.
Correlation between foot length and body mass index.
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Variables Minimum Maximum Range Mean SD N Correlation r P value
Height (cm) 135.2 195.2 60.0 161.88 13.45 1000 — —
Foot length
right (cm)








Height = 71.391 + 4.782 (foot length right)
Linear regression
equation
Height = 49.706 + 4.786 (foot length left)
Table 3.
Correlation of foot length and human stature.
Figure 3.
Measurement of foot breadth.
Figure 4.
Correlation between foot breadth and body mass index.
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Height (cm) 135.2 195.2 60.0 161.88 13.45 1000 — —
Foot length
right (cm)








Height = 71.391 + 4.782 (foot length right)
Linear regression
equation
Height = 49.706 + 4.786 (foot length left)
Table 3.
Correlation of foot length and human stature.
Figure 3.
Measurement of foot breadth.
Figure 4.
Correlation between foot breadth and body mass index.
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We also observed foot length on both sides. Mean foot length on the right side
was observed as 24.34 cm, and on the left side, it was 24.32 cm. Correlation of foot
length was conducted with human stature. Linear regression equation was derived
for both sides. Statistically highly significant positive correlation was observed
between height and foot length of both sides (P < 0.01). Table 3 reveals that foot
length of both sides was also significantly more among those having more height
(Figures 3 and 4).
Foot breadth was observed on both sides. Mean foot breadth on the right side
was observed as 8.95 cm, and on the left side, it was 8.96 cm. Correlation of foot
breadth was conducted with human stature. Linear regression equation was derived
Variables Minimum Maximum Range Mean SD N Correlation r P value
Height (cm) 135.2 195.2 60.0 161.88 13.45 1000 — —
Foot breadth right
(cm)








Height = 106.01 + 6.240 (foot breadth right)
Linear regression
equation
Height = 96.843 + 7.253 (foot breadth left)
Table 4.
Correlation of foot breadth and human stature.
Figure 5.
Measurement of human stature.
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for both sides. Statistically highly significant positive correlation was observed
between height and foot breadth of both sides (P < 0.01). Table 4 reveals that foot
breadth of the right or left side was significantly more in those participants whose
height was more (Figures 5 and 6).
Gender-wise comparison of observations was done. We observed very highly
significant difference in foot length, foot breadth, height and weight among males
and females. The foot length, foot breadth, height and weight were significantly
more in males compared to females, whereas body mass index was significantly
more in females as compared to males. The observations have been tabulated in
Table 5, Figures 7 and 8.
Postural sway was measured in the participants both male and female in
anteroposterior and mediolateral direction (Figure 9). Correlation of postural sway
with foot length and foot breadth was conducted. Mediolateral postural sway
amplitude was the same, that is, 0.3 cm in both males and females.
Figure 6.











Foot length right (cm) 25.18  1.32 23.39  1.19 Z = 30.07 P < 0.001, VHS
Foot length left (cm) 25.31  1.16 23.19  0.96 Z = 31.19 P < 0.001, VHS
Foot breadth right
(cm)
9.39  0.71 8.45  0.52 Z = 22.97 P < 0.001, VHS
Foot breadth left (cm) 9.35  0.59 8.52  0.47 Z = 23.21 P < 0.001, VHS
Height (cm) 169.28  11.75 153.42  9.75 Z = 22.26 P < 0.001, VHS
Weight (kg) 58.21  11.91 50.14  9.85 Z = 11.21 P < 0.001, VHS
BMI (kg/m2) 20.58  4.94 21.41  4.27 Z = 2.53 P < 0.05, S
NS, not significant; S, significant; HS, highly significant; VHS, very highly significant.
Table 5.
Gender-wise comparison of parameters.
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breadth of the right or left side was significantly more in those participants whose
height was more (Figures 5 and 6).
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and females. The foot length, foot breadth, height and weight were significantly
more in males compared to females, whereas body mass index was significantly
more in females as compared to males. The observations have been tabulated in
Table 5, Figures 7 and 8.
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anteroposterior and mediolateral direction (Figure 9). Correlation of postural sway
with foot length and foot breadth was conducted. Mediolateral postural sway
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Figure 7.
Correlation between foot breadth and stature.
Figure 8.
Multiple bar diagram represents gender-wise comparison of variables.
Figure 9.
Gender-wise comparison of parameters.
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Anteroposterior sway amplitude was .95 cm in females and  .10 cm in males.
It was observed that men exhibited more postural sway compared to
females in anteroposterior direction. The findings were statistically signifi-
cant. Refer to Table 6 for details.
8. Discussion
Few studies have worked on the relationship of foot anthropometry with bal-
ance. Clarke [25] analyzed the angle of foot. Swanenburg et al., [26] examined static
posturography using the center of pressure (COP) oscillation on a force platform.
Our study suggested association between greater foot length and higher
stabilometric parameters only in the male group. Our study observations matched
with those of Alonso et al. [27], Kejonen et al., [19] and Molikova et al., [13].
Previous studies by Alonso et al., [3] and Chou et al., [20] also demonstrated that an
increase in the size of the support base can improve the balance.
Our study states that neither the foot length nor the foot width influences
postural balance. These observations matched with Alonso et al., [28], but they had
conducted the study using unipedal standing balance task. Our findings
contradicted with those of Chiari et al.[12] in which foot width showed positive
correlation with postural balance. They conducted the study by bipedal standing
balance task. They stated that the increase in lean mass correlates to the decrease of
the amplitude of the postural sway. They added that the percentage of fat mass
explains part of the anteroposterior postural sway in men, but not in women.
Mainenti et al. [29] showed that elderly women with more fat mass had larger
balance sway and Winters and Snow [30] reported that 31% of postural sway
variability in premenopausal women was caused by the fat mass. Hence, it can be
concluded that the effect of fat mass on the postural control is age dependent.
Variables Foot length (cm) r(p) Foot breadth (cm) Angle (°)
Female
Mediolateral sway (cm) 0.01 (0.88) 0.01 (0.80) 0.01 (0.89)
Mediolateral ampl sway (cm) 0.05 (0.54) 0.01 (0.82) 0.03 (0.70)
Anteroposterior sway (cm) 0.07 (0.43) 0.05 (0.53) 0.12 (0.21)
Anteroposterior ampl sway (cm) 0.09 (0.35) 0.11 (0.25) 0.95 (0.35)
Sway velocity (cm/s) 0.05 (0.56) 0.12 (0.22) 0.11 (0.25)
Sway area (cm2) 0.67 (0.50) 0.24 (0.80) 0.12 (0.22)
Male
Mediolateral sway (cm) 0.32 (0.00) 0.02 (0.84) 0.04 (0.68)
Mediolateral ampl sway (cm) 0.27 (0.00) 0.02 (0.83) 0.03 (0.69)
Anteroposterior sway (cm) 0.29 (0.00) 0.00 (0.94) 0.11 (0.24)
Anteroposterior ampl sway (cm) 0.27 (0.00) 0.06 (0.52) 0.10 (0.31)
Sway velocity (cm/s) 0.15 (0.13) 0.08 (0.42) 0.09 (0.37)
Sway area (cm2) 0.36 (0.00) 0.02 (0.78) 0.10 (0.32)
Spearman’s correlation, *ρ ≤ 0.05. ampl, amplitude.
Table 6.
Correlation between foot anthropometric measurements and postural balance.
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Figure 7.
Correlation between foot breadth and stature.
Figure 8.
Multiple bar diagram represents gender-wise comparison of variables.
Figure 9.
Gender-wise comparison of parameters.
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Anteroposterior sway amplitude was .95 cm in females and  .10 cm in males.
It was observed that men exhibited more postural sway compared to
females in anteroposterior direction. The findings were statistically signifi-
cant. Refer to Table 6 for details.
8. Discussion
Few studies have worked on the relationship of foot anthropometry with bal-
ance. Clarke [25] analyzed the angle of foot. Swanenburg et al., [26] examined static
posturography using the center of pressure (COP) oscillation on a force platform.
Our study suggested association between greater foot length and higher
stabilometric parameters only in the male group. Our study observations matched
with those of Alonso et al. [27], Kejonen et al., [19] and Molikova et al., [13].
Previous studies by Alonso et al., [3] and Chou et al., [20] also demonstrated that an
increase in the size of the support base can improve the balance.
Our study states that neither the foot length nor the foot width influences
postural balance. These observations matched with Alonso et al., [28], but they had
conducted the study using unipedal standing balance task. Our findings
contradicted with those of Chiari et al.[12] in which foot width showed positive
correlation with postural balance. They conducted the study by bipedal standing
balance task. They stated that the increase in lean mass correlates to the decrease of
the amplitude of the postural sway. They added that the percentage of fat mass
explains part of the anteroposterior postural sway in men, but not in women.
Mainenti et al. [29] showed that elderly women with more fat mass had larger
balance sway and Winters and Snow [30] reported that 31% of postural sway
variability in premenopausal women was caused by the fat mass. Hence, it can be
concluded that the effect of fat mass on the postural control is age dependent.
Variables Foot length (cm) r(p) Foot breadth (cm) Angle (°)
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Mediolateral sway (cm) 0.01 (0.88) 0.01 (0.80) 0.01 (0.89)
Mediolateral ampl sway (cm) 0.05 (0.54) 0.01 (0.82) 0.03 (0.70)
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Sway area (cm2) 0.67 (0.50) 0.24 (0.80) 0.12 (0.22)
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Mediolateral sway (cm) 0.32 (0.00) 0.02 (0.84) 0.04 (0.68)
Mediolateral ampl sway (cm) 0.27 (0.00) 0.02 (0.83) 0.03 (0.69)
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The increase in body height indeed increases the postural sway. Hence, in our
study, the greater height in the male group may have been the reason for the greater
influence of this parameter on COP in comparison to the female participants.
In our study, conducted among young adults, without major health diseases or
other abnormalities, the anthropometric measurements showed gender-related dif-
ferences.
9. Conclusions
1.Bipedal postural sway shows sexual dimorphism.
2.Significance of body composition in maintenance of postural sway also shows
sexual dimorphism.
3.Lean muscle mass is inversely proportional to the degree of postural sway.
4.Soft tissue mass is directly proportional to the degree of postural sway.
5.Human height is directly proportional to the degree of postural sway.
6.Foot length and foot width do not influence postural balance.
7.Overweight individuals require greater movement from the center of gravity
to remain in the orthostatic position.
10. Suggestions
1.Gender-related variations in factors maintaining postural balance should be
considered during ankle and weight transfer strategies.
2.Foot anthropometric parameters should be taken into consideration while
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Abstract
Eating disorders, the most lethal of all the psychiatric disorders, are frequently
misdiagnosed as benign weight management problems, which contribute to their
being underdiagnosed and under-reported. Though eating disorders are typically
first identified through easily discernible weight change, their unseen origins lie in
genetic propensities, neurobiology, environmental and family influences, inborn
temperament, and trauma. Non-integrative, behaviorally based weight manage-
ment solutions that call for dieting and meal plans alone, by ignoring the psycho-
logical underpinnings and neurobiological origins of dysfunctions driving these
disorders, can potentially lead to loss of life and/or life quality. Conversely, generic
psychotherapy protocols typically fail to address and enforce the behavioral pre-
requisite to re-feed the malnourished eating disordered brain and body, which is
required to optimize therapy outcomes. It is for the intuitive and skillful diagnosti-
cian to determine whether the patient’s desire for weight change is based on health-
ful autonomous discretion or on the dictates of compulsions based in life-
threatening pathology, thus informing treatment. Eating disorders are disorders of
the core Self of self-regulation, self-perception, self-esteem and self-care, affecting
life spheres far exceeding eating-lifestyle and weight management. Healing weight
management problems requires integrative diagnosis and care, re-establishing one’s
healthy relationship with food, weight, and eating, as well as with one’s re-inte-
grated core self.
Keywords: weight management, diets, dieting, obesity, disordered eating, eating
disorders, anorexia nervosa, bulimia nervosa, obsessive compulsive disorder, binge
eating disorder, purging, food restriction, healthy eating, exercise bulimia,
refeeding edema, diabulimia
1. Introduction
Most individuals seeking advice about weight management issues approach
healthcare professionals with the intention of improving their health, well-being, and
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appearance by losing weight and altering their metabolic function. Typically, first
responders, be they parents, nutritionists, physicians, nurses, coaches, or personal
trainers, offer non-integrative behavioral approaches to weight management in the
form of prescriptive diet plans. In the absence of underlying pathology or compul-
sions that may drive dysfunctional eating behaviors, such simple solutions may be
adequate. But when the origin of an individual’s desire and efforts to lose weight
resides in underlying eating pathology, purely behavioral solutions can mask poten-
tially life-threatening dysfunctions. Sometimes hiding in plain sight, otherwise
benign disordered eating (DE) habits may ultimately take on an element of compul-
sivity, leading to chronic illnesses such as heart disease, diabetes, and/or as heart
disease or diabetes and/or the eventual onset of a life-threatening clinical eating
disorder (ED) in genetically susceptible individuals. It is for the astute and intentional
diagnostician to sniff out, intuit, or otherwise identify the potential for pathological
origins within a constellation of seemingly benign weight management dysfunctions
by determining whether a patient’s desire for weight change is based on healthful,
autonomous discretion or on the dictates of a tyrannical and potentially lethal eating
disorder. Overlooking the nature and severity of DE behaviors or warning signs of a
clinical ED can carry dire consequences. By partnering with the patient to affirm or
negate a diagnostic hunch, the clinician informs appropriate treatment, promoting
disease prevention or the achievement of a timely and sustainable problem resolution.
2. The continuum of healthy eating
The nature and quality of eating patterns reside along a continuum that includes
eating behaviors and self-care. Along the span of this continuum, healthy eating
patterns may evolve into disordered eating patterns, potentially leading to deadly
ED in genetically susceptible individuals. At one end of the continuum, healthy
eating behaviors mark the achievement of a fit and effectively functional body
capable of sustaining its own ideal set point weight through healthy eating and self-
care (Figure 1). At the opposite end of the continuum, life-threatening ED repre-
sent the tip of an underlying emotional, physiological, and neurobiological iceberg.
A clinical ED marks the fragmentation or loss of the core self and, with it, the
patient’s lost capacity for self-regulation, self-trust, self-esteem, and self-care.
Feelings of guilt and of shame typically foster secrecy, denial, and reluctance to seek
or sustain care. Ambiguous and inconstant DE behaviors exist somewhere between
the polarities of healthy eating and potentially life-threatening ED. Some DE pat-
terns that may appear to be pathological may actually represent variations of nor-
mal and benign behaviors, being shared by otherwise healthy eaters. As an example,
healthy eaters who choose to indulge excessively in the lavish offerings of dessert
buffets, typically consider such an opportunity benign and not-to-be-missed, guilt-
free, gastronomic sensory and aesthetic delight.
The evolution of dysfunction along the eating continuum is influenced by the
melding of eating lifestyle with genetic propensities, inborn temperament, value
Figure 1.
Along the continuum of healthy eating, the evolution of healthy eating to DE, and from DE to a clinical ED,
represents a journey of developing pathology; likewise, recovery from eating pathology represents a journey in the
opposite direction, towards developing health.
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systems, developmental life stages, and self-concept issues culminating in body
image perception and preoccupations. The confluence of normal child development
and early bodily maturation, environmental triggers gleaned through social media,
attitudes in the home, and peer pressure can lead to high-risk responses in teens and
young adults which might include dieting, excessive exercise, abuse of diet pills,
purging, food restriction, or eating only when hungry/skipping meals. In response
to a societal disconnect between biology and culture, as girls grow older, they are
expected to grow smaller. Studies show that 42% of first to third grade girls wish to
be thinner [1] and, in the attempt to change one’s natural body shape and size, 81%
of 10-year-old girls feel better about themselves when they are dieting [2], creating
a greater risk of obesity in adulthood. 25% of American men and 45% of American
women are dieting on any given day [3], giving rise to cravings, malnutrition,
metabolic dysfunction, and increased overweight once the individual “falls off the
dieting wagon.” It has been reported that 35% of “occasional dieters” progress to
pathological dieting and DE, and as many as 25% progress to partial or full syn-
drome eating disorders [4].
It is for the perceptive and responsive diagnostician to determine at what point,
along the healthy eating continuum, eating behaviors cross the thin line between
normal eating and various forms and degrees of eating pathology and compulsions.
A patient of mine with binge eating disorder (BED) assumed that she was in
“remission” until, “It suddenly occurred to me that this was not just about having an
extra piece of pie… this was starting to feel like an all-out binge.” Pathology exists
when food, exercise, or the abuse of dietary substances is used to resolve emotional
problems or in response to posttraumatic stress; when food serves purposes other
than satiating hunger, fueling the body, or sociability; when the act of eating evokes
guilt and fear; when eating habits become inflexible, immoderate, imbalanced, and
excessive; when compulsive thoughts, such as calculating caloric intake, and pre-
occupations about becoming fat preclude other thinking, interfering with learning
and normal daily function; and when attitudes and beliefs about food and eating are
misguided.
When a child who is a healthy eater runs out the door without breakfast because
(s)he is late for the school bus, she will surely want to snack during the morning or
eat a bigger lunch to make up for the calories lost. The child with an ED who runs
out the door without breakfast does so because (s)he would otherwise be wracked
with fear, anxiety, and guilt that the calories she might ingest would make her fat.
This child would feel compelled to calculate how many calories (s)he can allow
herself to ingest throughout the rest of the day so as not to gain a single ounce.
3. Weight management diagnosticians face multiple challenges
In the face of weight management issues, information that patients communi-
cate to clinicians is often not accurate or comprehensive; and what patients
request of health professionals is frequently not what they need. Falling between
the cracks of accurate assessment and appropriate treatment, DE and potentially
lethal ED all too frequently remain misunderstood, underdiagnosed, and
undertreated [5] by myopic, underinformed physicians, psychotherapists, and
nutritionists who lack an integrative “big picture” perspective of the possible
existence of underlying, co-occurring diagnoses that need to be revealed, moni-
tored, and treated. The diagnosis of a clinical ED remains elusive, with more than
one half of all cases remaining undetected [6].
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A patient of mine had been treated by a psychiatrist for 7 years, during which time,
she never told him that she vomited 30 times a day, for fear of his finding her
“disgusting” and therefore refusing to treat her. This physician failed to “read between
the lines” of her symptoms and to intuit and investigate the presence of an ED from the
constellation of personality traits, temperament, and behaviors that she did reveal to
him. Through our work together, she came to understand her problem and her self.
The quality of our relationship led to the improvement of all her significant relation-
ships—with food, with her self, and with others.
The unique requirements of weight management issues demand the uniquely
specialized skills of an informed, intentional, and intuitive diagnostician, capable of
hearing what has not yet been spoken. Within the context of initial history-taking,
the nature of weight-related dysfunctions is likely to remain elusive in the absence
of an active probe for problem origins in pathology. The diagnostician’s enlightened
line of questioning will substantiate, or negate, such a presence, revealing the
subtleties of distinctions between the nature of eating behaviors as they reside along
the healthy eating continuum. When eating behaviors do appear to cross the line
into pathology, the diagnostician takes on the role of crisis interventionist, through
immediate responsiveness to the needs of the moment through an investigation into
the past. Because the patient’s quality of life may depend upon assessment accuracy,
the obligation for first responders or clinicians to detect, explore, and interpret
issues yet to be unearthed becomes a unique challenge within the confines of the
limited timeframe of a single-session weight management consultation. On high
alert for potentially unseen issues, the proactive first responder must be prepared to
offer psychoeducation, a plan of action, and, where appropriate, referrals to collab-
orating experts and/or higher-level treatment milieus. If it looks like a duck and acts
like a duck, it is for the responsible practitioner to treat it like a duck, unless proven
otherwise, even before the assignment of a definitive diagnosis.
Esther was a 29-year-old woman who came to treatment for depression, poor self-
esteem, and relationship problems. In response to her description of her college days
during which she spoke of herself as perfectionistic, highly compulsive, anxious, and
depressed, I chose to wonder aloud if she had ever struggled with an ED or other
eating-related issues. “My God!” she responded. “How did you know? I have never
told a soul!” By understanding the nature of her personality structure and recognizing
characteristics of her emotional functioning, I was able to intuit and surmise the
possible existence of a past ED, which upon inquiry, I discovered had yet to be fully
resolved. Following the tenet of John Muir, “If we try to pick out anything by itself, we
find it hitched to everything else in the universe.” By following my hunch and having
made this discovery, I was able to launch the ED treatment process immediately.
Where the clinician’s depth and breadth of understanding of weight management
issues is limited and non-integrative, the patient is liable to leave the treatment office
with a diet plan in hand, yet without a practicable and sustainable solution for
pressing weight-related concerns. More significantly, the loss of a timely and poi-
gnant opportunity for the patient to discover unknown problem origins and aspects
of self and personality represents a lost opportunity for self-reflection, self-
awareness, and self-integration, all leading to healthier lifestyle choices.
Factors further clouding the differential diagnosis of eating-related pathology
include the elusive assessment of evolving and ambiguous DE patterns, and the
widespread misunderstanding and erroneous information surrounding the issues of
eating, weight control, and ED. In asking my ED patients what triggered the onset
of their ED, a frequently heard response is that they “started to diet in an effort to
lose weight, and ultimately found themselves feeling compelled to eat ‘healthier and
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healthier.’” The term “healthy eating” not infrequently becomes a euphemism for
food restriction, or ‘clean eating,’ potentially triggering the onset of orthorexia in ED
individuals. Further complicating the diagnostic process, ED symptoms vary appre-
ciably from patient to patient, with; every ED a ‘thumbprint.’ Fully half of the ED
population suffers from the difficult-to-identify condition called “other specified
feeding or eating disorder” (OSFED), previously known as “eating disorder not oth-
erwise specified” (EDNOS) [7]. OSFED describes atypical AN (without low weight)
and atypical BN or BED (with lower frequency of behaviors, purging disorder, and/or
night eating syndrome). Patients who do not meet the strict diagnostic cutoffs for full
criteria for AN and BN often remain undiagnosed despite the seriousness of their
illness, foregoing or delaying necessary treatment [8]. Patients with clinical ED are
often reticent, within a diagnostic interview, to divulge a stigmatized disorder. A
recent discovery, important for its potential to reduce the degree of stigma that is
associated with ED nondisclosure revealed that 20% of the neurobiology of AN could
be derived from metabolic genes (possibly activated by a state of starvation) [9].
3.1 Myths and misconceptions regarding clinical ED abound
Consider the following examples of decoys to the recogntion and understanding
of ED:
• People mistakenly assume that AN is easy to spot, believing that “all anorexic
individuals are exceedingly thin.”
• It is a commonly believed misconception that an AN individual’s full
restoration of weight marks a full recovery from an ED. In fact, ED recovery is
marked by neurobiological, emotional, cognitive, and behavioral changes that
lead to the reintegration of the individual’s core self and the normalization of
body fat mass and sexual hormones, which have a widespread impact on the
body and multiple pathways in the brain [10].
• Despite the widely accepted misconception that ED represent an incurable “life
sentence,” about half of those individuals with AN or BN attain a full recovery,
30% achieve a partial recovery, and 20% show no substantial improvement [11].
3.1.1 The physician’s role in weight management detection
Though early detection of ED warning signs is pivotal in disease prevention and/
or promoting a timely recovery, the medical community has been known to over-
look opportunities for early disease recognition.
• Because signs of an ED rarely appear in blood tests until advanced stages of
disease, normal test results in early stages of ED are often misconstrued to
represent a “clean bill of health.”
• Pediatricians frequently overlook the significance of precipitous weight loss in
children when their numbers fall within the range of normal on the growth
charts, precluding early disease prevention.
• Gynecologists regularly prescribe birth control pills for ED patients with
amenorrhea, erroneously assuming that hormone replacement will counteract
or reverse bone loss and improve reproductive functionality [12].
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• Cardiologists, in the face of a co-occurring activity disorder that takes the form
of excessive and compulsive exercise, frequently miss an ED diagnosis by
attributing a low heart rate and amenorrhea to “healthy athleticism.”
When driven by the fear of weight gain, individuals who suffer from ED, co-
occurring anxiety, and obsessive-compulsive disorders (OCD), are particularly sus-
ceptible to developing activity disorders. Also known as anorexia athletica, exercise
bulimia, or exercise addiction, ED individuals engage in such compensatory compul-
sions with the intention of burning calories. Between 40% and 80% of AN patients
are prone to excessive exercise in their efforts to avoid putting on weight [13].
Binny ran 10 miles a day, followed by 2 hours of working out. She ate no more than
750 calories a day while training regularly for countrywide marathon races. One
26.2-mile event landed her in a hospital, where her legs swelled and she required an
emergency blood transfusion. Because her eating and running regime provided her
with a sense of being “alive,” upon release from the hospital she felt incapable of
curtailing the compulsive behaviors that threatened her life. Her emergency room
doctors attributed her blood disorder and amenorrhea to her athleticism, failing to
recognize both conditions as signs of ED pathology.
4. Gaining clarity through defining terms
“The beginning of wisdom is to call things by their right names.”
Chinese Proverb
4.1 Understanding weight management
Barring origins in genetic, metabolic, or hormonal dysfunctions, weight man-
agement dysfunctions typically originate in an individual’s unhealthy relationship
with food, leading to a disordered eating lifestyle. The term “weight management”
describes the techniques and physiological processes that contribute to attaining
and maintaining an individual’s ideal weight. Healthy weight management tech-
niques encompass long-term lifestyle strategies promoting healthy eating and daily
physical activity, fostering sustainable change and well-being. In contrast,
unhealthy weight management strategies, lacking an integrative treatment per-
spective, fail to achieve sustainable weight goals. Examples of unhealthy weight
management include dieting, skipping meals, food restriction, eating only when
hungry, and forms of purging that may include vomiting, spitting, compulsive
exercise, and the abuse of laxatives, diet pills, and diuretics. Multiple studies have
found that dieting for purposes of weight management is associated with greater
weight gain and increased rates of binge eating in both boys and girls [14].
4.2 Understanding healthy eating
Healthy eating is guilt-free, balanced, and fearless eating, with flexibility in
accommodating the parameters of the dining moment. Healthy eating includes
three meals daily, each including all the nutritionally-dense food groups, as well as
snacks. There are no bad foods. What is bad is extremism, compulsivity, and
unhealthy attitudes about food and eating, i.e., how we feel about what we eat.
What is worse than eating Oreos is never eating Oreos, as forbidding a child to eat
Oreos can ultimately lead to sneaking, hiding, or stealing food. Healthy eating
results in healthy weight maintenance naturally, through the inherent wisdom of a
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body which, when fed healthfully, and having reached its ideal set point weight,
will predictably sustain that appropriate weight-to-height ratio indefinitely,
through its own natural functions. In most cases, the healthfully fed and exercised
body with a healthfully functioning metabolism needs no help from arbitrarily
devised dietary interventions to sustain a healthy weight throughout one’s lifetime.
4.3 Understanding disordered eating
At times we are all a little eating dysfunctional. Bombarded by nutritional
research and food fads in an age of pervasive social media, “normal” eating (i.e.,
eating all food groups, including moderate amounts of processed foods and sugar) is
no longer considered to be “healthy” eating. Certain patterns of DE, in light of their
prevalence, are becoming increasingly difficult to recognize as pathological. A study
found that nearly 91% of female college students use dieting as a weight control
mechanism [15], putting many of them at risk to develop a clinical ED. The preva-
lence of AN and BN is relatively rare among the general population [16], affecting
1% to 4% of adolescents and young adult women [17]; DE, however, which has
been defined as a psychological illness, [18], and the misguided attitudes about food
and weight management that lead to them, are widespread and prevalent among all
age groups. The consequences of DE, which include rampant dieting and body
image obsessions, can be devastating; though not the cause of eating disorders, they
are often precursors to their onset. Occasional DE, as well as certain behaviors that
manifest themselves in clinical ED, are not in themselves abnormal. Differentiating
normalcy from pathology is best accomplished by assessing the patient’s attitudes
towards food and eating. Benign forms of DE are fully discretionary, dependent
upon the individual’s capacity for self-awareness, self-regulation, and choice-
making through their own free will.
Picky eating syndrome is a DE pattern that originates in early childhood. Typically
indicative of a sensory processing disorder (SPD), food choices tend to be limited to
bland “white” foods (containing sugar and flour) of specific textures. Picky eating
often results in overweight. Studies show that 40% of overweight girls and 37% of
overweight boys are teased/bullied about their weight by peers or family members
and that traumatic experiences such as these during the formative years are predictive
of weight gain, binge eating, and extreme weight control measures [14]. DE patients
have experienced a higher frequency of traumas (childhood adversities in particular),
especially in circumstances related to childhood obesity [18]. Childhood picky eaters
who do not grow out of the condition and who become malnourished because of the
limited variety of foods that they eat qualify for a diagnosis of avoidant restrictive
food intake disorder (ARFID), a condition which typically extends into adulthood.
Rising obesity rates, the result of DE lifestyles, clinical ED, and hereditary factors
have become a major concern worldwide, especially in North America, where more
than 2 in 3 adults (70.2%) are considered to be overweight or obese [19]. Obesity, DE,
and ED are considered major health problems among adolescents because of their
increasing prevalence in this age group and their potentially serious physical and
psychosocial consequences [20, 21]. Dieting and unhealthful weight control practices
lead to eating psychopathology in DE, ED, and obesity, particularly when associated
with variables such as personality characteristics like perfectionism or anxious tem-
perament, a microbial imbalance, or a genetic predisposition to be influenced by an
obesogenic environment. Other possible causal mechanisms linking dieting to later
problems are neurophysiological mechanisms associated with food restriction (e.g.,
effects on neurotransmitters that could increase risks for either obesity or ED via
influences on food regulation processes) [21]. In the face of a genetic, hormonal, or
metabolic predisposition to obesity, following a healthy lifestyle in which the
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individual learns to eat differently, not less, may counteract gene-related risks. Indi-
viduals with obesity and co-occurring eating disorders are at higher risk for several
medical and psychosocial complications than individuals with either condition alone
[22]. Because obesity may become a precursor to an ED, and vice versa, collaborative
exchanges of experiences and specialized knowledge between healthcare profes-
sionals working in the fields of obesity and eating disorders are essential [22].
4.4 Understanding clinical eating disorders
ED onset is an integrative process, stimulated by contributing factors that include
genetics, neurobiological vulnerability, physiology, co-occurring mood and emotional
disorders, past trauma, and familial and cultural influence. For the individual with
AN, BN, BED, or OSFED, behavioral and emotionally based compulsions become
etched in neuronal pathways, impacting the structure and function of the brain. ED
patients consider their disorder to be a survival tool, an adaptive coping mechanism
that they cannot live without. Underlying the clinical ED is the primordial fear of
becoming fat. For the ED individual, food is “fattening,” and fat, the enemy of a body
that can never be too thin, becomes a “feeling,” a sensation, a perception. ED are self-
regulatory dysfunctions. All types of ED share a great number of symptoms and
issues, as aspects of the same disease syndrome; however, ED victims vary in the basic
structure and function of personality and emotional makeup, and treatment needs to
vary, reflecting these differences. BN behaviors tend to be marked by impulsivity,
followed by “undoing” practices, such as various forms of purging. AN behaviors
reflect behaviors and attitudes marked by rigidity, restriction, and containment.
Though ED are essentially not about food, their successful healing depends upon
the resumption and maintenance of a healthy weight and relationship with food
[22]. ED are disorders of the core self, characterized by diminished self-control,
self-regulation, self-attunement, self-trust, self-agency, self-reliance, self-
perception, self-sensing, and self-worth. A full ED recovery is defined by several
factors, including the return of a healthy and sustainable eating lifestyle and rela-
tionship with food; the reintegration of the mind, brain, and body, reconstituting a
fully integrated self; the arrival at one’s set point weight; and a full restoration of
healthful physiological functioning leading to the natural resumption of menstrua-
tion. Observable weight change is typically the factor that brings ED patients to
treatment. Once in treatment, additional predictive assessment factors include the
ED mentality, marked by perfectionistic, obsessive, black-and-white thinking, cog-
nitive rigidity, the compulsive quality of behaviors, the intolerance of uncertainty,
and the fear of gaining weight and becoming fat. It is important to note that many
individuals with various forms of ED maintain a normal weight, a phenomenon
observed particularly in BN and BED because of “weight cycling,” where patients
alternate between starvation and gorging or compulsive bingeing followed by
compensatory forms of purging.
ED do not stand still; any ED that is not in the process of healing is becoming
increasingly entrenched in the brain and nervous system, destroying life quality, if
not taking lives.
Pamela suffers from BED. She is not overweight, as might be expected, the result of
yo-yoing between gorging and starvation for days on end. Aware of her illness and
her need for professional help, she spoke of her frustration in not having been able to
get the attention of her family or the healthcare professional community, who
refused to acknowledge that she had an ED because her weight was “normal.”
Having been denied treatment, compassion, much needed support and attention,
upon arrival at my office, she spoke of feeling depressed, isolated, and hopeless.
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5. Weight management assessment as a form of crisis intervention
In looking beyond simple, nonlinear solutions for weight management prob-
lems, the single-session diagnostic assessment needs to become a discovery process,
uncovering the possibility of underlying sources of symptoms in eating pathology or
past trauma. In establishing a direction for future treatment, the assessment of DE
or ED requires treatment tools of subtle refinement that investigate the patient’s
current disease and recovery status, as well as the history of past efforts to heal.
Following Abraham Maslow’s hierarchy of human needs [23], the weight manage-
ment diagnostician attends to the needs of the patient in a sequence designed first to
save lives through medical stabilization, then to remediate life quality through
emotional stabilization. For ED patients, the need to refeed body and brain becomes
a first priority in minimizing the patient’s physiological risk, augmenting receptivity
to the therapeutic process and to an environment conducive to the use of medica-
tion. Physiological or emotional instability that could result in self-harm or death
demands an immediate referral to higher levels of care.
Psychoeducation lies at the core of the patient’s engagement in the healing
process as a mainstay of support, rectifying distorted attitudes and cognitive belief
systems; introducing a deeper understanding of weight management problems and
their implications; opening the patient’s eyes and mind to insights and self-
reflection; and creating the patient’s sense of trust in the clinician and the clinical
process as well as hope for a full recovery. Psychoeducation emphasizes the impor-
tance of maintaining a healthy eating and activity lifestyle to insure short-term and
long-term goals for unified mind, brain, and body health. A psychoeducational
explanation of the set point weight theory becomes critical in assuaging the AN
patient’s fear of excessive weight gain during refeeding by describing the wisdom of
the human body, which, once having restored optimized bodily functioning, will
sustain a constant weight. The AN patient also learns to anticipate that the natural
course of ED recovery will involve countless trials and setbacks in regaining lost
weight, with the recognition that every movement representing progress or
regression represents “grist for the learning mill.” Patients and clinicians need to
anticipate the emergence of previously buried feelings during the refeeding process,
evoking states of psychophysiological fear and/or emotional distress.
Psychoeducation is also of great benefit for the parents of eating dysfunctional
children or young adults living at home. Through family therapy, parents become
knowledgeable about the complexities and risks involved with their child’s eating
dysfunctions and the urgent need for total healing. As advocates for their ED child’s
recovery, skillfully coached parents become, and remain, effective agents for posi-
tive change throughout an ever-changing treatment and recovery landscape.
Aside from psychoeducation, the work of the initial diagnostic session or series
of early sessions needs to be richly flecked with trust-building and relationship
building, along with an action plan, devised even prior to the development of a
definitive diagnosis. The assignment of tasks such as journaling, requests for on-
going open and honest personal feedback, and contingency contracts all foster the
patient’s learning, trust, and treatment engagement. The initial session may include
professional referrals to prospective members of a treatment team, as needed,
initiating an integrative treatment process. Evoking motivation for change, the
quality of the initial patient/clinician connection awakens the patient’s recognition
and acceptance of oneself, of co-occurring diagnoses that may require attention,
and of the need for commitment to a treatment process that can accomplish full and
sustainable healing. Aside from identifying current behaviors, levels of function,
and past treatment and recovery efforts, history-taking needs to assess the patient’s
internal strengths, external resources, environmental influences and mood
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dysfunctions, always with attention to the possibility of past or current trauma.
Studies that include partial or subclinical forms of posttraumatic stress disorder
(PTSD) show that well over half of individuals with BN have PTSD or significant
PTSD symptoms [24]. In light of the prevalence of trauma in the background of ED
patients, trauma investigation needs to become a central focus within the initial
inquiry. The diagnostician does well to become self-aware of personal propensities
towards countertransference responses or cultural biases (reflecting weightism).
The latter are forces which might preclude the clinician’s recognition that many
overweight and genetically large individuals who eat healthfully and exercise regu-
larly are physically fit, healthy, and strong.
6. Medical ramifications of weight management in the treatment of DE
and ED
A heavy burden of medical comorbidities across multiple body systems, attrib-
utable to both the malnutrition of AN and the purging behaviors of BN, contribute
to the high mortality rates of these illnesses [25]. Restoration of weight and nutri-
tional status are key elements in the treatment of AN [26]. Nutritional and medical
treatment of extreme undernutrition present two very complex and conflicting
tasks: the need to avoid “refeeding syndrome” caused by a too fast correction of
malnutrition and “underfeeding” caused by a too cautious refeeding [27]. Meta-
bolic, endocrinological, and gastronomic consequences that may develop during the
refeeding process for ED individuals in recovery need to be understood and
addressed in treatment. For the most part, but not in all cases, adverse
consequences are reversible with recovery:
• Efforts of AN patients to restore weight within the refeeding process risk
derailment due to the irrational fear that normal eating behaviors will ultimately
lead to overweight or obesity following weight restoration. A psychoeducational
discussion of optimal set point weight can potentially diminish fears through the
knowledge that the body will maintain this optimized weight by using the same
energy intake as had been needed for weight restoration. With metabolic
normalization and biological functions coming back on line after their
dormancy during weight restriction, the extra energy used previously for
weight gain becomes expended on usual day-to-day functions [28].
• During initial phases of weight restoration, particularly for restricting ED
patients who begin treatment at lower weights, the metabolic rate may
overshoot normal levels in a “hypermetabolic” phase in which patients easily
lose weight and need to eat an even larger amount of food to gain and sustain
weight. This phenomenon is due to increased diet-induced thermogenesis
(with calories dissipated as heat) as well as a variety of neuroendocrine
alterations [26]. Despite the urgent need for the body to use restored
energy efficaciously to replenish fat reserves and repair tissues in the early
weeks and months of refeeding following prolonged semi-starvation, metabolic
function may not normalize for 3–6 months following weight restoration [28].
• Target weights offer invalid markers of metabolic normalization, providing
false indicators of ED recovery progress. It has been shown that ED patients
forced to gain weight in hospital settings typically plan to lose it upon discharge
[29]. Attempting to attain a target weight that is not reflective of the body’s
self-determined set point is predictive of a poor long-term prognosis.
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Establishing and maintaining a goal-weight range is but one of many integrative
physiological, neurobiological, nutritional, cognitive, emotional, and
environmental factors contributing to a complete and sustainable ED recovery.
• Weight gain from edema (swelling or bloating) can be caused by hormonal
changes brought on by starvation. AN can lead to kidney-related issues that
include severe electrolyte disturbances (hypokalemia, hypophosphatemia,
etc.), nephrolithiasis, and alterations in water metabolism (with hyponatremia
and edema.) Patients with the binge eating/purging subtype of AN are more
likely to have kidney disorders, particularly electrolyte disturbances and
volume depletion, than those with the restrictive subtype. ‘Refeeding edema’
occurs during the process of weight restoration [30].
• Weight gain is a common side effect for people who take insulin to manage
type 1 diabetes. The deliberate insulin underuse with type 1 diabetes for the
purpose of controlling weight is known as diabulimia, a condition leading to a
threefold increase in mortality risk [27].
• Sarcopenia, the loss of muscle mass in moderate to severe AN is frequently
overlooked by clinicians. Appropriate exercise is required to restore muscle
mass and strength [31].
• The strongest predictors of osteoporosis include low body weight and
amenorrhea. Hormonally based bone softening and/or bone loss may never
become restored to a state of normalcy, even following weight restoration.
• AN has consistently been associated with reduced gray matter and white
matter brain volumes. It remains unclear if gray matter alterations are present
following recovery from AN [32].
Issues complicating the achievement of full weight restoration matter a great
deal, as halting the process of weight restoration at much lower levels than needed
for full and sustainable recovery increases the rate of treatment dropout [33] and
relapse [34]. The restoration of nutrient status and weight needs to start slowly and
gradually, accelerating as tolerated. The refeeding process needs to focus on modi-
fying the disordered dietary patterns that AN patients commonly practice, which
might include slow and irregular eating, vegetarianism, and the consumption of a
restricted range of foods. Severely malnourished AN patients often need to be
admitted to a hospital in order to receive more aggressive treatment, with extra care
and monitoring required to prevent the occurrence of refeeding syndrome [26], a
clinical complication involving kidney dysfunction [30]. A person may finally be
considered “in remission” after maintaining a stable weight for a number of years
and experiencing the natural resumption of mensuration, as well as other normal
hormonal, metabolic, and gastroenterological processes. Sustained remission is
marked by the return of the reintegrated core self, following its fragmentation by
the encroachment of the ED “pseudo-self.”
7. Discovering and managing the roots of weight management problems
in current or past trauma
Trauma in the form of sexual abuse occurs in 30–65% of women with ED [35].
The vast majority of women and men with AN, BN, and BED report a history of
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dysfunctions, always with attention to the possibility of past or current trauma.
Studies that include partial or subclinical forms of posttraumatic stress disorder
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marked by the return of the reintegrated core self, following its fragmentation by
the encroachment of the ED “pseudo-self.”
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interpersonal trauma, with approximately one-third of women with BN meeting
criteria for lifetime PTSD [36]. Unresolved trauma and/or PTSD can be an impor-
tant perpetuating factor in the maintenance of ED symptoms [24]. DE and ED
behaviors typically serve the patient as coping tools and distractions that numb the
ongoing effects of traumatic memories. A trauma-focused approach to ED treat-
ment facilitates the resolution of traumatic experience that lies at the root of
behavioral, emotional, and neurobiological dysfunctions [37].
Unprocessed traumatic memories stored in the mid-brain region become
recycled when triggered, creating undischarged energy in the nervous system. Any
traumatic assault on, or insult to, the brain impairs brain integration. High stress
levels that lead to an overactive amygdala and hippocampus suppress the activities
of the prefrontal cortex, the thinking brain that helps to regulate emotions. Body
dysmorphic disorder, a common occurrence in ED individuals traumatized by sex-
ual abuse, represents a mind, brain, and body disconnection within the disparate
nervous system. BN and AN pathology reflects the disintegration of the structure of
the self within the distributed nervous system, resulting in the patient’s inaccurate
sensing of self-based experience and perception of self. Psychosomatic expressions
of traumatic experience are held as bodily sensations. ED heal in the same way as
trauma heals, through the neurophysiological and neurobiological reintegration of
the distributed nervous system, marking the return of the patient’s reintegrated
core self [38]. Because traumatic memories are encoded subcortically, the process of
healing ED that originate in trauma requires accessing, and gaining leverage within,
the structural coding of the brain and nervous system.
Neurophysiological effects of past trauma that are revealed in the present
become accessible and available for remediation [38]. Trauma resolution lies in
creating a psychophysiological state associated with decreased adrenergic activity,
decreased muscular neuromuscular arousal, and cognitive quieting [39]. The intro-
duction of neurophysiological (sensorimotor) and neurobiological (interpersonal,
attachment-based) treatment interventions into mainstream clinical treatment for
ED increases exposure to mindful embodied movement experience, fostering mind,
brain, and body connectivity. By stimulating integrative neuronal firing and synap-
tic activity, these “top-down” and “bottom-up” transactions enhance acuity in self-
sensing, self-perception, and body image coherence, supporting the unification of
the disparate self [38].
Trauma resolution becomes enhanced through a mindful, quality connection
between the therapist and patient. Rapid resolution therapy (RRT) is a body-based
talk therapy technique shown to alleviate negative effects of trauma and PTSD
without requiring the patient to recollect painful memories [40]. Trauma resides in
the limbic system and in the perceptual world within a neural network, which has
sufficient functional boundary thresholds to largely “disintegrate” it from the rest
of the nervous system. When negative feelings become dissociated or “split off”
(as they do within the bulimic “pseudo-self”), the potential exists to reintegrate
them through the patient’s connection with his/her best and resourceful self,
through solution discovery, or rediscovery, both past and present [40]. Trauma
resolution accesses neuroplasticity, through which neural networks that become lit-
up at the same time as the neural network associated with the problem result in the
problem’s loss of definition. This dynamic allows for a free flow of communication
with the rest of the nervous system, as the brain reinterprets new combinations of
neural connections to create meaning [40]. By creating connections within the
distributed nervous system in the context of a trusted human relationship, the
technique connects problems to solutions through consolidating memories of
human strengths and resourcefulness.
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For decades under the care of dietitians treating Charles’ disordered eating, dieting
efforts failed, leaving him intractably obese at 100 pounds overweight. Still “feeling
fat” following bariatric surgery, he came to therapy struggling to lose weight through
old patterns of food restriction, leading to junk food binges. At the start of our
treatment, history-taking revealed past trauma at the root of his current eating
dysfunction. Since childhood, Charles’ family had been forced to flee a war-torn
country with only a day’s notice, leaving their previously comfortable lives and
extended family behind. Moving from country to country, they struggled to survive
as refugees, grieving their losses and experiencing years of fear, hunger, and social
isolation. In response to the combined work of ED recovery and trauma resolution,
within the context of our quality therapy relationship, Charles began to experience a
sense of grounded integration and selfhood, evidenced in his growing capacity for
self-regulation and self-care. Within several months of treatment, he became a
normalized healthy eater and started to exercise regularly. Change in his distorted
body image perception as a fat person became apparent when he reported, “During
an exercise class, I noticed myself in the mirror and thought, ‘Who is that normal
weight person? Could that be me?’ Despite his weight management problems and
eating compulsions, the healthy personality at his core had resurfaced through
psychotherapy. In completing his treatment, he described himself as having become
“a happy and gratified human being, enjoying a fulfilled existence.”
In some instances, a skilled practitioner may be capable of discovering trauma
and shepherding the start of the trauma resolution process within the context of the
initial time-extended single-session weight management assessment.
It was the sudden recurrence of compulsive bingeing habits that she’d assumed were
“in remission” that brought this middle-aged woman with BED to treatment. “This
is the one area of my life that has always remained just beyond my grasp… . all I
know is that my hunger is insatiable.” In probing for the possibility of past trauma,
our discussion during that initial session uncovered the source of her erratic eating
compulsions in feelings of shame, emptiness, and emotional lability originating in
early childhood trauma, a connection that had remained outside of her conscious-
ness for 45 years. Her memories of neglect, alienation, and hunger that she suffered
at the hands of her parents throughout her growing-up years, having been buried for
decades within her limbic brain, now began to surface. Her brain’s rapidly firing
neuronal connections brought forth immediate new insights into herself, her current
feelings, and past emotions, evoking an enlightened clarity about her previously
“incomprehensible, over-reactive responses” (sobbing tears, sleeplessness, irrational
fears) in the face of certain types of stressful experiences throughout her life. She
wept with relief and gratitude upon leaving, recognizing that significant and sus-
tainable change for her would now be in the offing.
8. Conclusion
Weight management anomalies signify the patient’s unhealthy relationship with
food, potentially giving rise to chronic disease or the onset of genetically
predisposed clinical eating disorders and the metabolic, endocrinological, or gastro-
intestinal consequences that characterize them. Uncovering the origins of weight
management dysfunctions in DE or ED pathology, in providing a direction for
treatment, enhances the efficacy and sustainability of healing. From the perspective
of a hammer, all things look like a nail; in assessing weight management issues
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tic activity, these “top-down” and “bottom-up” transactions enhance acuity in self-
sensing, self-perception, and body image coherence, supporting the unification of
the disparate self [38].
Trauma resolution becomes enhanced through a mindful, quality connection
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talk therapy technique shown to alleviate negative effects of trauma and PTSD
without requiring the patient to recollect painful memories [40]. Trauma resides in
the limbic system and in the perceptual world within a neural network, which has
sufficient functional boundary thresholds to largely “disintegrate” it from the rest
of the nervous system. When negative feelings become dissociated or “split off”
(as they do within the bulimic “pseudo-self”), the potential exists to reintegrate
them through the patient’s connection with his/her best and resourceful self,
through solution discovery, or rediscovery, both past and present [40]. Trauma
resolution accesses neuroplasticity, through which neural networks that become lit-
up at the same time as the neural network associated with the problem result in the
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through a purely behavioral lens, first responders who fail to investigate and probe
an underlying emotional landscape are likely to recommend a non-integrative solu-
tion, such as dieting, missing the opportunity to address the full complement of
impinging psychological, neurobiological, and neurophysiological factors that con-
tribute to weight management dysfunctions. Dieting, and particularly the use of
unhealthful weight control behaviors, increase risk for weight gain and later eating-
and weight-related problems [21].
It is through a unique use of self within the diagnostic moment that the knowl-
edgeable and informed first responder approaches the uniquely challenging arena of
weight management. By “listening with a third ear,” the clinician with clear inten-
tion and exquisite sensitivity to implied and unspoken issues intuits and then
skillfully addresses the possibility of a yet unknown and unnamed condition as part
of a wider constellation of symptoms. The proactive diagnostician fosters the
patient’s self-reflection, self-acceptance, and incentive to heal dysfunctions sustain-
ably at their source; increased self-esteem and positive body image have been
shown to be best achieved through self-acceptance rather than weight reduction [41].
Research justifies the need for long-term implementation of interventions that
aim to simultaneously prevent the onset of obesity and ED through the prevention
of dieting behaviors and the promotion of healthful eating and physical activity as
ongoing lifestyle behaviors [21]. Research reveals that fitness center employees,
ideally placed to observe clients who exhibit an addiction-like relationship with
exercise in an effort to lose weight as part of an ED, require detailed guidelines for
intervention, including ways to start conversations to this end [42]. Bottom line,
first responders need to determine whether the patient’s desire for weight change is
based on healthful choices and discretion, or on the dictates of pathological com-
pulsions that underlie and drive dysfunctional eating behaviors. In either case, the
diagnostician sets the stage for the patient’s immediate and compelling engagement
in integrative treatment, creating the potential to save lives and promote life quality.
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Anorexia nervosa (AN) is a severe psychiatric condition primarily affecting 
young women, and AN has the highest mortality rate among psychiatric disor-
ders. AN continues to be a disorder refractory to psychological or pharmacologi-
cal treatment. An innovative approach arises from research in rats simultaneously 
placed on a restricted feeding schedule and given free access to an activity wheel. 
The detrimental effects of combining diet and exercise in rats can be reversed by 
a manipulation of ambient temperature (AT). Warming animals exposed to these 
experimental arrangements reverses running activity, preserves food intake, and 
enables rats to recover from acute weight loss. This represents a strong preclinical 
evidence that provides a rationale for a translational approach for the treatment 
of AN. However, heat application to AN patients was already a recommendation 
made by William Gull in his seminal paper on AN disorder. A historical perspec-
tive of supplying heat to AN patients reviews the circumstances and foundation 
of this practice. The manipulation of AT in activity-based anorexia (ABA) rats 
has ended with a period of neglect of AT that parallels the complete neglect of the 
role of AT in the human AN disorder, either as a risk factor, as a modulating fac-
tor in the course of the disorder, or in terms of its utility in the treatment of AN.
Keywords: heat treatment, translational research, ambient temperature, animal 
research, hyperactivity
1. Introduction
A recent publication analysing the top 100 most cited works on AN reported 
that only 12 of these papers dealt with treatment, leading the authors to conclude 
that much work is required to translate ‘progress in other areas into effective thera-
peutic strategies’ ([1], p. 13). In contrast to the dearth of literature on treatment, 
the category encompassing the largest number of papers, 35, addressed the mecha-
nisms underlying the disorder, i.e. ‘papers examining diverse theories on AN aetiol-
ogy and/or maintenance, including family linkage analyses, genetic and heritability 
studies, biological theories, personality, as well as psychosocial and cultural factors’ 
([1], p. 10). Moreover, the enterprise of translating theory into effective therapeutic 
strategies appears to be more challenging than expected. For example, only about 
10% of the 4500-word paper, ‘Building a model of the aetiology of eating disorders 
by translating experimental neuroscience into clinical practice’ [2], is dedicated to 
the implications for treatment.
[33] Fassino S, Pierò A, Tomba E, et al.
Factors associated with dropout from
treatment for eating disorders: A
comprehensive literature review. BMC
Psychiatry. 2009;9:67. DOI: 10.1186/
1471-244X-9-67
[34] Steinhausen HC, Seidel R,
Winkler MC. Evaluation of treatment
and intermediate and long-term
outcome of adolescent eating disorder.
Psychological Medicine. 2000;30:
1089-1098
[35] Deep AL, Lilenfeld LR,
Plotnicov KH, Pollice C, Kaye WH.
Sexual abuse in eating disorder subtypes
and control women: The role of co-
morbid substance dependence in
bulimia nervosa. The International
Journal of Eating Disorders. 1999;25:
1-10
[36] Mitchell KS, Mazzeo SE,
Schlesinger MR, Brewerton TD,
Smith BN. Comorbidity of partial and
sub-threshold PTSD among men and
women with eating disorders in the
National Comorbidity Survey
Replication Study. The International
Journal of Eating Disorders. 2012;45(3):
307-315. DOI: 10.1002/eat.20965
[37] Ross CC. Eating Disorders, Trauma,
and PTSD. National Eating Disorders




[38] Natenshon AH. Reclaiming the lost
self in the treatment of bulimia nervosa:
A neurobiological approach to recovery
that integrates mind, brain, and body.
In: Himmerich H, Jáuregui Lobera I,
editors. Anorexia and Bulimia Nervosa.








[39] Everly GS Jr, Benson H. Disorders of
arousal and the relaxation response:
Speculations on the nature and
treatment of stress-related diseases.
International Journal of Psychosomatics.
1989;36(1-4):15-21
[40] Quintal JS. Trauma resolution
treatment; rhizomatics and the
processes of change. In: Proceedings of
the Selah Freedom: Bringing Light into
the Darkness of Sex Trafficking.
Conference; 8-9 November (2018)
Winnetka, Illinois. 2018
[41] National Task Force on the
Prevention and Treatment of Obesity.
Dieting and the development of eating
disorders in overweight and obese
adults. Archives of Internal Medicine.
2000;160(17):2581-2589. DOI: 10.1001/
archinte.160.17.2581
[42] Colledge F, Cody R, Pühse U, et al.
Responses of fitness center employees to
cases of suspected eating disorders or
excessive exercise. Journal of Eating










Anorexia nervosa (AN) is a severe psychiatric condition primarily affecting 
young women, and AN has the highest mortality rate among psychiatric disor-
ders. AN continues to be a disorder refractory to psychological or pharmacologi-
cal treatment. An innovative approach arises from research in rats simultaneously 
placed on a restricted feeding schedule and given free access to an activity wheel. 
The detrimental effects of combining diet and exercise in rats can be reversed by 
a manipulation of ambient temperature (AT). Warming animals exposed to these 
experimental arrangements reverses running activity, preserves food intake, and 
enables rats to recover from acute weight loss. This represents a strong preclinical 
evidence that provides a rationale for a translational approach for the treatment 
of AN. However, heat application to AN patients was already a recommendation 
made by William Gull in his seminal paper on AN disorder. A historical perspec-
tive of supplying heat to AN patients reviews the circumstances and foundation 
of this practice. The manipulation of AT in activity-based anorexia (ABA) rats 
has ended with a period of neglect of AT that parallels the complete neglect of the 
role of AT in the human AN disorder, either as a risk factor, as a modulating fac-
tor in the course of the disorder, or in terms of its utility in the treatment of AN.
Keywords: heat treatment, translational research, ambient temperature, animal 
research, hyperactivity
1. Introduction
A recent publication analysing the top 100 most cited works on AN reported 
that only 12 of these papers dealt with treatment, leading the authors to conclude 
that much work is required to translate ‘progress in other areas into effective thera-
peutic strategies’ ([1], p. 13). In contrast to the dearth of literature on treatment, 
the category encompassing the largest number of papers, 35, addressed the mecha-
nisms underlying the disorder, i.e. ‘papers examining diverse theories on AN aetiol-
ogy and/or maintenance, including family linkage analyses, genetic and heritability 
studies, biological theories, personality, as well as psychosocial and cultural factors’ 
([1], p. 10). Moreover, the enterprise of translating theory into effective therapeutic 
strategies appears to be more challenging than expected. For example, only about 
10% of the 4500-word paper, ‘Building a model of the aetiology of eating disorders 
by translating experimental neuroscience into clinical practice’ [2], is dedicated to 
the implications for treatment.
Weight Management
180
As stated elsewhere [3, 4] given the astonishing contemporary panorama of 
an absence of psychopharmacological treatments for AN, research with animal 
analogous models of the human disorder may be helpful in generating new hypoth-
eses for improving AN treatment. A recent example of treatment translation is 
the reported anxiolytic effect of warmth in anorexia nervosa [5]. In this study 
postprandial anxiety was significantly reduced in patients resting immediately after 
lunch for half an hour in a room at 32°C. Bearing in mind the high level of premeal 
anxiety characteristic of AN patients [6], the significant decrease in postprandial 
anxiety in warmed AN patients was considerably greater than that achieved by 
conventional treatments in patients with comparable levels of premeal anxiety such 
as exposure and response prevention [7].
Interestingly, recent research has underscored the paramount importance of 
ambient temperature (AT) in the development and more importantly on the rever-
sal of exhaustive running activity, severe weight loss, and self-starvation in rats 
simultaneously placed on a restricted feeding schedule and given free access to an 
activity wheel [8–12]. Although self-starvation in rats exposed to this experimental 
arrangement was first described in the mid-1960s of the twentieth century [13], the 
term activity-based anorexia (ABA) quickly became dominant describing both the 
experimental procedure and its resulting behavioural outcome [14]. ABA stands 
as the best animal model reproducing the main signs of AN (overactivity, extreme 
weight loss, restricted eating, hypothermia, disturbed sleep, alterations in hypo-
thalamic-pituitary-adrenal/gonadal axis, alterations in diverse appetite-regulating 
hormones, and severe reductions in grey and white brain matter volume).
Supplying rats exposed to ABA with heat (AT raised to 32°C) reversed excessive 
activity, improved food intake, and allowed body weight recovery in animals. This 
reversion was particularly noteworthy as three circumstances concurred in these 
animals: (a) the increase in AT was delayed until rats had lost 20% of body weight, a 
point where the spontaneous recovery of rats is unattainable by the animals them-
selves; (b) animals continued being exposed to the 1.5 h/day restricted food sched-
ule and unrestricted access to the activity wheel; and (c) increased AT allowed for 
nearly 100% recovery in warmed rats, but there was no single recovery for animals 
maintained at room temperature (21°C), and a 100% of animals had to be removed 
to prevent death. This experimental effect of AT has been demonstrated in both 
male and female animals [10–12].
A more conclusive outcome regarding food intake and body weight was reported 
in a study [12] where sedentary rats housed at 21°C were food deprived (1.5 h/day) 
during the first phase of the study that lasted a week. During Phase 2, the animals 
continued to be submitted to the same restricted feeding schedule for two additional 
weeks, but AT was increased to 32°C for half of the animals, whereas the other half 
was maintained at 21°C.
During Phase 2, on average all the animals increased food intake in comparison 
with Phase 1, but animals maintained at 21°C ate on average 21.5% more than ani-
mals housed at 32°C. However, in terms of body weight, only the warmed animals 
gained a significantly greater amount of weight, and by the end of the experiment, 
both groups had a similar body weight.
Thus, according to the results, in terms of body weight gain, a warmer environ-
ment was more effective than overall food consumption as the buffering effect of 
higher AT on heat dissipation helped the body weight gain in warmed rats.
In line with this effect of AT on body weight, the same beneficial effect of 
warming would be expected in AN patients during weight restoration programmes. 
Moreover, the rate of body weight would be preserved even under a lower caloric 
supplementation provided that the standard AT of hospital wards was raised. Thus, 
we should bear in mind the difficulties patients have in gaining weight despite the 
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elevated caloric intake during conventional nutritional rehabilitation programmes 
[15] and that roughly a third of ingested calories cannot be processed by patients 
and are dissipated through elevated diet-induced thermogenesis [16, 17] that 
further heightens the anxiety of AN patients [18]. Recent data indicate that heat 
is crucial for reducing anxiety following meals when patients remain in a warmer 
environment at 32° [5].
Unfortunately, the manipulation of AT in ABA rats has been overlooked [19] 
which deprived us from recognizing the pivotal role of AT in the fate of rats exposed 
to ABA. Likewise, AN research has also been susceptible to a conspicuous neglect 
concerning the role of AT in the human disorder, either as a risk factor, as a modu-
lating factor in the course of the disorder, or last but not least its potential in the 
treatment of AN.
A historical review of the literature reveals that the suggestion of keeping 
patients warm is not new, since supplying AN patients with heat was first recom-
mended by William Gull [20]. Undoubtedly, the practice of supplying patients with 
heat was justified by the evidence accrued by a Swiss physiologist, Charles Chossat 
(1796–1875), [21] with starved animals.
2.  First report of heat for the treatment of AN patients: back to the 
nineteenth century
Although applying heat to AN patients was first prescribed by William Gull 
(1816–1890) in 1874, this recommendation has been overlooked for over 140 years. 
On Friday, October 24, 1873, William Gull first reported the use of an external heat 
supply to AN patients in his seminal presentation on AN to the Clinical Society of 
London which was published the following year in the Transactions of the Clinical 
Society of London [20]: ‘I have observed that in the extreme emaciation, when the 
pulse and respiration are slow, the temperature is below the normal standard. This 
fact together with the observation made by Chossat on the effect of starvation on 
animals, and their inability to digest food in the state of inanition, without the aid 
of external heat, has direct clinical bearings—it being often necessary to supply 
external heat as well as food to patients. The best means of applying heat is to place 
an india-rubber tube, having a diameter of 2 inches and a length of 3 or 4 feet, filled 
with a hot water along the spine of the patient, as suggested by Dr. Newington, of 
Ticehurst’ (p. 24).
Gull’s recommendation was based on the early preclinical animal starvation 
studies performed by Chossat who discovered the healing effects of heat on starved 
animals. Charles Chossat, a physiologist, physician, and politician from Geneva 
[22], performed detailed observations on the consequences of starvation in differ-
ent species. Chossat’s main work, Recherches expérimentales sur l’inanition [21], 
advanced many of the findings now established by experimental physiology on 
the effects of starvation on the contribution to weight loss by the different organs 
and tissues in animals starved to death. Thus, Ancel Keys and his colleagues in the 
Minnesota Starvation Experiment found the quantitative experimental studies of 
Chossat ‘were surprisingly elaborate for the time’ ([23], p. 198). Furthermore, in 
Chapter 9, entitled ‘Morphology of Some Organs and Tissues’, the authors pay trib-
ute to the work of Chossat in the section ‘The History of an Error’ referring to the 
erroneous assertion in the physiology textbooks regarding the absence of cardiac 
atrophy as a result of undernutrition and starvation in spite of the different findings 
of Chossat [21] regarding heart atrophy in starved animals.
In the 47-page fourth chapter of Recherches expérimentales sur l’inanition, 
entitled ‘Du réchauffement artificiel’, Chossat describes the results of 13 
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Ticehurst’ (p. 24).
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studies performed by Chossat who discovered the healing effects of heat on starved 
animals. Charles Chossat, a physiologist, physician, and politician from Geneva 
[22], performed detailed observations on the consequences of starvation in differ-
ent species. Chossat’s main work, Recherches expérimentales sur l’inanition [21], 
advanced many of the findings now established by experimental physiology on 
the effects of starvation on the contribution to weight loss by the different organs 
and tissues in animals starved to death. Thus, Ancel Keys and his colleagues in the 
Minnesota Starvation Experiment found the quantitative experimental studies of 
Chossat ‘were surprisingly elaborate for the time’ ([23], p. 198). Furthermore, in 
Chapter 9, entitled ‘Morphology of Some Organs and Tissues’, the authors pay trib-
ute to the work of Chossat in the section ‘The History of an Error’ referring to the 
erroneous assertion in the physiology textbooks regarding the absence of cardiac 
atrophy as a result of undernutrition and starvation in spite of the different findings 
of Chossat [21] regarding heart atrophy in starved animals.
In the 47-page fourth chapter of Recherches expérimentales sur l’inanition, 
entitled ‘Du réchauffement artificiel’, Chossat describes the results of 13 
Weight Management
182
experiments on the warming-up of 26 different animals (17 turtledoves, 7 pigeons, 
1 hen, and 1 guinea pig), after being starved close to death. The effects of heat on 
starved animals shocked Chossat himself: ‘I confess that this was not without the 
vivid satisfaction that I saw an animal arrived in a way by the starvation to the last 
term of the insensitivity, the prostration and the cooling, to revive somehow, and to 
retake very quickly a big degree of force muscular and of sensitivity, and it without 
food, without drink, and without other help than the application of the artificial 
heat’ ([21], p. 595, translated from the original in French).
The first animal to be successfully revived was a turtledove with 35% weight 
loss and a 23°C body temperature (19° below baseline temperature). As a result of 
rewarming, Chossat observed that ‘The appetite comes back at the animal’s inanities 
that one resuscitates by the artificial warming-up; because one sees them leaving 
the steams and going to tickle everything that they can meet’ ([21], p. 604).
However, Chossat found that the recovery of appetite was not necessarily equal 
to the recovery of the digestive faculties of the animals, as they could not digest 
food when artificial rewarming was suspended: ‘The digestion takes place, on the 
contrary, while continuing the artificial warming-up during one sufficient time’ 
([21], p. 605).
Furthermore, Chossat described the purposeful thermoregulatory behaviour 
of the animals which actively sought the warm walls of the heater: ‘I noticed that as 
the animals took their strength and their temperature, that they preferred to remain 
perched more and more on the edge of their steams, a position that they often 
preserved during several consecutive hours, receiving hardly a small amount of 
heat. It also happened to them to leave the steams and, when they had gotten more 
or less cold, often one saw them bringing closer to the stove and to warm themselves 
against its walls’ ([21], p. 615).
Was this the first example of translation from lab findings to human treatment?
According to William Gull’s reference to Chossat’s work, there is uncertainty 
as to whether the idea of applying heat to patients in advanced malnutrition was 
developed in Ticehurst in direct relation to Chossat’s studies or whether it was 
William Gull himself who associated the work of Chossat to the use of a heating 
device. In any case, regardless of who had established the connection with the 
work of Chossat, there is no doubt that supplying heat to patients represents the 
first example of translation of basic scientific findings in a laboratory setting into 
potential treatments for AN patients.
2.1  Ticehurst Asylum, the Newington’s, and William Gull: the first 
extrapolation of applied heat from animals to humans
Gull’s description of warming AN patients in advanced starvation was based 
on a device employed at the Ticehurst Asylum, which was widely acclaimed in 
political and medical circles as one of the most successful and highly reputable 
private asylums in England [24, 25], and Gull was the consultant who completed 
the required medical certification of some of the wealthy clientele who were 
admitted to Ticehurst [24]. Ticehurst Asylum was licenced as a private madhouse 
in 1792, and Samuel Newington (1739–1811), an apothecary and surgeon, was the 
first Newington in charge of the asylum erected in the grounds of his home, The 
Vineyard. Five generations of doctors from the Newington family, a ‘long estab-
lished’ Ticehurst family since the fifteenth century, owned and managed Ticehurst.
How this heat application method was adopted in Ticehurst Asylum is uncer-
tain, but the inventions of the Newingtons to facilitate the feeding of patients 
refusing voluntary feeding were inaugurated by Charles Newington (1781–1852), 
who published the description of ‘An instrument invented for administering food 
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and medicine to maniacs by the mouth during a closed state of the teeth’ [26]. 
According to Charles Newington’s obituary as printed in a local chronicle, he was a 
very ingenious man, and ‘Amongst his numerous inventions, was that of an instru-
ment for feeding those who were bent on self-destruction by starvation. This, in its 
present modified form, is still used, and has never been known to fail’ ([27], p. 55). 
Following the tradition inaugurated by Charles Newington, his grandson Theodore 
Newington published a description of an instrument developed while he served as 
an assistant medical officer at the Bethlem Royal Hospital. The instrument, a nasal 
tube, allowed feeding patients refusing eating without ‘the necessity of having to 
open the mouth, which, with patients with good teeth and strong jaws, is sometimes 
exceedingly difficult’ ([28], p. 83).
The relationship between William Gull and Ticehurst probably commenced 
after 1871 with his appointment as a consultant physician [29], a period when the 
asylum was run by Charles Newington’s grandchildren, Dr. Herbert Francis Hayes 
Newington (1847–1917) and his cousin Dr. Alexander Samuel Lysaght Newington 
(1846–1914, Theodore Newington’s brother). By 1873, Sir William Gull had been 
awarded the title of Baronet for his successful treatment of the Prince of Wales for a 
bout of typhoid fever. As an influential physician, Gull medically certified wealthy 
clientele admitted to Ticehurst, and his visit to Ticehurst Asylum in May 1876 was 
documented with his confirmation of the diagnosis of general paralysis by Hayes 
Newington [24].
Another unresolved question concerns the paternity of the idea of applying heat 
to patients. Undoubtedly, William Gull, lecturer in physiology and comparative 
anatomy at Guy’s Hospital from 1846 to 1856 [30], was familiar with the work of 
Chossat and in particular his work Recherches expérimentales sur l’inanition [21] 
which was awarded with the Montyon Prix in experimental physiology in 1841 by 
the Académie des Sciences de Paris.
Furthermore, the successive members of the Newington family running 
Ticehurst had completed their academic training in prestigious universities 
including Oxford and Cambridge. The work of Chossat had extensive diffusion 
in England both in academic circles and even among laypeople. For example, as 
soon as Chossat’s work was published, it was included in 1844 in the 16th volume 
of The Edinburgh Medical and Surgical Journal whose mission was ‘exhibiting a 
concise view of the latest and most important discoveries in medicine, surgery, 
and pharmacy’ [31]. In the same year, the Analytical and Critical Reviews section 
of June–April 1844 of the British and Foreign Medical Review; or Quarterly Journal 
of Practical Medicine and Surgery [32] included a harsh critical commentary on 
Chossat’s work criticizing the suffering inflicted on the animals. Thus, almost 30 
years before Gull’s speech before the Clinical Society of London, a direct link had 
already been explicitly established between Chossat’s ‘ingenious experiment of plac-
ing animals, whose death seemed impending, under the influence of artificial heat’ 
and the application of heat to people suffering starvation: ‘This is evidently a point 
of much practical importance; and the neglect of sufficient artificial calorification, 
or the too early suspension of it, has doubtless been a frequent cause of the want of 
success of the means taken to recover inanitiated persons’ ([32], p. 354).
Furthermore, the studies performed by Chossat were readily available even 
to laypeople in England and were extensively commented in the first scientific 
dissemination book for the general public written by George H. Lewes (1817–1878): 
The Physiology of Common Life [33]. Written the same year as On the Origin of 
Species by Charles Darwin (1809–1892), Lewes’ book was first serialized in The 
Cornhill Magazine [34]. Chapter VII of Volume I, entitled ‘Why we are warm, and 
how we keep so’ ([34], pp. 281–315), includes a detailed description of Chossat’s 
starvation experiments that Lewes concluded ‘are well known and the results are 
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accessible in almost every text-book’ ([34], p. 352). Chossat work was once again 
reported in The Cornhill Magazine [35], mostly read by laypeople in England. The 
1861 Russian translation of The Physiology of Common Life made a profound impres-
sion on the adolescent Ivan Pavlov, who as an elderly man could still quote long 
sections from it [36].
However, regardless of whether it was Gull or one of the Newingtons who was 
acquainted with the work of Chossat, the question remains as to why the application 
of heat was not maintained as a standard strategy and vanished as a treatment for 
AN patients. Gull’s lecture was widely echoed in publications. On November 1, 1873, 
1 week after his speech before the Clinical Society of London, the discussion by 
the attending physicians was included in the Report of the Societies’ section in The 
British Medical Journal [37]. The report in The British Medical Journal also appeared 
across the Atlantic in what was to be the last edition of The Half-Yearly Abstract of 
the Medical Sciences published in Philadelphia in 1873 [38].
Although there were several references to the relevance of warming for the treat-
ment of AN patients in the years following Gull’s 1874 paper, the interest appears 
to have waned by the turn of the century. One of the last mentions appeared in the 
editorial of The Lancet issued a week after what happened to be Gull’s last publica-
tion, a case note of a patient with AN stating ‘The cure consists of three things—
rest, warmth, and the regular and frequent introduction of food, in utter disregard 
of the anorexia of the patient’ ([39], p. 584).
As far as we are aware, despite the clinical bearing mentioned by Gull, we have 
found no justification for abandoning his specific recommendation, either founded 
on its verified clinical uselessness or due to a theoretical reasoning that would 
render it obsolete or any other reason for it falling into disuse. A plausible explana-
tion is that the initiation of forced feeding displaced the use of heat. As mentioned 
elsewhere [40], during a 63-day time span following Gull’s last publication in 1988, 
a total of eleven articles appeared commenting Gull’s last paper, of which four 
mentioned force feeding as the optimal strategy: ‘forcible administration of nour-
ishment so very simple a process that there need be no hesitation in resorting to it 
when necessary; these are at once safe and effective, and by their means nutrition 
can not only be carried on for an indefinite length’ ([41], p. 597). Forced feeding 
had already been voiced by two doctors (Dr. Williams and Dr. Edis) during the dis-
cussion that followed Gull speech before the Clinical Society of London on October 
24, 1873, but there was no mention on the employment of heat or to Chossat in the 
minutes of the meeting reported in The British Medical Journal [37].
One of the last mentions of the use of heat in the nineteenth century appeared in 
the first documented necropsy of a patient who died of self-starvation, which noted 
that all efforts were made to maintain her warm even by wrapping the patient with 
bandages [42].
In the twentieth century, references to warming AN patients were scarce. 
Dejerine and Gauckler refer to warming in their treatise The Psychoneuroses and 
Their Treatment by Psychotherapy when they stated ‘It may happen that, among 
certain patients who are extremely weak, one is obliged to seek for aid from ordi-
nary medical therapy; one may thus to give injections of serum, or hypodermics of 
caffeine, or camphor oil, to warm the patient by artificial means’ ([43], p. 321). In 
1931, a clinical report [44] informed a treatment of a series of 20 cases of functional 
anorexia treated at Ruthin Castle, a private hospital (1923–1950) for the investiga-
tion and treatment of obscure medical diseases [45], in which patients were kept 
in bed in a warm room (although the recommended room temperature was unusu-
ally low, 60°F, for today’s standards). Likewise, in the same decade, two German 
psychiatrists [46] mentioned in their report on the treatment of a 17-year-old girl 
the use of heating pads and an electric blanket for heating patients. Later, the use of 
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electric blankets was considered by psychoanalysts not on face value but as a regres-
sive substitute of the umbilical cord: ‘Our patient who lay in bed curled up ‘attached’ 
to the wall via the electric cord of a heater resting on her abdomen’ ([47], p. 395). 
Furthermore, this blurring of warming is evident in the only figure that appears in 
Selvini-Palazzolli’s book, Self-Starvation: From the Intrapsychic to the Transpersonal 
Approach to Anorexia Nervosa [48]. On page 65 there is an illustration of the analysis 
of a dream (the ugly yellow dog’s dream). In the picture drawn by the adolescent, 
she appears sitting on the floor covering her mouth while her mother looks from 
behind a hole in the wall. The girl’s back rests on the radiator of the wall, an aspect 
that is not mentioned at all in the psychoanalytic interpretation.
In relation to the historical journey regarding the use of heat as an adjunctive 
treatment for AN patients, it is worth noting two spontaneous improvements due to 
febrile conditions reported by Lasègue [49] and Weizsäcker [50].
Since then, as far as we are aware, we have had to wait until the end of the twen-
tieth century to see the reintroduction of the use of heat in three cases treated with 
three different strategies of heat application: continuous exposure to a warm envi-
ronment, wearing a thermal waistcoat, and sauna baths in an infrared cabin [51]. 
Besides putting an end to the long period of persistent disregard for the role of AT 
in AN, this paper demands a place for ABA research in AN treatment development.
3.  Uncovering the neglected role of ambient temperature in anorexia 
nervosa
With the exception of research on the effect of season of birth on the subsequent 
development of anorexia nervosa, AT has been neglected by researchers [52]. 
However, the first reference to the probable relationship of AN and AT appeared 
in an editorial in The Lancet on March 24, 1888 with a commentary on the paper 
published by W. Gull on AN that appeared the preceding week in the journal: ‘Most 
of the cases seem to occur in the colder months of the year, and possibly this may be 
more than a coincidence’ ([53], p. 584).
There is growing evidence that AT merits more attention in future research 
given its paramount importance with respect to several relevant signs of AN such 
as hyperactivity, body weight, and amenorrhea. Furthermore, there is indirect 
evidence that the world incidence of the disorder is bound not only to culture but to 
latitude too [54].
The relevance of AT on the body weight and physical activity of AN patients was 
first revealed in a study in which adolescent patients with AN showed significantly 
higher physical activity during the colder months of the year, October to April, 
than in the warmer months, April to October [55]. In contrast, patients from the 
warm group were less underweight than those of the cold group. The relationship 
between AT and physical activity was confirmed by analysing a subset of eight 
patients with a temperature difference of 6°C on two consecutive days during the 
monitoring of the patients’ physical activity. The physical activity of these patients 
was significantly higher on colder days, confirming the modulating role of environ-
mental temperature over physical activity beyond the eventual regulatory function 
of anxiety and negative effect or relevant dimensions of eating psychopathology as 
body dissatisfaction and drive for thinness. This within subject analysis discarded 
that the association between AT and activity was mediated by other climatic 
aspects associated with AT, such as day length or seasonality. It is remarkable that 
the greater activity of ANR patients during the winter months contrasts with that 
reported at temperate latitudes for normal body weight people where physical activ-
ity decreases in the colder months of the year [56].
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There is growing evidence that AT merits more attention in future research 
given its paramount importance with respect to several relevant signs of AN such 
as hyperactivity, body weight, and amenorrhea. Furthermore, there is indirect 
evidence that the world incidence of the disorder is bound not only to culture but to 
latitude too [54].
The relevance of AT on the body weight and physical activity of AN patients was 
first revealed in a study in which adolescent patients with AN showed significantly 
higher physical activity during the colder months of the year, October to April, 
than in the warmer months, April to October [55]. In contrast, patients from the 
warm group were less underweight than those of the cold group. The relationship 
between AT and physical activity was confirmed by analysing a subset of eight 
patients with a temperature difference of 6°C on two consecutive days during the 
monitoring of the patients’ physical activity. The physical activity of these patients 
was significantly higher on colder days, confirming the modulating role of environ-
mental temperature over physical activity beyond the eventual regulatory function 
of anxiety and negative effect or relevant dimensions of eating psychopathology as 
body dissatisfaction and drive for thinness. This within subject analysis discarded 
that the association between AT and activity was mediated by other climatic 
aspects associated with AT, such as day length or seasonality. It is remarkable that 
the greater activity of ANR patients during the winter months contrasts with that 
reported at temperate latitudes for normal body weight people where physical activ-
ity decreases in the colder months of the year [56].
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Related to the finding of lower body weight and BMI in AN patients during the 
colder months of the year, a retrospective study covering admissions during a 3-year 
period (2007–2010) of an adolescent inpatient eating disorders unit revealed that 
AT was a modulating factor in body mass index (BMI) at hospital admission [52]. 
The study revealed that AN restrictive (ANR) subtype patients differ from AN 
binge/purging (ANB/P) subtype patients with respect to the body weight fluctua-
tion pattern throughout the year. The study revealed that differences between both 
diagnostic subtypes only occurred during the cold semester, revealing that the dif-
ferences were due to the inverted annual pattern of body weight fluctuation in both 
groups of patients. Thus, while annual fluctuations in the weight of ANB/P patients 
were similar to those of the general population, i.e. having a higher BMI during 
the colder months of the year and a lower one during the warmer months [57], the 
pattern for ANR patients was the opposite.
Bearing in mind the above, it is hardly surprising that, in comparison to the 
warm semester, ANR patients admitted to hospital during the colder season had 
a longer hospital stay, a finding which has been inconsistently replicated in two 
different German samples [58, 59]. Moreover, due to their lower body weight during 
the cold semester, ANR patients had longer hospital stays than ANBP patients [52]. 
Moreover, other researchers have provided strong evidence of the effects of AT 
on menses recovery in AN patients. During the warmer months of the year, prob-
ability of menses recovery was twice as high as in autumn or winter, despite the fact 
that body weight of the patients were 2 kg less in the warm season than in the cold 
season, which was directly associated to lower energy expenditure associated with 
thermoregulation in the spring and summer months [60].
A possible explanation for this pattern of higher activity and lower body weight 
in AN patients was advanced [19] as a dramatic example of the energy balance 
equation in which AN patients are locked up. Given their restrictive eating pat-
tern, the lower the AT, the greater the weight loss and consequently the greater the 
increase in physical activity as a potential surrogate thermoregulation mechanism. 
However, as ABA research has shown, resorting to increased motor activity raises 
the body temperature in the short run, but the mobilization of fat reserves to 
maintain activity which supposes a reduction in body insulation. Moreover, defi-
cient insulation resulting from reduced subcutaneous fat in AN reduces protection 
against environmental hazards as Arthur Crisp pointed out that ‘Fat has general 
biological purposes as a reserve of energy and a contributor to body temperature 
regulation, both as a component of resting metabolic rate and, subcutaneously as 
insulation’ ([61], p. 481). Thus, all other things being equal, given the stable restric-
tive energy intake of ANR patients, a colder environment would impose a greater 
demand for the maintenance of body temperature. In this scenario, increased 
physical activity would perform a thermoregulatory function rather than being 
driven exclusively by psychological factors such as excessive preoccupation with 
body weight and shape [62].
Besides the aforementioned influence of AT on the hyperactivity and body 
weight of AN patients, there is also an underreported active search for heat by AN 
patients. For example, this was the case with the conspicuous absence of reports in 
the literature of sauna baths as a weight-losing strategy among AN patients [63]. 
This complete absence of reports contrasted with spontaneous mentions of the use 
of sauna baths AN patients in their chats on the Internet [64]. It has been suggested 
that among the possibilities underlying the absence of reports of the use of saunas, 
there was a possibility that regular sauna bathing may either act in preventing 
predisposed adolescents from developing the ‘full-blown’ syndrome or accelerat-
ing recovery from AN [63]. Hence, it may be more than mere coincidence that in 
Finland, where saunas are a substantial part of Finnish culture, the 5-year clinical 
187
Warming in Anorexia Nervosa: A Review
DOI: http://dx.doi.org/10.5772/intechopen.90353
recovery rates for DSM-IV anorexia nervosa were as high as 68.4% in patients 
undetected by the health-care system [65].
Furthermore, there is evidence that the world incidence of the disorder could 
be bound not only to cultural influences but to climate and latitude too [54]. This 
seems to be the case according to the results gathered by means of a bibliometric 
perspective where the worldwide distribution of scientific publications was deemed 
to be an indirect indicator of the incidence and prevalence of the disorder at differ-
ent latitudes. Two subsequent studies [66, 67] have reported that the distribution 
of references for anorexia nervosa have remained considerably stable over the last 
25 years, associated to higher but not extreme latitudes and to climates with regular 
seasons with no severe temperature variations across seasons. Thus, references to 
AN condense into a 40–55° latitude range in the Northern Hemisphere which closely 
parallels with the vast majority of epidemiological studies undertaken on popula-
tions living in this latitude range in the Northern Hemisphere [68].
4. Conclusion: listening to Hippocrates (460–377 BCE)
One of the most important treatises in the Hippocratic Corpus entitled On Airs, 
Waters and Places wisely begins with ‘Whoever wishes to pursue properly the sci-
ence of medicine must proceed thus. First, he ought to consider what effects each 
season of the year can produce; for the seasons are not at all alike, but differ widely 
both in themselves and at their changes’ ([69], p. 71). Without any reasonable 
doubt, AT has been systematically overlooked in AN research, which has hindered a 
better understanding of the use of heat in the treatment of AN.
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A Software-Assisted Qualitative 
Study on the Use of Music in 
People with Anorexia Nervosa
Briana Applewhite, Aishwarya Krishna Priya, 
Valentina Cardi and Hubertus Himmerich
Abstract
Anorexia nervosa (AN) is an eating disorder associated with a high mortality 
and an often chronic and disabling course. Thus, novel treatment options should 
be explored. We performed two focus groups with a total of six people with AN 
on their use of music and their thoughts about music as an additional therapeutic 
option. Interviews were transcribed and analyzed in-depth using the NVivo 12 
software package. The most prevalent theme throughout the focus groups involved 
positive expressions, emotions and memories related to music. This theme occurred 
in ~25% of the data. The importance of music was the second most common theme. 
Negative feelings and memories associated with music accounted for only ~10% of 
all references. All six patients expressed that they see benefit in using music therapy 
as an adjunct to their current treatment. Our analysis shows that people with AN 
connect music mainly with positive emotions and memories. Therapists might 
think about applying music more frequently during their sessions with AN patients 
and consider adding music therapy to their overall treatment concept. However, the 
results also suggest that music can influence mood not only positively but negatively 
as well. Quantitative research in bigger patient samples and randomized clinical 
trials will be necessary to verify these results.
Keywords: music, music therapy, eating disorders, anorexia nervosa, qualitative 
research, NVivo software
1. Introduction
Anorexia nervosa (AN) is one of the eating and feeding disorders. This group is 
characterized by a persistently disturbed eating behavior, which leads to changes 
in food intake, impaired physical health and psychosocial problems. According to 
the Diagnostic and Statistical Manual of mental disorders (DSM)-5, people with 
AN show a restrictive eating behavior, a body weight that is significantly too low 
for age, sex, and developmental trajectory, fear of gaining weight and a disturbance 
in the perception of one’s own body (body image disturbance) [1]. AN occurs in 
approximately 0.5% of the population, with women being affected about 10 times 
more often [2]. The risk of death in patients with AN is five times higher compared 
to people of the same age and gender [3]. The course of AN is often chronic and can 
lead to a permanent disability.
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The eating and feeding disorders cluster further includes bulimia nervosa (BN), 
binge eating disorder (BED), avoidant/restrictive food intake disorder (ARFID), 
pica and rumination disorder.
BN occurs in about 2% of the population with a male to female ratio of about 
1:10 [2]. The main criteria for diagnosing BN are recurrent binge eating, compensa-
tory behaviors and excessive concerns with body shape and weight [1]. BED is the 
most common eating disorder. It is about twice as common (approx. 4% of the 
population) as the BN, with the proportion of women in patients with BED being 
around 60% [2]. It is mainly characterized by binge eating without the use of com-
pensation strategies [1]. ARFID is hallmarked by a restrictive eating pattern that 
leads to malnutrition; pica means the consumption of non-food; and rumination 
disorder features choking up and chewing food again. Within those eating disor-
ders, clinical features may change over time, with some patients with AN changing 
to BN or BED. Therefore, we are dealing with a spectrum of eating disorders rather 
than well-defined disease entities [4].
According to the National Institute for Health and Care Excellence (NICE) [5], 
the main pillars of therapy for eating disorders such as AN are psychological ther-
apy, diet counseling as well as weight and physical health monitoring. Additional 
therapies can be family therapy, occupational and art therapy. Despite the avail-
ability of these therapies, a recent study that examined acutely ill AN patients over 
20 years showed that despite existing therapies, only about 30% recovered after 
about 10 years and only 60% after 20 years [6]. Thus, there is a demand for addi-
tional treatments, and music therapy could be such an additional approach.
In a recently conducted systematic review on the effects of music in people with 
or at risk for eating disorders, researchers found that the use of music as an adjunct 
treatment was beneficial in certain cases [7]. The review encompassed 16 studies and 
3792 participants using music in an experimental or observational study. Important 
studies cited in this review found that listening to classical piano improved food 
consumption with inpatients with AN [8] and that a “vodcast” of visual images and 
soothing music favorably influenced eating behaviors in patients with AN [9].
Apart from music therapy, the role music as such plays in daily life is expansive. 
Essentially, all cultures produce and use music in some way. Whether that is listening 
to a favorite song or dancing at a wedding, music seems to have an expansive power of 
triggering an emotional response. It is used as a source of healing and can be used as of 
source of comfort for many. The value of music on a person’s life is dependent on the 
context with which they hear it, how much they engage with it and the feeling that it 
evokes when listening to it [10]. Music can have transformative effects on stress levels 
and the autonomic nervous system. For instance, studies have shown that listening to 
slow and smooth music reduces blood pressure and regulates breathing, in comparison 
to fast paced music which can lead to increased blood pressure [11]. Music has also been 
shown to influence neurotransmission such as the amount of dopamine release [12].
We sought to conduct a software-assisted qualitative analysis of two in-depth 
interviews performed during focus groups with people with AN to find out how 
they use music in daily life, how they talk about music, and what they think about 
the therapeutic application of music. We used this qualitative approach, because we 
wanted to identify and conceptualize aspects of the use of music which are impor-
tant for them [13–16].
2. Methods
Study participants: Six female patients between 22 and 49 years with AN were 
recruited at the inpatient eating disorders service at the Bethlem Royal Hospital 
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and the outpatient eating disorders service at the Maudsley Hospital. Both hospitals 
are managed by the South London and Maudsley NHS Foundation trust (SLaM), 
London. Patients gave written informed content to participate in the focus groups. 
They also agreed that the focus group would be recorded and transcribed, the con-
tent analyzed, the results of this analysis harnessed for further service development 
and publication. They also agreed that their recorded and transcribed statements 
may be cited, potentially verbatim, in an anonymized way.
Study Design: Each patient took part in one of the two focus groups. The focus 
groups were advertised within both the inpatient and outpatient eating disorders 
units with posters including the information about the topic and the focus group’s 
research purpose. In preparation of the group, a questionnaire was devised 
containing 15 questions on listening to music, making music and music as a 
therapeutic strategy in order to guide the in-depth interviews (see Appendix). 
The focus groups were recorded, transcribed and subjected to thematic and 
content analysis [13–16].
Procedure: For evaluation of the transcribed focus groups, we used the NVivo 12 
software. NVivo is a qualitative data analysis computer software package for quali-
tative research on text-based information. It organizes and analyzes non-numerical 
or unstructured data and allows users to classify, sort and arrange information [17]. 
Using NVivo, themes were extracted, a word cloud developed, the most frequently 
used words, and the distribution of coded themes and references analyzed.
3. Results
Following the transcription of both focus groups from audio recordings, a list 
of 14 themes were extracted from the data collected. Using Nvivo 12 software, 
the themes derived from both focus groups highlight the effects music has on the 
participants lives, the emotions experienced while listening to music, as well as 
the sentiments expressed about music therapy and its uses when treating their 
AN. The themes generated are as follows: Benefit of Music Therapy, Frequency 
(of music listening), Genre Listened To, How Music Makes You Feel, Importance 
of Music, Interest In Music Therapy, Music Dislikes, Music Making, Music 
Preference, Negative Emotion Elicited, Negative Memory Association, Neutral 
Emotion Elicited, Positive Emotion Elicited, and Positive Memory Association. 
Table 1 illustrates the codebook of the analysis along with the description of the 
theme, file number and number of references within the data.
A word cloud of the two interviews was developed of the 1000 most frequently 
used words throughout both focus groups to illustrate which words/phrases 
appeared most frequently throughout data collection. Words most frequently 
used are indicated by the larger text size. These include ‘music,’ ‘think,’ ‘listen,’ and 
‘feel,’ suggesting that music elicits a thoughtful emotive reaction within individual 
participants (Figure 1). Music accounts for the most frequently used word amongst 
participants with a count of 378, while’ think’ had a count of 327 and ‘feel’ a count 
of 145 (Table 2).
The individual themes coded with the greatest number of text segments by 
participants include Music Preference, Positive Emotion Elicited, Positive Memory 
Association, Importance of Music and How Music Makes You Feel (Figure 2).
The themes were grouped into six main segments based on the content out-
lined by the participant in their responses: Music Therapy, Preference, Positives, 
Negatives, Neutrals, and Beliefs. The Positives grouping accounted for 25.1% 
of coded segments, while Preference and Beliefs accounted for 30.9 and 22.2%, 
 respectively (Table 3).
Weight Management
196
The eating and feeding disorders cluster further includes bulimia nervosa (BN), 
binge eating disorder (BED), avoidant/restrictive food intake disorder (ARFID), 
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ders, clinical features may change over time, with some patients with AN changing 
to BN or BED. Therefore, we are dealing with a spectrum of eating disorders rather 
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context with which they hear it, how much they engage with it and the feeling that it 
evokes when listening to it [10]. Music can have transformative effects on stress levels 
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We sought to conduct a software-assisted qualitative analysis of two in-depth 
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2. Methods
Study participants: Six female patients between 22 and 49 years with AN were 
recruited at the inpatient eating disorders service at the Bethlem Royal Hospital 
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and the outpatient eating disorders service at the Maudsley Hospital. Both hospitals 
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Throughout both focus groups, the most commonly shared themes represented 
positive associations with music, in the form of Positive Memory Associations 
(28 references) and Positive Emotion Elicited (24 references). A commonality 
that participants shared throughout the focus group discussions were the positive 
emotions that music makes them feel. One patient described music as “(it) can be 
a comfort; it can be something to move you up… (it’s) obviously something that’s a 
release of emotions…and it definitely cheers me up and makes me more determined 
and motivated”. This was a popular sentiment amongst and between the two focus 
groups, with one patient stating “(music) makes me feel good, content even.”
The importance of music was also a common theme for participants accounting 
for 24 references within the data. Patients discussed the uses of music within their 
day to day life and through their recovery process. One patient stated “(music) gives 
you space to kind of like describe stuff that you can’t necessarily put into words 
yourself,” and serves as an “incentive” or “motivator” throughout their recovery 
process.
The most commonly discussed themes fall under the Preference grouping with 
a total of 64 references throughout both focus groups. Accounting for 30.9% of 
the coded references, patients discussed their music preferences in great detail 
(Table 3). Patients listed the genres they listened to and how often they listened, 
if they participated in making music, and their music dislikes. Music preference 
Themes Description Files References
Benefit of music 
therapy
What are the benefits one associates with music 
therapy?
2 9
Frequency How often does one listen to music? 2 13
Genre listened to What type of music one listens to? 2 10
How music makes 
you feel
What feelings does one experience because of 
music?
1 22
Importance of music What value does music have on one’s life? 2 24
Interest in music 
therapy
Is there an interest in the therapeutic uses of 
music therapy as well as attending a music therapy 
session?
2 9
Music dislikes What music does one dislike? 2 14
Music making Playing an instrument, singing, recording, 
composition etc.
2 6
Music preference What does one prefer to listen to? (i.e. favorite 




Is there a negative emotion associated with music? 2 12
Negative memory 
association
Is there a negative memory associated with music? 2 9
Neutral emotion 
elicited
Is there an indifference/ impartiality to music? 2 6
Positive emotion 
elicited
Is there a positive emotion associated with music? 2 28
Positive memory 
association
Is there a positive memory associated with music? 2 24
Table 1. 
Codebook with themes, their description, their appearance in only one or both focus groups and their frequency 
(extracted from NVivo 12).
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accounted for 21 references within both focus groups where patients stated “clas-
sical” “pop” “soul” “literally anything” as the genre of choice as well as how they 
consume the music they listen to (“headphones,” “iPod,” “CD,” “radio”).
Neutral themes, defined as an indifference or impartiality to music, repre-
sented the smallest percent of coded references (3% of the coded data) (Table 3). 
However, Negative Emotion Elicited and Negative Memory Association accounted 
for 10.1% of all coded references (Table 3). Patients described music as channeling 
an emotion based on a certain song as well as having a negative memory linked to a 
Figure 1. 
Word cloud illustrating which words or phrases appeared most frequently throughout both focus groups.
Frequency 
rank
Word Length Count Weighted 
percentage
Similar Words
1 Music 5 378 3.52% Music, Musical, Music’s
2 Think 5 327 3.04% Think, Thinking
3 Listen 6 226 2.10% Listen, Listening, Listens
4 Really 6 187 1.74% Really
5 Feel 4 145 1.35% Feel, Feeling, Feelings, Feels
6 Play 4 126 1.17% Play, Played, Playful, Playing, 
Plays
7 Get 3 118 1.10% Get, Gets, Getting
8 Make 4 115 1.07% Make, Makes, Making
9 Song 4 106 0.99% Song, Songs
10 Words 5 100 0.93% Word, Words
Table 2. 
Top 10 most frequently used words including weighted percentages.
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piece of music. One patient describes a particularly sad event in their life that was 
tied to an artist, saying, “that would be with Frank Sinatra’s song, that was played 
at my Granddad’s funeral. So, again if I feel like I need to cry and let it all out… Ten 
out of ten it would make those tears fall.” Music seems to elicit an emotive reaction 
based on the participants life experience.
Music Therapy was discussed totaling 18 references throughout both focus 
groups (Figure 2). Patients were asked for their thoughts on music therapy, if music 
therapy can be helpful through their recovery process, as well as if they would 
be interested in attending a music therapy session. None of the patients had any 
experience with music therapy but all six of the patients unanimously agreed that 
they would be interested in attending a music therapy session.
There were nine references during the focus groups about the benefits of music 
therapy. One patient stated “I know it’s brilliant. And I know it could help me sort 
through a lot of issues,” while another stated its uses in a group setting with oth-
ers undergoing treatment for their eating disorder, saying “…a lot of girls I was 
in daycare with, music was definitely a thing that we did a lot. So, I think that 
sort of being able to mingle with other people through the recovery process too, I 
think would be really, really helpful.” Overall, patients all seemed to have a strong 
Figure 2. 
Distribution of the frequency of themes coded from both focus group.
Coded theme group Number of coded references Percentages of all coded references







Coded references by group.
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connection with music, specifically throughout their recovery process and viewed 
music as an important tool for healing throughout their lives.
4. Discussion
In this study, we conducted a software-assisted qualitative study exploring 
people with AN’s attitudes toward music, music therapy, and the uses of music 
throughout their life, treatment and recovery. The results of the study point to a 
promising potential for the varied uses of music throughout the recovery process for 
eating disorders. Patients were questioned in focus groups concerning the uses of 
music in their day to day life and as a therapeutic strategy. Responses were analyzed 
with NVivo 12 qualitative software for recurring themes throughout the discussions.
The most prevalent theme throughout the focus groups involved positive expres-
sions and positive memory associations related to music. This theme occurred in 
~25% of the data and totaled 52/207 of all of the coded themes (Table 3). This 
suggests patients have pleasant feelings about music and associate good things that 
have happened in their lives along with musical experiences. The importance of 
music was the second most common theme accounting for 24 references throughout 
the focus groups (Figure 2). Patients described the effect music had on their day to 
day life, with regulating emotions and providing an outlet of peace through their 
recovery process, suggesting that it was the study participants’ opinion that music 
could be used to improve their mental state throughout their recovery.
Negative feelings and negative memories associated with music accounted for 
only ~10% of all of the references from both focus groups (Table 3). Patients dis-
cussed how music they dislike can make them feel low in mood and also described 
negative memories linked to a certain genre or song. This suggests music can influ-
ence mood not only positively but negatively as well.
The final main result concerns the potential uses of music as a therapeutic 
adjunct to their treatment. When asked about music therapy, 6/6 patients stated 
they were interested in attending a music therapy session; in addition, all patients 
expressed that they see benefit in using music therapy as an adjunct to their current 
treatment for their eating disorder. This suggests music could be helpful for patients 
in the treatment of AN.
In previous studies on the use of music in eating disorder treatment, researchers 
found that patients with AN managed to eat more when listening to classical piano 
music and had a significant reduction in postprandial anxiety when participating 
and music therapy; listening to a violin concerto by Mozart induced the recall of 
autobiographical memories in patients with BN and reduced body width estimation 
[7–9, 18–20]. These previous findings align with the results of our current research 
as patients described that when listening to their favorite music, they generally 
feel happier and more positive. In addition, patients expressed their interest in 
attending music therapy citing the potential benefits it could have in their own life 
specifically with their treatment of their AN.
In other studies, however, negative symptoms presented when patients watched 
music videos. More specifically, researchers found that watching music videos was 
associated with an increase in body dissatisfaction [21], and sexually objectifying 
videos were associated with increased perception of body size in young women 
with suffering from low self-esteem [22]. In our study, we found that patients who 
listened to music outside their usual preference or that they did not like, as a result, 
had negative emotional reactions (i.e. crying, dissociation). This aligns with the 
previous findings suggesting that while music not only can produce positive side 
effects, it can also produce negatives as well [7].
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Our study has several limitations. The number of participants (N = 6) was small. 
All study participants suffered from AN. Due to the small sample size, we could not 
differentiate between the subtypes of AN (restricting vs. binge eating/purging), 
length of illness duration and their stage of recovery. Our sample was ethnically 
homogeneous with only white Caucasian participants, and all patients were female. 
Thus, the results are not generalizable to other ethnic groups or males. From our 
perspective, the lack of generalizability is a main problem of research in the area of 
music therapy for people with eating disorders, and specifically AN. Even though 
there is plenty of case studies (for a comprehensive review and further literature see 
[23]), randomized controlled trials (RCT) are scarce [7].
AN is one of several eating disorders. As we have explained in the introduction, 
eating disorders are not distinct entities, but should rather be seen as symptom 
clusters within a spectrum of serious problems related to body image disturbance, 
disordered eating and their physical and psychosocial consequences. Therefore, it 
might be worth investigating, whether our findings can be reproduced and con-
firmed in people with BN, BED, ARFID or other eating disorders.
Taken together, our analysis shows that people with AN connect music mainly 
with positive emotions and memories. Therefore, music may be used more 
frequently and more extensively in psychological therapies as a tool to modulate 
emotions. As patients would welcome music therapy as an adjunct treatment 
option during inpatient or outpatient treatment, therapist might think about 
including music therapy into their overall treatment concept. However, quantita-
tive research in bigger patient samples and RCTs will be necessary to verify these 
results.
5. Conclusions
Based on the current study and previous publications on music and music 
therapy in people with AN, the following preliminary conclusions can be drawn:
• Music elicits mainly positive emotions and memories in people with AN.
• Music is an integral and important part of life.
• Music can help with recovery, overcome anxieties and improve eating.
• People with AN would like to be offered music therapy as an adjunct to their 
usual treatment.
• Music may be used as a tool to provoke emotions during psychotherapy.
• Music may also elicit negative feelings and memories.
• Watching sexually objectifying music videos can increase body dissatisfaction 
and the perception of body size in vulnerable people.
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Appendix: questionnaire for the focus groups
Listening to music:
• How do you find listening to music?
• What impact does listening to your favorite music have on your body and 
brain?
• How often do you listen to music?
• What type of music do you prefer to listen to?
 ◯ Genre, style
 ◯ Instrumental, vocals, both
 ◯ Stimulating, relaxing
• How do you prefer to listen to music?
 ◯ Recordings, live music
 ◯ TV, radio, DVD, CD, MP3
• How often do you listen to something that is not your usual preference?
• How does listening to music relate to your emotions?
• Can you name of experience where music made you feel happy or sad?
• Is there a time in your life that you connect a certain situation with a specific 
song?
• How does it make you feel, if you have to listen to music you do not like?
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AN is one of several eating disorders. As we have explained in the introduction, 
eating disorders are not distinct entities, but should rather be seen as symptom 
clusters within a spectrum of serious problems related to body image disturbance, 
disordered eating and their physical and psychosocial consequences. Therefore, it 
might be worth investigating, whether our findings can be reproduced and con-
firmed in people with BN, BED, ARFID or other eating disorders.
Taken together, our analysis shows that people with AN connect music mainly 
with positive emotions and memories. Therefore, music may be used more 
frequently and more extensively in psychological therapies as a tool to modulate 
emotions. As patients would welcome music therapy as an adjunct treatment 
option during inpatient or outpatient treatment, therapist might think about 
including music therapy into their overall treatment concept. However, quantita-
tive research in bigger patient samples and RCTs will be necessary to verify these 
results.
5. Conclusions
Based on the current study and previous publications on music and music 
therapy in people with AN, the following preliminary conclusions can be drawn:
• Music elicits mainly positive emotions and memories in people with AN.
• Music is an integral and important part of life.
• Music can help with recovery, overcome anxieties and improve eating.
• People with AN would like to be offered music therapy as an adjunct to their 
usual treatment.
• Music may be used as a tool to provoke emotions during psychotherapy.
• Music may also elicit negative feelings and memories.
• Watching sexually objectifying music videos can increase body dissatisfaction 
and the perception of body size in vulnerable people.
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Appendix: questionnaire for the focus groups
Listening to music:
• How do you find listening to music?
• What impact does listening to your favorite music have on your body and 
brain?
• How often do you listen to music?
• What type of music do you prefer to listen to?
 ◯ Genre, style
 ◯ Instrumental, vocals, both
 ◯ Stimulating, relaxing
• How do you prefer to listen to music?
 ◯ Recordings, live music
 ◯ TV, radio, DVD, CD, MP3
• How often do you listen to something that is not your usual preference?
• How does listening to music relate to your emotions?
• Can you name of experience where music made you feel happy or sad?
• Is there a time in your life that you connect a certain situation with a specific 
song?




• Have you played, or do you play an instrument or sing?
 ◯ Singing alone/in a choir
 ◯ Play instrument alone/in a band/in an orchestra
Music as a therapeutic strategy:
• How could listening to music be helpful to cope with difficult emotions or 
problems in your life?
• Do you feel that there could be an effect of music in your life?
• Do you have any experience with music therapy?
• Would you attend a music therapy session?
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Abstract
Anorexia nervosa (AN) is a serious and often highly persistent psychiatric disorder, 
whereby sufferers struggle to maintain a healthy weight. Its complexity creates 
challenges regarding treatment, however psychological therapy is recommended by 
the National Institute for Heath and Care Excellence (NICE). There are four major 
evidence-based psychotherapies recommended for treating adults – enhanced cogni-
tive behavioural therapy (CBT-E), the Maudsley model of anorexia nervosa treatment 
for adults (MANTRA), specialist supportive clinical management (SSCM) and focal 
psychodynamic therapy (FPT)—and three main psychotherapies recommended for 
treating adolescents with anorexia-family therapy for anorexia nervosa (FT-AN), 
enhanced cognitive behavioural therapy (CBT-E) and adolescent focused therapy for 
anorexia nervosa (AFP-AN). Additionally, several novel adjunct treatments are under 
examination, two of which—cognitive remediation therapy (CRT) and cognitive 
remediation and emotion skills training (CREST)—are also discussed in this chapter. 
Other relevant areas regarding psychological treatment include: combinations of 
medication or occupational therapy and psychotherapy, treating individuals with 
comorbidities, the challenges of studying psychological treatment for anorexia and 
future directions of psychotherapies for anorexia, and are also discussed.
Keywords: anorexia nervosa, predisposing factors, precipitating factors, 
perpetuating factors, treatment, psychological therapy, psychotherapy
1. Introduction
Anorexia Nervosa (AN) is a serious and often highly persistent psychiatric 
disorder, whereby sufferers struggle to maintain a healthy weight. According to the 
Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), the 
diagnostic criteria for AN are as follows:
a. the restricting of energy intake to a level lower than required in order to main-
tain a healthy body weight resulting in significantly low body weight relevant 
to a person’s age, gender, development stage and physical health
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1. Introduction
Anorexia Nervosa (AN) is a serious and often highly persistent psychiatric 
disorder, whereby sufferers struggle to maintain a healthy weight. According to the 
Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), the 
diagnostic criteria for AN are as follows:
a. the restricting of energy intake to a level lower than required in order to main-
tain a healthy body weight resulting in significantly low body weight relevant 
to a person’s age, gender, development stage and physical health




c. disturbances to one’s view of their body, e.g., the body being an unusually high 
basis for self-evaluation or an inability to recognise the seriousness of the low 
body weight [1].
It should be noted, here, the significant changes to the diagnostic criteria pre-
sented in the DSM-5 compared to the previous edition. These are revised guidelines 
for determining weight loss severity, revised weight loss criterion (specifying the 
significance of weight in relation to differences in individuals’ age, gender, develop-
mental stage or physical health), the omission of amenorrhoea and the absence of 
the need for the explicit verbalisation of fear of weight gain, so long as behaviours 
intentionally inhibiting weight gain are evident [1, 2]. Consistent with the DSM-5, 
AN can be divided into two subtypes, restricting and binge-eating/purging. A suf-
ferer with restricting subtype predominantly uses dieting, fasting and/or excessive 
exercise to achieve a low body weight, with the absence of any recurrent binging or 
purging behaviours in the 3 months before diagnosis. Binging and purging behav-
iours include self-induced vomiting and/or laxative, diuretic or enema abuse. The 
binge-eating/purging subtype is characterised by repeated displays of such behav-
iours in the 3 months before diagnosis [1].
Anorexia can affect any individual, irrelevant of their age, gender, race or ethnic-
ity, however it has been found to be most common in adolescent and young females 
[3]. Whilst some research has found a higher prevalence of AN in white adults, these 
findings are quite inconsistent, with others indicating no significant differences in 
rates of AN for different ethnicities [4]. Anorexia is highly comorbid, with signifi-
cant numbers of sufferers reporting diagnoses of other psychiatric illnesses such as 
substance use disorders, personality disorders, anxiety disorders, mood disorders, 
obsessive–compulsive disorders and autism spectrum disorders [3, 5, 6], as well as 
an increased suicide risk [7]. Additionally, many negative physical consequences 
and health complications are associated with anorexia, including cardiovascular, 
gastrointestinal, endocrine and metabolic, pulmonary and dermatologic complica-
tions. Almost all of the body’s organ systems can be negatively impacted as a result 
of malnutrition or other behaviours associated with AN (e.g., purging), and despite 
varying outcomes, anorexia is often extremely persistent, has a relatively high risk 
of relapse, and the highest mortality rate among psychiatric disorders [7].
2. Predisposing, precipitating and perpetuating factors of AN
A functional analysis of anorexia by Slade [8] describes “antecedent events”, 
divided into “general setting conditions” and “specific psychosocial stimuli”, that 
cause changes in an individual’s behaviour/biological adaptation, the consequences 
of which lead to anorexia. Setting conditions such as low self-esteem, issues during 
development or perfectionistic tendencies, combine with specific psychosocial 
stimuli such as comments from others about weight or learnt dieting behaviour 
and trigger initial food restricting behaviour, indicating the first step towards an 
eating disorder. Changes in behaviour/biological adaptation are shown in response 
to these events, specifically restricting food intake and weight loss, and endocrine 
disturbances that may result in amenorrhoea in females, either due to the effects 
of low weight or due to a stress induced functional disorder. Slade then describes 
“consequences” of these behaviours in the form of positive reinforcers, feelings of 
control, success etc., and negative reinforcers, avoiding weight gain, or changes in 
body shape. These limited “antecedent events,” “specific psychosocial stimuli” and 
“consequences” discussed by Slade are now commonly referred to as predisposing, 
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precipitating and perpetuating factors and cover a wide range of potential contribu-
tory factors to the development, onset and maintenance of anorexia.
It is now widely accepted that anorexia is developed, triggered and maintained 
by a combination of many different biological, psychological and social factors [9] 
with various models theorising the involvement of different core factors to different 
extents [10, 11]. Separating factors into those that predispose a person to anorexia 
and those that perpetuate the illness is crucial for identifying which are relevant for 
preventative strategies (i.e., predisposing or risk factors) and which are relevant to 
treatment and interventions (perpetuating or maintaining factors) [12]. It is also 
important to note that there is some overlap between factors as they converge and 
combine to increase risk of anorexia, for example some predisposing factors may 
also act as perpetuating factors. Additionally, some factors do not work indepen-
dently and may be closely linked or impact upon each other, for example a social 
factor might serve to reinforce an existing psychological factor [11]. Table 1 gives a 
summary of the predisposing, precipitating and perpetuating factors for anorexia 
and demonstrates how they can be categorised into psychological, biological and 
socio-cultural factors.
Many theories and models of anorexia nervosa consider there to be a vital role 
for psychological factors in predisposing an individual to the disorder, such as 
personality and cognitive variables [13]. Literature frequently discusses personality 
characteristics that are thought to be common among individuals with anorexia 
including: traits associated with anxiety and depression, obsessive–compulsive 
traits such as rigidity and concern with detail, perfectionism, being high achieving, 
socially withdrawn, sensitive and introverted. These characteristics combine with 
other risk factors and increase an individual’s vulnerability to the illness [14, 15]. In 
addition to personality characteristics, combinations of experiences and events lead 
to the creation of various distorted cognitions, creating vulnerability in an indi-
vidual for developing anorexia, for example beliefs about the importance of thin-
ness and the need to feel in control, or a cognitive bias towards food, eating, weight 
or body shape information processing. Fairburn et al.’s [16] cognitive behavioural 
theory focuses on the need for control as a central feature of anorexia and suggests 
that a combination of existing feelings of ineffectiveness, perfectionistic tendencies 
and low self-esteem underpin this need for control. Other predisposing cognitive 
factors for anorexia include difficulties switching between tasks (set shifting) and a 
preference for ‘detail-focused’ thinking rather than ‘bigger picture’ thinking (poor 
central coherence) [9]. Biological models highlight a number of genetic predisposi-
tions and neurobiological factors involved in the development of anorexia [14], 
such as malfunctions of particular neurotransmitters that may increase risk of 
anorexia by altering appetite regulation and increasing locomotor activity levels, or 
specific inherited genes that may be responsible for altered mechanisms involved 
in energy metabolism or appetite and feeding regulation. For a full review see 
[17]. Sociocultural influences might also predispose an individual to anorexia, for 
example insecure attachment types as a child or stressful or traumatic life events 
can result in interpersonal issues and emotional avoidance, common in those with 
anorexia [14, 18, 19].
With existing predisposing factors in place, the onset of the illness may be 
triggered by one or more precipitating factors [14] such as periods of isolation or 
self-doubt, interpersonal conflict, existing loss or trauma, culture among particular 
occupations, e.g., ballet dancers, models or athletes, disrupted family dynamics 
and peer influence, for example dieting behaviour, teasing or body dissatisfaction. 
Additionally, biological factors like pregnancy [20–22] or weight loss [23] may 
influence eating disorder symptomology, psychopathology or behaviours.
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an increased suicide risk [7]. Additionally, many negative physical consequences 
and health complications are associated with anorexia, including cardiovascular, 
gastrointestinal, endocrine and metabolic, pulmonary and dermatologic complica-
tions. Almost all of the body’s organ systems can be negatively impacted as a result 
of malnutrition or other behaviours associated with AN (e.g., purging), and despite 
varying outcomes, anorexia is often extremely persistent, has a relatively high risk 
of relapse, and the highest mortality rate among psychiatric disorders [7].
2. Predisposing, precipitating and perpetuating factors of AN
A functional analysis of anorexia by Slade [8] describes “antecedent events”, 
divided into “general setting conditions” and “specific psychosocial stimuli”, that 
cause changes in an individual’s behaviour/biological adaptation, the consequences 
of which lead to anorexia. Setting conditions such as low self-esteem, issues during 
development or perfectionistic tendencies, combine with specific psychosocial 
stimuli such as comments from others about weight or learnt dieting behaviour 
and trigger initial food restricting behaviour, indicating the first step towards an 
eating disorder. Changes in behaviour/biological adaptation are shown in response 
to these events, specifically restricting food intake and weight loss, and endocrine 
disturbances that may result in amenorrhoea in females, either due to the effects 
of low weight or due to a stress induced functional disorder. Slade then describes 
“consequences” of these behaviours in the form of positive reinforcers, feelings of 
control, success etc., and negative reinforcers, avoiding weight gain, or changes in 
body shape. These limited “antecedent events,” “specific psychosocial stimuli” and 
“consequences” discussed by Slade are now commonly referred to as predisposing, 
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precipitating and perpetuating factors and cover a wide range of potential contribu-
tory factors to the development, onset and maintenance of anorexia.
It is now widely accepted that anorexia is developed, triggered and maintained 
by a combination of many different biological, psychological and social factors [9] 
with various models theorising the involvement of different core factors to different 
extents [10, 11]. Separating factors into those that predispose a person to anorexia 
and those that perpetuate the illness is crucial for identifying which are relevant for 
preventative strategies (i.e., predisposing or risk factors) and which are relevant to 
treatment and interventions (perpetuating or maintaining factors) [12]. It is also 
important to note that there is some overlap between factors as they converge and 
combine to increase risk of anorexia, for example some predisposing factors may 
also act as perpetuating factors. Additionally, some factors do not work indepen-
dently and may be closely linked or impact upon each other, for example a social 
factor might serve to reinforce an existing psychological factor [11]. Table 1 gives a 
summary of the predisposing, precipitating and perpetuating factors for anorexia 
and demonstrates how they can be categorised into psychological, biological and 
socio-cultural factors.
Many theories and models of anorexia nervosa consider there to be a vital role 
for psychological factors in predisposing an individual to the disorder, such as 
personality and cognitive variables [13]. Literature frequently discusses personality 
characteristics that are thought to be common among individuals with anorexia 
including: traits associated with anxiety and depression, obsessive–compulsive 
traits such as rigidity and concern with detail, perfectionism, being high achieving, 
socially withdrawn, sensitive and introverted. These characteristics combine with 
other risk factors and increase an individual’s vulnerability to the illness [14, 15]. In 
addition to personality characteristics, combinations of experiences and events lead 
to the creation of various distorted cognitions, creating vulnerability in an indi-
vidual for developing anorexia, for example beliefs about the importance of thin-
ness and the need to feel in control, or a cognitive bias towards food, eating, weight 
or body shape information processing. Fairburn et al.’s [16] cognitive behavioural 
theory focuses on the need for control as a central feature of anorexia and suggests 
that a combination of existing feelings of ineffectiveness, perfectionistic tendencies 
and low self-esteem underpin this need for control. Other predisposing cognitive 
factors for anorexia include difficulties switching between tasks (set shifting) and a 
preference for ‘detail-focused’ thinking rather than ‘bigger picture’ thinking (poor 
central coherence) [9]. Biological models highlight a number of genetic predisposi-
tions and neurobiological factors involved in the development of anorexia [14], 
such as malfunctions of particular neurotransmitters that may increase risk of 
anorexia by altering appetite regulation and increasing locomotor activity levels, or 
specific inherited genes that may be responsible for altered mechanisms involved 
in energy metabolism or appetite and feeding regulation. For a full review see 
[17]. Sociocultural influences might also predispose an individual to anorexia, for 
example insecure attachment types as a child or stressful or traumatic life events 
can result in interpersonal issues and emotional avoidance, common in those with 
anorexia [14, 18, 19].
With existing predisposing factors in place, the onset of the illness may be 
triggered by one or more precipitating factors [14] such as periods of isolation or 
self-doubt, interpersonal conflict, existing loss or trauma, culture among particular 
occupations, e.g., ballet dancers, models or athletes, disrupted family dynamics 
and peer influence, for example dieting behaviour, teasing or body dissatisfaction. 
Additionally, biological factors like pregnancy [20–22] or weight loss [23] may 
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It has been suggested that the most useful models for understanding the ill-
ness in terms of advancing treatment are maintenance models, focusing more 
specifically on factors that maintain the illness rather than those involved in the 
development of it [19, 24], though there is often a lot of overlap with some factors 
acting not only as perpetuating factors but also precipitating or predisposing ones. 
Many models of AN discuss psychological factors that perpetuate anorexia, either 
internally (self-perpetuating factors) or externally. Fairburn et al.’s [16] cogni-
tive behavioural theory proposes a number of psychological maintaining factors. 
Fairburn et al. posit that achieving successful dietary restriction creates a sense of 
self-control in an individual, in turn improving their self-worth until restriction 
becomes an indication of both self-control and self-worth. This may be exacerbated 
by a highly perfectionist individual applying their high standards to restriction in 
the form of strict dietary rules. A second maintaining factor suggested in the theory 
is the direct effect of starvation on cognition. Intense feelings of hunger, exagger-
ated feelings of fullness, poorer concentration and preoccupation with food may 
cause an individual to feel their self-control is threatened or failing and strengthen 
the value that controlling food holds on the individual’s self-control and self-worth. 
Finally, Fairburn et al. suggest extreme concerns about weight or shape is involved 
in perpetuating the illness, whereby an individual evaluates their self-worth highly 
on their weight and shape. This may be exacerbated by body checking behaviours, 
particularly when an individual is in an aroused and anxious state, which serves 
to enhance the individual’s perceived imperfections regarding their body shape, 
encouraging further restricting and creating a vicious cycle. As a consequence of 
starvation, many of the aforementioned maintaining factors are worsened, facili-
tating the formation of vicious cycles that allow these maintaining factors and the 
illness to persist [15]. Further psychological, biological and social perpetuating 
factors are listed in Table 1.
3. History of treatment for AN
Historically, treatment for AN relied heavily on antipsychotic medication up 
until the second half of the 1990s when the shift towards a more complex approach 
to treatment began, taking into account an individual’s biological and developmen-
tal factors and involving individual psychotherapy [25]. Advancements were made 
following this shift such as the introduction of cognitive and behavioural treat-
ments. For example, an operant conditioning technique used from the mid-1960s 
involved the delivery of positive (e.g., more freedom) or negative reinforcers (e.g., 
bed rest) in response to desired behaviour (e.g., completing a meal). Despite being 
deemed effective at the time, questions surrounding its durability and wider impact 
(not just on weight), along with concerns about its coercive and controlling nature 
and lack of regard for other maintaining factors of the illness, dispute the claim of 
its superiority to other existing approaches for intervention [26].
A number of the cognitive techniques used at the time resemble a more basic 
and general version of cognitive therapy still used in present times [27], originating 
from the work of Bruch [28]. Bruch argued that psychotherapy to treat anorexia 
should be aimed at addressing the distorted thinking patterns and flawed core 
beliefs/assumptions that the sufferer holds, acquired as a result of their experi-
ences during development. This might be accomplished using cognitive techniques 
such as decentering (adopting a less egocentric perspective for example by asking 
oneself ‘do I notice this as much in others as I do in myself?’) or decatastrophising 
(encouraging patients to imagine right through to the end of a feared situation to 
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It has been suggested that the most useful models for understanding the ill-
ness in terms of advancing treatment are maintenance models, focusing more 
specifically on factors that maintain the illness rather than those involved in the 
development of it [19, 24], though there is often a lot of overlap with some factors 
acting not only as perpetuating factors but also precipitating or predisposing ones. 
Many models of AN discuss psychological factors that perpetuate anorexia, either 
internally (self-perpetuating factors) or externally. Fairburn et al.’s [16] cogni-
tive behavioural theory proposes a number of psychological maintaining factors. 
Fairburn et al. posit that achieving successful dietary restriction creates a sense of 
self-control in an individual, in turn improving their self-worth until restriction 
becomes an indication of both self-control and self-worth. This may be exacerbated 
by a highly perfectionist individual applying their high standards to restriction in 
the form of strict dietary rules. A second maintaining factor suggested in the theory 
is the direct effect of starvation on cognition. Intense feelings of hunger, exagger-
ated feelings of fullness, poorer concentration and preoccupation with food may 
cause an individual to feel their self-control is threatened or failing and strengthen 
the value that controlling food holds on the individual’s self-control and self-worth. 
Finally, Fairburn et al. suggest extreme concerns about weight or shape is involved 
in perpetuating the illness, whereby an individual evaluates their self-worth highly 
on their weight and shape. This may be exacerbated by body checking behaviours, 
particularly when an individual is in an aroused and anxious state, which serves 
to enhance the individual’s perceived imperfections regarding their body shape, 
encouraging further restricting and creating a vicious cycle. As a consequence of 
starvation, many of the aforementioned maintaining factors are worsened, facili-
tating the formation of vicious cycles that allow these maintaining factors and the 
illness to persist [15]. Further psychological, biological and social perpetuating 
factors are listed in Table 1.
3. History of treatment for AN
Historically, treatment for AN relied heavily on antipsychotic medication up 
until the second half of the 1990s when the shift towards a more complex approach 
to treatment began, taking into account an individual’s biological and developmen-
tal factors and involving individual psychotherapy [25]. Advancements were made 
following this shift such as the introduction of cognitive and behavioural treat-
ments. For example, an operant conditioning technique used from the mid-1960s 
involved the delivery of positive (e.g., more freedom) or negative reinforcers (e.g., 
bed rest) in response to desired behaviour (e.g., completing a meal). Despite being 
deemed effective at the time, questions surrounding its durability and wider impact 
(not just on weight), along with concerns about its coercive and controlling nature 
and lack of regard for other maintaining factors of the illness, dispute the claim of 
its superiority to other existing approaches for intervention [26].
A number of the cognitive techniques used at the time resemble a more basic 
and general version of cognitive therapy still used in present times [27], originating 
from the work of Bruch [28]. Bruch argued that psychotherapy to treat anorexia 
should be aimed at addressing the distorted thinking patterns and flawed core 
beliefs/assumptions that the sufferer holds, acquired as a result of their experi-
ences during development. This might be accomplished using cognitive techniques 
such as decentering (adopting a less egocentric perspective for example by asking 
oneself ‘do I notice this as much in others as I do in myself?’) or decatastrophising 
(encouraging patients to imagine right through to the end of a feared situation to 
gauge the realistic likelihood of an event occurring and how bad it will be, rather 
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than assuming the worst and catastrophising immediately) [29]. After further 
refining of Bruch’s (1973) ideas, a cognitive-behavioural approach to treatment for 
AN based on Beck’s cognitive model of depression was developed by Garner and 
Bemis [16, 29, 30], which involved a mixture of cognitive techniques like those 
mentioned, along with behavioural techniques such as “scheduling pleasant events” 
(to help establish other reinforcers for pleasure other than those driving the eating 
disorder) and “behavioural rehearsal” (e.g., role playing scary events to they can be 
better coped with) [30]. Other research around this time emphasised the impor-
tance of therapy that addresses the need for control [8]. Garner et al.’s [31] model of 
cognitive-behavioural therapy for anorexia became the leading approach of its time 
and involved addressing core maintaining mechanisms such as low weight, the use 
of weight and shape as means of achieving self-control/self-worth and body check-
ing, as well as other issues such as low self-esteem, poor emotion recognition and 
expression, disruptions in the family and interpersonal difficulties [16]. Following 
this, and with more recent research and models highlighting the importance of 
other maintaining factors for the illness, cognitive-behavioural therapy (CBT) for 
anorexia was further adapted and developed to become more focused on the central 
mechanisms involved in the maintenance of the disorder, with the suggestion 
that other issues only be targeted by treatment if they are preventative of change 
[16, 32], allowing a more person-centred treatment [9].
Family therapy for the treatment of eating disorders was introduced in the 
1970s following changes to the accepted general beliefs and assumptions of the role 
family processes play in the development and maintenance of anorexia [25, 33]. 
For example, Minuchin et al.’s [34] psychosomatic family model argues that family 
processes involving rigidity, over-involvement and conflict avoidance, along with 
existing psychological vulnerability in the individual, underpin the development of 
anorexia, and therapy should therefore involve the family to work towards changing 
the family dynamic. Until this time, families were generally considered to hinder 
treatment and so patients were treated in isolation from their parents [35]. Other 
associations between eating disorders and family dynamics have since been exam-
ined suggesting specific areas where families have an impact, such as attachment, 
parenting style, communication orientation or family conflict [18, 36, 37], though 
more recent models hold in mind that no blame should be attributed to the family, 
rather treatment works with the family [33].
By the end of the twentieth century AN was rarely treated with medication 
alone, instead using a multifaceted approach involving both medication and 
psychological intervention to better suit the individual [25].
4. Evidence-based psychological treatment for AN
The current recommended treatment for AN is guided by The National Institute 
for Health Care and Excellence (NICE) guidelines and aims to improve care for 
sufferers of anorexia by providing details of what are considered to be the most 
effective interventions for AN in both adults, children and young people, and 
allowing for an individualized and integrated approach to be adopted. According 
to the guidelines, treatment for anorexia should involve one or more psychologi-
cal therapy, along with additional support including psychoeducation about the 
illness, monitoring of mental and physical health including weight and risk factors, 
family/carer involvement and a multidisciplinary team approach from health-care 
professionals. The recommended psychological interventions differ for adults and 
children and young people as indicated below [38]. See Table 2 for a brief summary 
of the psychological therapies for AN in adults and adolescents.
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4.1 Psychotherapies for AN in adults
The NICE guidelines recommend four major evidence-based psychological 
interventions for the treatment of AN in adults. These are: individual eating-
disorder-focused cognitive behavioural therapy (CBT-ED), Maudsley Anorexia 
Nervosa Treatment for Adults (MANTRA), specialist supportive clinical manage-
ment (SSCM) and eating-disorder-focused focal psychodynamic therapy (FPT). 
The guidelines recommend beginning with the first three mentioned therapies and, 
if found to be unsuitable or ineffective, then considering FPT [38].
4.1.1 Eating-disorder-focused cognitive behavioural therapy (CBT-ED)
CBT-ED is delivered on an individual basis, consisting of 20–40 sessions over 
20 weeks, depending on the version used. An enhanced version of CBT is most com-
monly used (CBT-E) which originated from CBT for bulimia nervosa (CBT-BN), 
though as a “transdiagnostic” treatment can be used to treat a broad range of eating 
disorders including anorexia. It has two versions, a focused version which is shorter 
and just involves the core treatment, and a broad version which addresses further 
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Maudsley Anorexia Nervosa 
Treatment for Adults (MANTRA)
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for anorexia nervosa (AFP-AN)
−/+ N/A
Novel treatments
Psychological treatments for AN in adults
Cognitive Remediation Therapy 
(CRT)
+ −/+
Cognitive Remediation and Emotion 
Skills Training (CREST)
−/+ N/A
Abbreviations: Not tested (N/A), negative study results (−), positive study result (+), inconsistent or limited results 
(−/+), recommended in the NICE guidelines ( ), not mentioned in the NICE guidelines ( ).
Table 2. 
Psychological therapies for AN in adults and adolescents: Evidence from clinical studies (including feasibility 
studies and non-randomised trials) and randomised controlled trials (RCTs) and whether they are 
recommended by the NICE guidelines.
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that other issues only be targeted by treatment if they are preventative of change 
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family processes play in the development and maintenance of anorexia [25, 33]. 
For example, Minuchin et al.’s [34] psychosomatic family model argues that family 
processes involving rigidity, over-involvement and conflict avoidance, along with 
existing psychological vulnerability in the individual, underpin the development of 
anorexia, and therapy should therefore involve the family to work towards changing 
the family dynamic. Until this time, families were generally considered to hinder 
treatment and so patients were treated in isolation from their parents [35]. Other 
associations between eating disorders and family dynamics have since been exam-
ined suggesting specific areas where families have an impact, such as attachment, 
parenting style, communication orientation or family conflict [18, 36, 37], though 
more recent models hold in mind that no blame should be attributed to the family, 
rather treatment works with the family [33].
By the end of the twentieth century AN was rarely treated with medication 
alone, instead using a multifaceted approach involving both medication and 
psychological intervention to better suit the individual [25].
4. Evidence-based psychological treatment for AN
The current recommended treatment for AN is guided by The National Institute 
for Health Care and Excellence (NICE) guidelines and aims to improve care for 
sufferers of anorexia by providing details of what are considered to be the most 
effective interventions for AN in both adults, children and young people, and 
allowing for an individualized and integrated approach to be adopted. According 
to the guidelines, treatment for anorexia should involve one or more psychologi-
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illness, monitoring of mental and physical health including weight and risk factors, 
family/carer involvement and a multidisciplinary team approach from health-care 
professionals. The recommended psychological interventions differ for adults and 
children and young people as indicated below [38]. See Table 2 for a brief summary 
of the psychological therapies for AN in adults and adolescents.
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4.1 Psychotherapies for AN in adults
The NICE guidelines recommend four major evidence-based psychological 
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maintaining mechanisms, such as perfectionism, low self-esteem or interpersonal 
difficulties, in addition to the core treatment. CBT-E aims to alter faulty cognitions 
by focusing on behavioural changes and monitoring the effects and implications of 
behaviours that reinforce the eating disorder [38, 39].
CBT-E is delivered in four main stages, the first of which aims to encourage the 
patient to engage with treatment, identify the processes that are maintaining the 
individual’s illness, provide psychoeducation and introduce two essential elements 
of the therapy: weighing and regular eating. Stage two is a chance for the patient 
and therapist to review progress so far and plan for stage three, the main body of 
treatment. This main stage is tailored to the individual and targets the patient’s own 
maintaining processes. These processes generally fall under six core headings: the 
over-evaluation of shape and weight, the over-evaluation of control over eating, 
dietary restraint, dietary restriction, being underweight and event- or mood-
triggered changes in eating. If the patient has additional factors that are creating 
a barrier to change, e.g., high perfectionism, core low self-esteem or pronounced 
interpersonal problems, the broad form of therapy might be used and these addi-
tional maintaining mechanisms are addressed more specifically. Mood intolerance 
was originally included as an additional mechanism to be addressed in the broad 
form of therapy however is now included in the core treatment. Finally, stage four 
is in place to ensure changes are maintained following treatment ending and to 
minimise the risk of relapse [40].
A review of treatments for adults with anorexia concludes that there is a 
moderate evidence base for CBT-E for adults, with evidence suggesting that it 
produces a moderate and lasting beneficial effect. This is an improvement on 
the older version of CBT which was found to have weak evidence base and only 
a slight beneficial effect [9]. Another review found a large effect of CBT-E on 
EDE-Q (Eating Disorder Examination Questionnaire—indicating eating disorder 
psychopathology) outcomes specifically for AN [41]. Generally, studies show that 
CBT-E produces good outcomes regarding increases in BMI and decreases in eating 
disorder psychopathology and conclude that it is an effective and viable treatment 
option for anorexia. However, there does not yet appear to be any consistent con-
vincing evidence to suggest it is superior to comparable psychotherapies [42–50]. 
There is some evidence to suggest that CBT-E may be feasible to deliver in a group 
setting for patients with eating disorders, including those with anorexia, without 
losing the desired positive outcomes regarding weight gain and reduction in eating 
disorder psychopathology [51], however sample sizes are small and so this requires 
further examining.
Despite its apparent success in the treatment of other eating disorders such as 
bulimia or binge eating disorder, and theoretical suitability for treating anorexia, 
there is less evidence to support its success in those with anorexia [49, 52]. It 
has been suggested that a combination of the malnourished brain, as a result of 
extremely low weight, and the ego-syntonic nature of anorexia makes motivation 
to engage with treatment low and the challenging of distorted cognitions even more 
difficult and distressing for the individual [52, 53].
4.1.2 Maudsley anorexia nervosa treatment for adults (MANTRA)
MANTRA is a flexible treatment based around a patient workbook and delivered 
over 10–20 sessions depending on the complexity of the patient’s problems [38]. 
It is based on Schmidt and Treasure’s [24] cognitive-interpersonal maintenance 
model and aims to target the maintaining factors of anorexia, for example unhelp-
ful thinking styles, including rigidity, perfectionism and obsessive–compulsive 
traits, faulty cognition and beliefs, e.g., the benefits of AN, emotion avoidance and 
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responses from others that do not support recovery such as criticism or enabling of 
behaviours [15, 54]. MANTRA is taught in modules that address various aspects of 
the patient’s life and recovery, for example nutrition, identity, cognitive styles or 
interpersonal relationships. It can be individualised once the core module of case 
formulation is complete by emphasising the optional modules to a greater or lesser 
extent depending on how ready or motivated the individual is, and by tailoring 
the therapy to match an individual’s clinical symptoms, personality and neuropsy-
chological traits. It is specifically designed for anorexia treatment and is tailored to 
suit the common temperamental traits associated with the illness, delivered using 
elements of motivational interviewing and CBT [9, 55].
In a number of RCTs comparing treatment for anorexia, MANTRA was found 
to have positive outcomes regarding BMI and eating disorder psychopathology 
though was not statistically significantly different in comparison with CBT-E or 
SSCM. However, MANTRA was more favourably rated by patients and resulted 
in increasing weight even in severely unwell patients [44, 54, 55]. A review of 
evidence from RCTs comparing treatments for anorexia concluded that MANTRA 
has a moderate evidence base which shows that it produces a moderate and lasting 
beneficial effect [9].
4.1.3 Specialist supportive clinical management (SSCM)
SSCM was developed as a standardised outpatient treatment to help support 
individuals with anorexia through education, advice, therapeutic guidance and 
reassurance [56, 57]. It is delivered in an outpatient setting as weekly sessions for 
20 or more weeks depending on the severity of the individual’s illness. The treat-
ment aims to support the patient in gradually normalising their eating behaviour 
and gaining weight through physical health monitoring, clinical management and 
therapeutic content. This includes psychoeducation, nutritional advice and support 
in setting goals and understanding the link between their symptoms and abnormal 
eating behaviour [9, 38].
Evidence from RCTs suggests SSCM to be at least comparable to CBT and IPT 
regarding improved outcomes and global anorexia rating [56, 58]. Compared to 
MANTRA, SSCM seems to perform equally well overall, however in the treatment 
of particularly severely ill patients SSCM is slightly less successful in producing 
longer-term weight gain than MANTRA. There is the suggestion that SSCM might 
produce quicker responses to treatment and be best used for patients with less 
severe cases of anorexia who have higher motivation for treatment [54, 55, 58]. Still, 
other findings show no significant differences in outcome regarding BMI, eating 
disorder psychopathology or general psychopathology between SSCM, MANTRA 
and CBT-E [44]. Despite some mixed findings, a review of evidence from RCTs 
comparing treatments for anorexia concluded that SSCM has a moderate evidence 
based that demonstrates its moderate beneficial effect [9].
4.1.4 Eating-disorder-focused focal psychodynamic therapy (FPT)
Designed as an outpatient treatment, FPT is a person-centred treatment 
whereby an individualised hypothesis is created regarding how the person 
experiences their own symptoms. The patient’s relevant central psychodynamic 
features are identified by the therapist using a standardised interview tool. 
Treatment is then delivered in three rough phases, the first of which centres 
around building a good therapeutic relationship, self-esteem, pro-AN beliefs 
and the ego-syntonic nature of anorexia. The second phase is focused on the link 
between interpersonal relationships and eating disorder behaviours, and the 
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maintaining mechanisms, such as perfectionism, low self-esteem or interpersonal 
difficulties, in addition to the core treatment. CBT-E aims to alter faulty cognitions 
by focusing on behavioural changes and monitoring the effects and implications of 
behaviours that reinforce the eating disorder [38, 39].
CBT-E is delivered in four main stages, the first of which aims to encourage the 
patient to engage with treatment, identify the processes that are maintaining the 
individual’s illness, provide psychoeducation and introduce two essential elements 
of the therapy: weighing and regular eating. Stage two is a chance for the patient 
and therapist to review progress so far and plan for stage three, the main body of 
treatment. This main stage is tailored to the individual and targets the patient’s own 
maintaining processes. These processes generally fall under six core headings: the 
over-evaluation of shape and weight, the over-evaluation of control over eating, 
dietary restraint, dietary restriction, being underweight and event- or mood-
triggered changes in eating. If the patient has additional factors that are creating 
a barrier to change, e.g., high perfectionism, core low self-esteem or pronounced 
interpersonal problems, the broad form of therapy might be used and these addi-
tional maintaining mechanisms are addressed more specifically. Mood intolerance 
was originally included as an additional mechanism to be addressed in the broad 
form of therapy however is now included in the core treatment. Finally, stage four 
is in place to ensure changes are maintained following treatment ending and to 
minimise the risk of relapse [40].
A review of treatments for adults with anorexia concludes that there is a 
moderate evidence base for CBT-E for adults, with evidence suggesting that it 
produces a moderate and lasting beneficial effect. This is an improvement on 
the older version of CBT which was found to have weak evidence base and only 
a slight beneficial effect [9]. Another review found a large effect of CBT-E on 
EDE-Q (Eating Disorder Examination Questionnaire—indicating eating disorder 
psychopathology) outcomes specifically for AN [41]. Generally, studies show that 
CBT-E produces good outcomes regarding increases in BMI and decreases in eating 
disorder psychopathology and conclude that it is an effective and viable treatment 
option for anorexia. However, there does not yet appear to be any consistent con-
vincing evidence to suggest it is superior to comparable psychotherapies [42–50]. 
There is some evidence to suggest that CBT-E may be feasible to deliver in a group 
setting for patients with eating disorders, including those with anorexia, without 
losing the desired positive outcomes regarding weight gain and reduction in eating 
disorder psychopathology [51], however sample sizes are small and so this requires 
further examining.
Despite its apparent success in the treatment of other eating disorders such as 
bulimia or binge eating disorder, and theoretical suitability for treating anorexia, 
there is less evidence to support its success in those with anorexia [49, 52]. It 
has been suggested that a combination of the malnourished brain, as a result of 
extremely low weight, and the ego-syntonic nature of anorexia makes motivation 
to engage with treatment low and the challenging of distorted cognitions even more 
difficult and distressing for the individual [52, 53].
4.1.2 Maudsley anorexia nervosa treatment for adults (MANTRA)
MANTRA is a flexible treatment based around a patient workbook and delivered 
over 10–20 sessions depending on the complexity of the patient’s problems [38]. 
It is based on Schmidt and Treasure’s [24] cognitive-interpersonal maintenance 
model and aims to target the maintaining factors of anorexia, for example unhelp-
ful thinking styles, including rigidity, perfectionism and obsessive–compulsive 
traits, faulty cognition and beliefs, e.g., the benefits of AN, emotion avoidance and 
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responses from others that do not support recovery such as criticism or enabling of 
behaviours [15, 54]. MANTRA is taught in modules that address various aspects of 
the patient’s life and recovery, for example nutrition, identity, cognitive styles or 
interpersonal relationships. It can be individualised once the core module of case 
formulation is complete by emphasising the optional modules to a greater or lesser 
extent depending on how ready or motivated the individual is, and by tailoring 
the therapy to match an individual’s clinical symptoms, personality and neuropsy-
chological traits. It is specifically designed for anorexia treatment and is tailored to 
suit the common temperamental traits associated with the illness, delivered using 
elements of motivational interviewing and CBT [9, 55].
In a number of RCTs comparing treatment for anorexia, MANTRA was found 
to have positive outcomes regarding BMI and eating disorder psychopathology 
though was not statistically significantly different in comparison with CBT-E or 
SSCM. However, MANTRA was more favourably rated by patients and resulted 
in increasing weight even in severely unwell patients [44, 54, 55]. A review of 
evidence from RCTs comparing treatments for anorexia concluded that MANTRA 
has a moderate evidence base which shows that it produces a moderate and lasting 
beneficial effect [9].
4.1.3 Specialist supportive clinical management (SSCM)
SSCM was developed as a standardised outpatient treatment to help support 
individuals with anorexia through education, advice, therapeutic guidance and 
reassurance [56, 57]. It is delivered in an outpatient setting as weekly sessions for 
20 or more weeks depending on the severity of the individual’s illness. The treat-
ment aims to support the patient in gradually normalising their eating behaviour 
and gaining weight through physical health monitoring, clinical management and 
therapeutic content. This includes psychoeducation, nutritional advice and support 
in setting goals and understanding the link between their symptoms and abnormal 
eating behaviour [9, 38].
Evidence from RCTs suggests SSCM to be at least comparable to CBT and IPT 
regarding improved outcomes and global anorexia rating [56, 58]. Compared to 
MANTRA, SSCM seems to perform equally well overall, however in the treatment 
of particularly severely ill patients SSCM is slightly less successful in producing 
longer-term weight gain than MANTRA. There is the suggestion that SSCM might 
produce quicker responses to treatment and be best used for patients with less 
severe cases of anorexia who have higher motivation for treatment [54, 55, 58]. Still, 
other findings show no significant differences in outcome regarding BMI, eating 
disorder psychopathology or general psychopathology between SSCM, MANTRA 
and CBT-E [44]. Despite some mixed findings, a review of evidence from RCTs 
comparing treatments for anorexia concluded that SSCM has a moderate evidence 
based that demonstrates its moderate beneficial effect [9].
4.1.4 Eating-disorder-focused focal psychodynamic therapy (FPT)
Designed as an outpatient treatment, FPT is a person-centred treatment 
whereby an individualised hypothesis is created regarding how the person 
experiences their own symptoms. The patient’s relevant central psychodynamic 
features are identified by the therapist using a standardised interview tool. 
Treatment is then delivered in three rough phases, the first of which centres 
around building a good therapeutic relationship, self-esteem, pro-AN beliefs 
and the ego-syntonic nature of anorexia. The second phase is focused on the link 
between interpersonal relationships and eating disorder behaviours, and the 
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third attends to the transfer from treatment to real life and preparing the patient 
for the end of treatment [9, 43, 59].
Although being an effective treatment in terms of weight gain, when compared 
to other specialist psychological treatments (family therapy and cognitive analytical 
therapy), FPT does not appear to be superior [60]. Additionally, FPT has shown no 
greater success than CBT-E and TAU regarding weight gain or reduction in anorexic 
psychopathology after treatment, though at 12-month follow up has shown signifi-
cantly higher recovery rates than TAU as measured by global outcome (a combina-
tion of BMI and eating disorder psychopathology) [43].
One review of treatment for anorexia conclude there is a moderate evidence base 
for the treatment, and a moderate and lasting beneficial treatment effect of FPT 
for adults with anorexia [9]. There is the suggestion from existing eating disorder 
literature that due to the interpersonal element in psychodynamic interventions, 
they may need a longer timeframe for their positive effects to be exhibited [58]. In 
light of this, and due to a large part of FPT being focused on interpersonal relation-
ships, there is the possibility that its strength lies in better long-term results [43].
4.2 Psychological treatment for AN in children and young people
For treating anorexia in children and young people, the NICE guidelines recom-
mend one of the following: anorexia-nervosa-focused family therapy (FT-AN), 
CBT-ED or adolescent-focused psychotherapy for anorexia nervosa (AFP-AN). It is 
recommended that FT-AN is considered first, with CBT-ED or AFP-AN being con-
sidered if FT-AN is unacceptable, ill-advised or ineffective for the individual [38].
4.2.1 Anorexia-nervosa-focused family therapy (FT-AN)
FT-AN (or family-based therapy; FBT) is typically delivered in 10–20 sessions 
over 6 months to a year and is structured in three rough phases. FBT has a behav-
ioural focus, whereby the family is encouraged to take some control and support 
the patient with weight restoration, making healthy diet decisions and gaining 
autonomy around eating. Despite an emphasis on the role that an individual’s family 
has in their recovery, care should be taken to ensure no blame is attributed to either 
the patient or their family. The family should be encouraged to temporarily be part 
of helping the individual to manage their eating. The first phase of treatment is 
centred on the forming of therapeutic relationships between the therapist, patient 
and family members, weight restoration and a return to a more physically healthy 
state. The next phase involves supporting the patient to gradually acquire some 
autonomy that is appropriate for their age and development, for example portion-
ing their own meals under the supervision of a parent or carer. Finally, phase three 
aims to identify any anticipated developmental challenges for the young person and 
how to manage them and establish plans following termination of treatment or in 
case of relapse [38, 61]. Family therapy is thought to be particularly useful for treat-
ing adolescents with the illness as it is during this time that individuals are going 
through critical development times that are often taking place in a home environ-
ment among family [62].
Reviews of FBT have summarised studies comparing different formats of FBT, 
and different types of family therapy to FBT [33, 61], finding no significant dif-
ferences between the various formats and types. For example, comparing conjoint 
therapy (for family and patient together) to separate therapy (patient and family 
seen separately), studies have found no significant differences in outcomes [63, 64]. 
Additionally, a comparison of FBT of different lengths found no significant 
differences between short- and long-term FBT at end of treatment and 4-year 
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follow-up [65]. Comparisons of FBT with different types of family therapy, for 
example systemic family therapy, which is concerned more with the family system 
and issues surrounding relationships, interactions and dynamics [66], reveal no 
significant differences in terms of primary outcome, though FBT did produce 
more rapid weight gain and less incidents of hospitalisation for those assigned to 
it. Several reviews conclude that no one format for content/delivery of FT-AN has 
consistently been significantly more successful than another [50, 62, 67].
An expanding pool of evidence exists that supports the use of FBT as the 
primary intervention for treating children and young people with anorexia [9, 68] 
however there is still limited evidence to suggest FBT is consistently superior 
to other psychological treatments or treatment as usual [33]. Despite much of 
the research on anorexia treatment for adolescents focusing on FT-AN, a lack of 
high-quality studies comparing FT-AN to individual treatments means it cannot 
reliably be deemed superior [69]. Other reviews have concluded that FBT is no more 
successful in addressing anorexic psychopathology than other psychotherapies [70] 
and highlight the issue that it is not necessarily successful for all adolescents, for 
example for families with single or separated parents, or where the young person 
has high levels of obsessive–compulsive traits [61, 71].
4.2.2 Eating-disorder-focused cognitive behavioural therapy (CBT-ED)
Although designed as a treatment for adults, CBT-E for eating disorders can be 
adapted to be suitable for treating young people several ways. For example, many 
young people live at home in a family unit where they might become dependent 
on a parent or carer, therefore treatment should be delivered in such a way that 
encourages and facilitates the young person to take some responsibility and develop 
independence so that a return to normal adolescent development can be made 
following treatment. Due to the family involvement that is common and expected 
among young people living at home, care should also be taken to ensure the best use 
of the family’s involvement, without the patient perceiving this as over-involvement 
and threating their autonomy. Motivation for treatment is often quite low in 
younger patients making it important to incorporate strategies to engage the patient 
with the therapy. The therapy itself is delivered in largely the same way for children 
and adolescents as it is for adults, though minor adaptations may be made to ensure 
it is suitable and meets the additional needs of young people [72].
Studies show some promise from CBT-E regarding weight gain and reduced eat-
ing disorder and general psychopathology among adolescents with anorexia which 
lasted at follow up [73–75], and suggest that CBT-E may be even more successful in 
adolescents than adults [76]. Despite this, one study review concluded that there is 
a weak to moderate evidence base for CBT for young people with eating disorders, 
with inconsistent results regarding effects of treatment for CBT and only slightly 
beneficial effects for CBT-E [9].
4.2.3 Adolescent-focused psychotherapy for anorexia nervosa (AFP-AN)
AFP-AN (previously named ego-oriented individual therapy before being 
manualised) [77] is delivered primarily through up to around 40 individual sessions 
with the individual, with an additional 8–12 sessions involving the patient’s fam-
ily or carer(s) to support the individual work. Treatment begins more intensively, 
with regular sessions aiming to allow the therapist to establish a strong therapeutic 
relationship with the patient, as well as build the patient’s motivation for behaviour 
change. The aim of AFP-AN is to facilitate independence and self-efficacy around 
eating behaviour through sessions focusing on the link between the person’s eating 
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third attends to the transfer from treatment to real life and preparing the patient 
for the end of treatment [9, 43, 59].
Although being an effective treatment in terms of weight gain, when compared 
to other specialist psychological treatments (family therapy and cognitive analytical 
therapy), FPT does not appear to be superior [60]. Additionally, FPT has shown no 
greater success than CBT-E and TAU regarding weight gain or reduction in anorexic 
psychopathology after treatment, though at 12-month follow up has shown signifi-
cantly higher recovery rates than TAU as measured by global outcome (a combina-
tion of BMI and eating disorder psychopathology) [43].
One review of treatment for anorexia conclude there is a moderate evidence base 
for the treatment, and a moderate and lasting beneficial treatment effect of FPT 
for adults with anorexia [9]. There is the suggestion from existing eating disorder 
literature that due to the interpersonal element in psychodynamic interventions, 
they may need a longer timeframe for their positive effects to be exhibited [58]. In 
light of this, and due to a large part of FPT being focused on interpersonal relation-
ships, there is the possibility that its strength lies in better long-term results [43].
4.2 Psychological treatment for AN in children and young people
For treating anorexia in children and young people, the NICE guidelines recom-
mend one of the following: anorexia-nervosa-focused family therapy (FT-AN), 
CBT-ED or adolescent-focused psychotherapy for anorexia nervosa (AFP-AN). It is 
recommended that FT-AN is considered first, with CBT-ED or AFP-AN being con-
sidered if FT-AN is unacceptable, ill-advised or ineffective for the individual [38].
4.2.1 Anorexia-nervosa-focused family therapy (FT-AN)
FT-AN (or family-based therapy; FBT) is typically delivered in 10–20 sessions 
over 6 months to a year and is structured in three rough phases. FBT has a behav-
ioural focus, whereby the family is encouraged to take some control and support 
the patient with weight restoration, making healthy diet decisions and gaining 
autonomy around eating. Despite an emphasis on the role that an individual’s family 
has in their recovery, care should be taken to ensure no blame is attributed to either 
the patient or their family. The family should be encouraged to temporarily be part 
of helping the individual to manage their eating. The first phase of treatment is 
centred on the forming of therapeutic relationships between the therapist, patient 
and family members, weight restoration and a return to a more physically healthy 
state. The next phase involves supporting the patient to gradually acquire some 
autonomy that is appropriate for their age and development, for example portion-
ing their own meals under the supervision of a parent or carer. Finally, phase three 
aims to identify any anticipated developmental challenges for the young person and 
how to manage them and establish plans following termination of treatment or in 
case of relapse [38, 61]. Family therapy is thought to be particularly useful for treat-
ing adolescents with the illness as it is during this time that individuals are going 
through critical development times that are often taking place in a home environ-
ment among family [62].
Reviews of FBT have summarised studies comparing different formats of FBT, 
and different types of family therapy to FBT [33, 61], finding no significant dif-
ferences between the various formats and types. For example, comparing conjoint 
therapy (for family and patient together) to separate therapy (patient and family 
seen separately), studies have found no significant differences in outcomes [63, 64]. 
Additionally, a comparison of FBT of different lengths found no significant 
differences between short- and long-term FBT at end of treatment and 4-year 
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follow-up [65]. Comparisons of FBT with different types of family therapy, for 
example systemic family therapy, which is concerned more with the family system 
and issues surrounding relationships, interactions and dynamics [66], reveal no 
significant differences in terms of primary outcome, though FBT did produce 
more rapid weight gain and less incidents of hospitalisation for those assigned to 
it. Several reviews conclude that no one format for content/delivery of FT-AN has 
consistently been significantly more successful than another [50, 62, 67].
An expanding pool of evidence exists that supports the use of FBT as the 
primary intervention for treating children and young people with anorexia [9, 68] 
however there is still limited evidence to suggest FBT is consistently superior 
to other psychological treatments or treatment as usual [33]. Despite much of 
the research on anorexia treatment for adolescents focusing on FT-AN, a lack of 
high-quality studies comparing FT-AN to individual treatments means it cannot 
reliably be deemed superior [69]. Other reviews have concluded that FBT is no more 
successful in addressing anorexic psychopathology than other psychotherapies [70] 
and highlight the issue that it is not necessarily successful for all adolescents, for 
example for families with single or separated parents, or where the young person 
has high levels of obsessive–compulsive traits [61, 71].
4.2.2 Eating-disorder-focused cognitive behavioural therapy (CBT-ED)
Although designed as a treatment for adults, CBT-E for eating disorders can be 
adapted to be suitable for treating young people several ways. For example, many 
young people live at home in a family unit where they might become dependent 
on a parent or carer, therefore treatment should be delivered in such a way that 
encourages and facilitates the young person to take some responsibility and develop 
independence so that a return to normal adolescent development can be made 
following treatment. Due to the family involvement that is common and expected 
among young people living at home, care should also be taken to ensure the best use 
of the family’s involvement, without the patient perceiving this as over-involvement 
and threating their autonomy. Motivation for treatment is often quite low in 
younger patients making it important to incorporate strategies to engage the patient 
with the therapy. The therapy itself is delivered in largely the same way for children 
and adolescents as it is for adults, though minor adaptations may be made to ensure 
it is suitable and meets the additional needs of young people [72].
Studies show some promise from CBT-E regarding weight gain and reduced eat-
ing disorder and general psychopathology among adolescents with anorexia which 
lasted at follow up [73–75], and suggest that CBT-E may be even more successful in 
adolescents than adults [76]. Despite this, one study review concluded that there is 
a weak to moderate evidence base for CBT for young people with eating disorders, 
with inconsistent results regarding effects of treatment for CBT and only slightly 
beneficial effects for CBT-E [9].
4.2.3 Adolescent-focused psychotherapy for anorexia nervosa (AFP-AN)
AFP-AN (previously named ego-oriented individual therapy before being 
manualised) [77] is delivered primarily through up to around 40 individual sessions 
with the individual, with an additional 8–12 sessions involving the patient’s fam-
ily or carer(s) to support the individual work. Treatment begins more intensively, 
with regular sessions aiming to allow the therapist to establish a strong therapeutic 
relationship with the patient, as well as build the patient’s motivation for behaviour 
change. The aim of AFP-AN is to facilitate independence and self-efficacy around 
eating behaviour through sessions focusing on the link between the person’s eating 
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disorder and their self-image, emotion processing and regulation, and interpersonal 
processes. This helps the individual develop an understanding of how their self-
concept perpetuates the illness and how they use their anorexia as a coping strategy. 
Unlike CBT, however, AFP is more concerned with employing strategies to chal-
lenge underlying psychological or developmental deficits rather than issues directly 
associated with food, weight or shape, for example. AFP supports the individual to 
manage fears surrounding weight gain and find alternative ways to cope with stress 
or adverse emotions, as well as providing psychoeducation about the consequences 
of malnourishment and the importance of nutrition and weight gain. As treatment 
is in its final stage, the emphasis is on applying the skills and knowledge acquired 
from treatment in real life situations [38, 71, 77, 78].
AFP was found to match FBT in terms of treatment completion and outcome 
in a clinical trial comparing the two [78]. However, at follow-up AFP was found 
to be statistically inferior to FBT regarding outcome, suggested to be due to fewer 
instances of full-remission threshold being met following treatment, as well as 
higher relapse rates, in individuals who completed AFP. One trial also found that 
AFP was less successful in treating patients with severe eating disorder psychopa-
thology than FBT [79].
4.3 Conclusion
Though there appears to be some success for psychotherapies, still it is prov-
ing difficult to achieve consistently good outcomes with the treatments that are 
currently available for anorexia, particularly in adults [44]. Additionally, there is 
a consensus that despite a growing evidence-base for treatments for anorexia and 
a preference for psychotherapy as treatment, there still remains no established 
leading treatment [9, 80]. A number of treatment reviews conclude that among 
a variety of psychotherapies, including the aforementioned treatments recom-
mended by the NICE guidelines, there is no convincing evidence to suggest one 
consistently superior intervention for treating adults, children or adolescents with 
anorexia nervosa [44, 50, 69, 81]. This is largely due to the difficulty of trialling 
treatments for anorexia because of difficulty recruiting participants, high rates of 
patient drop-out or non-adherence to treatment and withdrawal from clinicians as a 
result of risk not being stabilised [50]. Still, psychotherapies that include the family 
seem to be more promising and tentatively deemed most appropriate and preferred 
in the treatment of children and adolescents with anorexia [81].
5. Novel adjunct psychological treatments for AN
In addition to the aforementioned NICE recommended treatments, a number of 
novel adjunct treatments are being used and explored, generally in addition to other 
more established intensive psychotherapies [82]. The two adjunct psychological 
interventions are relatively new, though a growing evidence base for them is emerg-
ing. Table 2 gives a brief indication of the current climate regarding the literature 
for the two following treatments.
5.1 Cognitive remediation therapy (CRT)
CRT was originally developed to be used for the rehabilitation of individu-
als with various neuropsychological issues, however has since been adapted to 
address the common problem of cognitive inflexibility (i.e., poor set shifting—
inability to move flexibly between different tasks or stimuli—and weak central 
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coherence—inability to process information as a whole leading to a focus on details) 
among individuals with anorexia. The therapy aims to encourage switching between 
tasks, multitasking and bigger picture thinking to break inflexible thinking patterns 
and habits through the practice of simple tasks and mental exercises. After practic-
ing these tasks, patients are encouraged to reflect on what cognitive style they have 
used to complete the task, explore how this may be helpful or unhelpful in day-to-
day life and learn new strategies to help make small positive behavioural changes. 
CRT can be delivered either on a 1:1 basis typically over 10 45-min sessions, or as a 
briefer format in a group setting over 5 or 6 sessions. It can be used with adults or 
children and adolescents and is suitable even for patients with very low BMI, unlike 
most talking therapies, allowing them to engage in psychological work early on in 
treatment [83–85].
Based on evidence from randomised treatment trials, CRT reduces drop-out 
rates, with a 10–20% drop-out rate reported across these studies, suggesting that 
CRT can be a useful step to begin patient engagement with psychological interven-
tions. In addition to low drop-out rates, qualitative feedback about CRT from both 
patients and therapists is very positive [86–88]. There is evidence from several 
RCTs that CRT improves performance and subjective evaluation of cognitive 
processes. This general improvement in cognition supports better general func-
tioning [84, 85]. Available research across the lifespan suggests CRT can be used 
as an adjunct therapy to engage patients, improve cognitive processes and prepare 
grounds for further psychological work. However, CRT is not a stand-alone treat-
ment for eating disorders, does not directly target weight change and, as such, is 
not included in the NICE guidelines.
5.2 Cognitive remediation and emotion skills training (CREST)
CREST is an intervention developed to address problems with identifying, man-
aging and expressing emotions among individuals with anorexia nervosa. Like CRT, 
it is an intervention that can be offered early on in treatment when patients may not 
be able to use more complex psychological therapies. CREST is generally delivered 
over 8–10 sessions. Typically, if a patient has previously had CRT, they are offered 
eight individual sessions of CREST. If patients have not had any experience of CRT, 
they will first have two sessions focused on thinking styles, followed by eight ses-
sions involving the psychoeducation and experiential elements of CREST [89].
The main evidence for CREST comes from qualitative and quantitative evalua-
tion of the case series in individual (8–10 sessions) and group format (5–6 sessions). 
Whilst the majority of studies available examine the efficacy of CREST for adults, 
showing some promise, more recently there have been some studies published 
investigating CREST for adolescents with anorexia and findings suggest that is 
may also be suitable for this patient group [90]. At the present time, the efficacy 
of CREST in individual and group formats is still being examined. Detailed stud-
ies using qualitative data and self-report questionnaires offer positive feedback 
and show promise; however, more studies with RCT methodology are required to 
endorse this.
6. Discussion
The current chapter has given a brief introduction to the diagnosis of anorexia 
nervosa and a short history of its treatment. It has then described the current 
evidence-based psychological treatments for anorexia, as recommended by the 
NICE guidelines, and presented a summary of the literature regarding the efficacy 
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disorder and their self-image, emotion processing and regulation, and interpersonal 
processes. This helps the individual develop an understanding of how their self-
concept perpetuates the illness and how they use their anorexia as a coping strategy. 
Unlike CBT, however, AFP is more concerned with employing strategies to chal-
lenge underlying psychological or developmental deficits rather than issues directly 
associated with food, weight or shape, for example. AFP supports the individual to 
manage fears surrounding weight gain and find alternative ways to cope with stress 
or adverse emotions, as well as providing psychoeducation about the consequences 
of malnourishment and the importance of nutrition and weight gain. As treatment 
is in its final stage, the emphasis is on applying the skills and knowledge acquired 
from treatment in real life situations [38, 71, 77, 78].
AFP was found to match FBT in terms of treatment completion and outcome 
in a clinical trial comparing the two [78]. However, at follow-up AFP was found 
to be statistically inferior to FBT regarding outcome, suggested to be due to fewer 
instances of full-remission threshold being met following treatment, as well as 
higher relapse rates, in individuals who completed AFP. One trial also found that 
AFP was less successful in treating patients with severe eating disorder psychopa-
thology than FBT [79].
4.3 Conclusion
Though there appears to be some success for psychotherapies, still it is prov-
ing difficult to achieve consistently good outcomes with the treatments that are 
currently available for anorexia, particularly in adults [44]. Additionally, there is 
a consensus that despite a growing evidence-base for treatments for anorexia and 
a preference for psychotherapy as treatment, there still remains no established 
leading treatment [9, 80]. A number of treatment reviews conclude that among 
a variety of psychotherapies, including the aforementioned treatments recom-
mended by the NICE guidelines, there is no convincing evidence to suggest one 
consistently superior intervention for treating adults, children or adolescents with 
anorexia nervosa [44, 50, 69, 81]. This is largely due to the difficulty of trialling 
treatments for anorexia because of difficulty recruiting participants, high rates of 
patient drop-out or non-adherence to treatment and withdrawal from clinicians as a 
result of risk not being stabilised [50]. Still, psychotherapies that include the family 
seem to be more promising and tentatively deemed most appropriate and preferred 
in the treatment of children and adolescents with anorexia [81].
5. Novel adjunct psychological treatments for AN
In addition to the aforementioned NICE recommended treatments, a number of 
novel adjunct treatments are being used and explored, generally in addition to other 
more established intensive psychotherapies [82]. The two adjunct psychological 
interventions are relatively new, though a growing evidence base for them is emerg-
ing. Table 2 gives a brief indication of the current climate regarding the literature 
for the two following treatments.
5.1 Cognitive remediation therapy (CRT)
CRT was originally developed to be used for the rehabilitation of individu-
als with various neuropsychological issues, however has since been adapted to 
address the common problem of cognitive inflexibility (i.e., poor set shifting—
inability to move flexibly between different tasks or stimuli—and weak central 
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coherence—inability to process information as a whole leading to a focus on details) 
among individuals with anorexia. The therapy aims to encourage switching between 
tasks, multitasking and bigger picture thinking to break inflexible thinking patterns 
and habits through the practice of simple tasks and mental exercises. After practic-
ing these tasks, patients are encouraged to reflect on what cognitive style they have 
used to complete the task, explore how this may be helpful or unhelpful in day-to-
day life and learn new strategies to help make small positive behavioural changes. 
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NICE guidelines, and presented a summary of the literature regarding the efficacy 
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of these treatments. In addition to the standard treatment for anorexia, a number 
of more recently developed adjunct therapies are under examination. Two of these 
are described and again a summary of the literature investigating their efficacy is 
presented.
An alternative to psychotherapy alone for anorexia nervosa is to treat using com-
binations of treatment types and approaches. The following presents some of the 
current combinations under examination in the treatment of anorexia. Adapting 
treatment approach may be particularly important for treating individuals with 
comorbid diagnoses, which is discussed in this section, as well as some of the dif-
ficulties conducting studies that explore psychotherapy for anorexia, limitations of 
this chapter and future directions of the literature.
6.1 Combinations of medications and psychological therapy
One recognised potential treatment alternative to psychotherapy alone is the 
use of oxytocin, a hormone and neuropeptide that is involved in the modulation 
of a number of functions including eating behaviour and food consumption, 
emotional reactivity, stress and anxiety, trust and social interactions and bond 
formation [82, 91]. Evidence from reviews of the literature suggest that the oxy-
tocin system becomes disrupted in individuals with anorexia, affecting oxytocin 
levels in response to stimulation or after a meal, among other things, that may 
return to “normal” following recovery [92]. If this is the case, there is the potential 
for oxytocin administration to be beneficial for treating anorexia. On the contrary, 
findings from RCTs show no significant weight gain following oxytocin adminis-
tration in people with anorexia, however do propose that it may reduce the stress 
response in anticipation of food [91, 93]. Alternatively, oxytocin might impact some 
of the maintaining factors of anorexia, such as attachment and interpersonal issues 
or aspects of social cognition, e.g., emotion recognition [94–96]. With the sugges-
tion that difficulties with emotional processing contribute to less effectivity from 
cognitive therapy [97], the addition of oxytocin to such psychotherapies may be 
beneficial, however findings on this remain inconclusive [94, 98, 99].
D-cycloserine is another drug that is suggested to show some promise in aug-
menting psychological treatment for anorexia [100]. For example, d-cycloserine 
is suggested to enhance CBT, by contributing to the consolidation of therapeutic 
learning from the treatment, and exposure therapy, by strengthening the mecha-
nisms involved in fear extinction [101]. However, the results of one trial did not 
support this, finding that administering d-cycloserine to individuals with anorexia 
led to no significant differences in outcome measures following four exposure-
therapy based training meals, though it was noted that the lack of effect may be 
due to the small sample size used [102]. On the other hand, a later RCT found that 
the administration of d-cycloserine with exposure therapy for individuals with 
anorexia led to significantly greater increases in BMI following treatment compared 
to placebo [103]. Still, there is certainly a need for a better understanding of the 
effect of combinations of medications and psychotherapies and it is clear that many 
more trials are required to investigate the impact of drugs such as oxytocin and 
d-cycloserine on treatment for anorexia [103, 104].
6.2 Combinations of occupational therapy (OT) and psychological therapy
Psychological treatment for anorexia nervosa should be part of a whole thera-
peutic programme including diet counselling, as well as weight and physical health 
monitoring, but may additionally offer occupational therapy (OT) and art therapy, 
typically led by occupational therapists [105]. OT is a profession which enables 
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engagement and performance [106]. It is a patient-centred health profession 
concerned with promoting health and well-being through occupation by enabling 
people to participate in activities they want to do, need to do and are expected to 
do [107]. Occupational therapists use psychotherapeutic skills and approaches and 
reflect on their relationship with the patients and families. They use approaches 
from psychodynamic therapy and DBT such as transference and countertransfer-
ence. Occupational therapists use similar frames of reference to psychologists but 
through an activity-orientated approach in order to maximise the person’s level of 
psychosocial functioning [108]. Eating disorders influence people’s lives and the 
way they engage in meaningful occupations and OT can explore the meaning of 
new occupations which can emerge from the eating disorder. Through specific OT 
assessments using the Model of Human Occupation [109], OT can examine people’s 
motivation, routine, habits, roles and skills in a range of areas such as self-care, lei-
sure and productivity in order to promote a more adaptive occupational participa-
tion in daily activities. OT provides a unique opportunity to implement individual 
and group work provided in eating disorders services supporting plans made for the 
patients within the multidisciplinary team. OT works with the person within their 
social and physical environments using meaningful activities, which often support 
CBT and psychological changes in different areas of life. Providing occupation-
ally focused interventions means that most goals can be addressed using everyday 
activities. Through OT interventions, people can learn to transfer their experience 
and skills from intervention to daily life. OT teams can receive psychotherapeutic 
supervision and are involved in handovers, meetings and ward rounds to feed 
information back to the multidisciplinary team, and thus contribute to or even lead 
the psychotherapeutic process by bringing a unique perspective of function to the 
team. Its contribution can be beneficial regarding improvements to self-awareness, 
self-esteem and greater independence [110]. For some patients, additional physio-
therapy including strength training does also seem to be beneficial [111].
6.3 Psychological treatment for people with comorbidities
Autism spectrum disorder (ASD) is significantly overrepresented among 
individuals with eating disorders and a relatively common comorbidity of anorexia 
[112, 113]. Evidence suggests that this comorbidity is associated with more severe 
presentation, poorer illness outcomes and can hinder engagement with usual 
treatment, negatively impacting treatment outcome. This is perhaps due to some 
overlap in traits, e.g., poor flexibility, weak central coherence, emotional difficulties 
and poor introspection potentially exacerbating the maintaining factors of AN, 
such as rules and rigidity, which may be applied to food restriction or exercise, for 
example [6, 112, 114, 115]. There is the suggestion that cognitive remediation may 
be beneficial in the treatment of individuals high in traits like weak central coher-
ence and poor flexibility, common to both ASD and AN [116]. As discussed, CRT 
and CREST are of interest in eating disorder literature and have attracted some 
attention regarding their use with individuals with both ASD and anorexia. Small 
trials and case studies indicate some potential and suitability for CRT and CREST in 
the treatment of AN, though further investigating is required regarding the efficacy 
of psychological treatment for anorexia in those with and without ASD traits, with 
the potential of adapting treatments to be more appropriate for use with individuals 
with both AN and ASD [115, 117, 118].
Also of a high comorbidity with anorexia are personality disorders (PD), 
with estimates of over 50% of individuals with eating disorders having comorbid 
diagnoses of PDs, most commonly borderline personality disorder (BPD), avoid-
ant personality disorder (APD) and obsessive–compulsive personality disorder 
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from psychodynamic therapy and DBT such as transference and countertransfer-
ence. Occupational therapists use similar frames of reference to psychologists but 
through an activity-orientated approach in order to maximise the person’s level of 
psychosocial functioning [108]. Eating disorders influence people’s lives and the 
way they engage in meaningful occupations and OT can explore the meaning of 
new occupations which can emerge from the eating disorder. Through specific OT 
assessments using the Model of Human Occupation [109], OT can examine people’s 
motivation, routine, habits, roles and skills in a range of areas such as self-care, lei-
sure and productivity in order to promote a more adaptive occupational participa-
tion in daily activities. OT provides a unique opportunity to implement individual 
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[112, 113]. Evidence suggests that this comorbidity is associated with more severe 
presentation, poorer illness outcomes and can hinder engagement with usual 
treatment, negatively impacting treatment outcome. This is perhaps due to some 
overlap in traits, e.g., poor flexibility, weak central coherence, emotional difficulties 
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such as rules and rigidity, which may be applied to food restriction or exercise, for 
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trials and case studies indicate some potential and suitability for CRT and CREST in 
the treatment of AN, though further investigating is required regarding the efficacy 
of psychological treatment for anorexia in those with and without ASD traits, with 
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with estimates of over 50% of individuals with eating disorders having comorbid 
diagnoses of PDs, most commonly borderline personality disorder (BPD), avoid-
ant personality disorder (APD) and obsessive–compulsive personality disorder 
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(OCPD) [119]. There is the suggestion that a comorbid diagnosis of a PD with 
anorexia may lead to adverse implications regarding more chronic illness course, 
lower levels of functioning, higher rates of treatment termination and less positive 
outcomes. Such implications may be due to various influences of PD traits includ-
ing increased self-harm/suicide risk, a lack of trust in the therapist interfering with 
therapy engagement, poor insight into own illness and exacerbated maintaining 
factors of anorexia like dysregulated emotion control [114, 119–121]. In light of 
this there appears to be a need for adapting the therapy approach used to better 
suit these individuals and their co-occurring symptoms [122], for example using 
adapted versions of alternative psychotherapies such as dialectical behavioural 
therapy (DBT) to treat individuals with comorbid diagnoses of anorexia and BPD 
[123, 124]. Likewise, similar dysfunctions in brain circuitry suggested to underlie 
both obsessive–compulsive personality traits and impairments to cognitive flex-
ibility may explain some of the overlap in diagnoses of anorexia and OCPD and 
obsessive–compulsive disorder (OCD). Perhaps, then, therapies that target these 
cognitive maintaining factors of anorexia, such as CRT or CREST, could be most 
appropriate for treating individuals with comorbid diagnoses of OCPD or OCD 
and AN, though this merits further examination [125].
6.4 Difficulties conducting studies exploring psychotherapy for anorexia
Several factors make exploring the efficacy of psychotherapy for anorexia 
nervosa particularly difficult, leaving almost all treatment trials in the field inher-
ently methodologically limited before they have even begun [50]. For example, the 
severity of the illness makes recruiting participants challenging and participant 
that are recruited are almost always female only samples, with very few studies 
investigating the efficacy of treatments for males or minority groups with anorexia 
[50, 126]. This leaves an absence of knowledge regarding the way males respond 
to treatment and the impact of culture, race, gender and sexuality on treatment, 
creating a large gap in the literature regarding the efficacy of treatments for males 
and minority groups with anorexia [81]. Additionally, drop-out rates are particu-
larly high leading to small or incomplete data sets, or a lack of follow-up data. These 
issues create problems regarding cost, statistical power, interpretation and com-
parison of results, and potentially undermine research results, biasing estimates of 
treatment effects [50, 126]. One suggested explanation for the high drop-out rates is 
the role of personality. With PDs having relatively high comorbidity with anorexia, 
issues forming and maintaining interpersonal therapeutic relationships may be 
exacerbated due to the nature of the PD, making continued engagement in therapy 
difficult [119].
Despite the growing evidence base for psychotherapies for anorexia, another 
major issue that persists is the absence of untreated comparison groups or control 
groups altogether [69]. Due to the severity of the physical effects of anorexia, as 
well as its high mortality rate and often chronic course of development, it is unethi-
cal for patient groups to remain untreated or on waiting lists as a control group 
as part of a study. For this reason, it is only possible to evaluate the superiority 
of a treatment when compared to an alternative active treatment, often referred 
to as “treatment as usual” (TAU), rather than its real efficacy when compared to 
no treatment. However, this creates further methodological issues as TAU varies 
from study to study and so does not provide a common comparison group, mean-
ing findings supporting a treatment’s superiority, or inferiority, to another still 
cannot be reliably compared [50, 69]. Likewise, with recovery rates varying due 
to different definitions of recovery, varying outcome measures and inconsistent 
follow-up lengths between studies, the problem of reliably comparing treatments 
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for anorexia is exacerbated [82]. Poor clarity of the “criteria” for recovery and 
measures of recovery being based on physical changes, such as weight gain, skews 
the apparent efficacy of treatment, sometimes ignoring the impact of the par-
ticipants’ initial weights (some perhaps being much lower than others), as well as 
cognitive and behavioural changes that might indicate recovery leading to outcomes 
appearing more or less positive [69, 81]. For example, one systematic review found 
that family-based therapies yielded a very slight superiority regarding impact 
on weight outcome, but the same was not true for psychological outcomes [127]. 
Furthermore, a lack of independently replicated studies comparing treatments for 
anorexia contributes to the lack of reliable estimates of which treatments are most 
 efficacious [69].
6.5 Limitations of chapter
Several limitations of this chapter should be noted. The chapter has summarised 
some of the literature relevant to psychological therapies for anorexia nervosa how-
ever is not a systematic review, therefore does not present all of the current research 
in the field. Additionally, the therapies discussed that make up the main section 
of the chapter are those recommended by the National Institute for Health and 
Care Excellence (NICE) who provide recommendations for health and care only in 
the UK [128]. Therefore these are not necessarily the first choice of treatment for 
other countries, though it does not go unrecognised that many other countries have 
developed practices and guidelines for treating eating disorders including anorexia. 
This is relevant as despite a consensus regarding the importance of psychotherapy 
in the treatment of anorexia across a number of countries’ guidelines, including 
several European countries, Australia, New Zealand and the US, there still remains 
some inconsistencies regarding the recommended first-line treatment, optimal 
intensity of treatment (i.e., inpatient, outpatient or day patient) for different stages 
of the illness and criteria for hospitalisation. Furthermore, many of the available 
studies evaluating the various therapies for anorexia come from highly Westernised, 
English speaking countries such as the UK, US, Australia and some of Europe, with 
few to none from places such as Africa, South America, Eastern Europe and Asia. 
This may impact heavily on the efficacy of different treatments and their formats, 
as well as treatment adherence, due to sociocultural influences such as family ties, 
cultural beliefs and values, parenting styles and education [81]. Thus, this chapter 
may be most helpful for colleagues who practice in the UK or for readers who are 
interested in the psychological treatment of AN in the UK, but our chapter does not 
provide a comprehensive worldwide view on the topic.
6.6 Future directions
There appears to still be a lot of progression required regarding treatment for 
anorexia nervosa and what is most effective, though looking to the future there are 
a number of suggestions under investigation. For example, identifying individuals 
who may not be suitable for conventional treatments, perhaps those with co-
morbidities, and adapting treatments in response to this may increase the number 
of patients that treatments are efficacious for. For example, systemic family therapy 
may be more beneficial than FBT for individuals with obsessive–compulsive traits 
[66], and an adapted version of DBT might be a more suitable and effective way 
of treating individuals with comorbid diagnoses of anorexia and PD [123, 124]. 
For individuals with a comorbid diagnosis of ASD, specific maintaining factors of 
AN, such as weak central coherence, poor flexibility and emotional difficulties, are 
often particularly apparent and problematic. Therefore, for these patients it may 
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[66], and an adapted version of DBT might be a more suitable and effective way 
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For individuals with a comorbid diagnosis of ASD, specific maintaining factors of 
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that treatments that target these traits, e.g., CRT or CREST, could be most effec-
tive [116], particularly if modified to suit these individuals’ needs [129]. Perhaps, 
then, the answer to this could be identifying patient subgroups that might respond 
particularly well (or not) to one treatment over another and tailoring treatment 
accordingly [69], though this is yet to be examined fully.
An additional consideration looking forward it that much of the current research 
is conducted in outpatient settings, omitting those most critically ill (who are 
most likely to be using inpatient services) from being participants and limiting the 
ability of researchers to evaluate the impact that different treatment settings have 
on the efficacy of psychological treatments, how successfully treatments translate 
to different levels of care and make recommendations regarding the best setting for 
treatment [50]. More intense treatment contexts such as inpatient or day-patient 
typically mean that patients live-in or spend up to around 10 h at the treatment 
location, which is significantly more therapeutic input than the typical 1 h per week 
of treatment offered to less chronically ill patients who access outpatient treat-
ment [130]. Despite this, research indicates that evidence comparing inpatient and 
outpatient treatment shows there to be little or no differences regarding outcome 
between the two treatment settings and the majority of young people suffering 
with anorexia can be kept safe and managed well as outpatients, with high levels of 
patient satisfaction and significantly lower costs [131, 132]. Though the severity of 
some cases might mean that inpatient treatment is necessary to reduce immediate 
risk, research shows that a short inpatient stay followed by day-patient treatment 
was no less successful or safe than inpatient treatment [133], and extended hospital 
admissions might actually have adverse impacts on long-term recovery [134]. 
Considering such research, further investigation about effective settings for psy-
chological treatment would be beneficial so that better informed decisions can be 
made regarding efficacy, safety, suitability for various age groups or stages of illness 
and cost effectiveness of treatment for anorexia in various settings.
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that treatments that target these traits, e.g., CRT or CREST, could be most effec-
tive [116], particularly if modified to suit these individuals’ needs [129]. Perhaps, 
then, the answer to this could be identifying patient subgroups that might respond 
particularly well (or not) to one treatment over another and tailoring treatment 
accordingly [69], though this is yet to be examined fully.
An additional consideration looking forward it that much of the current research 
is conducted in outpatient settings, omitting those most critically ill (who are 
most likely to be using inpatient services) from being participants and limiting the 
ability of researchers to evaluate the impact that different treatment settings have 
on the efficacy of psychological treatments, how successfully treatments translate 
to different levels of care and make recommendations regarding the best setting for 
treatment [50]. More intense treatment contexts such as inpatient or day-patient 
typically mean that patients live-in or spend up to around 10 h at the treatment 
location, which is significantly more therapeutic input than the typical 1 h per week 
of treatment offered to less chronically ill patients who access outpatient treat-
ment [130]. Despite this, research indicates that evidence comparing inpatient and 
outpatient treatment shows there to be little or no differences regarding outcome 
between the two treatment settings and the majority of young people suffering 
with anorexia can be kept safe and managed well as outpatients, with high levels of 
patient satisfaction and significantly lower costs [131, 132]. Though the severity of 
some cases might mean that inpatient treatment is necessary to reduce immediate 
risk, research shows that a short inpatient stay followed by day-patient treatment 
was no less successful or safe than inpatient treatment [133], and extended hospital 
admissions might actually have adverse impacts on long-term recovery [134]. 
Considering such research, further investigation about effective settings for psy-
chological treatment would be beneficial so that better informed decisions can be 
made regarding efficacy, safety, suitability for various age groups or stages of illness 
and cost effectiveness of treatment for anorexia in various settings.
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Obesity is a major health problem worldwide responsible for increased mor-
bidity/mortality and high cost for the society. Management of obesity requires 
multidisciplinary approaches including diet, food supplement, exercise, behavior 
change, drug, medical device, gut microbiome manipulation, and surgery. Anti-
obesity medical devices are an option for subjects who have not responded to more 
conservative medical treatments but want an alternative to surgery. Compared to 
bariatric surgery, they have the advantage of being less invasive, easier to perform, 
and reversible. In the United States of America (USA), based on the expected 
weight loss, the Center for Devices and Radiological Health (CDRH) of the Food 
and Drug Administration (FDA) categorizes anti-obesity medical devices as weight-
loss devices or weight-management devices. The weight-loss devices include gastric 
band devices, gastric space-occupying devices, and gastric emptying devices. 
The weight-management devices include oral removable palatal space-occupying 
devices and ingested transient gastric space-occupying devices. The effectiveness, 
safety, and cost of anti-obesity medical devices vary considerably by the type 
of medical device. Their use should always be combined with lifestyle changes. 
Considering the large market size of obesity treatment, anti-obesity medical devices 
can play a major role in the management of obesity.
Keywords: medical devices, obesity, weight loss, weight management
1. Introduction
Obesity is excess body weight for a given height, defined by a body mass index 
(BMI) ≥ 30 kg/m2. In some Asian countries (e.g., Japan), the threshold to define 
obesity is lower (25 kg/m2). Obesity is a major health problem worldwide associated 
with increased morbidity/mortality and high cost for the society. The prevalence 
of obesity has doubled in more than 70 countries since 1980. The number of adult 
subjects with obesity is around 700 million worldwide. Nearly 4 million subjects die 
each year from the consequences of obesity. The annual cost of obesity is more than 
$2 trillion [1–3].
Management of obesity requires multidisciplinary approaches including diet, 
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decades, the number of medical devices has increased exponentially. Anti-obesity 
medical devices are positioned to bridge the gap between more conservative treat-
ments (e.g., lifestyle) and more aggressive interventions (e.g., bariatric surgery). 
Compared to bariatric surgery, they have the advantage of being less invasive, 
easier to perform, and reversible. Anti-obesity medical devices are available upon 
prescription or as over-the-counter products.
2. Heterogeneity of anti-obesity medical devices
Anti-obesity medical devices represent a heterogeneous family of devices in 
terms of presentation, usage/administration, mechanism of action, effectiveness, 
safety, regulation, availability, and cost [8, 11–14]. The devices can be as different 
as an intragastric balloon, a stomach aspiration system, or particles administered 
orally in capsule.
3. General characteristics of anti-obesity medical devices
Unlike anti-obesity drugs that act chemically through specific receptors, 
anti-obesity medical devices act rather mechanically. They do not have systemic 
absorption, specific metabolism, or receptors. Their research and development 
pattern follow specific models. The terminology used for medical devices differs 
slightly from that used for drugs (e.g., sham instead of placebo, effectiveness 
instead of efficacy). With some medical devices, it is not possible to use a sham 
for ethical and/or technical reasons. Compared to drugs, medical devices have 
different effectiveness dynamics. Unlike drugs, for some anti-obesity medical 
devices, there is no compliance issue with the device use since the device is placed 
in the body for several months and there is no need for repeated administration 
that might be affected by the subject’s discipline. Because there is no systemic 
absorption, there are no side effects related to the impact of medical devices on 
different organs through the bloodstream. The regulatory systems ruling anti-
obesity medical devices are based on short product life cycles. The marketing and 
sales of anti-obesity medical devices are based on different models as compared 
to drugs.
4. Mechanism of action of anti-obesity medical devices
Anti-obesity medical devices can cause weight loss through different mecha-
nisms by acting at different levels.
4.1 Decrease in food intake
Although the primary impact of the anti-obesity medical devices is mechani-
cal, the final effect may be achieved through changes in several factors controlling 
appetite and food intake, especially the gastrointestinal hormones (e.g., decrease in 
ghrelin, increase in glucagon-like peptide-1).
4.1.1 Oral cavity
An anti-obesity medical device can decrease the food intake by limiting the bite 





An anti-obesity medical device can decrease the food intake by reducing the 
available stomach volume.
4.1.3 Others
Other levels of impact to achieve food intake reduction are possible and have 
been or will be investigated.
4.2 Decrease in available/absorbed nutrient
4.2.1 Stomach
An anti-obesity medical device can decrease the amount of available nutrient by 
removing part of the gastric contents.
4.2.2 Intestine
An anti-obesity medical device can decrease the absorbed nutrient by bypassing 
part of the intestine.
5. Challenges in developing anti-obesity medical devices
The main challenges in the development of anti-obesity medical devices are due 
to lack of unique regulatory guidance and disparities in time and cost of approval 
processes in different countries.
6. Regulation and approval/clearance of anti-obesity medical devices
The regulation of anti-obesity medical devices varies by countries or group of 
countries. There are important differences in the regulatory processes, cost, and 
time to approval between the USA and Europe [15].
Over-the-counter anti-obesity medical devices may or may not need regulation 
and approval/clearance depending on the devices and countries.
6.1 USA
In the USA, the regulation of medical devices is centralized since 1976 through 
the FDA. This centralized process allows a better coordination and enforcement of 
rules. The CDRH is in charge of approval/clearance of anti-obesity medical devices. 
There are three regulatory classes of medical devices: Class I (low risk), Class II 
(moderate risk), and Class III (high risk). Based on the expected weight loss, two 
categories of anti-obesity medical devices have been defined: weight-loss devices 
(“more” weight loss) and weight-management devices (“less” weight loss). The 
approval/clearance is through premarket notification process [510(k)] or premarket 
approval (PMA) process and is based on safety and effectiveness.
A new guidance using benefit-risk approaches is in preparation by the CDRH 
taking into account the weight loss (extent and duration), the rate of responders 
(≥ 5% weight loss), the reduction of comorbidities (e.g., hypertension, dyslipid-
emia, type 2 diabetes), and the safety [rate and severity of adverse events (AEs)].
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Since its formation in 1993, the European Union (EU), currently a group of 27 
countries (after the recent removal of the United Kingdom), has established rules for 
the approval of medical devices. Anti-obesity medical devices are regulated under 
directive 93/42/EC. There are four regulatory classes of medical devices: Class I (low 
risk), Class IIa (low-moderate risk), Class IIb (moderate-high risk), and Class III 
(high risk). Each member country has a regulatory entity called Competent Authority 
(CA). The CA certifies/notifies entities called Notified Bodies (NBs) in each country. 
The NBs are private, for-profit companies responsible for conformity assessment 
and CE (Conformité Européenne) mark. There are over 50 NBs in the EU. The NBs 
contract with the manufacturers to supply the CE mark and the approval is based on 
safety and performance. Clinical effectiveness is not a requirement. An anti-obesity 
medical device with a CE mark can be marketed in any EU member country.
In the EU, the approval process is more flexible, faster, and less expensive in 
comparison to the USA.
6.3 Other countries
Other countries have different regulatory procedures. The approval process has 
varying degrees of sophistication and challenges. In Japan for example, the appli-
cation is processed by the Pharmaceutical and Medical Device Agency (PMDA). 
Although the Japanese market is very attractive for foreign manufacturers, the 
approval process is complicated, long, and expensive due to multiple factors (e.g., 
lack of translated documents from Japanese, need to perform specific and costly 
studies in the Japanese population).
Several countries accept the FDA approval/clearance or the CE mark.
7. Approved/cleared anti-obesity medical devices
Several anti-obesity medical devices have been approved/cleared in the USA, 
in the EU, and in other countries. Some devices have been approved first in the EU 
before being approved several years later in the USA. This section focuses on anti-
obesity medical devices regulated in the USA.
Below are the anti-obesity medical devices approved/cleared in the USA 
(Table 1). Their use should always be in conjunction with lifestyle recommenda-
tions on diet and exercise.
Medical device Approval date Indication
Lap-Band® June 5, 2001 Weight-loss device (BMI ≥ 35 kg/m2)
Orbera™ Intragastric Balloon 
System
August 5, 2015 Weight-loss device (BMI 30–40 kg/m2)
AspireAssist® June 14, 2016 Weight-loss device (BMI 35–55 kg/m2)
Obalon Balloon System September 8, 2016 Weight-loss device (BMI 30–40 kg/m2)
SmartByte Device May 18, 2017 Weight-management device (BMI 27–35 kg/m2)
Plenity™ April 12, 2019 Weight-management device (BMI 25–40 kg/m2)
TransPyloric Shuttle April 16, 2019 Weight-loss device (BMI 30–40 kg/m2)
Table 1. 





7.1.1 Gastric band devices
7.1.1.1 Lap-Band®
Lap-Band® (BioEnterics Corporation) is an adjustable silicone band placed 
laparoscopically around the proximal stomach immediately below the gastro-
esophageal junction and attached to a subcutaneous reservoir (Figure 1). The level 
of pressure is adjusted by varying the amount of fluid that is inserted into the band. 
The technique is reversible, has low procedural risk, and can be performed in an 
outpatient setting. Lap-Band® can be revised and/or replaced as needed. The pres-
sure imposed to the proximal stomach causes early satiety and a decrease in food 
intake with subsequent weight loss [8].
In the pivotal study, 292 subjects (247 females, 45 males, mean BMI = 47.4 
kg/m2) were implanted with Lap-Band® and had follow-up evaluations for 
36 months. The primary effectiveness endpoint, assessed in the per protocol 
population at Month 36, was the excess weight loss. Safety analysis also included 
an additional seven subjects who previously received a similar device. At Month 
36, the excess weight loss was 36.2%, relatively stable over the previous 18 months 
(the weight loss was 18.0%). AEs were observed in 266 subjects (89.0%). Most 
AEs were of gastrointestinal origin (mainly nausea/vomiting, gastroesophageal 
reflux, and abdominal pain, mild in the majority of cases). Serious AEs (SAEs) 
were observed in 16 subjects (5.4%), mainly port leakage and 2 deaths (unrelated 
to device).
Overall, Lap-Band® is relatively safe and has a strong effectiveness. The device 
was approved by the FDA in June 2001. It is indicated for weight loss in severe obe-
sity with BMI ≥ 40 kg/m2 or obesity with BMI ≥ 35 kg/m2 in the presence of one or 
more severe comorbidities, in conjunction with lifestyle recommendations, in sub-
jects who failed to respond to diet, exercise, and behavior change. It is contraindi-
cated in several conditions including pregnancy, non-adult subjects, inflammatory 
diseases of the gastrointestinal tract, upper gastrointestinal bleeding conditions, 
Figure 1. 
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Figure 1. 
Lap-Band® (BioEnterics Corporation—Picture downloaded from the internet).
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portal hypertension, and severe cardiopulmonary diseases (non-exhaustive list). 
Complications include proximal gastric enlargement, erosion or migration of the 
band, and leaks of the band system (non-exhaustive list).
7.1.2 Gastric space-occupying devices
7.1.2.1 Orbera™ Intragastric balloon system
Orbera™ Intragastric Balloon System (Apollo Endosurgery, Inc.) is a balloon 
made of silicone placed endoscopically in the stomach (Figure 2). The balloon is 
filled with saline mixed with methylene blue (450–700 mL). The methylene blue 
is a marker for balloon dysfunction. In case of balloon rupture, the methylene blue 
will be systematically absorbed and change the color of urine to blue. The procedure 
is minimally invasive and can be performed in an outpatient setting. The balloon 
is removed endoscopically after 6 months. By occupying gastric volume, Orbera™ 
Intragastric Balloon System causes early satiety and a decrease in food intake with 
subsequent weight loss [8, 11, 13, 14].
In the pivotal study, 255 subjects (229 females, 26 males, mean BMI = 35.3 
kg/m2) were randomized into Orbera™ Intragastric Balloon System (n = 125) or 
control (no intragastric intervention, n = 130) arms for 6 months and 6 months 
follow-up after Orbera™ Intragastric Balloon System removal. Safety analysis also 
included an additional 35 run-in, non-randomized subjects who received Orbera™ 
Intragastric Balloon System. All subjects were given lifestyle recommendations. 
The co-primary effectiveness endpoints, assessed in the modified intention-
to-treat (mITT) population at Month 9, were the excess weight loss in Orbera™ 
Intragastric Balloon System arm and a significantly greater weight loss in Orbera™ 
Intragastric Balloon System arm compared to control arm. At Month 9, the excess 
weight loss was 26.5% in Orbera™ Intragastric Balloon System arm, and the weight 
losses were 9.1 and 3.4% in Orbera™ Intragastric Balloon System and control arms, 
respectively. The study did not meet the first co-primary effectiveness endpoint 
but met the second co-primary effectiveness endpoint. At Month 6, the weight 
losses were 10.2 and 3.3% in Orbera™ Intragastric Balloon System and control 
arms, respectively. A total of 810 device-related AEs was observed (mainly nau-
sea/vomiting, gastroesophageal reflux, and abdominal pain, mild or moderate in 
the majority of cases). Fourteen device- or procedure-related SAEs were observed, 
mainly device intolerance but no death.
Figure 2. 




Overall, Orbera™ Intragastric Balloon System is relatively safe and has a strong 
effectiveness. The device was approved by the FDA in August 2015. It is indicated 
for weight loss in obesity with BMI between 30 and 40 kg/m2, in conjunction with 
lifestyle recommendations, in subjects who failed to respond to diet, exercise, and 
behavior change. It is contraindicated in several conditions including pregnancy, 
non-adult subjects, prior bariatric surgery, inflammatory diseases of the gastro-
intestinal tract, upper gastrointestinal bleeding conditions, and liver deficiency 
(non-exhaustive list). Complications include balloon migration, intestinal obstruc-
tion, gastric ulcer, and gastric perforation (non-exhaustive list).
7.1.2.2 Obalon Balloon System
Obalon Balloon System (Obalon Therapeutics, Inc.) is a swallowable balloon 
made of nylon and polyethylene contained within a gelatin capsule (attached to 
a thin inflation catheter) that is taken orally. The correct position of the capsule 
is confirmed with fluoroscopy. The capsule disintegrates in the stomach and 
releases the balloon. The balloon is filled with air (250 cc of nitrogen and sulfur 
hexafluoride gas mixture). Up to three balloons can be placed in the same session or 
sequentially over a 6-month period (Figure 3). The procedure is minimally invasive 
and can be performed in an outpatient setting without endoscopy. The balloon 
is removed endoscopically after 6 months. By occupying gastric volume, Obalon 
Balloon System causes early satiety and a decrease in food intake with subsequent 
weight loss [8, 13, 14].
In the pivotal study, 387 subjects (341 females, 46 males, mean BMI = 35.2 kg/m2) 
were randomized into Obalon Balloon System (n = 198) or control (sham capsule, 
n = 189) arms for 6 months. At Month 6, the eligible control arm subjects were 
permitted to crossover and receive Obalon Balloon System for 6 months. All subjects 
were given lifestyle recommendations. The co-primary effectiveness endpoints, 
assessed in the mITT population at Month 6, were a significantly greater weight loss 
in Obalon Balloon System arm compared to control arm (super-superiority) and 
the responder rate at 5% weight loss in Obalon Balloon System arm. Device-related 
safety analysis also included 138 subjects who switched at Month 6 from control to 
Obalon Balloon System. At Month 6, the weight losses were 6.6 and 3.4% in Obalon 
Balloon System and control arms, respectively, and the responder rate at 5% weight 
loss in Obalon Balloon System arm was 62.1%. The study met both co-primary effec-
tiveness endpoints. Most device-related AEs were of gastrointestinal origin (mainly 
abdominal pain and nausea/vomiting, mild in the majority of cases), observed in 
Figure 3. 
Obalon Balloon System (Obalon Therapeutics, Inc.—Picture downloaded from the internet).
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were randomized into Obalon Balloon System (n = 198) or control (sham capsule, 
n = 189) arms for 6 months. At Month 6, the eligible control arm subjects were 
permitted to crossover and receive Obalon Balloon System for 6 months. All subjects 
were given lifestyle recommendations. The co-primary effectiveness endpoints, 
assessed in the mITT population at Month 6, were a significantly greater weight loss 
in Obalon Balloon System arm compared to control arm (super-superiority) and 
the responder rate at 5% weight loss in Obalon Balloon System arm. Device-related 
safety analysis also included 138 subjects who switched at Month 6 from control to 
Obalon Balloon System. At Month 6, the weight losses were 6.6 and 3.4% in Obalon 
Balloon System and control arms, respectively, and the responder rate at 5% weight 
loss in Obalon Balloon System arm was 62.1%. The study met both co-primary effec-
tiveness endpoints. Most device-related AEs were of gastrointestinal origin (mainly 
abdominal pain and nausea/vomiting, mild in the majority of cases), observed in 
Figure 3. 
Obalon Balloon System (Obalon Therapeutics, Inc.—Picture downloaded from the internet).
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300 subjects (89.3%). Device- or procedure-related SAEs were observed in one 
subject (0.3%), a case of peptic ulcer disease.
Overall, Obalon Balloon System is relatively safe and has a modest effectiveness. 
The device was approved by the FDA in September 2016. It is indicated for weight 
loss in obesity with BMI between 30 and 40 kg/m2, in conjunction with lifestyle 
recommendations, in subjects who failed to respond to diet, exercise, and behavior 
change. It is contraindicated in several conditions including pregnancy, non-adult 
subjects, prior bariatric surgery, inflammatory diseases of the gastrointestinal tract, 
gastric diseases, and eating disorders (non-exhaustive list). Complications include 
balloon migration, intestinal obstruction, gastric ulcer, and gastric perforation 
(non-exhaustive list).
7.1.2.3 TransPyloric Shuttle
TransPyloric Shuttle (BAROnova, Inc.) is a device placed endoscopically in 
the stomach (Figure 4). It is not strictly a balloon but functions like a balloon. It 
has two asymmetrical bulbs made of silicone connected by a flexible catheter. The 
procedure is minimally invasive and can be performed in an outpatient setting. 
The shuttle is removed endoscopically after 12 months. By creating intermit-
tent obstruction to gastric outflow that delays gastric emptying, TransPyloric 
Shuttle causes early satiety and a decrease in food intake with subsequent weight 
loss [8, 13].
In the pivotal study, 270 subjects (252 females, 18 males, mean BMI = 36.6 kg/m2) 
were randomized into TransPyloric Shuttle (n = 181) or control (sham endoscopic 
procedure, n = 89) arms for 12 months. The TransPyloric Shuttle was successfully 
placed in 171 subjects. The study also included an additional 32 open-label subjects 
who received TransPyloric Shuttle. All subjects were given lifestyle recommenda-
tions. The co-primary effectiveness endpoints, assessed in the per protocol popula-
tion at Month 12, were a significantly greater weight loss in TransPyloric Shuttle arm 
compared to control arm and the responder rate at 5% weight loss in TransPyloric 
Shuttle arm. At Month 12, the weight losses were 9.5 and 2.8% in TransPyloric 
Shuttle and control arms, respectively, and the responder rate at 5% weight loss in 
TransPyloric Shuttle arm was 66.8%. The study met both co-primary effectiveness 
endpoints. Most device-related AEs were of gastrointestinal origin (mainly nausea/
vomiting, abdominal pain, and dyspepsia, mild or moderate in the majority of 
Figure 4. 




cases), observed in 200 subjects (98.5%). Device- or procedure-related SAEs were 
observed in six subjects (3.0%), mainly device impaction but no death.
Overall, TransPyloric Shuttle is relatively safe and has a strong effectiveness. 
The device was approved by the FDA in April 2019. It is indicated for weight loss 
in obesity with BMI between 35 and 40 kg/m2 or obesity with BMI between 30 
and < 35 kg/m2 in the presence of one or more comorbidities, in conjunction with 
lifestyle recommendations, in subjects who failed to respond to diet, exercise, 
and behavior change. It is contraindicated in several conditions including preg-
nancy, non-adult subjects, prior bariatric surgery, inflammatory diseases of the 
gastrointestinal tract, gastric diseases, and eating disorders (non-exhaustive list). 
Complications include device impaction and gastric ulcer (non-exhaustive list).
7.1.3 Gastric emptying devices
7.1.3.1 AspireAssist®
AspireAssist® (Aspire Bariatrics, Inc.) is a device attached to a percutaneous 
endoscopic gastrostomy tube implanted endoscopically (Figure 5). It allows the 
aspiration of gastric contents 20–30 minutes after each major meal (a meal contain-
ing more than 200 calories). Thorough chewing of food is required to facilitate 
aspiration with the 6-mm-diameter tube. The procedure is minimally invasive and 
can be performed in an outpatient setting. The device is removed when the desired 
body weight is reached. By allowing the removal of approximately 30% of ingested 
calories over 5–10 minutes, AspireAssist® causes decreased absorption of gastroin-
testinal nutrients with subsequent weight loss [8, 11–14].
In the pivotal study, 171 subjects (149 females, 22 males, mean BMI = 41.6 kg/
m2) were randomized into AspireAssist® (n = 111) or control (no intragastric 
intervention, n = 60) arms for 12 months. All subjects were given lifestyle recom-
mendations. The co-primary effectiveness endpoints, assessed in the mITT popula-
tion at Month 12, were a significantly greater excess weight loss in AspireAssist® 
arm compared to control arm (super-superiority) and the responder rate at 25% 
excess weight loss in AspireAssist® arm. At Month 12, the excess weight losses were 
31.5 and 9.8% in AspireAssist® and control arms, respectively, and the responder 
rate at 25% excess weight loss in AspireAssist® arm was 56.8%. The study met the 
first co-primary effectiveness endpoint but not the second co-primary effectiveness 
endpoint. At Month 12, the weight losses were 12.1 and 3.6% in AspireAssist® and 
Figure 5. 
AspireAssist® (Aspire Bariatrics, Inc.—Picture downloaded from the internet).
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control arms, respectively. Device- or procedure-related AEs were observed in 93 
subjects (83.8%, mainly peristomal granulation tissue, abdominal pain, and nausea/
vomiting, mild in the majority of cases). Device- or procedure-related SAEs were 
observed in four subjects (3.6%), including peritonitis but no death.
Overall, AspireAssist® is relatively safe and has a strong effectiveness. The 
device was approved by the FDA in June 2016. It is indicated for weight loss in 
obesity with BMI between 35 and 55 kg/m2, in conjunction with lifestyle rec-
ommendations, in subjects who failed to respond to non-surgical weight-loss 
therapy. It is contraindicated in several conditions including pregnancy, non-adult 
subjects, upper gastrointestinal bleeding conditions, chronic abdominal pain, 
severe cardiopulmonary diseases, and eating disorders (non-exhaustive list). 
Complications include skin irritation, infection, and electrolyte abnormalities 
(non-exhaustive list).
7.2 Weight-management devices
7.2.1 Oral removable palatal space-occupying devices
7.2.1.1 SmartByte Device
SmartByte Device (Scientific Intake) is an oral device occupying space on 
the upper palate. It includes a temperature-recording sensor to monitor usage 
(Figure 6). It is worn in mouth during meal consumption. The device is renewed 
every 12 months. By creating limited bite size and slower eating, SmartByte Device 
causes a decrease in food intake with subsequent weight loss [16].
In the pivotal study, 173 subjects (BMI between 26 and 36 kg/m2) were random-
ized into SmartByte Device (n = 102) or control (no oral intervention, n = 71) arms 
for 4 months. All subjects were given lifestyle recommendations. The primary 
effectiveness endpoint, assessed in the ITT population at Month 4, was a greater 
responder rate at 5% weight loss in SmartByte Device arm compared to control arm. 
At Month 4, the responder rates at 5% weight loss were 20.6 and 5.6% in SmartByte 
Device and control arms, respectively. The study did not meet the primary effec-
tiveness endpoint. At Month 4, the weight losses were 1.7 and 0.4% in SmartByte 
Device and control arms, respectively. Device-related AEs were observed in five 
subjects (4.9%, including two episodes of transient choking on food). No device-
related SAEs were observed.
Figure 6. 




Overall, SmartByte Device is safe and has a weak effectiveness. The device 
was cleared by the FDA in May 2017. It is indicated to aid in weight management 
in overweight and obesity with BMI between 27 and 35 kg/m2, in conjunction 
with lifestyle recommendations. It is contraindicated in pregnancy and eating 
disorders. Complications include choking on food and mouth soreness (non-
exhaustive list).
7.2.2 Ingested transient gastric space-occupying devices
7.2.2.1 Plenity™
Plenity™ (Gelesis, Inc.) is a superabsorbent hydrogel (cellulose and citric acid, 
forming a three-dimensional matrix) administered orally in capsules with 500 mL 
of water (three capsules, 20–30 minutes before lunch and dinner). The hydrogel 
particles hydrate up to 100 times their initial weight in the stomach and intestine 
(Figure 7). The particles mix with ingested food and create a larger volume with 
higher elasticity and viscosity. The particles degrade in the colon and are eliminated 
in the feces. By creating a larger volume with higher elasticity in the stomach and 
intestine, Plenity™ causes early satiety and a decrease in food intake with subse-
quent weight loss [17].
In the pivotal study, 436 subjects (245 females, 191 males, mean BMI = 33.8 kg/m2) 
were randomized into Plenity™ (n = 223) or control (sham capsule, n = 213) arms for 
6 months. All subjects were given lifestyle recommendations. The co-primary effective-
ness endpoints, assessed in the ITT population (multiple imputation) at Month 6, were 
a significantly greater weight loss in Plenity™ arm compared to control arm (super-
superiority) and the responder rate at 5% weight loss in Plenity™ arm. At Month 6, 
the weight losses were 6.4 and 4.4% in Plenity™ and control arms, respectively, and 
the responder rate at 5% weight loss in Plenity™ arm was 58.6%. The study did not 
meet the first co-primary effectiveness endpoint but met the second co-primary 
effectiveness endpoint. Most device-related AEs were of gastrointestinal origin (mainly 
abdominal distension, diarrhea, infrequent bowel movements, and flatulence, mild in 
the majority of cases), observed in 84 subjects (37.7%). No device-related SAEs were 
observed.
Overall, Plenity™ is safe and has a modest effectiveness. The device was 
cleared by the FDA in April 2019. It is indicated to aid in weight management in 
overweight and obesity with BMI between 25 and 40 kg/m2, in conjunction with 
lifestyle recommendations. It is contraindicated in pregnancy, non-adult subjects, 
and history of allergic reaction to the components of Plenity™ capsule. No relevant 
complications have been reported.
Figure 7. 
Plenity™ (Gelesis, Inc.—Picture downloaded from the internet).
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Comparative effectiveness of the above anti-obesity medical devices is reported 
in Table 2.
Relevant complications (non-exhaustive list), some being very rare, of the above 
anti-obesity medical devices are reported in Table 3.
Cost of the above anti-obesity medical devices is reported in Table 4.
Medical device Treatment 
duration
Relevant complication
Lap-Band® 36 months Proximal gastric enlargement, band erosion or 
migration, system leaks
AspireAssist® 12 months Skin irritation, infection, electrolyte abnormalities
Orbera™ Intragastric Balloon 
System
6 months Balloon migration, intestinal obstruction, gastric 
ulcer, gastric perforation
TransPyloric Shuttle 12 months Device impaction, gastric ulcer
Obalon Balloon System 6 months Balloon migration, intestinal obstruction, gastric 
ulcer, gastric perforation
Plenity™ 6 months None
SmartByte Device 4 months Choking on food, mouth soreness
Table 3. 
Relevant complications of the approved/cleared anti-obesity medical devices in the USA in pivotal studies.
Medical device Average cost (Range)
Lap-Band® $15,000 ($10,000–$30,000)
AspireAssist® $10,000 ($7,000–$13,000)
Orbera™ Intragastric Balloon System $6,000 ($3,000–$9,000)
TransPyloric Shuttle To be determined




Cost of the approved/cleared anti-obesity medical devices in the USA.
Medical device Treatment duration Total body weight loss
Lap-Band® 36 months 18.0%
AspireAssist® 12 months 12.1%
Orbera™ Intragastric Balloon System 6 months 10.2%
TransPyloric Shuttle 12 months 9.5%
Obalon Balloon System 6 months 6.6%
Plenity™ 6 months 6.4%
SmartByte Device 4 months 1.7%
Table 2. 
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8. Anti-obesity medical devices withdrawn from the market in the USA
Several anti-obesity medical devices have been withdrawn by the manufacturers 
from the market in the USA after approval by the FDA (e.g., Maestro Rechargeable 
System, Realize Adjustable Gastric Band, ReShape Integrated Dual Balloon System, 
Garren Gastric Bubble).
9.  Anti-obesity medical devices under investigation or pending  
approval
Several anti-obesity medical devices are currently in development in different 
countries (e.g., Epitomee Device [18]).
EndoBarrier® has obtained a CE mark in the EU but its approval in the USA has 
been challenged for safety reasons [8, 11–14].
10. Over-the-counter anti-obesity medical devices
A variety of anti-obesity medical devices are available as over-the-counter 
products (e.g., NozNoz, slow control fork, slipper genie).
11. Conclusions
Anti-obesity medical devices represent a heterogenous family of devices in terms of 
presentation, usage/administration, mechanism of action, effectiveness, safety, regu-
lation, availability, and cost. They offer an attractive approach in managing obesity. 
Anti-obesity medical devices are positioned to bridge the gap between more conser-
vative treatments (e.g., lifestyle) and more aggressive interventions (e.g., bariatric 
surgery). Their use should always be combined with lifestyle changes.
Considering the large market size of obesity treatment and the small percentage 
of subjects treated with drugs or bariatric surgery, anti-obesity medical devices can 
play a major role in the management of obesity.
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Obesity is a worldwide pandemic causing increased morbidity/mortality 
and high cost for the society. Management of obesity requires multidisciplinary 
approaches including diet, food supplement, exercise, behavior change, drug, 
medical device, gut microbiome manipulation, and surgery. Over the past two 
decades, there has been a growing awareness of the importance of gut microbiome 
in human health and disease. Profound changes affecting the diversity and the 
abundance of gut microbiome are associated with several disorders including obe-
sity. A decrease in microbiome diversity and an increase in the ratio of Firmicutes-
to-Bacteroidetes phyla have been reported in obese subjects. The gut microbiome 
can be manipulated to change the host metabolism and manage obesity. Potential 
interventions include diet (e.g., low calories, low fat, and high fiber), prebiotics 
(e.g., inulin, lactulose, and resistant starch), probiotics (e.g., yogurt, cheese, and 
milk), synbiotics (combination of prebiotics and probiotics), bariatric surgery 
(e.g., Roux-en-Y gastric bypass), and fecal microbiota transplantation (through 
colonoscopy, esophagogastroduodenoscopy, orogastric tube, or oral capsule). A 
better understanding of the interactions between different diets and gut microbi-
ome should help the development of new guidelines for the prevention and man-
agement of obesity.
Keywords: gut microbiome, obesity, weight management
1. Introduction
Obesity is excess body weight for a given height, defined by a body mass 
index (BMI) ≥ 30 kg/m2. In some Asian countries (e.g., Japan), the threshold to 
define obesity is 25 kg/m2. The main cause of obesity is an imbalance between 
energy intake and energy expenditure. Obesity is a worldwide pandemic asso-
ciated with increased morbidity/mortality and high cost for the society. The 
prevalence of obesity is increasing exponentially. The number of adult subjects 
with obesity is around 700 million worldwide. Near 4 million subjects die each 
year from the consequences of obesity. The annual cost of obesity is more than 
$2 trillion [1–3].
Management of obesity requires multidisciplinary approaches including diet, 
food supplement, exercise, behavior change, drug, medical device, gut microbiome 
manipulation, and surgery [1, 4–9]. The annual obesity treatment market is around 
$6 billion.
The human intestine harbors a complex and diverse microbial ecosystem 
referred to as gut microbiome [10–14]. This rich community of microorganisms 
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has co-evolved in a symbiotic relationship with humans. Its diversity is 
influenced by several factors including host genetics, mode of birth, age, 
gender, pregnancy, BMI, diet, medications, and surgery [12, 15–31]. The 
understanding of the gut microbiome evolves at a rapid pace, but the practi-
cal application of this knowledge is still in its infancy. The gut microbiome 
is essential for the maintenance of human health. It is involved in protection 
against pathogens and regulation of immune system and metabolism [32]. 
Profound changes affecting the diversity and the abundance of gut microbiome 
(dysbiosis) are associated with several disorders including obesity [33]. The 
prevention and management of obesity may benefit from manipulation of gut 
microbiome.
2. Gut microbiome description and composition
Gut microbiome is a complex community of microorganisms living in the 
digestive tract, mainly in the colon (Figure 1). Variable pH and oxygen concentra-
tion affect the abundance of gut microbiome across the gastrointestinal tract. Gut 
microbiome represents up to 60% of the dry mass of feces (biomass around 1.5 kg), 
has more cells than host somatic cells and at least 100 times more genes than human 
genome [10–14].
Gut microbiome is established within the few first years of life and contains up 
to 100 trillion microbes, mainly bacteria (more than 1,000 species) but also fungi, 
protozoa, archaea, and viruses. The taxonomic ranking of gut microbiome includes 
species, genera, families, orders, classes, and phyla. Most of the species belong to 
Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobia 
phyla. The predominant phyla (90%) are Firmicutes (e.g., Ruminococcus and 
Lactobacillus genera) and Bacteroidetes (e.g., Bacteroides and Prevotella genera). 
Three enterotypes with functional differences have been defined based on variation 
in the level of genera: Enterotype 1 (Bacteroides), Enterotype 2 (Prevotella), and 
Enterotype 3 (Ruminococcus).
Figure 1. 
Gut microbiome is mainly located in the colon (Picture downloaded from the internet).
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3. Gut microbiome projects
There are two major gut microbiome projects: European Megagenomics of the 
Human Intestinal Tract and US Human Microbiome Project [11]. For gut micro-
biome studies, multiple fecal collections of the same subject are recommended. 
The assessments are DNA-based methods (16S rDNA sequencing, whole genome 
shotgun sequencing) (Figure 2) [32, 34, 35]. The challenges in the assessments of 
gut microbiome are due to the diversity and the inter/intra-individual variability 
caused by different factors such as age and diet.
4. Gut microbiome metabolism
4.1 Nutrition sources
The sources for nutrition of gut microbiome are ingested dietary components (car-
bohydrate, protein, lipid) and host-derived components (shed epithelial cells, mucus).
4.2 Metabolites
Several metabolites are produced by gut microbiome. They include short-chain 
fatty acids (following carbohydrate fermentation), phenolic substances (following 
protein fermentation), and vitamins (vitamin B, vitamin K).
5. Gut microbiome changes
Gut microbiome is diverse, varies between individuals, and can fluctuate over 
time. Western gut microbiome has less species than non-Western gut microbiome.
In addition to several pathological conditions that can alter gut microbiome 
composition, multiple factors are responsible for the changes in gut microbiome 
(Figure 3) [12, 15–31].
Figure 2. 
Assessment of gut microbiome (Picture downloaded from the internet).
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There are possible relations between host genetic profile and gut microbiome 
composition, but additional studies are needed for a better understanding of these 
relations [15].
5.2 Mode of birth
Mode of birth has an important influence on gut microbiome composition 
[12, 16]. With vaginal delivery, infants are colonized by maternal vaginal bacteria 
(dominated by Lactobacillus and Prevotella genera) while following C-section deliv-
ery, infants are colonized by maternal skin bacteria (dominated by Staphylococcus, 
Corynebacterium, and Propionibacterium genera).
5.3 Age
Age is associated with important changes in gut microbiome [12, 17]. The 
changes occur mainly before 20 and after 70 years. The diet plays a significant role. 
In preterm infants, there is a predominance of Proteobacteria phylum. There are 
marked changes in infants. The choice of diet after birth (breast milk or formula 
milk) affects the colonization process in the newborn. With age, the introduction 
of solid food from 2 years and the production of sex hormones from puberty (to 
menopause in females) bring additional richness and complexity to gut micro-
biome. There is a relative stability of gut microbiome between 20 and 70 years 
(predominance of Firmicutes phylum). In elderly subjects, Bacteroidetes phylum is 
predominant.
Figure 3. 
Multiple factors can impact gut microbiome (Picture downloaded from the Internet).
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5.4 Gender
Gender specificity of gut microbiome appears at puberty with the production 
of sex hormones [12, 18]. There is a lower abundance of Bacteroidetes phylum in 
women (role of estrogen).
5.5 Pregnancy
Elevated levels of estrogen and progesterone observed during pregnancy have 
important impact on gut microbiome [12, 16, 19]. The changes are characterized 
by a decrease in richness of gut microbiome, a higher abundance of Proteobacteria 
and Actinobacteria phyla, a decrease in Faecalibacterium genus, and an increase in 
Firmicutes-to-Bacteroidetes phyla ratio.
5.6 BMI
BMI is associated with gut microbiome composition particularly in women 
[18]. Bacteroidetes phylum is less abundant in subjects with high BMI. The role of 
estrogen has been proposed.
5.7 Diet
Diet has an important influence on gut microbiome composition [20–25]. 
However, there is a high interindividual variability. A diet high in fat (≥ 55% of total 
macronutrients) is associated with increased Firmicutes and Proteobacteria phyla 
and decreased Bacteroidetes phylum while a diet rich in fiber (≥ 30 g/day) has the 
opposite effect. The changes in gut microbiome (composition and functionality) 
induced by diet can be observed as early as 2 days. However, major changes in gut 
microbiome require long-term change in dietary habits.
Important differences in gut microbiome have been reported in children 
between Europe and rural African village of Burkina Faso (polysaccharide-rich 
diet) with Firmicutes-to-Bacteroidetes phyla ratios of 2.8 and 0.5, respectively [26].
Diet may also contribute to the seasonal variations of gut microbiome likely due 
to different availability of fresh produce containing complex carbohydrates [27].
5.8 Medication
Several medications (e.g., antibiotics, nonsteroidal anti-inflammatory drugs, 
proton pump inhibitors, and metformin) affect gut microbiome [28–30]. The use of 
antibiotics is associated with increased Firmicutes phylum, with higher sensitivity 
in infants.
The impact of prebiotics and probiotics on gut microbiome is presented in 
Section 8.
5.9 Surgery
Since colon is the main reservoir of gut microbiome, surgical removal of colon 
may affect gut microbiome [31]. Indeed, right hemicolectomy for colorectal cancer 
has been reported to be associated with a decrease in diversity and richness of gut 
microbiome.
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Gender specificity of gut microbiome appears at puberty with the production 
of sex hormones [12, 18]. There is a lower abundance of Bacteroidetes phylum in 
women (role of estrogen).
5.5 Pregnancy
Elevated levels of estrogen and progesterone observed during pregnancy have 
important impact on gut microbiome [12, 16, 19]. The changes are characterized 
by a decrease in richness of gut microbiome, a higher abundance of Proteobacteria 
and Actinobacteria phyla, a decrease in Faecalibacterium genus, and an increase in 
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5.6 BMI
BMI is associated with gut microbiome composition particularly in women 
[18]. Bacteroidetes phylum is less abundant in subjects with high BMI. The role of 
estrogen has been proposed.
5.7 Diet
Diet has an important influence on gut microbiome composition [20–25]. 
However, there is a high interindividual variability. A diet high in fat (≥ 55% of total 
macronutrients) is associated with increased Firmicutes and Proteobacteria phyla 
and decreased Bacteroidetes phylum while a diet rich in fiber (≥ 30 g/day) has the 
opposite effect. The changes in gut microbiome (composition and functionality) 
induced by diet can be observed as early as 2 days. However, major changes in gut 
microbiome require long-term change in dietary habits.
Important differences in gut microbiome have been reported in children 
between Europe and rural African village of Burkina Faso (polysaccharide-rich 
diet) with Firmicutes-to-Bacteroidetes phyla ratios of 2.8 and 0.5, respectively [26].
Diet may also contribute to the seasonal variations of gut microbiome likely due 
to different availability of fresh produce containing complex carbohydrates [27].
5.8 Medication
Several medications (e.g., antibiotics, nonsteroidal anti-inflammatory drugs, 
proton pump inhibitors, and metformin) affect gut microbiome [28–30]. The use of 
antibiotics is associated with increased Firmicutes phylum, with higher sensitivity 
in infants.
The impact of prebiotics and probiotics on gut microbiome is presented in 
Section 8.
5.9 Surgery
Since colon is the main reservoir of gut microbiome, surgical removal of colon 
may affect gut microbiome [31]. Indeed, right hemicolectomy for colorectal cancer 
has been reported to be associated with a decrease in diversity and richness of gut 
microbiome.
The impact of bariatric surgery on gut microbiome is presented in Section 8.
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6. Gut microbiome functions
The gut microbiome is involved in multiple physiological functions (Table 1) 
[32, 36–41].
6.1 Protection against pathogens
Gut microbiome can protect against pathogens by killing or inhibiting unwanted 
organisms (e.g., Clostridium difficile genera) that are competing for nutrients.
6.2 Regulation of immune system
Gut microbiome regulates immune system by influencing the production of 
cytokines and antibodies.
6.3 Regulation of metabolism
Gut microbiome is involved in several metabolic processes. These processes 
include regulation of energy homeostasis and body weight, production of short-
chain fatty acids (following fermentation of nondigestible fibers) and vitamins 
(vitamins B, vitamin K) [32, 36], glycemic control [37, 38], interaction with incre-
tins [39], and metabolism of lipids [40] and bone [41].
7. Gut microbiome in diseases
Dysbiosis is observed in several medical conditions including obesity, malnutri-
tion, type 2 diabetes, inflammatory bowel diseases, neurological disorders, and 
cancer [33, 42–48]. The dysbiosis can be the cause and/or the consequence of these 
diseases.
Gut microbiome influences drug pharmacokinetics and bioavailability, and thus, 
affects the efficacy and safety of several drugs used to treat diseases [49].
8. Gut microbiome and obesity
8.1 Gut microbiome composition in obesity
Although there are some conflicting data, most studies have reported that in 
obesity, there is a lower gut microbiome diversity, a higher abundance of Firmicutes 
Function of gut 
microbiome
Mechanism and target
Protection Killing or inhibiting unwanted organisms competing for nutrients
Immune system Influencing production of cytokines and antibodies
Metabolism Regulating energy homeostasis, producing short-chain fatty acids and vitamins, 
impacting glycemic control, interacting with incretins, regulating metabolism of 
lipids and bone
Table 1. 
Physiological functions of gut microbiome.
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phylum, a lower abundance of Bacteroidetes phylum, and a higher Firmicutes-
to-Bacteroidetes phyla ratio [33, 42–45]. There is also a higher abundance of 
Lactobacillus (genus belonging to Firmicutes phylum).
According to most studies, the low-grade inflammation stimulated by lipopoly-
saccharide production is the prime mechanism by which gut microbiome induces 
obesity [50].
8.2 Gut microbiome in obesity management
Gut microbiome can be manipulated for the purpose of obesity management 
using different tools (Table 2) [20, 21, 50–60].
8.2.1 Diet
Diet is an important factor for the manipulation of gut microbiome and manage-
ment of obesity. The amount of daily caloric intake and the content of food signifi-
cantly affect gut microbiome but with high interindividual variability [20, 21, 51]. 
A diet that is low in calories, low in fat (< 20% of total macronutrients), and high in 
fiber (≥ 30 g/day) has a favorable effect on gut microbiome (increase in richness, 
decrease in Firmicutes-to-Bacteroidetes phyla ratio) and weight control (weight loss).
8.2.2 Prebiotics
Prebiotics are chemicals (nondigestible food ingredients) inducing growth and/
or activity of bacteria [50, 52]. Prebiotics must be able to resist gastric acidity, resist 
enzymatic hydrolysis, resist absorption in the upper gastrointestinal tract, and be 
fermentable by the gut microbiome. Examples are inulin, lactulose, and resistant 
starch. Prebiotics can be found in many foods (e.g., leek, asparagus, onion, and 
soybean).
By modulating gut microbiome and lowering the production of lipopolysac-
charide, prebiotics have the potential to manage obesity. In a double-blind, 
placebo-controlled clinical study, administration of oligofructose-enriched inulin 
(8 g/day) to overweight/obese children for 16 weeks caused a significant increase 
in Bifidobacterium (genus belonging to Actinobacteria phylum) and significantly 
slowed the body weight gain compared with placebo [53].
8.2.3 Probiotics
Probiotics are nonpathogenic living microorganisms with direct or indirect 
effect on gut microbiome [50, 54, 55]. Products containing probiotics should be 
Tool for gut microbiome manipulation Description
Diet Low calories, low fat, high fiber
Prebiotics Inulin, lactulose, resistant starch
Probiotics Yogurt, cheese, milk
Synbiotics Combination of prebiotics and probiotics
Bariatric surgery Roux-en-Y gastric bypass
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6. Gut microbiome functions
The gut microbiome is involved in multiple physiological functions (Table 1) 
[32, 36–41].
6.1 Protection against pathogens
Gut microbiome can protect against pathogens by killing or inhibiting unwanted 
organisms (e.g., Clostridium difficile genera) that are competing for nutrients.
6.2 Regulation of immune system
Gut microbiome regulates immune system by influencing the production of 
cytokines and antibodies.
6.3 Regulation of metabolism
Gut microbiome is involved in several metabolic processes. These processes 
include regulation of energy homeostasis and body weight, production of short-
chain fatty acids (following fermentation of nondigestible fibers) and vitamins 
(vitamins B, vitamin K) [32, 36], glycemic control [37, 38], interaction with incre-
tins [39], and metabolism of lipids [40] and bone [41].
7. Gut microbiome in diseases
Dysbiosis is observed in several medical conditions including obesity, malnutri-
tion, type 2 diabetes, inflammatory bowel diseases, neurological disorders, and 
cancer [33, 42–48]. The dysbiosis can be the cause and/or the consequence of these 
diseases.
Gut microbiome influences drug pharmacokinetics and bioavailability, and thus, 
affects the efficacy and safety of several drugs used to treat diseases [49].
8. Gut microbiome and obesity
8.1 Gut microbiome composition in obesity
Although there are some conflicting data, most studies have reported that in 
obesity, there is a lower gut microbiome diversity, a higher abundance of Firmicutes 
Function of gut 
microbiome
Mechanism and target
Protection Killing or inhibiting unwanted organisms competing for nutrients
Immune system Influencing production of cytokines and antibodies
Metabolism Regulating energy homeostasis, producing short-chain fatty acids and vitamins, 
impacting glycemic control, interacting with incretins, regulating metabolism of 
lipids and bone
Table 1. 
Physiological functions of gut microbiome.
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phylum, a lower abundance of Bacteroidetes phylum, and a higher Firmicutes-
to-Bacteroidetes phyla ratio [33, 42–45]. There is also a higher abundance of 
Lactobacillus (genus belonging to Firmicutes phylum).
According to most studies, the low-grade inflammation stimulated by lipopoly-
saccharide production is the prime mechanism by which gut microbiome induces 
obesity [50].
8.2 Gut microbiome in obesity management
Gut microbiome can be manipulated for the purpose of obesity management 
using different tools (Table 2) [20, 21, 50–60].
8.2.1 Diet
Diet is an important factor for the manipulation of gut microbiome and manage-
ment of obesity. The amount of daily caloric intake and the content of food signifi-
cantly affect gut microbiome but with high interindividual variability [20, 21, 51]. 
A diet that is low in calories, low in fat (< 20% of total macronutrients), and high in 
fiber (≥ 30 g/day) has a favorable effect on gut microbiome (increase in richness, 
decrease in Firmicutes-to-Bacteroidetes phyla ratio) and weight control (weight loss).
8.2.2 Prebiotics
Prebiotics are chemicals (nondigestible food ingredients) inducing growth and/
or activity of bacteria [50, 52]. Prebiotics must be able to resist gastric acidity, resist 
enzymatic hydrolysis, resist absorption in the upper gastrointestinal tract, and be 
fermentable by the gut microbiome. Examples are inulin, lactulose, and resistant 
starch. Prebiotics can be found in many foods (e.g., leek, asparagus, onion, and 
soybean).
By modulating gut microbiome and lowering the production of lipopolysac-
charide, prebiotics have the potential to manage obesity. In a double-blind, 
placebo-controlled clinical study, administration of oligofructose-enriched inulin 
(8 g/day) to overweight/obese children for 16 weeks caused a significant increase 
in Bifidobacterium (genus belonging to Actinobacteria phylum) and significantly 
slowed the body weight gain compared with placebo [53].
8.2.3 Probiotics
Probiotics are nonpathogenic living microorganisms with direct or indirect 
effect on gut microbiome [50, 54, 55]. Products containing probiotics should be 
Tool for gut microbiome manipulation Description
Diet Low calories, low fat, high fiber
Prebiotics Inulin, lactulose, resistant starch
Probiotics Yogurt, cheese, milk
Synbiotics Combination of prebiotics and probiotics
Bariatric surgery Roux-en-Y gastric bypass
Fecal microbiota transplantation Addition of healthy stool
Table 2. 
Different tools used for gut microbiome manipulation in obesity management.
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tested for safety risks before marketing. Probiotics can be found in several foods 
(e.g., yogurt, cheese, and milk).
Probiotics can manage obesity by reducing the production of lipopolysaccharide 
through an impact on gut microbiome. In a double-blind, placebo-controlled clini-
cal study, administration of fermented milk containing Lactobacillus gasseri species 
(LG2055) to overweight/obese adults for 12 weeks caused a significant decrease in 
body weight [56].
8.2.4 Synbiotics
Synbiotics are combination of prebiotics and probiotics. They have the potential 
to induce more effects on gut microbiome and body weight than prebiotics or 
probiotics alone.
8.2.5 Bariatric surgery
Bariatric surgery can modify gut microbiome and further affect body weight 
[57, 58]. The mechanisms include reduced caloric intake, reduced gastric emptying, 
and alterations in gastric acid production and bile acids.
After Roux-en-Y gastric bypass surgery in obese subjects, there is a decrease in 
Firmicutes-to-Bacteroidetes phyla ratio and an increase in Proteobacteria phylum 
[57, 58].
8.2.6 Fecal microbiota transplantation
Fecal microbiota transplantation, which consists of transfer of feces from a 
healthy donor to a recipient, is an exciting therapy with important potential. It can 
modify gut microbiome for the purpose of obesity management [59, 60]. The addition 
of healthy stool can be done through colonoscopy, orogastric tube, esophagogastro-
duodenoscopy, or oral capsule. It is important to carefully select and screen the donor 
to avoid risk of infection, aggravation of obesity, or other complications [61, 62].
Available clinical data are very preliminary and limited. Several studies are 
ongoing. There is no regulatory guidance for the use of fecal microbiota transplan-
tation in the management of obesity.
8.2.7 Cost of gut microbiome manipulation
Cost of gut microbiome manipulation in obesity management is reported in 
Table 3.
Tool for gut microbiome manipulation Average cost (range)




Bariatric surgery (Roux-en-Y gastric bypass) $23,000 ($20,000–$30,000)
Fecal microbiota transplantation $1,800 ($1,600–$2,000) + cost of administration/dose
Table 3. 
Cost of different tools used for gut microbiome manipulation in obesity management in the USA.
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8.3 Gut microbiome after weight loss
After successful weight loss, there is a decrease in Firmicutes phylum, an 
increase in Bacteroidetes phylum, and a decrease of Firmicutes-to-Bacteroidetes 
phyla ratio [45, 51, 57, 58].
9. Clinical study design to assess gut microbiome in obesity
Well-designed clinical studies are urgently needed to better understand the 
interactions between obesity/obesity treatment and gut microbiome.
Several factors affect the quality of weight-loss studies aimed to assess gut 
microbiome. A well-calculated sample size allowing subgroup analysis is a key 
factor. Relevant stratification factors (e.g., race, age, gender, BMI, diet, and medica-
tions) at randomization will make the study more informative. Any underestima-
tion of these stratification factors, as it has been the case in several clinical studies, 
especially in relation to diet and medications, may lead to misleading and conflict-
ing results. The duration of the clinical studies has to be sufficient to allow both 
short-term and long-term/follow-up assessments. Adequate adjustments should be 
made during the statistical analysis.
10. Ideal gut microbiome
An ideal gut microbiome should have high diversity. At the level of phyla, the 
ideal gut microbiome should have low Firmicutes phylum and high Bacteroidetes 
phylum with a Firmicutes-to-Bacteroidetes phyla ratio < 1.0. At the level of genera, 
the ideal gut microbiome should be rich in Prevotella genus.
The recommended diet to reach the above objectives is a diet adequate in calories 
(adjusted to the activity), low in fat (< 20% of total macronutrients), and rich in 
fiber (≥ 30 g/day).
11. Conclusions
Gut microbiome influences normal physiology and susceptibility to diseases. 
Profound changes affecting the diversity and the abundance of gut microbiome 
are associated with obesity. A decrease in microbiome diversity and an increase 
in the ratio of Firmicutes-to-Bacteroidetes phyla have been reported in obese 
subjects.
Gut microbiome can be manipulated to change the host metabolism and man-
age obesity. Potential interventions include diet, prebiotics, probiotics, synbiotics, 
bariatric surgery, and fecal microbiota transplantation.
A better understanding of the interactions between different diets and gut 
microbiome should help the development of new guidelines for feeding humans to 
prevent or manage obesity.
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The intestinal barrier is constantly exposed to potentially harmful environmen-
tal factors including food components and bacterial endotoxins. When the intestinal
barrier function and immune homeostasis are compromised, inflammatory condi-
tions may be developed and impact overall health. Evidence from experimental
animal and cell-culture studies suggests that exposure of intestinal mucosa to
proanthocyanidin-rich plant products may contribute to maintain the barrier func-
tion and to ameliorate the inflammation present in prevalent pathologies such as
diet-induced obesity and inflammatory bowel disease. In this review, we aim to
update the current knowledge on the bioactivity of PACs in experimental models of
altered intestinal permeability and in humans, emphasizing the beneficial effects
of grape-seed proanthocyanidin extracts in intestinal health and giving insights into
the subjacent biochemical and molecular mechanism.
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1. Introduction
The primary function of the intestinal tract is to digest food components and
absorb nutrients and water from the lumen to the systemic circulation. The intes-
tine is also a physical barrier that is in contact with the environment. As a result, the
intestinal epithelium is constantly exposed to potentially pathogenic microorgan-
isms, toxins, and harmful components of the diet. When there are disturbances in
the barrier function and mucosal immune homeostasis, the influx of intestine
luminal content triggers barrier dysfunction and an exaggerated mucosal immune
response [1]. Ultimately, chronic exposition to these detrimental environmental
stimuli may lead to the development of local and systemic inflammatory conditions
[2, 3] that contribute to barrier dysfunction.
Natural products have been recognized as a source of therapeutic agents for
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Abstract
The intestinal barrier is constantly exposed to potentially harmful environmen-
tal factors including food components and bacterial endotoxins. When the intestinal
barrier function and immune homeostasis are compromised, inflammatory condi-
tions may be developed and impact overall health. Evidence from experimental
animal and cell-culture studies suggests that exposure of intestinal mucosa to
proanthocyanidin-rich plant products may contribute to maintain the barrier func-
tion and to ameliorate the inflammation present in prevalent pathologies such as
diet-induced obesity and inflammatory bowel disease. In this review, we aim to
update the current knowledge on the bioactivity of PACs in experimental models of
altered intestinal permeability and in humans, emphasizing the beneficial effects
of grape-seed proanthocyanidin extracts in intestinal health and giving insights into
the subjacent biochemical and molecular mechanism.
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1. Introduction
The primary function of the intestinal tract is to digest food components and
absorb nutrients and water from the lumen to the systemic circulation. The intes-
tine is also a physical barrier that is in contact with the environment. As a result, the
intestinal epithelium is constantly exposed to potentially pathogenic microorgan-
isms, toxins, and harmful components of the diet. When there are disturbances in
the barrier function and mucosal immune homeostasis, the influx of intestine
luminal content triggers barrier dysfunction and an exaggerated mucosal immune
response [1]. Ultimately, chronic exposition to these detrimental environmental
stimuli may lead to the development of local and systemic inflammatory conditions
[2, 3] that contribute to barrier dysfunction.
Natural products have been recognized as a source of therapeutic agents for
many years [4]. Some plant-derived phenolic compounds show promising
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anti-inflammatory effects and have been associated with the prevention of certain
chronic diseases [5]. Proanthocyanidins (PACs), also known as condensed tannins,
are oligo- and polymeric end products of the flavonoid biosynthesis pathway in
plants [6]. There has been extensive laboratory research into the effects of both
pure PAC molecules and PAC-rich extracts on overall health. These phytochemicals
show a wide range of physiological activities [7], including anti-inflammatory and
barrier-protective effects in the intestine [8–10], which may be interesting in the
context of diet-induced obesity and inflammatory bowel disease (IBD).
We have reported previously that grape-seed PACs and other flavonoids have
beneficial effects on inflammation [11–13] and protect the intestine against alter-
ations associated with diet-induced obesity in rats [8, 9, 14, 15]. In addition,
research conducted during the last decade with cell culture and animal models has
made significant progress in determining the underlying mechanism of the health-
promoting properties of PACs in the gastrointestinal tract and peripheral tissues.
2. Altered networks in intestinal dysfunction: barrier integrity
and inflammatory response
The intestinal epithelium is a single cell-layer responsible for separating under-
lying mucosal tissues from the environment and is the largest exposed surface area
in the body [16]. As there is a prolific commensal microbial community in the
intestinal lumen (intestinal microbiota), epithelial integrity plays a pivotal role in
maintaining overall health [16, 17]. The intestinal epithelium is integrated by sev-
eral cell types with specialized functions. The enterocytes are responsible for the
absorptive function and constitute the most abundant epithelial cell lineage. The
goblet cells are implicated in the synthesis of secretory mucin glycoproteins that
form the mucus layer [18]. Other cellular types integrating the epithelium,
microfold (M) [19], Paneth and enteroendocrine cells are specialized in antigen
sampling and presentation to dendritic cells, synthesis of antimicrobial peptides,
and secretion of hormones, respectively.
The first strategy the host tissue has to maintain its homeostatic relationship
with the intestinal microbiota is to minimize the physical interaction with microor-
ganisms, thus limiting microbial translocation and physiological inflammation
[20, 21]. The thick mucus layer secreted by goblet cells represents a primary defense
line against environmental insults [18]. In addition, the enterocytes are joined
together forming an intricately and well-regulated barrier sustained by intercellular
junctions linked to the cell cytoskeleton, such as tight junctions (TJs), desmosomes,
and adherent junctions. TJs partially seal the paracellular space and prevent passive
transport of large molecules, including microbial components and other potentially
harmful agents [1, 22].
The paracellular and transcellular pathways are the two major pathways medi-
ating transmembrane transfer of intestinal bacterial substances. Both mechanisms
may be involved in intestinal mucosal barrier damage and bacterial translocation.
The paracellular pathway is integrated by tight junctions (TJs), consisting of
zonulin/zonula occludens (ZO)-1, occludin, claudins, junction adhesion molecules
(JAMs), and actin-myosin cytoskeletal proteins. Previous studies have shown that
inflammatory cytokines and bacterial antigens can affect the expression level and
assembly of these elements, thereby exerting an influence on TJ functions [23].
Immune cells, including neutrophils, dendritic cells, and monocytes, have also been
directly implicated in inducing disturbances in TJ barrier function. It has been
postulated that pro-inflammatory cytokine-induced opening of the intestinal TJ
barrier is an important mechanism contributing to the TJ barrier defects present in
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various inflammatory conditions of the gut [24]. Previous studies [25–28] have
shown that myosin light chain kinase (MLCK) plays a central role in the regulation
of intestinal TJ permeability. The activation of MLCK catalyzes the phosphorylation
of myosin light chain (MLC), inducing contraction of the peri-junctional actin-
myosin filaments and the opening of the TJ barrier. In contrast, inhibition of MLCK
activation prevents this effect [27]. It has been suggested that the cytokine-
mediated barrier dysfunction could be mediated by an increase in Nuclear
Factor (NF)-kB, which, in turn, activates MLCK gene and protein expression [29]
(Figure 1).
Once intestinal bacteria and endotoxins enter the portal vein and/or lymphatic
system, they can reach other tissues and organs, leading to a cascade response
modulated by inflammatory mediators. This situation can induce a systemic
inflammatory response, which further damages the function of the intestinal barrier
[30]. The endotoxin-signaling pathway includes the binding of LPS to LPS-binding
protein (LBP) and its subsequent transfer to the CD14 receptor. LBP-bound LPS
initiates inflammation via TLRs associated with membrane-anchored CD14 [31].
TLRs are a family of pattern-recognition receptors that play a key role in the innate
immune system. Among all, the TLR4 is expressed at high levels in the intestinal
tract, and given that LPS is its specific ligand, TLR4 could be considered the first
barrier for recognition of bacterial presence in the gastrointestinal tract. NF-kB is
the final effector transcription factor of the TLR4 signaling pathway. It promotes
the development of many intestinal diseases and also plays a pivotal role in the
translation and transcription of inflammatory mediators [30].
In mammals, the NF-kB family comprises five proteins, including p65 (RelA),
RelB, c-Rel, p105/p50 (NF-kB1), and p100/p52 (NF-kB2), which associate with
each other to form transcriptionally distinct homo- and heterodimeric complexes;
the p65:p50 heterodimer is the most abundant and the most relevant for inflamma-
tion [32]. In resting cells, the p65:p50 NF-kB heterodimer is sequestered in the
cytoplasm by binding to its inhibitory protein, IkappaB (IkB). In response to an
inflammatory stimulus, such as LPS, the classical NF-kB activation pathway leads to
the activation of the IkB kinase (IkkB), a member of the IKK complex, triggering
IkB-a phosphorylation (pIkB-a). Then, pIkB-a is recognized by the ubiquitin ligase
machinery, resulting in its polyubiquitination and subsequent proteasomal
Figure 1.
Protective properties of PACs in the intestinal barrier function. (A) Chronic exposition to detrimental
environmental stimuli may lead to dysbiosis, breakdown of the intestinal barrier, influx of bacterial endotoxins
and mucosal inflammation. (B) PACs ameliorate loss of barrier function blocking the activation of MLCK
mediated by NF-κB and MAPK signaling. See text for details.
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anti-inflammatory effects and have been associated with the prevention of certain
chronic diseases [5]. Proanthocyanidins (PACs), also known as condensed tannins,
are oligo- and polymeric end products of the flavonoid biosynthesis pathway in
plants [6]. There has been extensive laboratory research into the effects of both
pure PAC molecules and PAC-rich extracts on overall health. These phytochemicals
show a wide range of physiological activities [7], including anti-inflammatory and
barrier-protective effects in the intestine [8–10], which may be interesting in the
context of diet-induced obesity and inflammatory bowel disease (IBD).
We have reported previously that grape-seed PACs and other flavonoids have
beneficial effects on inflammation [11–13] and protect the intestine against alter-
ations associated with diet-induced obesity in rats [8, 9, 14, 15]. In addition,
research conducted during the last decade with cell culture and animal models has
made significant progress in determining the underlying mechanism of the health-
promoting properties of PACs in the gastrointestinal tract and peripheral tissues.
2. Altered networks in intestinal dysfunction: barrier integrity
and inflammatory response
The intestinal epithelium is a single cell-layer responsible for separating under-
lying mucosal tissues from the environment and is the largest exposed surface area
in the body [16]. As there is a prolific commensal microbial community in the
intestinal lumen (intestinal microbiota), epithelial integrity plays a pivotal role in
maintaining overall health [16, 17]. The intestinal epithelium is integrated by sev-
eral cell types with specialized functions. The enterocytes are responsible for the
absorptive function and constitute the most abundant epithelial cell lineage. The
goblet cells are implicated in the synthesis of secretory mucin glycoproteins that
form the mucus layer [18]. Other cellular types integrating the epithelium,
microfold (M) [19], Paneth and enteroendocrine cells are specialized in antigen
sampling and presentation to dendritic cells, synthesis of antimicrobial peptides,
and secretion of hormones, respectively.
The first strategy the host tissue has to maintain its homeostatic relationship
with the intestinal microbiota is to minimize the physical interaction with microor-
ganisms, thus limiting microbial translocation and physiological inflammation
[20, 21]. The thick mucus layer secreted by goblet cells represents a primary defense
line against environmental insults [18]. In addition, the enterocytes are joined
together forming an intricately and well-regulated barrier sustained by intercellular
junctions linked to the cell cytoskeleton, such as tight junctions (TJs), desmosomes,
and adherent junctions. TJs partially seal the paracellular space and prevent passive
transport of large molecules, including microbial components and other potentially
harmful agents [1, 22].
The paracellular and transcellular pathways are the two major pathways medi-
ating transmembrane transfer of intestinal bacterial substances. Both mechanisms
may be involved in intestinal mucosal barrier damage and bacterial translocation.
The paracellular pathway is integrated by tight junctions (TJs), consisting of
zonulin/zonula occludens (ZO)-1, occludin, claudins, junction adhesion molecules
(JAMs), and actin-myosin cytoskeletal proteins. Previous studies have shown that
inflammatory cytokines and bacterial antigens can affect the expression level and
assembly of these elements, thereby exerting an influence on TJ functions [23].
Immune cells, including neutrophils, dendritic cells, and monocytes, have also been
directly implicated in inducing disturbances in TJ barrier function. It has been
postulated that pro-inflammatory cytokine-induced opening of the intestinal TJ
barrier is an important mechanism contributing to the TJ barrier defects present in
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various inflammatory conditions of the gut [24]. Previous studies [25–28] have
shown that myosin light chain kinase (MLCK) plays a central role in the regulation
of intestinal TJ permeability. The activation of MLCK catalyzes the phosphorylation
of myosin light chain (MLC), inducing contraction of the peri-junctional actin-
myosin filaments and the opening of the TJ barrier. In contrast, inhibition of MLCK
activation prevents this effect [27]. It has been suggested that the cytokine-
mediated barrier dysfunction could be mediated by an increase in Nuclear
Factor (NF)-kB, which, in turn, activates MLCK gene and protein expression [29]
(Figure 1).
Once intestinal bacteria and endotoxins enter the portal vein and/or lymphatic
system, they can reach other tissues and organs, leading to a cascade response
modulated by inflammatory mediators. This situation can induce a systemic
inflammatory response, which further damages the function of the intestinal barrier
[30]. The endotoxin-signaling pathway includes the binding of LPS to LPS-binding
protein (LBP) and its subsequent transfer to the CD14 receptor. LBP-bound LPS
initiates inflammation via TLRs associated with membrane-anchored CD14 [31].
TLRs are a family of pattern-recognition receptors that play a key role in the innate
immune system. Among all, the TLR4 is expressed at high levels in the intestinal
tract, and given that LPS is its specific ligand, TLR4 could be considered the first
barrier for recognition of bacterial presence in the gastrointestinal tract. NF-kB is
the final effector transcription factor of the TLR4 signaling pathway. It promotes
the development of many intestinal diseases and also plays a pivotal role in the
translation and transcription of inflammatory mediators [30].
In mammals, the NF-kB family comprises five proteins, including p65 (RelA),
RelB, c-Rel, p105/p50 (NF-kB1), and p100/p52 (NF-kB2), which associate with
each other to form transcriptionally distinct homo- and heterodimeric complexes;
the p65:p50 heterodimer is the most abundant and the most relevant for inflamma-
tion [32]. In resting cells, the p65:p50 NF-kB heterodimer is sequestered in the
cytoplasm by binding to its inhibitory protein, IkappaB (IkB). In response to an
inflammatory stimulus, such as LPS, the classical NF-kB activation pathway leads to
the activation of the IkB kinase (IkkB), a member of the IKK complex, triggering
IkB-a phosphorylation (pIkB-a). Then, pIkB-a is recognized by the ubiquitin ligase
machinery, resulting in its polyubiquitination and subsequent proteasomal
Figure 1.
Protective properties of PACs in the intestinal barrier function. (A) Chronic exposition to detrimental
environmental stimuli may lead to dysbiosis, breakdown of the intestinal barrier, influx of bacterial endotoxins
and mucosal inflammation. (B) PACs ameliorate loss of barrier function blocking the activation of MLCK
mediated by NF-κB and MAPK signaling. See text for details.
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degradation. After pIkB-a degradation, the p65:p50 heterodimers are able to
translocate to the nucleus, where they bind to the kB motif found in the promoter
or enhancer regions of numerous pro-inflammatory genes to induce their
expression [33].
NF-kB target genes include cytokines (e.g., tumor necrosis factor (TNF)-α and
interleukins), adhesion molecules, acute phase proteins, and inducible enzymes
(inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2)), among
others [11]. All of these genes contain verified NF-kB binding sites in their
sequences, providing strong experimental evidence for their direct control by
NF-kB [34]. Among all of these genes, the expression of iNOS and COX2 has been
widely studied in relation to intestinal inflammation. In this regard, sustained high
nitric oxide (NO) production by iNOS plays a role in the pathology of chronic
inflammatory bowel disease [35, 36]. During the last decade, it has become increas-
ingly clear that NO overproduction by iNOS is deleterious to intestinal function
[37], thus contributing significantly to gastrointestinal immunopathology.
Cyclooxygenases are enzymes that are responsible for the metabolism of
arachidonic acid, converting it into prostaglandins. These products influence a wide
variety of biological processes, ranging from homeostasis to inflammation [38].
There are two cyclooxygenase isoforms: the constitutive COX1 isoform and the
inducible COX2 isoform [38, 39]. As a result of COX2 induction, prostaglandin E2
levels increase at the site of inflammation and can also be detected systemically.
Multiple environmental factors have been identified as potential triggers of
intestinal inflammatory conditions, including Western dietary habits [40]. It has
been described that saturated fats play a direct role in inflammatory signaling.
Saturated fatty acids (SFA) such as lauric (C12:0) and palmitic (C16:0) directly
induce NF-κB activation, acting as non-microbial TLR2 and TLR4 agonists in mac-
rophages [41]. Data suggest that activation of TLRs by SFA is mediated by TLR
dimerization and recruitment into lipid rafts [42]. We have reported mild intestinal
inflammation and increased permeability in rats feeding on a cafeteria diet
consisting of high-saturated fat/high-refined sugar food products [43]. This
enhanced permeability has been shown to favor bacterial LPS and other potentially
pro-inflammatory molecules entering the systemic circulation, which is known as
metabolic endotoxemia [15].
Taken together, these data suggest that HF diet-induced changes in the intestinal
microbiota could be responsible for metabolic endotoxemia and for the onset of the
corresponding diseases. The causative link between changes in intestinal bacteria
populations, endotoxemia, and metabolic disease needs further assessment [44],
but the mechanisms likely include altered epithelial permeability, translocation of
bacterial products, and upregulation of pro-inflammatory cytokines and hormones
produced by gut endocrine cells, mechanisms which might be modulated by PACs.
3. PACs: chemical structure, occurrence, and intake
PACs consist of flavan-3-ol subunits with a degree of polymerization (DP) equal
to or greater than 2, mainly linked by (4 ! 8) or (4 ! 6) carbon-carbon bonds (B-
type PACs) [45]. In some botanical sources an additional (2 ! 7) ether-linkage also
occurs (A-type PACs) [46] (Figure 2). Depending on the type of monomers, PACs
can be classified into procyanidins, prodelphinidins, and propelargonidins. The
most abundant group, procyanidins, consists exclusively of (+)- catechin and
(�)- epicatechinmonomers [47]. Prodelphinidins and propelargonidins are composed
of (�)- gallocatechin/(�)- epigallocatechin and (+)- afzelechin/(�)- epiafzelechin
monomers, respectively [45], and have a more limited distribution
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Dietary assessment studies have shown that PACs, especially procyanidins are
among the most abundant polyphenols in the human diet [6], as they are present in
a variety of botanical sources and plant food products such as tea, fruits, nuts, cacao
products, legumes, and cereal grains [1, 2]. However, PAC intake varies widely
between geographical regions and cultures and is greatly dependent on eating
habits, lifestyle behaviors, and socioeconomic status [48]. The daily PAC (dimers
to polymers) intakes in adult populations from Korea, the U.S., Mexico, and EU
were estimated as 71 [49], 73 [48], 103 [50], and 123–180 mg [51, 52], respectively,
but intakes up to 230 mg d1 have been reported in some regions of Spain and
Norway [53].
4. The fate of PACs after ingestion
Flavan-3-ols are remarkably stable during gastric transit in humans [54]. Mono-
mers such as (+)- catechin and ()- epicatechin are readily absorbed in the upper
sections of the small intestine [55, 56], recognized as xenobiotics and then subjected
to an extensive phase II metabolism that generates glucuronidated, sulfated, and
methylated conjugates [57]. Flavan-3-ol monomers and their conjugated metabo-
lites reach peak plasma concentration 1–4 h after flavan-3-ol-rich food consumption
[58–60]. Studies conducted in cultivated epithelial monolayers [61–63], rats
[64, 65], and humans [60, 66] indicate that PAC absorption is conversely more
Figure 2.
Chemical structures of PACs. Flavan-3-ol monomers differ based on the hydroxylation pattern and their cis- or
trans-configuration. Dimers A1/A2 and B1/B2 are shown as example of A- and B-type PACs, respectively.
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others [11]. All of these genes contain verified NF-kB binding sites in their
sequences, providing strong experimental evidence for their direct control by
NF-kB [34]. Among all of these genes, the expression of iNOS and COX2 has been
widely studied in relation to intestinal inflammation. In this regard, sustained high
nitric oxide (NO) production by iNOS plays a role in the pathology of chronic
inflammatory bowel disease [35, 36]. During the last decade, it has become increas-
ingly clear that NO overproduction by iNOS is deleterious to intestinal function
[37], thus contributing significantly to gastrointestinal immunopathology.
Cyclooxygenases are enzymes that are responsible for the metabolism of
arachidonic acid, converting it into prostaglandins. These products influence a wide
variety of biological processes, ranging from homeostasis to inflammation [38].
There are two cyclooxygenase isoforms: the constitutive COX1 isoform and the
inducible COX2 isoform [38, 39]. As a result of COX2 induction, prostaglandin E2
levels increase at the site of inflammation and can also be detected systemically.
Multiple environmental factors have been identified as potential triggers of
intestinal inflammatory conditions, including Western dietary habits [40]. It has
been described that saturated fats play a direct role in inflammatory signaling.
Saturated fatty acids (SFA) such as lauric (C12:0) and palmitic (C16:0) directly
induce NF-κB activation, acting as non-microbial TLR2 and TLR4 agonists in mac-
rophages [41]. Data suggest that activation of TLRs by SFA is mediated by TLR
dimerization and recruitment into lipid rafts [42]. We have reported mild intestinal
inflammation and increased permeability in rats feeding on a cafeteria diet
consisting of high-saturated fat/high-refined sugar food products [43]. This
enhanced permeability has been shown to favor bacterial LPS and other potentially
pro-inflammatory molecules entering the systemic circulation, which is known as
metabolic endotoxemia [15].
Taken together, these data suggest that HF diet-induced changes in the intestinal
microbiota could be responsible for metabolic endotoxemia and for the onset of the
corresponding diseases. The causative link between changes in intestinal bacteria
populations, endotoxemia, and metabolic disease needs further assessment [44],
but the mechanisms likely include altered epithelial permeability, translocation of
bacterial products, and upregulation of pro-inflammatory cytokines and hormones
produced by gut endocrine cells, mechanisms which might be modulated by PACs.
3. PACs: chemical structure, occurrence, and intake
PACs consist of flavan-3-ol subunits with a degree of polymerization (DP) equal
to or greater than 2, mainly linked by (4 ! 8) or (4 ! 6) carbon-carbon bonds (B-
type PACs) [45]. In some botanical sources an additional (2 ! 7) ether-linkage also
occurs (A-type PACs) [46] (Figure 2). Depending on the type of monomers, PACs
can be classified into procyanidins, prodelphinidins, and propelargonidins. The
most abundant group, procyanidins, consists exclusively of (+)- catechin and
(�)- epicatechinmonomers [47]. Prodelphinidins and propelargonidins are composed
of (�)- gallocatechin/(�)- epigallocatechin and (+)- afzelechin/(�)- epiafzelechin
monomers, respectively [45], and have a more limited distribution
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Dietary assessment studies have shown that PACs, especially procyanidins are
among the most abundant polyphenols in the human diet [6], as they are present in
a variety of botanical sources and plant food products such as tea, fruits, nuts, cacao
products, legumes, and cereal grains [1, 2]. However, PAC intake varies widely
between geographical regions and cultures and is greatly dependent on eating
habits, lifestyle behaviors, and socioeconomic status [48]. The daily PAC (dimers
to polymers) intakes in adult populations from Korea, the U.S., Mexico, and EU
were estimated as 71 [49], 73 [48], 103 [50], and 123–180 mg [51, 52], respectively,
but intakes up to 230 mg d1 have been reported in some regions of Spain and
Norway [53].
4. The fate of PACs after ingestion
Flavan-3-ols are remarkably stable during gastric transit in humans [54]. Mono-
mers such as (+)- catechin and ()- epicatechin are readily absorbed in the upper
sections of the small intestine [55, 56], recognized as xenobiotics and then subjected
to an extensive phase II metabolism that generates glucuronidated, sulfated, and
methylated conjugates [57]. Flavan-3-ol monomers and their conjugated metabo-
lites reach peak plasma concentration 1–4 h after flavan-3-ol-rich food consumption
[58–60]. Studies conducted in cultivated epithelial monolayers [61–63], rats
[64, 65], and humans [60, 66] indicate that PAC absorption is conversely more
Figure 2.
Chemical structures of PACs. Flavan-3-ol monomers differ based on the hydroxylation pattern and their cis- or
trans-configuration. Dimers A1/A2 and B1/B2 are shown as example of A- and B-type PACs, respectively.
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limited and is highly dependent on DP, and that the permeation of larger oligomers
(DP > 5) and polymers is negligible. No PAC transporter has been identified in the
enterocyte membrane in the small intestine. Thus, dimers to tetramers are passively
transported across the intestinal epithelium essentially by paracellular diffusion.
Although transcellular passive diffusion is not likely to occur due to the hydrophilic
nature of PACs conferred by the multiple hydroxyl groups, uptake might be possi-
ble by endocytic mechanisms [62].
In humans, a study assessed the contribution of the ingested cocoa flavan-3-ols
and procyanidins to the systemic pool, and found that the plasma (�)- epicatechin
came from the orally administered cocoa (�)- epicatechin and not from their
oligomers or polymers [67]. This is in agreement with the evidence obtained with
rats that suggests that PACs from different sources do not depolymerize to mono-
mers after ingestion [68, 69]. Stalmach et al. [56] conducted a study with
ileostomized patients who were administered green tea, and found 70% of the
ingested flavan-3-ol in the ileal fluid after 24 h. Altogether, these findings suggest
that substantial amounts of ingested flavan-3-ol monomers and PACs remain
unabsorbed in the small intestine and reach the colon. There, they are efficiently
transformed by the colonic microbiota into low molecular weight phenolic com-
pounds that can be absorbed by colonocytes [57].
In vitro fermentation of purified procyanidin dimers with human fecal
microbiota has shown to produce mainly 2-(30,40-dihydroxyphenyl) acetic acid and
5-(30,40-dihydroxyphenyl)-γ-valerolactone [70]. In agreement with this, a random-
ized cross-over study in healthy humans found that a great portion of the ingested
(�)- epicatechin and procyanidin B1 was metabolized by the colonic microbiota to
produce phenyl-γ-valerolactones as the major microbial metabolites [60]. In this
study, microbial degradation of larger procyanidins was substantially lower, possi-
bly to the inhibition of digesting enzymes or to the antibacterial properties
exhibited by these compounds. Other human studies analyzing the bioavailability of
flavan-3-ols, reported high levels of phenyl-γ-valerolactones in the circulation and
urinary excretion after ingestion of a red grape pomace drink [71] and apple juice
[72]. In the colonocytes and hepatocytes, these microbial products undergo further
metabolism by phase II enzymes to produce conjugated derivatives. Margalef et al.
[73] analyzed the tissue distribution of metabolites derived from a grape-seed
proanthocyanidin extract (GSPE) 2 h after ingestion by rats. These authors detected
a few microbial metabolites (methyl conjugated phenols) at low concentrations in
the colon tissue, while most phase II metabolites (glucuronidated and methyl-
glucuronidated forms) were found in the kidneys and liver. In humans, the major
contributors to the excretion of phenyl-γ-valerolactones after ingestion of a red
grape pomace drink, are sulfated and glucuronidated conjugates of 5-(30,40-
dihydroxyphenyl)-γ-valerolactone [71].
5. In vitro, in vivo and ex vivo studies on the benefits of PACs
for intestinal dysfunction
During the last decade, the beneficial properties of PACs for intestinal function
have been reported in several studies performed with cell-culture models and
experimental animals (Tables 1 and 2). This experimental data indicate that PACs
contribute to maintaining the intestinal barrier and improving mucosal inflamma-
tion induced by environmental insults. However, there are few studies on the
effect of PACs on human intestinal health, although epidemiological



























































Beneficial Effects of Proanthocyanidins on Intestinal Permeability and Its Relationship…
DOI: http://dx.doi.org/10.5772/intechopen.91212
limited and is highly dependent on DP, and that the permeation of larger oligomers
(DP > 5) and polymers is negligible. No PAC transporter has been identified in the
enterocyte membrane in the small intestine. Thus, dimers to tetramers are passively
transported across the intestinal epithelium essentially by paracellular diffusion.
Although transcellular passive diffusion is not likely to occur due to the hydrophilic
nature of PACs conferred by the multiple hydroxyl groups, uptake might be possi-
ble by endocytic mechanisms [62].
In humans, a study assessed the contribution of the ingested cocoa flavan-3-ols
and procyanidins to the systemic pool, and found that the plasma (�)- epicatechin
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pounds that can be absorbed by colonocytes [57].
In vitro fermentation of purified procyanidin dimers with human fecal
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5-(30,40-dihydroxyphenyl)-γ-valerolactone [70]. In agreement with this, a random-
ized cross-over study in healthy humans found that a great portion of the ingested
(�)- epicatechin and procyanidin B1 was metabolized by the colonic microbiota to
produce phenyl-γ-valerolactones as the major microbial metabolites [60]. In this
study, microbial degradation of larger procyanidins was substantially lower, possi-
bly to the inhibition of digesting enzymes or to the antibacterial properties
exhibited by these compounds. Other human studies analyzing the bioavailability of
flavan-3-ols, reported high levels of phenyl-γ-valerolactones in the circulation and
urinary excretion after ingestion of a red grape pomace drink [71] and apple juice
[72]. In the colonocytes and hepatocytes, these microbial products undergo further
metabolism by phase II enzymes to produce conjugated derivatives. Margalef et al.
[73] analyzed the tissue distribution of metabolites derived from a grape-seed
proanthocyanidin extract (GSPE) 2 h after ingestion by rats. These authors detected
a few microbial metabolites (methyl conjugated phenols) at low concentrations in
the colon tissue, while most phase II metabolites (glucuronidated and methyl-
glucuronidated forms) were found in the kidneys and liver. In humans, the major
contributors to the excretion of phenyl-γ-valerolactones after ingestion of a red
grape pomace drink, are sulfated and glucuronidated conjugates of 5-(30,40-
dihydroxyphenyl)-γ-valerolactone [71].
5. In vitro, in vivo and ex vivo studies on the benefits of PACs
for intestinal dysfunction
During the last decade, the beneficial properties of PACs for intestinal function
have been reported in several studies performed with cell-culture models and
experimental animals (Tables 1 and 2). This experimental data indicate that PACs
contribute to maintaining the intestinal barrier and improving mucosal inflamma-
tion induced by environmental insults. However, there are few studies on the
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In vitro models of inflammation have been fundamental in the comprehension
of cellular mechanisms driving physiological effects of bioactive molecules. Studies
on intestinal dysfunction have employed human colon carcinoma cell lines, being
Caco-2 the most well-established and widely used model of the human intestine
barrier ([89] and Table 1). Mucus producer [79], macrophages [90], and B cell lines
[91] have been employed in co-culture systems to explore the interaction between
cell populations. Although there is a strong trend in the industry toward replacing
animal experiments with human cell-culture based models [92, 93], there are no
in vitro models of the human intestine that replicate the complex interplay between
cell types and the regulation of the barrier function by the mucosal innate and
adaptive immunity. Therefore, most physiologically relevant data on intestinal
dysfunction comes from the animal model. Most in vivo studies testing the effect of
PAC supplementation on intestinal health have been performed in diet-induced
obesity models and chemical-induced colitis models. The first resemble intestinal
alterations seen in humans with metabolic syndrome [43]. The latter closely mimic
histopathological features of human colitis and are frequently used to study the
pathophysiology of IBD and the effectiveness of novel therapeutic drugs [94].
Notably, PAC-rich grape-seed extracts (GSPE) are among the most studied botan-
ical extracts, mainly by in vivo approaches in rodents (Table 2).
5.1 In vitro studies of barrier integrity
The data available on the interaction between PACs and permeability and
inflammation markers in cell models of intestinal dysfunction are summarized in
Table 1. Caco-2-based models have shown to be responsive to pro-inflammatory
stimulation, producing a wide range of inflammatory mediators and increasing the
paracellular permeability. Pro-inflammatory agents such as LPS, phorbol 12-
myristate 13-acetate (PMA), and cytokines (TNF-α and IL-1β) have been used in
multiple studies testing the effect of PAC molecules and PAC-rich botanical extracts
on Caco-2 cells [10, 74, 77, 78]. Stimulated-Caco-2 cell monolayers incubated with
PACs generally show a reduction in gene expression and secretion of TNFα, IL-6,
and IL-8 [10, 74, 75, 77], which is often linked to the downregulation of NF-κB
signaling at different levels [10, 76, 77]. An increased expression of antioxidant
enzymes, such as glutathione peroxidase (GPx), superoxidase dismutase (SOD),
and hemeoxygenase 1 (HO-1), has also been reported [10].
When permeable support systems such as transwell or Ussing chamber (UCh)
are used, alterations in barrier integrity and paracellular permeability of epithelial
cell monolayers are evaluated by transepithelial electrical resistance (TEER), an
electrophysiological parameter that measures ion conductance across the mono-
layer, and by the transepithelial transport of molecular markers such as Lucifer
yellow (LY) and fluorescently labeled dextrans (FD) [95, 96]. Some in vitro studies
have associated PACs with increased TEER and decreased transport of permeability
markers in the context of barrier dysfunction [77, 78, 80]. The expression levels of
TJ proteins (claudins, occludins, and ZOs) often correlate, but not always [79], with
intestinal permeability and are also considered markers of epithelial integrity. Bitzer
et al. [78] found that the dextran sodium sulfate (DSS)-induced loss of barrier
function in Caco-2 cells was significantly inhibited by polymeric PACs of cocoa but
not by oligomers. Moreover, a higher barrier-protective activity was determined in
PACs with DP ≥ 7, which were able to reduce the detrimental effect of DSS in a
dose-dependent fashion [78]. Effectiveness of procyanidin B2 ameliorating dextran
sodium sulfate (DSS)-induced permeability alterations was examined using a Caco-
2/HT29-MTX co-culture model [79]. Although procyanidin B2-incubated cells
showed increased levels of the TJ proteins claudin-7, occludin, and ZO-1, these
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changes did not reduce TEER loss. Altogether, these results suggest that the ability
of PACs to strengthen the intestinal barrier integrity depends on the degree of
polymerization (DP).
5.2 In vivo studies of diet-induced intestinal permeability
The cafeteria (CAF) diet is a self-selected high-saturated fat/high-refined sugar
diet that stimulates hyperphagia and a rapid weight gain in experimental animals
[97, 98]. In this feeding regime, highly palatable and energy dense foods commer-
cially available, such as muffins, biscuits, bacon, sausages, and sugared milk, are
offered ad libitum [15, 99]. A long-term CAF diet (62% carbohydrate (mostly
sugar), 23% lipid, and 13% protein) has negative effects on intestinal function in
rodents, increasing intestinal permeability, and inducing mucosal inflammation
[43]. We have described the beneficial effects of administering GSPE against the
intestinal dysfunction induced by a long-term CAF diet (17–18 weeks) in Wistar
rats [8, 14, 15]. The composition of the GSPE used in these studies has been
analyzed in detail [100]. Both nutritional (5–50 mg kg1 [14]) and pharmacological
(100–500 mg kg1 [8, 15]) doses of GSPE administered orally as a preventive [8] or
counteractive treatment [14, 15], tended to reduce intestinal inflammatory markers
such as TNF-α release or myeloperoxidase (MPO) activity (an indicator of neutro-
phil infiltration in tissues). The reduction of plasma ovalbumin (OVA), an in vivo
marker of intestinal permeability, was supported by (1) the increase in TEER in
small and large intestine segments. This parameter is determined ex vivo by UCh-
based protocols [8, 15]; and (2) by the upregulation of TJ proteins such as ZO-1 [14]
and claudin-1 [8, 15]. Notably, the protective effect of GSPE in the intestinal barrier
function was linked to the amelioration of metabolic endotoxemia (reduction of
plasma LPS) and systemic inflammation (reduction of plasma TNF-α) in obese rats
[15, 101]. Other authors have also reported the upregulation of ZO-1 and claudin-1
TJ proteins in high-fat fed rats supplemented with other PAC-rich extracts [81].
5.3 In vivo studies of chemical-induced intestinal dysfunction
Chemical agents administered orally to induce colitis in rodents include
trinitrobenzene sulfonic acid (TNBS) and DSS. These agents erode the colonic
mucosal lining and produce the loss of the intestinal barrier function and colonic
inflammation. In these models, the severity of outcomes depends on the dose of the
chemical agent and the frequency of administration. Li et al. [102] found that
intragastric administration of GSPE in rats at pharmacological doses (100–
400 mg kg1 d1) prior to TNBS-induced recurrent colitis, reduced weight loss, and
attenuated macro- and microscopic tissue damage scores in the colon. This protec-
tive effect was accompanied by a reduction in oxidative stress (malondialdehyde;
MDA), inflammation (IL-1β), and neutrophil infiltration (MPO activity) in colonic
tissues. Remarkably, the beneficial effects of low to high doses of GSPE were
comparable to those of sulfasalazine (200 mg kg1 d1), a potent inhibitor of NF-
κB. Subsequent studies carried out by these authors with the same model, con-
firmed the role of the GSPE down-regulating NF-κB response [83, 84]. A preventive
effect of procyanidin B2 was also evidenced in a mouse model of DSS-induced
colitis [85]. Administration of procyanidin B2 (10–40 mg kg1 d1) attenuated the
severity of tissue damage in the colon and reduced the levels of matrix
metalloproteinase-9 (MMP-9), a marker of macrophage infiltration. In addition,
inhibition of the NF-κB signaling and of NLRP3 inflammasome activation was
observed, with a concomitant reduction in the gene expression of pro-inflammatory
cytokines. Overall, the benefits of procyanidin B2 administration, especially at the
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In vitro models of inflammation have been fundamental in the comprehension
of cellular mechanisms driving physiological effects of bioactive molecules. Studies
on intestinal dysfunction have employed human colon carcinoma cell lines, being
Caco-2 the most well-established and widely used model of the human intestine
barrier ([89] and Table 1). Mucus producer [79], macrophages [90], and B cell lines
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cell populations. Although there is a strong trend in the industry toward replacing
animal experiments with human cell-culture based models [92, 93], there are no
in vitro models of the human intestine that replicate the complex interplay between
cell types and the regulation of the barrier function by the mucosal innate and
adaptive immunity. Therefore, most physiologically relevant data on intestinal
dysfunction comes from the animal model. Most in vivo studies testing the effect of
PAC supplementation on intestinal health have been performed in diet-induced
obesity models and chemical-induced colitis models. The first resemble intestinal
alterations seen in humans with metabolic syndrome [43]. The latter closely mimic
histopathological features of human colitis and are frequently used to study the
pathophysiology of IBD and the effectiveness of novel therapeutic drugs [94].
Notably, PAC-rich grape-seed extracts (GSPE) are among the most studied botan-
ical extracts, mainly by in vivo approaches in rodents (Table 2).
5.1 In vitro studies of barrier integrity
The data available on the interaction between PACs and permeability and
inflammation markers in cell models of intestinal dysfunction are summarized in
Table 1. Caco-2-based models have shown to be responsive to pro-inflammatory
stimulation, producing a wide range of inflammatory mediators and increasing the
paracellular permeability. Pro-inflammatory agents such as LPS, phorbol 12-
myristate 13-acetate (PMA), and cytokines (TNF-α and IL-1β) have been used in
multiple studies testing the effect of PAC molecules and PAC-rich botanical extracts
on Caco-2 cells [10, 74, 77, 78]. Stimulated-Caco-2 cell monolayers incubated with
PACs generally show a reduction in gene expression and secretion of TNFα, IL-6,
and IL-8 [10, 74, 75, 77], which is often linked to the downregulation of NF-κB
signaling at different levels [10, 76, 77]. An increased expression of antioxidant
enzymes, such as glutathione peroxidase (GPx), superoxidase dismutase (SOD),
and hemeoxygenase 1 (HO-1), has also been reported [10].
When permeable support systems such as transwell or Ussing chamber (UCh)
are used, alterations in barrier integrity and paracellular permeability of epithelial
cell monolayers are evaluated by transepithelial electrical resistance (TEER), an
electrophysiological parameter that measures ion conductance across the mono-
layer, and by the transepithelial transport of molecular markers such as Lucifer
yellow (LY) and fluorescently labeled dextrans (FD) [95, 96]. Some in vitro studies
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278
Weight Management
changes did not reduce TEER loss. Altogether, these results suggest that the ability
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severity of tissue damage in the colon and reduced the levels of matrix
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cytokines. Overall, the benefits of procyanidin B2 administration, especially at the
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highest dosage (40mg kg1), were comparable to those of mesalazine (200
mg kg1), a COX inhibitor. The authors suggest that these effects were largely due
to the reduction in activated macrophages infiltrating colonic tissues, probably
driven by ROS clearance.
5.4 Other in vivo studies with animal models
The IL-10 deficient mouse is a classic knockout model that develops spontaneous
colitis under pathogen-free conditions. Some authors have explored the influence of
GSPE in this model, supplementing colitic animals with 0.1–1 g 100 g1 of dry feed
weight for 12–16 days [86, 87]. These studies evidenced a reduction of multiple
inflammatory markers in the jejunum and colon, such as TNF-α, IL-1β, IL-6, and
IFN-γ gene expressions, as well as MPO activity. This anti-inflammatory effect was
associated with the inhibition of the NF-κB signaling. Interestingly, GSPE supple-
mentation also increased the density of goblet cells in the jejunum of treated ani-
mals, suggesting that there is an alternative mechanism by which inflammation is
attenuated.
Cardoso et al. [13] recently tested both dietary (75 mg kg1) and pharmacolog-
ical doses of GSPE (375 mg kg1) in a rat model of mild intestinal dysfunction
induced by intraperitoneal injection of LPS. GSPE was administered daily by oral
gavage for 15 days prior to LPS-induced intestinal dysfunction. LPS enhanced
intestinal permeability and induced both oxidative stress and inflammation. GSPE-
treated animals reduced OVA permeation to the circulation, MPO activity and
COX-2 in the small intestine tissues, and reactive oxygen species (ROS) levels in the
colon. Furthermore, a gene expression analysis with a low-density microarray tech-
nique revealed that unlike the dietary dose of GSPE, the pharmacological dose had a
striking effect on the LPS-gene expression profile, showing a strong modulation of
multiple genes associated with chemokines and ILs, including upregulation of the
anti-inflammatory cytokine IL-13.
5.5 Human ex vivo studies
Although the use of animal models is the predominate approximation at pre-
clinical stages for testing novel therapies in intestinal permeability, there is a strong
trend in the industry towards replacing animal experiments with human cell-
culture based models [92, 93]. Nevertheless, advantages related to the usefulness of
in vitro models for screening of bioactives and exploring action mechanisms, are
offset by limitations regarding the mimicking of the in vivo situation and transla-
tion to the human [103]. Thus, some human ex vivo models have been proposed to
test immunomodulatory properties of drug candidates in intestinal explants from
IBD patients [104, 105]. Intestinal function can also be studied with UCh-based
protocols. The UCh system consists of two halves with an opening between them,
where mucosal tissue is adapted, thus isolating the apical and basolateral sides of the
tissue. This technique has been applied for studying drug absorption [106] and
secretion of enterohormones [107] in human endoscopic biopsies. An advantage of
UCh models over explant-based models is that UCh models make it possible to
measure the electrophysiological parameters, including TEER [106]. All these set-
ups permit analyzing the cytokine profiling of intestinal explants or biopsies
retaining their in situ conditioning in a polarized fashion [105, 108]. We have
employed the UCh to determine TEER and cytokine release (TNF-α) in intestinal
tissues from cafeteria diet-induced obese rats treated with GSPE [8, 15]. It could
also be useful for testing the effect of bioactives on dysfunctional human intestine.
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A feature of ex vivo models is that screening of drug effects does not compromise
the patients by exposing them to unknown outcomes.
5.6 Clinical trials
Translation of doses of PAC-rich extracts used in rodent models of intestinal
dysfunction to human equivalent doses (HED) indicates that pharmacological doses
(up to 5 g d1 for a 60 kg person) could be required to achieve beneficial effects in
clinical trials [14, 15]. Thus, the first uncertainty involved in assessing the use of
PACs as therapy agents in humans, is safety. Grape seed and skin
proanthocyanidin-rich extracts have been subjected to toxicological tests in rats to
determine their safety for use in functional foods [109–111]. In these studies, the
median lethal dose (LD50) was found to be greater than 5000 mg kg1 bw (HED of
≈50 g) when administered once by oral gavage, and 1400–2000 mg kg1 d1 (HED
of ≈14–20 g d1) was found to be the no-observed-adverse-effect level (NOAEL)
for systemic toxicity in sub-chronic administration. A recent study evaluated the
safety and tolerability of GSPE intake (up to 2.5 g d1) in a small number of healthy
adults for a 4-week period and found a good tolerability without adverse effects on
hematological or biochemical parameters [47].
To date, there are few clinical studies that evaluate the influence of PACs on
intestinal inflammatory conditions. A clinical study revealed that the postprandial
increase of plasma LPS associated with the intake of a high-fat meal was signifi-
cantly reduced in obese subjects who consumed 1 g of GSPE [112]. As translocation
of LPS to the circulation is considered an indicator of intestinal permeability and a
critical factor in the appearance of systemic low-grade inflammation in patients
with metabolic syndrome [113], reduction of postprandial endotoxemia could be
particularly interesting from a therapeutic perspective. Large double-blind clinical
studies need to be conducted to provide more information on PAC clinical efficacy
in intestinal dysfunction so that these phytochemicals can be used therapeutically to
improve intestinal health in obese and IBD individuals.
6. Biochemical and molecular mechanisms underlying the barrier-
protective and anti-inflammatory properties of PAC in the intestine
PACs were often considered to be nutritionally undesirable due to their ability to
form complexes with macronutrients and reduce the activity of virtually any
enzyme implicated in digestion [114, 115]. Nevertheless, based on the anti-
cancerous, anti-mutagenic, and anti-microbial activities these phytochemicals
elicited in laboratory experiments, a role in the modulation of the metabolism and
immune system was suggested [115]. The ability of PACs to form cross-links with
biomolecules can be attributed to the hydroxyl groups and aromatic rings in their
structure that can establish hydrogen bonds and hydrophobic interactions [116].
PACs have a significant affinity for proline-rich proteins and peptides [117]. In
general, binding to proteins seems to increase with the DP as larger PAC molecules
have more potential binding sites for the associations with proline residues [117].
The interaction results in effects determined by the biological function of the target
protein. Thus, PACs not only alter enzymatic activity, but they may also prevent
ligand-receptor interactions and the binding of transcription factors to their specific
sites in DNA. In addition, some PAC molecules can be adsorbed non-specifically
onto biomembrane surfaces [118], affecting their physical characteristics, such as
fluidity and density, and potentially altering membrane-dependent processes,
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GSPE in this model, supplementing colitic animals with 0.1–1 g 100 g1 of dry feed
weight for 12–16 days [86, 87]. These studies evidenced a reduction of multiple
inflammatory markers in the jejunum and colon, such as TNF-α, IL-1β, IL-6, and
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induced by intraperitoneal injection of LPS. GSPE was administered daily by oral
gavage for 15 days prior to LPS-induced intestinal dysfunction. LPS enhanced
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COX-2 in the small intestine tissues, and reactive oxygen species (ROS) levels in the
colon. Furthermore, a gene expression analysis with a low-density microarray tech-
nique revealed that unlike the dietary dose of GSPE, the pharmacological dose had a
striking effect on the LPS-gene expression profile, showing a strong modulation of
multiple genes associated with chemokines and ILs, including upregulation of the
anti-inflammatory cytokine IL-13.
5.5 Human ex vivo studies
Although the use of animal models is the predominate approximation at pre-
clinical stages for testing novel therapies in intestinal permeability, there is a strong
trend in the industry towards replacing animal experiments with human cell-
culture based models [92, 93]. Nevertheless, advantages related to the usefulness of
in vitro models for screening of bioactives and exploring action mechanisms, are
offset by limitations regarding the mimicking of the in vivo situation and transla-
tion to the human [103]. Thus, some human ex vivo models have been proposed to
test immunomodulatory properties of drug candidates in intestinal explants from
IBD patients [104, 105]. Intestinal function can also be studied with UCh-based
protocols. The UCh system consists of two halves with an opening between them,
where mucosal tissue is adapted, thus isolating the apical and basolateral sides of the
tissue. This technique has been applied for studying drug absorption [106] and
secretion of enterohormones [107] in human endoscopic biopsies. An advantage of
UCh models over explant-based models is that UCh models make it possible to
measure the electrophysiological parameters, including TEER [106]. All these set-
ups permit analyzing the cytokine profiling of intestinal explants or biopsies
retaining their in situ conditioning in a polarized fashion [105, 108]. We have
employed the UCh to determine TEER and cytokine release (TNF-α) in intestinal
tissues from cafeteria diet-induced obese rats treated with GSPE [8, 15]. It could
also be useful for testing the effect of bioactives on dysfunctional human intestine.
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A feature of ex vivo models is that screening of drug effects does not compromise
the patients by exposing them to unknown outcomes.
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(up to 5 g d1 for a 60 kg person) could be required to achieve beneficial effects in
clinical trials [14, 15]. Thus, the first uncertainty involved in assessing the use of
PACs as therapy agents in humans, is safety. Grape seed and skin
proanthocyanidin-rich extracts have been subjected to toxicological tests in rats to
determine their safety for use in functional foods [109–111]. In these studies, the
median lethal dose (LD50) was found to be greater than 5000 mg kg1 bw (HED of
≈50 g) when administered once by oral gavage, and 1400–2000 mg kg1 d1 (HED
of ≈14–20 g d1) was found to be the no-observed-adverse-effect level (NOAEL)
for systemic toxicity in sub-chronic administration. A recent study evaluated the
safety and tolerability of GSPE intake (up to 2.5 g d1) in a small number of healthy
adults for a 4-week period and found a good tolerability without adverse effects on
hematological or biochemical parameters [47].
To date, there are few clinical studies that evaluate the influence of PACs on
intestinal inflammatory conditions. A clinical study revealed that the postprandial
increase of plasma LPS associated with the intake of a high-fat meal was signifi-
cantly reduced in obese subjects who consumed 1 g of GSPE [112]. As translocation
of LPS to the circulation is considered an indicator of intestinal permeability and a
critical factor in the appearance of systemic low-grade inflammation in patients
with metabolic syndrome [113], reduction of postprandial endotoxemia could be
particularly interesting from a therapeutic perspective. Large double-blind clinical
studies need to be conducted to provide more information on PAC clinical efficacy
in intestinal dysfunction so that these phytochemicals can be used therapeutically to
improve intestinal health in obese and IBD individuals.
6. Biochemical and molecular mechanisms underlying the barrier-
protective and anti-inflammatory properties of PAC in the intestine
PACs were often considered to be nutritionally undesirable due to their ability to
form complexes with macronutrients and reduce the activity of virtually any
enzyme implicated in digestion [114, 115]. Nevertheless, based on the anti-
cancerous, anti-mutagenic, and anti-microbial activities these phytochemicals
elicited in laboratory experiments, a role in the modulation of the metabolism and
immune system was suggested [115]. The ability of PACs to form cross-links with
biomolecules can be attributed to the hydroxyl groups and aromatic rings in their
structure that can establish hydrogen bonds and hydrophobic interactions [116].
PACs have a significant affinity for proline-rich proteins and peptides [117]. In
general, binding to proteins seems to increase with the DP as larger PAC molecules
have more potential binding sites for the associations with proline residues [117].
The interaction results in effects determined by the biological function of the target
protein. Thus, PACs not only alter enzymatic activity, but they may also prevent
ligand-receptor interactions and the binding of transcription factors to their specific
sites in DNA. In addition, some PAC molecules can be adsorbed non-specifically
onto biomembrane surfaces [118], affecting their physical characteristics, such as
fluidity and density, and potentially altering membrane-dependent processes,
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including protein receptor activity [119]. Altogether, these effects lead ultimately to
the alteration of cell signaling pathways and the modulation of gene expression.
6.1 Modulation of TJ integrity
The precise mechanisms underlying the improvement in intestine paracellular
permeability due to PACs in inflammation are not yet completely elucidated; how-
ever, it is known that they lead ultimately to the upregulation (e.g., ZO-1 and
claudin-1 [8, 13]) or downregulation (e.g., claudin-2 [86]) of TJ protein expression.
Loss of TJ integrity in the pro-inflammatory state is mediated by the NF-κB signal-
ing pathway and by the activation of protein kinases MAPKs, PI3Ks, AMPK, and
MLCK [120]. MLCK is particularly crucial in actomyosin-based cytoskeletal func-
tions and multiple studies highlight its important role in intestinal TJ remodeling
[121, 122]. PACs reduce the production of pro-inflammatory mediators (e.g., TNF-
α) and reactive oxygen species (i.e., iNOS activity) associated with enhancing
intestinal permeability by antagonizing the NF-κB signaling pathway. In addition,
PACs are potent inhibitors of kinases including MLCK [120, 123]. Contreras et al.
[124] also suggested that there is an upstream novel mechanism associated with
flavan-3-ols that leads to the prevention of TNF-α-induced intestinal permeability.
In this study, TNF-α-stimulated Caco-2 monolayers incubated with ()-
epicatechin showed a reduction of NOX activity, an enzyme that also facilitates
activation of TNF-α signaling. This effect was directly associated with the inhibition
of ERK1/2 MAPK activity of IκB phosphorylation and of MLCK activation.
6.2 Interaction with bacterial endotoxins
Delehanty et al. [125] demonstrated that naturally occurring A- and B-type
cranberry PACs were able to bind the lipid A moiety of LPS, exhibiting an affinity
similar to that of polymyxin B, a potent LPS-binding molecule. In this study, PACs
efficiently blocked endocytosis of bacterial LPS in a dose-dependent manner in
HEK 293 (human embryonic kidney cells) that expressed receptors TLR4/MD-2
and CD14, thus preventing the induction of the NF-κB signaling pathway without
any interaction with cellular components. However, other authors reported that
PACs isolated from cocoa beans did not abrogate the binding of LPS to TLR4 in
cultivated human dendritic cells [126]. PAC-LPS binding has been linked to the
reduction of the post prandial increase in blood LPS associated with the ingestion of
a high-fat meal in obese subjects ingesting an oral dose of GSPE [112].
7. PACs modulation of intestinal microbiota
Diet plays an important role in the composition of intestine microbiota, pro-
moting or inhibiting growth of microorganisms [127]. Alterations in the composi-
tion and metabolism of the intestinal microbiota (dysbiosis) have also been
associated with the consumption of high-saturated fat diets in rodents and humans
[128, 129]. In fact, metagenomic analysis of the intestinal microbiome in Western
populations has shown a reduction not only of microbial diversity, but also of
functional potential [130]. Dysbiosis is linked to obesity-associated intestinal
inflammation, although the “egg or hen” question related to the cause-effect rela-
tionship is not answered yet [131]. High-fat intake in rodents often decreases overall
diversity of microbiota and the abundance of Bacteroidetes, and increases the
relative abundance of Firmicutes [132, 133]. Several human studies have described
similar associations [134, 135], but the importance of the ratio Firmicutes to
Bacteroidetes remains controversial [136, 137], and some authors state that the
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experimental results are not sufficiently consistent [138]. Interestingly, the exis-
tence of a colitogenic microbiota was demonstrated in T-bet/  RAG2/
deficient mice whose spontaneous ulcerative colitis was horizontally transmissible
to wild-type individuals when co-housed [139]. Although mechanisms by which
dysbiosis trigger intestinal dysfunction are not fully understood, it is known that
they involve the loss of immune tolerance due to local immune homeostasis disrup-
tion and continuous abnormal activation of TLRs [140].
Several authors have suggested that both dietary PACs, which are the substrates
of intestinal bacteria, and the metabolites produced during PACs degradation in the
colon may modulate and induce oscillations in the composition of the microbiota
populations by means of prebiotic and antimicrobial effects against gut pathogenic
microorganisms [141–144]. Dietary PACs, specifically longer polymers, reach the
distal intestine nearly intact, where they become fermentable substrates for the
commensal microbiota [145]. PACs have been associated with prebiotic properties,
boosting the composition of several kinds of probiotics such as Bifidobacterium spp.,
Lactobacillus spp. [146] and the stimulator of mucus production Akkermansia
muciniphila [147, 148]. Nevertheless, current evidence is somewhat controversial as
effects described in different in vivo studies mainly performed with rodents, do not
always agree. This suggests that interactions between PACs and microbiota depend
largely on the botanical source, the types of molecules present in the extracts tested
and the animal model [149].
A recent study by Casanova-Marti et al. [150] found that oral administration of
GSPE in Wistar rats for 8 days resulted in profound changes in the cecal microbiota
composition, reducing diversity indices and the ratio of Firmicutes to Bacteroidetes.
Similar results were found in diet-induced obese Sprague Dawley rats
supplemented with a PAC-rich extract of the Pyracantha fortuneana fruit, although
in this study an increase in microbiota diversity was also reported [81]. GSPE
supplementation in IL-10 deficient mice resulted in an increased abundance of
Bacteroides and Lactobacilli [86]. Xing et al. [148] reported that the administration
of procyanidin B2 in rabbits feeding a high-fat-cholesterol diet, promoted an
increase in the relative abundance of Akkermansia. These authors proposed that the
reduction of metabolic endotoxemia found in animals treated with procyanidin B2
was attributed to the ability of Akkermansia to retain the thickness of the intestinal
mucus layer, thus reducing intestinal permeability and the leakage of LPS into the
circulation [151].
Cueva et al. [146] found that in vitro fermentation of grape-seed monomers and
PACs in human feces resulted in a reduced abundance of Clostridium histolyticum.
Inhibition of the growth of some infectious microorganisms, such as the mentioned
C. histolyticum in the intestine and Helicobacter pylori in the stomach [152], may be
related to the anti-adherence activity that PACs have demonstrated in in vitro
studies [153], as adherence to the epithelium is a prerequisite for colonization and
infection of the intestinal gastrointestinal mucosa.
Finally, phenolic acids and phenyl-γ-valerolactones resulting from the colonic
fermentation of PACs also exhibit a significant bioactivity in cell models and
experimental animals [154]. They therefore may partially account for the beneficial
anti-inflammatory effects reported in intestinal and peripheral tissues in vivo. Fur-
ther research is needed to clarify the importance of these microbial products in
health-promoting properties associated with the intake of PACs.
8. Conclusions and future perspectives
The health-promoting properties of PACs in the intestine are attributed not only
to the antioxidant activity inherent to phenolic compounds, but also to the capacity
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[124] also suggested that there is an upstream novel mechanism associated with
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activation of TNF-α signaling. This effect was directly associated with the inhibition
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similar to that of polymyxin B, a potent LPS-binding molecule. In this study, PACs
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and CD14, thus preventing the induction of the NF-κB signaling pathway without
any interaction with cellular components. However, other authors reported that
PACs isolated from cocoa beans did not abrogate the binding of LPS to TLR4 in
cultivated human dendritic cells [126]. PAC-LPS binding has been linked to the
reduction of the post prandial increase in blood LPS associated with the ingestion of
a high-fat meal in obese subjects ingesting an oral dose of GSPE [112].
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moting or inhibiting growth of microorganisms [127]. Alterations in the composi-
tion and metabolism of the intestinal microbiota (dysbiosis) have also been
associated with the consumption of high-saturated fat diets in rodents and humans
[128, 129]. In fact, metagenomic analysis of the intestinal microbiome in Western
populations has shown a reduction not only of microbial diversity, but also of
functional potential [130]. Dysbiosis is linked to obesity-associated intestinal
inflammation, although the “egg or hen” question related to the cause-effect rela-
tionship is not answered yet [131]. High-fat intake in rodents often decreases overall
diversity of microbiota and the abundance of Bacteroidetes, and increases the
relative abundance of Firmicutes [132, 133]. Several human studies have described
similar associations [134, 135], but the importance of the ratio Firmicutes to
Bacteroidetes remains controversial [136, 137], and some authors state that the
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fermentation of PACs also exhibit a significant bioactivity in cell models and
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ther research is needed to clarify the importance of these microbial products in
health-promoting properties associated with the intake of PACs.
8. Conclusions and future perspectives
The health-promoting properties of PACs in the intestine are attributed not only
to the antioxidant activity inherent to phenolic compounds, but also to the capacity
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of these phytochemicals to interact with multiple biomolecules, including proteins,
biomembrane lipids, and endotoxins. Bioactivity of PACs is highly structure-
dependent and enriched botanical extracts composed by a large variety of molecular
structures exert a wide range of unrelated physiological effects. In this way, PAC-
rich extracts can modulate kinase activity, several signal transduction pathways
implicated in the inflammatory response and the remodeling of TJs. Flavan-3-ol
monomers and short PAC oligomers are absorbed by enterocytes and immune cells
and exert a direct action on kinases and transcription factors. Bioactivity of larger
oligomers and polymeric PACs do not require direct intestinal absorption and are
able to bind protein receptors on the enterocyte and immune cell surfaces as well as
luminal bacterial endotoxins, thus inhibiting pro-inflammatory signaling and
improving barrier integrity. Due to the negligible absorption of large PACmolecules
in the small intestine, phenyl-γ-valerolactones and phenolic acids produced by the
microbiota metabolism in the colon are thought to play an important role in these
health-promoting effects, and thus need to be further researched.
The barrier-protective properties of PACs are emerging as a potential adjunctive
support to current therapies for managing obesity related intestinal dysfunction and
IBD. However, there have been no large, well-designed clinical trials establishing
the efficacy of these phytochemicals in chronic conditions. At preclinical stages, the
use of animal models is the predominant approach for testing novel therapies for
intestinal dysfunction, although several strategies for replacing animal experiments
have been proposed. As there are still no studies on the impact of PACs on human
intestinal health, ex vivo models of the human intestine could be a more physiolog-
ically reliable alternative to human cell lines and an alternative to animal experi-
mentation in preclinical development.
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Nowadays, sugar*free food is very popular because of its low calorie value. 
So food industries make use of various artificial sweeteners of low calorie as an 
alternative to high calorie sugars and they provide low glycemic response. The 
U.S. Food and Drug Administration has approved artificial sweeteners such as 
saccharin, acesulfame-K, sucralose, aspartame, etc. as per acceptable daily intake 
value (ADI) value, but these artificial sweeteners that breakdown products during 
metabolism in turn are known to have health and metabolic effects. Hence, in this 
work, we will discuss about artificial sweeteners, types, and their metabolic and 
health effects.
Keywords: artificial sweeteners, adverse effects, potential toxicity
1. Introduction
In the recent scenario, the people are more concerned about health and better 
quality of life and so they avoid consumption of food rich in sugars, salt or fat so 
as to protect themselves from obesity and other non-communicable diseases. With 
the concern of reducing energy intake, food products containing artificial sweeten-
ers other than simple sugars (monosaccharides and disaccharides) have become 
increasingly popular. Natural sweeteners add to more of nutritional value so they 
are called nutritive sweeteners. However, synthetic (artificial) sweeteners do not 
contain nutritional value so they are known as non- nutritive sweeteners On the 
contrary, artificial sweeteners are gaining very popular because they help reduce 
calories, control weight, manage diabetes, and prevent cavities. However, their 
safety has been controversial. In general, artificial sweeteners undergo a safety 
evaluation to assess their benefits and risks before using them. A health organiza-
tion such as FDA evaluating all scientific studies and determines the maximum 
amount that can be eaten on a day without causing any adverse effects for each 
sweetener. The aim of this paper is to give an idea about the sweeteners, artificial 
sweetener, their chemical structure and properties and their potential health 
effects in humans.
2. Sweeteners
A sugar substitute is a food additive that provides a sweet taste like that of sugar 
is called sweeteners and classification of sweeteners based on calorific value was 
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Nutritive sweeteners are otherwise called as carbohydrate sweeteners (caloric). 
These sweeteners provide high-quality sweet taste and have an acceptable texture 
and shape and therefore remain as the most popular sweetener. Example for nutri-
tive sweeteners are:
2.1.1 Monosaccharide polyols
Monosaccharide alcohol is the general term for the chain – like polyalcohol 
obtained by reducing the carboxyl group of sugars.
2.1.1.1 Sorbitol (D-glucitol)
Sorbitol occurs naturally in cherries, plums, apples, many berries, seaweeds and 
algae. It is moderately sweet, relatively inexpensive and has less shelf life because of 
hygroscopic property.
2.2 Non-nutritive sweeteners
These are low-calorie sweeteners (referred to as non-nutritive sweeteners, 
artificial sweeteners or sugar calories) added to foods, yogurt, medicinal prepara-
tion, dentifrices, mouthwash and beverages to provide sweetness without adding 
a calorie. The non-caloric sweeteners are generally much sweeter than sucrose and 
can, therefore, be used in small amounts.
2.2.1 Requirements for an ideal artificial sweetener
• It should provide sweetness with no unpleasant after taste.






• More economical in productivity.
• Should be resistant to heat when cooked.




Aspartame is an artificial non saccharide sweetener of molecular formula.
C14H18N2O5 and finds its use in food and beverages as sugar substitute. 
Aspartame is a methyl ester of aspartic acid/phenylalanine dipeptide and marketed 
under the name NutraSweet, Equal and Canderel. In 1965, Aspartame was reported 
and U.S. Food and Drug Administration (FDA) in 1981 approved its use in the food 
products (Figure 2).
2.3.1.1 Metabolism and health aspect
Aspartame is one of the low calorie sweetener used in low, reduced calorie 
foods and also used in beverages. It is also a low calorie table top sweetener used 
in gums, breakfast cereals and dry foods. Upon breaking Aspartame produces 
about 4 calories of energy per gram. On prolonged heating aspartame decom-
poses and therefore it cannot be used for food items involving cooking and 
also converts into liquid on storage. The breakdown products upon ingestion 
are aspartic acid, phenylalanine, methanol and further breakdown products 
including formaldehyde, formic acid and diketopiperazine. FDA insisted 
that food products with aspartame should have warning in the label that the 
person with the rare genetic disorder phenylketonuria should avoid ingest-
ing aspartame. Phenylketonuria is an inborn disease associated with error of 
metabolism that leads to attenuated metabolism of the amino acid phenylalanine. 
Phenylketonuria leads to behavioral problems and mental disorders. Peoples 
suffering from phenylketonuria will have insufficient level of enzyme phenylala-
nine hydroxylase which is required for the breakdown of phenylalanine [1] and 
as a result phenyl alanine accumulates in case of people affected with phenyl-
ketonuria. The breakdown products of aspartame like methanol, phenylalanine 
and aspartic acid leads to headache, blurred vision, brain tumors, eye problems, 
memory loss and nausea [2]. The aspartic acid one of the breakdown products 
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stimulating the nerve cells to either damage or kills and may lead to spinal cord 
injury, stroke and hearing loss [3].
2.3.2 Acesulfame-K
Acesulfame potassium also known as Acesulfame-K is a calorie-free sugar 
substitute (artificial sweetener) marketed as Sunett and Sweet One. Acesulfame 
potassium is the potassium salt of 6-methyl-1,2,3-oxathiazine-4(3H)-one 
2,2-dioxide. Acesulfame-K is a white crystalline powder having molecular formula 
of C4H4KNO4S and molecular weight 201.24 g/mol. It is approximately 120 times 
sweeter than sucrose and has high water solubility. Acesulfame-K is heat stable and 
can be used in cooking and baking. Ace-K is often blended with other sweeteners 
(Sucralose or Aspartame) (Figure 3).
2.3.2.1 Metabolism and health aspect
Acesulfame-K is not metabolized in the body and excreted in urine without 
undergoing any modification and not stored in the body. Pharmaco kinetic studies 
show that 95% of the consumed sweeteners basically excreted in the urine. It does 
not influence potassium in take despite of its potassium content. In 1988 UFDA 
approved to use Ace-K as a general purpose sweetener in a variety of dry products 
and in alcoholic beverages [4]. The breakdown product of Ace-K is acetoacetamide 
known to be toxic if consumed in very large doses but human exposure to break-
down products is negligible. Acesulfame-K contains methylene chloride and may 
lead to headache, depression, nausea, mental confusion, liver and kidney effects [5].
2.3.3 Sucralose
Sucralose is an artificial sweetener and sugar substitute having the molecular 
formula of C12H19Cl3O8 and molecular mass 397.64 g/mol. In the European Union 
it is known with the E number E955 and marketed under the name Splenda. 
Chlorination of sucrose leads to formation of sucralose. Sucralose is approximately 
320–1000 times sweeter than sucrose and three times as sweet as aspartame and 
acesulfame potassium, and twice than sodium saccharin (Figure 4).
2.3.3.1 Metabolism and health aspect
Although sucralose is made from sugar, the human body does not recognize it as 
a sugar and does not metabolize. It does not produce any calories [6]. Sucralose is 
responsible for the shrunken thymus glands with diets of 5% sucralose, and also it 







Sodium saccharin of molecular formula C7H5NO3S (benzoic sulfimide) is an 
artificial sweetener with no calories. It is about 300–400 times as sweet as sucrose 
but has a bitter after taste at higher amount of intake. Saccharin finds use in prod-
ucts such as drinks, candies, cookies, and medicines. Saccharin is often blended 
with other artificial sweeteners because of taste purpose and when used in such 
combinations reduced sugar levels are preferred. In case of oral hygiene products, 
saccharin masks undesired tastes of other ingredients. Saccharin when used as a 
starter feed for livestock reduces feed intake after weaning. Besides its applications 
as an artificial sweetener, saccharin also finds application in electrolytic nickel 
deposition. Addition of saccharin to the nickel salt solutions increases the hardness 
and brightness of the nickel plate. This effect is important characteristic feature of 
saccharin compared to other sweeteners (Figure 5).
2.3.4.1 Metabolism and health aspect
The FDA tried to ban saccharin in 1977 because animal studies have revealed that 
it caused cancer in rat. But there is no supportive evidence to show the carcinogenic 
effect of saccharin at lower doses. Saccharin is now permitted to use in beverages, pro-
cessed food and sugar substitutes and level of saccharin is to be indicated in the label 
[7]. Saccharin causes a headache, breathing difficulties, skin eruptions and diarrhea.
2.3.5 Sodium cyclamate
Sodium cyclamate is an artificial sweetener of molecular formula C6H12NNaO3S. 
It is 30–50 times sweeter than sucrose (table sugar) and because of this it is least 
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other artificial sweeteners; especially saccharin in the ratio of 10:1 that is 10 parts of 
cyclamate to 1 part of saccharin. It is less expensive than most sweeteners including 
sucralose and stable under heat. Cyclamates are being banned in the United States 
and other countries due to safety reasons. But European Union considers them as 
safe (Figure 6).
2.3.5.1 Metabolism and health aspects
Cyclamate itself shows very slow toxicity but it is metabolized to cyclohex-
ylamine which shows greater toxicity because of the nature of the cyclamate 
metabolism [8]. The possible exposure to cyclahexylamine from cyclamate 
metabolism in humans over a period is relevant to the establishment of ADI for 
cyclamate.
2.3.6 Neotame
Neotame is the low calorie artificial sweetener of molecular formula 
C20H30N2O5 and molecular mass 378.469 g mol−1 and it is the derivative of aspar-
tame. A t-butyl group is added to the free amine group of aspartic acid. It is 8000 
times sweetener than sucrose. It can be used alone or often blended with other 
sweeteners especially saccharin. Neotame is used in carbonated soft drinks, cakes, 
drink powders, table top sweetener and bubble gums. The neotame was approved 
in 2002 as a general purpose sweetener, excluding in meat and poultry by FDA 
(Figure 7).
2.3.6.1 Metabolism and health aspects
Neotame is rapidly metabolized by esterase present throughout the body into 
methyl ester and also forms a minor amount of methanol. This metabolic process 
yields de-esterified neotame which is completely eliminated from the body in urine 
and feces within 72 h. It is safer to use with people suffering from phenylketonuria 
because t-butyl group is added to the free amine group of aspartic acid breaks the 
peptide bond between the aspartic acid and phenylalanine, thus reduce the avail-
ability of phenylalanine which is responsible for phenylketonuria [9]. Neotame 
causes some of the toxic effects at high doses in the human such as it to reveal 
changes in body weight and food consumption and headache.
2.3.7 Alitame
Alitame of molecular formula C14H25N3O4S is an aspartic acid-containing dipep-
tide sweetener. It was developed by Pfizer in the early 1980s and currently marketed 
in some countries under the brand name Aclame. It is an intense sweetener with 
sweetness potency 200 times greater than that of sucrose (Figure 8).
Figure 6. 




2.3.7.1 Metabolism and health aspects
Alitame is readily absorbed in gastrointestinal tract and then rapidly metabo-
lized and excreted [10]. Alitame consists of two main components namely aspartic 
acid and alanine amide. The aspartic acid component is metabolized normally and 
alanine amide passes through the body with minimal changes.
3. Conclusion
The increased concern about obesity and the associated metabolic comorbidities 
have led to a reduced consumption of simple sugars and an increase in the intake 
of artificial sweeteners. These sweeteners, which appear as sugar alternatives, have 
been critically evaluated by the FDA and EFSA. Artificial sweeteners are not car-
bohydrates and so they will not increase blood sugar levels leading to diabetics but 
instead every gram of table sugar contains four calories and contributes to obesity 
[11]. The artificial sweeteners like saccharin, acesulfame-K and aspartame induces 
DNA damage in human peripheral lymphocytes [11]. The degradation products of 
acesulfame-K under basic conditions such as acetoacetic acid and acetoacetamide-N-
sulfonic acid may cause DNA strand breaks [5]. Aspartame leads to gastrointestinal 
problems. The toxic potential of various artificial sweeteners for the human body 
was shown in Table 1. Therefore artificial sweeteners provide some potential health 
benefits. In addition they are toxic at high concentrations for the long time exposure. 
Artificial sweeteners consumption has been shown to cause mild to serious side 
effects including life threatening brain damages at high concentrations. But however 
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200 0 Baked goods, frozen 
desserts, candies, 






but not in 
meat or 
poultry
Alitame Aclame Pending 2000 1.4 Baked goods, hot 
and cold beverages, 
milk products, frozen 
desserts and mixes, 
fruit preparations, 





















0 Baked goods, soft 
drinks, chewing 
gum, frosting, frozen 
desserts, jams, jellies, 
gelatins, puddings, 
processed fruit and 
fruit juices, toppings, 
syrups
Saccharin Sweet’N Low, 
Sweet Twin, 
Necta Sweet
GRAS 200–700 0 Tabletop sweetener, 
baked goods, soft 
drinks, jams, chewing 
gum
Sucralose Splenda 1998—in 
15 food 
categories
~600 0 Tabletop sweetener, 
beverages, chewing 






FDA, Food and Drug Administration; GRAS, generally recognized as safe.
Table 1. 
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Long-Term Weight Loss 
Maintenance
Martin Fischer, Nadine Oberänder and Arved Weimann
Abstract
Weight maintenance can be considered a challenge for all patients who are in 
a reduced obese state. In this chapter, we first provide an overview of the chances 
for maintaining weight loss, how physiological adaptations and psychological 
dynamics lead to weight regain in the long-term, and of the factors that have 
been associated with long-term success. Then we review what is known about the 
patient perspective on that critical time period following weight loss, focusing on 
the experience of barriers and facilitators as well as attempted strategies. Finally, 
we introduce an approach for providing a targeted and individualized support at 
this stage.
Keywords: obesity, weight loss, weight loss maintenance, weight regain,  
lifestyle intervention, behavior change
1. Introduction: is weight maintenance a losing battle?
The importance of weight loss for people in the western world is reflected by a 
growing diet industry that is providing easier, faster, and more powerful products. 
In addition to public demand, the diet industry keeps growing because many of 
their products simply work, i.e., they do enable customers to reduce their body 
weight short-term. Socio-cultural ideals of beauty and attractiveness are major 
motivators for reducing body weight even if it already falls within a healthy norm. 
However, for approximately 20% of adults in western societies, losing weight has 
become a health-related issue as they are suffering from obesity. It has been shown 
that comorbidities of obesity such as cardiovascular diseases, joint damage, or 
diabetes as well as quality of life significantly improve when weight is reduced [1]. 
However, the same way it has been shown that short-term weight loss is achievable 
for many people, it has become clear that only few are successful in the long-term 
[2, 3]. The authors of a recent systematic review concluded that substantial weight 
loss cannot be sustained by the average person in the absence of a continued follow-
up intervention [4]. Moreover, behavioral treatments have been questioned ethi-
cally with respect to the claim of permanent weight loss [5]. However, recent data 
suggest that treatment programs comprising of intensified lifestyle interventions 
with continued support can lead to longer-term weight loss [6]. Therefore, a better 
understanding of the interaction between physiological and psychological barriers 
to weight maintenance has been recommended as well as the development of more 
individualized and targeted strategies.
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2. What makes weight loss maintenance challenging?
A number of physiological and psychological factors have to be emphasized 
in order to understand the challenge of weight loss maintenance. Physiologically, 
weight loss induces metabolic adaptations that favor weight regain by creating an 
energy gap [7–9]. These comprise the hormonal regulation of appetite, satiety, 
and satiation as well as resting energy expenditure. Energy expenditure is lowered 
beyond what changes of body composition predict and this might be due to adap-
tive thermogenesis, that is, the capability of the human body to reduce energy 
expenditure by producing less body heat [10]. Moreover, there is evidence that at 
least some of these changes can last over several years, even after partial weight 
regain [11, 12].
Psychologically, it is known that the effect of health behavior interventions 
generally diminishes over time, and that behavior maintenance has to be regarded 
as a separate challenge [13]. Five overarching themes have been associated with 
behavior maintenance and may explain why it is difficult to achieve, i.e., mainte-
nance motives [...], self-regulation, resources, habits, and contextual influences 
[13]. With respect to weight maintenance, it has to be considered that adherence 
not just to a single but to a whole set of behavior is required in order to balance and 
regulate energy intake and expenditure [14]. These changes comprise areas such as 
meal structure, eating behavior, food shopping, calorie counting, alcohol consump-
tion, exercise, stress management, sleep, leisure activities, and vacation. Although 
they are referred to as a single change of lifestyle, the difficulties to maintain each 
associated behavior change may rather accumulate than complement. In accor-
dance with this is the observation that even after several years of successful weight 
maintenance, its execution is still experienced as a burden [15].
Taken together, weight loss maintenance is a challenge because it requires 
actively counteracting a possibly infinite physiological resistance against weight 
reduction as well as the psychological tendency to relapse from health behavior 
changes of which many are necessary for long-term maintenance. Therefore, after 
successful weight loss, obese patients should not be treated as cured, normal-weight 
people, but rather as reduced obese individuals [16].
3. Factors associated with weight loss maintenance
Despite its physiological and psychological challenges, a considerable number 
of patients are able to minimize weight regain [17]. This has been attributed to 
personal characteristics such as internal motivation, social support, self-efficacy, 
novelty seeking, or sleep chronotype, as well as to a set of specific behaviors 
observed in successful maintainers such as high levels of physical activity, compli-
ance to a low-energy diet with a regular meal rhythm, flexible eating restraint, 
portion control, control of over-eating, self-monitoring, immediate regulation of 
weight gain, and active problem solving [18–23].
Notably, successful maintenance practices seem to differ from successful 
weight loss practices [24]. In recent reviews, energy intake on one side and energy 
expenditure on the other have been used as a framework to explain how different 
determinants may affect weight maintenance [8, 20]. According to this view, any 
factor or strategy that enables a weight-reduced patient to permanently reduce 
calorie intake will support weight maintenance. Similarly, any strategy that 
enables a patient to permanently increase energy expenditure will support main-
tenance as well. It has to be noted that none of these determinants are believed to 
alter the physiological adaptations associated with weight loss but rather help to 
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minimize their impact. In other words, it is assumed that a cognitive control of 
energy regulation is an inevitable necessity.
Although several determinants of successful weight loss maintenance have been 
observed, intervention studies reported mainly disappointing results [17, 25, 26]. 
An increase of physical activity and exercise, for example, is clearly predictive of 
weight loss maintenance, but when applied as a clinical intervention in randomized 
controlled trials, its effectiveness remains questionable, especially in the long-term 
[27, 28]. The reason for this is still not clear but an important factor could be adher-
ence. Therefore, additional mediators need to be identified that may explain why 
some patients continue pursuing weight maintenance behaviors and some others 
are not [22]. For example, the contribution of novel neuropsychological factors such 
as executive functioning and neurocognitive control to weight loss maintenance 
have been recently discussed [16, 29]. Another important approach for improving 
long-term adherence might be the provision of more tailored and multidisciplinary 
weight loss maintenance strategies [14]. This requires a deeper understanding of the 
patient perspective [30].
4. The patient perspective
In order to provide a tailored support after weight loss, it is crucial to understand 
the patient perspective on weight loss maintenance. What do patients experience 
during this time? How do the physiological and psychological challenges translate 
into the individual’s perception and what measures do they undertake in response 
to that and with what kind of perceived success? These questions can be answered 
by identifying factors that patients perceive as threats and factors that they perceive 
as facilitators during weight loss maintenance. It might also be useful to identify the 
different maintenance strategies patients rely on and their experience with them. 
Most studies have used qualitative designs to explore how patients experience and 
explain their success or failure during weight maintenance, respectively. Although 
the transferability of a single qualitative study may be limited, a more valid view 
can be generated by thematically synthesizing many of them [31]. To expand 
insights gathered by qualitative studies, it could also be helpful to utilize quantita-
tive designs in future studies of patient perspective [30, 32].
4.1 Barriers
A great variety of barriers to weight maintenance have been revealed by reviews 
of qualitative studies on patient perspective (Table 1). For example, in one review, 
the identified barriers included bad weather conditions such as extreme winters, 
poor health and sickness, lack of motivation (e.g., due to previous failure, body 
image, or eating for reasons other than hunger), lack of time management, prob-
lems at home (e.g., due to the inability to afford a healthy lifestyle), festivities, and 
past stigmatizing experiences [33]. Additional barriers, identified in another review 
included maladaptive habits, poor self-regulation skills, emotional problems, 
social-cultural factors (e.g., pressure, saboteurs, and social commitments), and 
environmental limitations (e.g., feeling unsafe to exercise in the neighborhood) 
[34]. Identity conflicts and negative beliefs about weight management are two more 
barriers patients experience during weight loss maintenance [31]. It is possible that 
a considerable overlap between some of these barriers exists and that they can be 
reduced to a small number of main barriers [30]. It is also noteworthy that the per-
ception of barriers and their relevance for actual weight regain could change over 
time and there might even be moments when some patients are not experiencing 
Weight Management
310
2. What makes weight loss maintenance challenging?
A number of physiological and psychological factors have to be emphasized 
in order to understand the challenge of weight loss maintenance. Physiologically, 
weight loss induces metabolic adaptations that favor weight regain by creating an 
energy gap [7–9]. These comprise the hormonal regulation of appetite, satiety, 
and satiation as well as resting energy expenditure. Energy expenditure is lowered 
beyond what changes of body composition predict and this might be due to adap-
tive thermogenesis, that is, the capability of the human body to reduce energy 
expenditure by producing less body heat [10]. Moreover, there is evidence that at 
least some of these changes can last over several years, even after partial weight 
regain [11, 12].
Psychologically, it is known that the effect of health behavior interventions 
generally diminishes over time, and that behavior maintenance has to be regarded 
as a separate challenge [13]. Five overarching themes have been associated with 
behavior maintenance and may explain why it is difficult to achieve, i.e., mainte-
nance motives [...], self-regulation, resources, habits, and contextual influences 
[13]. With respect to weight maintenance, it has to be considered that adherence 
not just to a single but to a whole set of behavior is required in order to balance and 
regulate energy intake and expenditure [14]. These changes comprise areas such as 
meal structure, eating behavior, food shopping, calorie counting, alcohol consump-
tion, exercise, stress management, sleep, leisure activities, and vacation. Although 
they are referred to as a single change of lifestyle, the difficulties to maintain each 
associated behavior change may rather accumulate than complement. In accor-
dance with this is the observation that even after several years of successful weight 
maintenance, its execution is still experienced as a burden [15].
Taken together, weight loss maintenance is a challenge because it requires 
actively counteracting a possibly infinite physiological resistance against weight 
reduction as well as the psychological tendency to relapse from health behavior 
changes of which many are necessary for long-term maintenance. Therefore, after 
successful weight loss, obese patients should not be treated as cured, normal-weight 
people, but rather as reduced obese individuals [16].
3. Factors associated with weight loss maintenance
Despite its physiological and psychological challenges, a considerable number 
of patients are able to minimize weight regain [17]. This has been attributed to 
personal characteristics such as internal motivation, social support, self-efficacy, 
novelty seeking, or sleep chronotype, as well as to a set of specific behaviors 
observed in successful maintainers such as high levels of physical activity, compli-
ance to a low-energy diet with a regular meal rhythm, flexible eating restraint, 
portion control, control of over-eating, self-monitoring, immediate regulation of 
weight gain, and active problem solving [18–23].
Notably, successful maintenance practices seem to differ from successful 
weight loss practices [24]. In recent reviews, energy intake on one side and energy 
expenditure on the other have been used as a framework to explain how different 
determinants may affect weight maintenance [8, 20]. According to this view, any 
factor or strategy that enables a weight-reduced patient to permanently reduce 
calorie intake will support weight maintenance. Similarly, any strategy that 
enables a patient to permanently increase energy expenditure will support main-
tenance as well. It has to be noted that none of these determinants are believed to 
alter the physiological adaptations associated with weight loss but rather help to 
311
Long-Term Weight Loss Maintenance
DOI: http://dx.doi.org/10.5772/intechopen.92103
minimize their impact. In other words, it is assumed that a cognitive control of 
energy regulation is an inevitable necessity.
Although several determinants of successful weight loss maintenance have been 
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ence. Therefore, additional mediators need to be identified that may explain why 
some patients continue pursuing weight maintenance behaviors and some others 
are not [22]. For example, the contribution of novel neuropsychological factors such 
as executive functioning and neurocognitive control to weight loss maintenance 
have been recently discussed [16, 29]. Another important approach for improving 
long-term adherence might be the provision of more tailored and multidisciplinary 
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patient perspective [30].
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to that and with what kind of perceived success? These questions can be answered 
by identifying factors that patients perceive as threats and factors that they perceive 
as facilitators during weight loss maintenance. It might also be useful to identify the 
different maintenance strategies patients rely on and their experience with them. 
Most studies have used qualitative designs to explore how patients experience and 
explain their success or failure during weight maintenance, respectively. Although 
the transferability of a single qualitative study may be limited, a more valid view 
can be generated by thematically synthesizing many of them [31]. To expand 
insights gathered by qualitative studies, it could also be helpful to utilize quantita-
tive designs in future studies of patient perspective [30, 32].
4.1 Barriers
A great variety of barriers to weight maintenance have been revealed by reviews 
of qualitative studies on patient perspective (Table 1). For example, in one review, 
the identified barriers included bad weather conditions such as extreme winters, 
poor health and sickness, lack of motivation (e.g., due to previous failure, body 
image, or eating for reasons other than hunger), lack of time management, prob-
lems at home (e.g., due to the inability to afford a healthy lifestyle), festivities, and 
past stigmatizing experiences [33]. Additional barriers, identified in another review 
included maladaptive habits, poor self-regulation skills, emotional problems, 
social-cultural factors (e.g., pressure, saboteurs, and social commitments), and 
environmental limitations (e.g., feeling unsafe to exercise in the neighborhood) 
[34]. Identity conflicts and negative beliefs about weight management are two more 
barriers patients experience during weight loss maintenance [31]. It is possible that 
a considerable overlap between some of these barriers exists and that they can be 
reduced to a small number of main barriers [30]. It is also noteworthy that the per-
ception of barriers and their relevance for actual weight regain could change over 
time and there might even be moments when some patients are not experiencing 
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any barriers to weight loss maintenance [30, 35]. Also, despite the experience of 
external barriers and facilitators, many patients may still take mostly personal 
responsibility for weight maintenance as excess weight is oftentimes attributed to 
unhealthy, modifiable behaviors [34].
In one of our studies, we found that patients who had been successfully treated 
for severe obesity were experiencing four main barriers to weight loss maintenance 
during the first 3 years after treatment completion [30]. The first barrier, ‘Hedonic 
Hunger’, reflected difficulties arising from food-related pleasure and the struggle 
with availability of highly palatable foods. The second barrier, ‘mental distress’, 
reflected difficulties arising from stress, emotional eating, and mental issues. The 
third barrier, ‘Binge Eating’, reflected difficulties arising from subclinical loss of con-
trol eating, binge episodes, boredom, and craving. The last barrier, ‘Demoralization’, 
reflected several difficulties arising from an implicit demoralized state, a low 
self-efficacy and helplessness such as lacking social support, finances, health, and 
motivation. Each barrier was found to be relevant for weight regain, but also that 
time could be a mediator. In particular, “Binge Eating” was found to be most critical 
at the beginning of weight loss maintenance and ‘Mental Distress” at later stages.
4.2 Facilitators
Perceived facilitators of weight maintenance that have been revealed by reviews 
of qualitative studies include an identity shift (e.g., living healthily became a need), 
a psychological commitment, and preparedness to integrate weight management 
strategies into everyday life, environmental factors (e.g., healthy choices are visible, 
available and attractive), socio-cultural factors (e.g., support and engagement by 
friends, family, colleagues, and professionals), and an improved self-perception 
due to successful weight loss (Table 1) [8, 31, 33, 34]. However, the experience of 
facilitation can differ inter-individually. For example, for some patients, social sup-
port seems to be irrelevant [36], and past stigmatizing experiences seem to inhibit 
Barriers Facilitators Strategies
• Bad weather conditions
• Poor health and sickness
• Lack of motivation
• Lack of time management
• Problems at home
• Festivities
• Past stigmatizing experiences
• Maladaptive habits





• Negative beliefs about weight 
management
• Identity shift
• Psychological commitment 
and preparedness to integrate 








• Adoption of a food choice 
system
• Establishing a non-food reward 
system
• Habit formation
• Restructuring the environment
• Accepting and committing to 
weight loss maintenance as a 
lifelong challenge
• Balancing eating restraint and 
flexibility
• Being open for building new 
relationships
aMain themes according to recent reviews of qualitative studies [31, 33, 34].
Table 1. 
Main barriers, facilitators, and strategies of weight loss maintenance from patient perspective.a
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some patients for a long time, whereas others are rather motivated by them in the 
short- and long-term [33].
4.3 Strategies
Patients who are able to maintain weight loss report several strategies to explain 
their success including self-motivating and reinforcing strategies (e.g., consciously 
enjoying physical activity as a new quality of a weight-reduced life; intentionally 
turning dieting and exercise into meaningful hobbies), self-monitoring (e.g., app-
based monitoring of food intake, physical activity, and body weight), adoption of a 
food choice system to reduce energy intake (e.g., preferring high-grade, unprocessed 
foods), establishing a nonfood reward system for weight maintenance (e.g., buying 
clothes), habit formation (e.g., avoiding the candy isle; parking faraway), restruc-
turing the environment (e.g., food storage at home; avoiding high-risk situations), 
accepting and committing to weight loss maintenance as a lifelong challenge, balanc-
ing eating restraint and flexibility (e.g., having a slightly relaxed mind-set, faith 
in the process, testing limits, and consciously plan for occasional treats and even 
lapses), and being open for building new relationships (e.g., when former relation-
ships loosen due to an incompatibility with the new lifestyle) (Table 1) [15, 36–38]. It 
should be noted though that successful weight maintainers may not use these strate-
gies consistently, and the differences to unsuccessful patients could therefore be less 
pronounced than previously assumed [36]. Also, the burden patients associate with 
implementing weight maintenance strategies seems to remain much higher compared 
to lifetime weight stable persons who are relying on comparable strategies [15].
So far, mainly strategies that successful patients employ have been explored. In 
contrast, it is less clear which strategies less successful patients try to employ and 
how that relates to their weight regain and failed recovery attempts. For example, 
less successful patients oftentimes end up not eating breakfast, a strategy consis-
tently reported by weight maintainers [23]. Is that because they have never man-
aged to eat breakfast on a regular basis, because they discontinued it prior to regain, 
or because they discontinued it after weight began to regain? In other words, is it a 
lack of behavior change, behavior maintenance, or self-efficacy?
4.4 The experience of tension as a psychological core issue
According to a recent psychological model that integrated findings from 26 
qualitative studies on perceived barriers, facilitators, and strategies, the core issue 
for patients during weight loss maintenance is the experience of tension [31]. This 
tension is a conceptualization of the aforementioned burden that patients associate 
with adhering to the strategies required for long-term success. However, the novelty 
of this model is that it (a) assumes variability of the tension, (b) suggests that 
barriers, facilitators, and strategies are relevant to the degree they are affecting a 
patients’ individual tension, and (c) classifies all of these factors with respect to one 
of four key concepts, that is, “sources of tension”, “modifiers of tension”, strategies 
for “managing tension”, and strategies for “reducing the tension”:
• “Sources of tension” are comprised of psychological factors such as old habits 
and impulses, beliefs about identity, beliefs about weight management, and 
unmet needs.
• “Modifiers of tensions” are comprised of barriers and facilitators such as envi-
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or because they discontinued it after weight began to regain? In other words, is it a 
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According to a recent psychological model that integrated findings from 26 
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• Strategies for “reducing the tension” are comprised of developing automaticity, 
meeting needs more healthily, and changing beliefs and self-concept.
• Strategies for “managing the tension” are comprised of learning and insight, 
self-regulation, managing internal and external influences, and willpower or 
motivation.
Most of the patient experience revealed by qualitative studies can be explained 
by using this framework, and therefore, the introduction of this model could be an 
important step to shift the research focus forward. Particularly, there is a need for 
prospective studies to evaluate the predictive value of patient perspective ensuring 
that it does not reflect merely post-hoc rationalizations. Furthermore, the contribu-
tion of physiological adaptations, probably as a “source of tension”, to the psycho-
logical dynamics of weight maintenance should be evaluated.
5. Providing support during weight loss maintenance
With respect to the available findings on patient perspective as well as our own 
experience, we suggest that an ideal weight loss maintenance treatment program 
comprises of two components, one provided during and immediately after weight 
loss in a structured manner, and one provided and tailored as part of a longer-term 
follow-up care.
5.1 Structured component of a weight loss maintenance program
The structured component of a weight loss maintenance program should 
promote early (i.e., already at the weight loss stage) cognitive-behavioral changes 
such as habit formation that will later help reduce the tension of weight loss main-
tenance. Additionally, during the transition from weight loss to maintenance, this 
component should support the development of strategies for managing the tension 
(Table 2) [31]. An important cognitive goal of this component is to help patients 
accept the challenge of weight loss maintenance early, so they have time to make a 
psychological commitment and be prepared for integrating weight management 
strategies into everyday life (facilitator of WLM). Therefore, weight loss main-
tenance treatment ideally begins during the last weeks of the weight loss stage, 
when weight reduction is just starting to level off. Ways to support early acceptance 
include psychoeducation, cognitive restructuring (e.g., by increasing awareness 
of already achieved improvements), and introduction of former patients as role 
models. This acceptance also requires acceptance of the end of the current weight 
loss episode. The latter is not easy for many patients because they are experiencing 
weight loss as a rather euphoric state with rapid success and regular reinforcement 
due to social adoration, improved quality of life, and health. Also, they are feeling in 
control of their disease and some might even feel cured, expecting to continue until 
some far-away ideal weight is being reached. Therefore, it is essential for them to 
gain insight into the fact that weight loss is going to cease, largely due to physiologi-
cal adaptations, and that it is psychologically healthier, easier, and more functional 
to start focusing on maintenance than further weight loss. For this purpose, it can 
be helpful to emphasize differences between the two (Table 3).
5.2 Tailored longer-term follow-up care
The second component of an ideal weight loss maintenance treatment program 
should provide tailored interventions as part of a longer-term follow-up care. 
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The time frame should be at least 3 years after weight loss, as these years are most 
critical with respect to weight regain [39]. During this time, a continuous assess-
ment of body weight change, cognitive-behavioral changes, emergence of barriers, 
and loss of facilitators should be performed to allow immediate intervention. To get 
a more valid picture, data can be recorded by patients prior to a consultation [36]. 
With respect to the different barriers patients are experiencing, at least five tailored 
interventions may need to be offered.
A first intervention should be targeted towards patients who are primarily 
experiencing difficulties due to festivities, environmental factors such as food 
availability, social-cultural factors such as peer pressure, and old habits. Practicing 
Strategya Interventional tools Examples
Reducing the tension




• Eating before food shopping
• Parking further away from the office
• Move the TV out of the living room
• Joining a fitness tracker community









• Identify pleasant aspects of vacations that 
are not food related
• Feeling healthy by eating healthy food
• Learning to say ‘no’
• Using exercise performance as an indicator 
of success
Changing identity Cognitive restructuring • Showing others who you were and who you 
want to be
• Associate personal values with healthy 
choices
• Photo shoot
• Joining a Nordic walking group





• Appreciating the weight loss outcome
• Accepting the weight maintenance challenge







• Using social accountability
• Becoming aware of personal risk factors
• Flexible eating restraint
• Recognizing lapses and relapses
• Owning up to and growing from lapses
• Relapse recovery





• Anticipating, planning, and avoiding at-risk 
situations
• Defusing food cravings
Willpower or motivation Buddying
Self-help
• Patient-led workshops
• Sharing success with new patients
aStrategies adopted from a conceptual model of the dynamics of weight loss maintenance [31].
Table 2. 
Approach to a structured weight loss maintenance treatment.
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promote early (i.e., already at the weight loss stage) cognitive-behavioral changes 
such as habit formation that will later help reduce the tension of weight loss main-
tenance. Additionally, during the transition from weight loss to maintenance, this 
component should support the development of strategies for managing the tension 
(Table 2) [31]. An important cognitive goal of this component is to help patients 
accept the challenge of weight loss maintenance early, so they have time to make a 
psychological commitment and be prepared for integrating weight management 
strategies into everyday life (facilitator of WLM). Therefore, weight loss main-
tenance treatment ideally begins during the last weeks of the weight loss stage, 
when weight reduction is just starting to level off. Ways to support early acceptance 
include psychoeducation, cognitive restructuring (e.g., by increasing awareness 
of already achieved improvements), and introduction of former patients as role 
models. This acceptance also requires acceptance of the end of the current weight 
loss episode. The latter is not easy for many patients because they are experiencing 
weight loss as a rather euphoric state with rapid success and regular reinforcement 
due to social adoration, improved quality of life, and health. Also, they are feeling in 
control of their disease and some might even feel cured, expecting to continue until 
some far-away ideal weight is being reached. Therefore, it is essential for them to 
gain insight into the fact that weight loss is going to cease, largely due to physiologi-
cal adaptations, and that it is psychologically healthier, easier, and more functional 
to start focusing on maintenance than further weight loss. For this purpose, it can 
be helpful to emphasize differences between the two (Table 3).
5.2 Tailored longer-term follow-up care
The second component of an ideal weight loss maintenance treatment program 
should provide tailored interventions as part of a longer-term follow-up care. 
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availability, social-cultural factors such as peer pressure, and old habits. Practicing 
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stimulus control techniques, social skills, and mindfulness eating might help these 
patients to gain back control over externally triggered hedonic eating motives.
A second intervention should be targeted towards patients who primarily report 
emotional problems, lack of time management, or negative beliefs about weight 
management. Stress prevention and reduction trainings might help these patients 
to free the resources necessary to pursue healthy behaviors again and to not rely on 
emotional eating as a coping mechanism. Of note, some of these patients may need 
to be referred to psychotherapy to treat an underlying affective disorder.
A third intervention should be made available to patients who primarily experi-
ence a lack of control over eating in the absence of clear external or emotional 
causes. A training comprising of acceptance-based and cognitive-behavioral 
techniques, proven effective for the treatment of binge eating disorder, might be 
helpful.
A fourth intervention should be made available for patients whose primary issue 
is a directly experienced lack of motivation or who are demoralized by the experi-
ence of barriers seemingly out of their control such as bad weather conditions, 
poor health and sickness, financial problems at home, a lack of social support, or 
poor body image. Training these patients in problem-solving might enable them to 
find solutions for their respective issues and more importantly, may increase their 
self-efficacy and beliefs in long-term success. Self-efficacy can be further promoted 
by applying methods such as mentoring, adequate goal setting, action planning, and 
motivational interviewing. With respect to body weight, it should be considered 
that stabilization of a partly regained weight is a more realistic goal for recovery 
than anew weight loss [40].
A fifth intervention should be made available for patients who are experiencing 
identity conflicts as their primary issue such as discomfort with the new body, social 
insecurities, or inhibition by past stigmatizing experiences. Cognitive-behavioral 
techniques can be used to dispute potentially idealizing of the former obese self or 
Weight loss period Weight loss maintenance period
Main goal Body weight reduction (fat mass 
reduction)
Identity change (“healthily living 
person”)
Time frame 3–6 months 3+ years
Dietary focus Calorie reduction (“less”)
Rigid adherence
High-grade (“better”)





Adhere to exercise plans
Habitual physical activity
Enjoying physical activity/exercise
Motivation Continuous success due to weight loss 




Improved mobility, new choices, new 
freedom
Healthy lifestyle as a hobby (experiences, 
insights, exchange, role model)
Continuous success due to exercise 













Like-minded people and groups
Professional consultation
Table 3. 
Example for how weight loss maintenance can be emphasized as a separate challenge to patients.
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an exaggerated significance of body image to self-worth. They can also be used to 
help patients seek and build on self-esteem fostering situations. Psychoeducation 
about optional plastic surgery after weight loss might be offered as well.
As described before, it is likely that patients are experiencing several of the 
barriers in parallel or intermittently during weight maintenance. However, we think 
it is still beneficial to treat one barrier at a time in order to focus on behavior and 
cognition instead of weight loss to achieve long-term improvements.
6. Conclusion
Weight loss maintenance is a complex physiological and psychological challenge 
associated with a high risk of failure. Studies on patient perspective have revealed 
valuable information on how this process is experienced. Although generally expe-
rienced as an ongoing burden, the underlying psychological tension is variable and 
moderated by a number of now well-defined barriers, facilitators, and strategies. 
With this novel information, a more tailored long-term support can be provided 
which may help improve weight loss maintenance.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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stimulus control techniques, social skills, and mindfulness eating might help these 
patients to gain back control over externally triggered hedonic eating motives.
A second intervention should be targeted towards patients who primarily report 
emotional problems, lack of time management, or negative beliefs about weight 
management. Stress prevention and reduction trainings might help these patients 
to free the resources necessary to pursue healthy behaviors again and to not rely on 
emotional eating as a coping mechanism. Of note, some of these patients may need 
to be referred to psychotherapy to treat an underlying affective disorder.
A third intervention should be made available to patients who primarily experi-
ence a lack of control over eating in the absence of clear external or emotional 
causes. A training comprising of acceptance-based and cognitive-behavioral 
techniques, proven effective for the treatment of binge eating disorder, might be 
helpful.
A fourth intervention should be made available for patients whose primary issue 
is a directly experienced lack of motivation or who are demoralized by the experi-
ence of barriers seemingly out of their control such as bad weather conditions, 
poor health and sickness, financial problems at home, a lack of social support, or 
poor body image. Training these patients in problem-solving might enable them to 
find solutions for their respective issues and more importantly, may increase their 
self-efficacy and beliefs in long-term success. Self-efficacy can be further promoted 
by applying methods such as mentoring, adequate goal setting, action planning, and 
motivational interviewing. With respect to body weight, it should be considered 
that stabilization of a partly regained weight is a more realistic goal for recovery 
than anew weight loss [40].
A fifth intervention should be made available for patients who are experiencing 
identity conflicts as their primary issue such as discomfort with the new body, social 
insecurities, or inhibition by past stigmatizing experiences. Cognitive-behavioral 
techniques can be used to dispute potentially idealizing of the former obese self or 
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an exaggerated significance of body image to self-worth. They can also be used to 
help patients seek and build on self-esteem fostering situations. Psychoeducation 
about optional plastic surgery after weight loss might be offered as well.
As described before, it is likely that patients are experiencing several of the 
barriers in parallel or intermittently during weight maintenance. However, we think 
it is still beneficial to treat one barrier at a time in order to focus on behavior and 
cognition instead of weight loss to achieve long-term improvements.
6. Conclusion
Weight loss maintenance is a complex physiological and psychological challenge 
associated with a high risk of failure. Studies on patient perspective have revealed 
valuable information on how this process is experienced. Although generally expe-
rienced as an ongoing burden, the underlying psychological tension is variable and 
moderated by a number of now well-defined barriers, facilitators, and strategies. 
With this novel information, a more tailored long-term support can be provided 
which may help improve weight loss maintenance.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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